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ABSTRACT
It was hoped that secosteroids of the type 107, and to a lesser degree secosteroids 
such as 60 and 65, and flbeosteroids 117 and 128 would probe conformational 
requirements for inducing and maintaining general anaesthesia after intravenous 
administration.
The 3-acetoxy-5a-hydroxy steroid 38 underwent fragmentation of the C(5)-C(10) 
bond after treatment with eerie ammonium nitrate in refluxing acetonitrile, with 
the formation of 10-membered ring containing 5,10-secosteroidal compounds with 
a A1,10 double bond. The synthesis afforded exclusively the (E)-form 39, the 
configuration of the double bond being assigned by means of NMR spectrometry. 
Epoxidation of the A1,10 double bond occurred stereoselectively to give the 
ip,10a-epoxide, which served as a protecting group for the olefin and allowed 
deoxygenation of the 5-carbonyl. Selective hydrolysis of the 3-acetate in the 
presence of the 20-acetate allowed manipulation of both the head and tail ends of 
the seco- and abeosteroids to afford the 3a-hydroxyl and 20-keto moieties, 
required for optimum anaesthetic potency (detailed in the review o f steroidal 
anaesthetics, see Appendix). It was hoped that the 3a-hydroxyl and 20-keto 
moieties would be less constrained and thus more free to adopt a suitable 
conformation for GABAa receptor binding.
Cyclization of the (E)-5,10-secosteroids of the type 39 under thermal conditions 
afforded compounds of the 5(10—>lpH)<2Z?e<? type 117, exclusively the trans 
lp,5a-configuration. Also incorporation of a good leaving group at position C(5) 
facilitated the facile transannular reaction to afford 5(10—*lpH)fl&e0 Steroids of the 
type 117. The ease of the transannular reaction plus results of conformational 
studies indicates that the transannular interaction of the double bond with the
— V  —
carbonyl group may strongly influence the thermodynamic stability of the system.
Conformational studies on the (E)-5,10-seco-pregnene 39 showed the 
cyclodecenone ring to adopt an extended crown conformation, and analysis of the 
lH-NMR data of the 3a-silyl ether revealed that in solution the 10-membered ring 
exists in at least 2 distinct forms.
X-ray analysis of the 5(10—*1 pH)abeo diol 117 revealed the unusual configuration 
of the 19a-methyl group plus a solid state molecular packing dominated by 
intermolecular hydrogen bonds through the corresponding hydroxyl groups. The 
consequence of these hydrogen bonds is an array of infinite herringbone polymers, 
unique to this type of structure.




AFU - anaesthetic fish unit
AIBN - azobisisobutyronitrile
Ar - aryl




CAN - eerie ammonium nitrate
C.I. - chemical ionisation
CNS - central nervous system
CTMS - chlorotrimethylsilane
2D COSY - two dimensional correlated spectroscopy
DCA - desoxycorticosterone acetate
DDQ - 2,3-dichloro-5,6-dicyano-1,4-benzoquionone
DEAD - diethyl azodicarboxylate





DMSO - dimethyl sulphoxide
DPPC - dipalmitoylphosphatidylcholine
e d 50 (AD50) - 50 percent effective dose
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E.I. - electron ionisation
Et - ethyl
FAB - Fast Atom Bombardment
GABA - gamma-amino-rt-butyric acid
GAD - glutamic acid decarboxylase
h - hour
HCG - human chorionic gonadotrophin




J  - coupling constant
Kd - dissociation constant for a given drug
KJ - kilo joule
LD50 - 50 percent lethal dose
LH - luteinizing hormone
MAC - minimum alveolar concentration
Me - methyl
min - minute
m.p. - melting point
NMDA - N-methyl-D-aspartate
NMO - 4-methylmorpholine N-oxide
NMR - nuclear magnetic resonance
PCC - pyridinium chlorochromate
PCN - 3(B-hydroxy-20-oxo-5a-pregnan-16a-carbonitrile
Ph - phenyl
PMS - pregnant mare serum
ppm - parts per million
p-TSA - para-toluenesulphonic acid
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rbf - round bottomed flask
REM - rapid eye movement
Rf - retention factor
rt - room temperature
SAR - structure activity relationship
t - tert-
TBAF - tetrabutylammonium fluoride
tBDMS - r-butyldimethylsilyl
TBPS - r-butyl bicyclophosphorothionate
Tf - triflate
THF - tetrahydrofuran
T.I. - therapeutic index
tic - thin layer chromatography
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NOMENCLATURE
General
The chemical name of a compound specifies its stereochemistry but not the 
conformation. Though all steroids can be assigned a unique systematic name 
based on IUPAC nomenclature1, trivial and non-systematic names are used 
persistantly. For example, the trivial name for pregn-4-ene-3,20-dione is 
progesterone.
The systematic names are based on certain fundamental stem names and the 
stereochemistry implied in them. Substituents are indicated by systematic 
application of the rules of general organic chemical nomenclature. According to 
the IUPAC rules hydroxyl and keto groups appear after the name of the parent 
compound, characterized by the ending "-ol" or "-one" respectively, added to the 
number of the carbon atom to which it is attached, while all other substituents are 
listed before the parent name in order of their position on the steroid skeleton. 
Prefixes and suffixes are added to the parent name, their positions being indicated 
by the number of the carbon atoms to which they are attached. The prefix A is 
used as an alternative to denote a double bond. The standard atom numbering 
scheme and the lettering of the rings of the steroid skeleton are shown in Figure 1. 
The carbon atoms are numbered around the rings, starting from the top of ring A.
Additional to these rules are the application of the methods of skeleton 
modification, such as the use of nor for group elimination.
When the rings of a steroid are denoted as projections onto the plane of the paper,
4Figure 1. Numbering scheme of steroid skeleton and ring lettering. Asterisks denote
asymmetric C - atoms, 
the standard formula should be oriented as used here. This convention corresponds
to the absolute configuration of the nucleus of natural steroid molecules. In
structural formulae, the configuration of groups attached to the nucleus which are
above the plane of the ring system is termed |3, and for groups below the plane it is
termed a. For a steroid name, the configuration at an asymmetric centre is
indicated by these Greek letters prefixed by the appropriate numeral. Bonds to
atoms or groups lying below the plane of the paper are shown as broken lines, and
bonds to atoms or groups lying above the plane of the paper are shown as solid
lines preferably thickened. Substituents lying in the plane of the nucleus are
equatorial whereas those extending away are axial substituents (Figure 2).
Figure 2. A/B-ring junction and configuration of substituents 
a) A/B cis, b) A/B trans
There are two A/B-ring fusions which occur naturally. These are the cis fusion 
and the trans fusion (Figure 2). Common steroids have all rings trans fused.
Anaesthetic steroids
The structures of the parent skeletons that are relevant to anaesthetic steroids are 
depicted in Figure 3.
Figure 3. Basic chemical structures of pregnanes, from which steroid
The basic skeleton of all known steroid anaesthetics is the pregnane ring system, 
which is derived from the basic, cyclopentanophenanthrene (steran) ring (Figure 
3). Pregnanes contain 21 carbon atoms, as distinguished from the estranes, 
androstanes, and ethiochoianes, which contain 19 carbon atoms. The pregnane 
skeleton is common to progesterone and many synthetic steroids with 
progestational activity.
Pregnanes occur in two stereoisomeric forms ; 5a-pregnane (allopregnane) and 
5p-pregnane (epipregnane). These differ only with respect to the steric positions 
of the H and methyl substituents at the C-5 and C-10 carbon atoms of the A ring, 
respectively. In 5a-pregnane the relative position of the two groups is trans 
(opposite), while in 5p-pregnane it is cis (parallel).
Substitutions, usually by "-OH" (hydroxyl) or ,,= 0 ” (keto) groups, may occur at 




anaesthetics are derived. a)Steran, b)Pregnane.
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and 21 carbons. The freely rotating hydroxyl groups may point "upward" from the 
plane of the ring system ((3-position) or "downward" from the plane (a-position).
The structure of progesterone differs from that of most metabolites because the 
C(4)-C(5) double bond eliminates a C(5)-C(10) steric constellation. Furthermore, 
its two keto groups, in contrast to hydroxyl groups, are sterically fixed (Figure 4).
O
Figure 4. Progesterone (Pregn-4-ene-3,20-dione).
- x i i i -
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1.1 What is anaesthesia?
"....it has an agreeable taste, so that even chickens take it gladly, and 
thereafter fall asleep for a long time, awaking unharmed...., its use may be 
recommended for painful illness, and it will mitigate the disagreeable 
complications of them"
-Paracelsus, sixteenth century alchemist on diethyl ether.
Anaesthesia is the art or science of rendering the patient unaware, thus producing 
partial or total loss of the sense of pain, providing an indispensable foundation for 
surgery. Since the introduction of anaesthesia into medical practice in the first half 
of the nineteenth century, considerable progress has been achieved in the form of 
safer and more effective anaesthetic agents and vastly improved surgical 
techniques. Thus anaesthesia has played an indirect, yet vital part in the major 
advance in the quality of human life.
There are two types of anaesthesia, general and local anaesthesia. Local or 
regional anaesthesia is brought about by pharmacological agents capable of 
producing a loss of sensation in a circumscribed area of the body ranging from a 
wart to the entire abdomen and lower limbs. Local anaesthetic is a clinical term 
and should be used only to refer to blocking agents that produce reversible clinical 
local anaesthesia.
In contrast, general anaesthesia is described as a condition wherein the patient has 
cerebral cortical depression, loss of the sensation of pain, loss of motor responses,
- 2 -
and is generally unconscious. As evidenced by alterations in physiological 
responses, general anaesthetics act by depressing nervous function. As higher 
concentrations of anaesthetic agents in nervous tissue are obtained, depth of 
anaesthesia increases.
Anaesthesia was divided into four separate stages, which were subsequently 
subdivided by Gillespie2;
Stage I. Analgesia. A mild depression of higher cortical centres, suitable 
for surgical procedures not requiring extensive muscular relaxation.
Stage II. Delirium. Excitement as a result of depression of cortical motor 
centres resulting in possible extensive involuntary activity.
Stage III. Surgical anaesthesia. Subdivided into four planes representing 
progressive increases in depth of anaethesia as characterised by; first, loss of spinal 
reflexes; second, decreased muscle reflexes; third, paralysis of intercostal muscles; 
and fourth, disapppearance of muscle tone.
Stave IV. Respiratory paralysis. More correctly referred to as toxic or 
overdose stage involving respiratory and vasomotor cessation.
All anaesthetics do not bring about analgesia. They do produce insensitivity to 
pain, but this is related to loss of consciousness rather than to specific analgesic 
response. Anaesthetic-induced analgesia is related to an induced release of 
endorphin3.
Stage II extends from the loss of consciousness to the beginning of surgical 
anaethesia and may be accompanied by uncoordinated muscular movements
- 3 -
associated with delirium, urinary incontinence and related responses. Depression 
of cerebral cortex and reticular formation may cause excitement, which in turn 
increases heart rate, blood pressure, and respiration. The first two stages are termed 
the "induction period", which is ideally short and free of excitement, involuntary 
activity, and irritation.
Most surgical procedures are carried out during stage III, which is characterised by 
regular, involuntary breathing, roving eyeball movements, and the absence of 
certain reflexes. As surgical anaesthesia deepens these physical signs 
progressively change, differentiating the four planes of surgical anaesthesia.
Effects on respiration as patients enter stage III vary with different anaesthetic 
agents.
Cessation of respiration generally signifies stage IV, and breathing must be 
assisted until anaesthetic effect decreases.
The best estimate of anaesthetic potency is MAC - the minimum alveolar 
concentration (at 1 atmosphere) of an agent that produces immobility in 50 percent 
of those subjects exposed to a noxious stimulus. In humans the stimulus is a 
surgical skin incision, whereas in animals it is produced by clamping the tail or by 
passing an electrical current through subcutaneous electrodes.
The anaesthetic concentration that abolishes the righting reflex in 50 percent of the 
animals is often used to measure anaesthetic potencies in smaller animals. That is, 
it is an anaesthetic 50 percent effective dose (ED50). It must be noted that the 
tail-clamp ED50 (MAC) and the righting-reflex ED50 are not identical. The 
tail-clamp ED50 is higher than the righting-reflex ED50. This implies that the 
righting-reflex is depressed, at least in part, by a different mechanism from that 
which depresses the response to the application of a tail clamp. Thus the relative
- 4 -
potencies of anaesthetics may depend on the end point measured.
1.2 History of anaesthesia
1.21 History of anaesthetic practice
Operations have been performed for centuries but always for superficial diseases - 
a fracture, amputation, cataract extraction, or removal of bladder calculus. To 
these ends, the anaesthetic properties of hypnosis and trance, pressure over 
peripheral nerves and blood vessels, application of cold, alcohol intoxication, 
ingestion of herbal concoctions, or even physical restraint or shock were used.
With techniques of anaesthesia administration more or less divided into schools, 
the choice now lies among inhalation, intravenous, regional techniques, or 
combinations thereof. The seeds of all three methodologies were implanted during 
the middle ages.
Inhalational anaesthesia
Around 1540, Paracelsus, a swiss physician and alchemist, sweetened the feed of 
fowl with sweet oil of vitriol, a substance earlier prepared by Valerius Cordus, then 
named Aether by Frobenius - the familiar diethyl ether that would later be inhaled 
by most surgical patients over a span of 100 years or more. Paracelsus claimed 
that the diethyl ether was taken unwittingly by chickens, which then fell asleep and 
later awakened without harm.
Local anaesthesia
In the 16th century slaves were paid off in coca leaves, an effective method of
- 5 -
increasing and prolonging their productivity. Customarily, coca leaves bound into 
a ball (cocada) with guano and cornstarch were chewed with lime or alkaline ash to 
release the active alkaloid. Documentation of that era indicates that trephination 
was successful, as the operator permitted cocaine-drenched saliva to drip from the 
mouth onto the wound, thereby providing creditable local anaesthesia.
Intravenous anaesthesia
Following Harvey’s studies of the circulation Percival Christopher Wren, in 1665 
wrote that he could "...easily contrive a way to convey a liquid thing immediately 
into the circulating mass of blood; thus, in pretty big and lean dogs, by making 
ligatures on the veins and then opening them on the side of the ligature towards the 
heart; and by putting into them slender syringes or quills, fastened to bladders 
containing the matter to be infacted....whereof the success was that opium, being 
soon circulated into the brain did within a short time stupefy, though not kill the 
dog; but a large dose of the crocus metallorum, made another dog vomit up life and 
all".
The dried crocus or saffron was at the time employed as a stimulant, or 
antispasmodic.
1.22 A brief history of steroidal anaesthetics 
The anaesthetic properties of some steroids, notably progesterone and 
desoxycorticosterone acetate were first reported4 by Hans Selye in 1941. It was 
later claimed, also by Selye5 that 5P-pregnane-3,20-dione exhibited enhanced 
activity. It took another 13 years before Pfizer introduced the first water-soluble 
steroidal intravenous anaesthetic agent, viz. hydroxydione6 - a hemisuccinate salt.
It possessed a good therapeutic index but several disadvantages, namely slow 
induction time, low potency and a high incidence of thrombophlebitis. However it
- 6 -
was marketed for many years before being withdrawn due to its side effects.
Glaxo7 and Syntex made the next significant development towards a better 
steroidal i.v. anaesthetic by introducing a range of 3a-hydroxy steroids as potent 
hypnotic agents. Glaxo went on to develop 3a-hydroxy-5|3-pregnan-l 1,20-dione 
3-phosphate disodium which was water soluble, stable, did not cause 
thrombophlebitis and induced anaesthesia although not instantly. Although the 
agent was anaesthetic in man it also caused paraesthesia.8
In 1971 the Glaxo group introduced Althesin, a 3:1 mixture of alphaxalone and 
alphadalone acetate in cremaphor EL-water. Althesin produced a moderate 
duration of surgical anaesthesia, had a high therapeutic index and was compatable 
with common pre- and post-anaesthetic agents and inhalation anaesthetics. 
Unfortunately it had to be withdrawn from the market as it was found to cause a 
sometimes fatal allergic reaction due to the cremaphor EL. Althesin is discussed 
in more detail later, in a review of steroidal anaesthetics (see Appendix).
Glaxo’s follow-up was the water-soluble i.v. steroidal anaesthetic minaxolone 
(Figure 5), in 1979. However this drug was also withdrawn due to excitation 
during induction and a slow recovery time.9
(CH3)2N,„.





Figure 5. Two anaesthetically potent steroids. a)Minaxolone, b)ORG. 9843
A review by Witzel10 and subsequent reports by Glaxo11 and Syntex12 groups 
suggested that water-soluble salts of anaesthetic steroidal conjugates are usually
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less active and slower acting than the alcohol from which they are derived. 
Organon Teknika discovered that this was also the case with salts of aminated 
pregnanolones. For instance 3a-hydroxy-5ot-pregnan-20-one is more active than 
the 2p-morpholinyl derivative when adminstered in aqueous solution as a salt, eg. 
the hydrochloride - Org. 9843 (Figure 5). But the steroid, Org. 9843, had an 
interesting level of anaesthetic activity and for this reason Organon Teknika is 
involved in the synthesis and biological evaluation of water soluble analogues 
related in Org. 984313.
1.3 Local anaesthesia
Local anaesthetic agents belong to that special class of pharmacological agents that 
are purposely administered as close to the site of action as possible. A local effect 
is, in fact specifically desired, and absorption in the general circulation and 
subsequent redistribution in the body can lead to undesirable systemic effects and 
toxicity. The desired local effect is a selective analgesia or anaesthesia of some 
part of the body. This localised effect is due to inhibition at nerve endings or to a 
conduction in a peripheral nerve.
Types of local anaesthesia consist of epidural, spinal and topical anaesthesia. All 
are types of central neural blocks. Epidural anaesthesia is used in caesarian 
pregancies and allows the patient to be awake, but feel no pain. Topical 
anaesthesia refers to a diversity of sites of application that includes for example, 
the skin, the cornea, the tracheobronchial tree and the gastrointestinal tract.14 
Depending on the characteristics of the site of application, specific agents and even 
specifically formulated vehicles may be required in order to effect local 
anaesthesia of acceptable intensity and duration.
- 8 -
1.31 Local anaesthetic agents
Cocaine, a naturally occurring alkaloid, was isolated from "Erythroxylon coca" 
Lam. (1860) and was also prepared from a semisynthetic procedure, from 
ecgonine, Figure 6, obtained from natural sources.
Figure 6. a)Ecgonine, b)Cocaine, [3(S)-benzoxy-2(R)-methoxycarbony-
l-l(R)-tropane].
Although today cocaine is of greater historic than practical importance (allergic 
reactions, tissue irritation, poor stability in aqueous solution, and serious addiction 
liability), few developments in the chemistry of local anaesthetics can disclaim 
relationship to cocaine.
In 1903, Braun observed that by combining cocaine and other available agents with 
the natural endogenous hormone epinephrine, the duration of action of anaesthesia 
was considerably prolonged.15 When a local anaesthetic is administered in vivo, 
its duration is primarily influenced by its removal from the site of administration in 
the local blood supply. Local anaesthetic drugs tend to have a vasodilator activity 
and therefore tend to potentiate their own removal from the site of administration 
by increasing the local blood supply. Because epinephrine causes vasoconstriction 
it has been hypothesized that it reduces the local blood supply and thereby allows 




Shortly after Braun’s observation there followed the introduction of the first
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injectable local anaesthetic agent (1905) into the clinic - Procaine, synthesised by 
Einhom.16
The intrinsic potency of this compound was low and the duration of action was 
relatively short, but both were considerably enhanced when it was combined with 
epinephrine.
Following the clinical introduction of procaine hundreds of compounds were 
synthesised, most of which were structurally related to procaine and cocaine. The 
major advancement during this period was the introduction of tetracaine by Eisleb 
in 1931.
This agent was found to be 8 to 10 times as potent as procaine, gave a long 
duration of anaesthesia and could be used safely even though it was toxic. Clinical 
use also gave the first indication that blockade of nerve conduction for several 
hours did not lead to irreversible nerve damage. Tetracaine and chloroprocaine are 
procaine-like agents that remain in current use.
The next major development in local anaesthetic agents was the synthesis of 
lidocaine (Figure 7) by Lofgren17 in 1946. Lidocaine was the first generally 
acceptable local anaesthetic that did not contain the ester linkage present in 
cocaine, procaine and tetracaine, and therefore its introduction led to chemical 
synthesis on a much broader base. In place of the ester linkage lidocaine possessed 
an amide linkage. Lidocaine was found to be more potent than procaine and this 
combined with its short onset of action and reasonable degree of toxicity, made it a 
superior and more reliable agent. The incidence of allergic reactions with 
lidocaine was low, but was observed fairly often with ester type anaesthetics. A 
further practical advantage of lidocaine is its stability in aqueous solution, which 
allows heat sterilization and guarantees pharmacological activity after prolonged
- 1 0 -
storage. Other amide substances include mepivacine, prilocaine, bupivacaine, and 
etidocaine.
Since 1948 there have been many developments in the field of local anaesthesia, 
but in the fields of neurophysiology and neurochemistry rather than synthetic 
medicinal chemistry. In the near future, this research may lead to more specific 
and more potent nerve blocking agents.
1.32 Structure-activity relationships
The clinically useful drugs fall essentially into two chemical categories; agents 
with an ester link between the aromatic end of the molecule and the intermediate 
chain (procaine-like) and agents with an amide link between the aromatic portion 
and the intermediate group (lidocaine-like).
Chemical compounds that demonstrate clinically useful local anaesthetic activity 
possess the following chemical arrangement: aromatic portion - intermediate 
chain - amino portion or alternatively, lipophilic portion - intermediate chain - 
hydrophilic portion (Figure 7). Alteration in any portion or sequence will modify 
their anaesthetic activity. Lengthening of the intermediate chain tends to increase 
anaesthetic potency until a certain length beyond which potency decreases.
Chemical modification of either end of the molecule will affect the lipid solubility 
and protein-binding characteristics. For example, within the ester series tetracaine, 
which is formed by the addition of a butyl group to the aromatic end of the 
procaine molecule, is an agent of increased lipid solubility and protein binding, 
greater intrinsic anaesthetic potency, and longer duration of anaesthetic activity 
(Figure 7).
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Figure 7. Local anaesthetic agents according to in vivo potency and 
duration of action.
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In the amide series the addition of the same butyl group to the amine end of 
mepivacaine transforms this agent into a compound, bupivacaine, which is also 
more lipid soluble, more highly protein bound, more potent and longer acting 
(Figure 7). Alterations in the chemical structure of homologous compounds may 
also affect their rate of degradation and therefore, their intrinsic toxicity. Thus 
tetracaine, which is hydrolysed at a considerable slower rate than is procaine, has a 
considerably greater toxicity.
The basic difference between heterologous types of local anaesthetic agents, i.e. 
the ester and amide compounds, residues in; the rate and manner in which they are 
metabolised, their allergic potential, and their physiochemical properties such as 
lipid solubility and protein-binding, which alter their anaesthetic properties. This 
last point is more so for chemical alterations within a homologous group, i.e. 
within the ester group or the amide group.
1.4 General anaesthesia
General anaesthesia is brought about by a wide range of substances which are 
administered at high concentrations and gain access to all parts of the body. They 
exert their actions on peripheral organs, such as the neuromuscular function and 
the heart, as well as their primary target(s) in the central nervous system. The 
central nervous system is extremely complex and our rudimentory understanding 
of its physiology has prevented elucidation of how general anaesthetics reversibly 
depress consciousness.
The phenomenon of general anaesthesia can be brought about by a remarkable 
range of substances - from the inert gas xenon to the steroid althesin (Figure 8). 
This suggests that no single, structurally specific receptor for general
- 1 3 -
anaesthetics exists. Given this, there are two possible overall classes of 
mechanism which might give rise to general anaesthesia. The first mechanism 
assumes that a non-specific locus of action is involved, with which general 
anaesthetics of all molecular classes can interact. For example, the lipid bilayer of 
neuronal membranes may provide such a site. This is consistant with there being 
no known chemical antagonist of general anaesthesia and leads to the so-called 
unitary hypothesis, which states that a single molecular mechanism underlies 
general anaesthesia. The second mechanism assumes that there are a number of 
different ways of causing general anaesthesia. For example, one structural class of 
anaesthetic might act on a binding site on a protein in one region of the brain and 
another structural class on a differently shaped protein site elsewhere in the brain. 
Alternatively, one protein might possess a number of different binding sites, each 
capable of interacting with one structural class of general anaesthetic. This has 
been called the degenerate perturbation hypothesis of general anaesthetic action22, 
see chapter on nerve impulse and receptor pharmacology.
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Figure 8. The structures of some general anaesthetics.
It is not unthinkable that general anaesthetics can exert both types of action, when 
one considers the high concentrations at which general anaesthetics are
- 1 4 -
administered and the number of side effects they exert.
Thus there is no one theory to account for all drugs which can be anaesthetic. 
Briefly, gases of one atom (xenon), simple gases (nitrous oxide) and vapours 
(hydrocarbons and complex ethers) or the large molecular structures of steroids 
(althesin) can all cause reversible depression of the central nervous system.
General anaesthetic agents may be divided into three classes; gases, volatile liquids 
and intravenous or fixed anaesthetics. The last class are called the 
ultrashort-acting babiturates.
The gases and volatile liquids are grouped together as inhaled anaesthetics. During 
administration of a volatile anaesthetic its concentration in the blood rapidly 
increases toward that in the inspired gas. As the anaesthetic enters tissues, this 
concentration approaches that of the arterial blood supply. Organs transfused by a 
large amount of blood, such as the brain, rapidly acquire high concentrations of 
anaesthetic. Depth of anaesthesia is a function of the amount of anaesthetic in the 
brain, and the time of induction and recovery are determined by the rate of change 
of concentration in the brain. Thus induction and recovery are determined by the 
solubility of the agent in blood. Relatively soluble agents, such as diethyl ether, 
have slow induction and recovery times, whereas relatively insoluble agents, such 
as cyclopropane, have short induction and recovery periods. Before appreciable 
amounts of anaesthetic diffuse into brain tissue, the blood reservoir must be nearly 
saturated.
In contrast to the inhalation agents, intravenous anaesthetics are extremely easy to 
administer, in fact, fatally so. Delayed onset of anaesthesia may tempt the unwary 
to continue injection, thereby adding to the dose that is already making its way to 
the patients brain. Unlike inhalation anaesthetics rapid elimination by controlled
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ventilation is impossible.
The ultrashort-acting barbiturates are used to produce both surgical and basal 
anaesthesia. When injected intravenously they quickly produce unconsciousness, 
and emergence is rapid. Ultrashort-acting barbiturates are frequently used in 
combination with a volatile anaesthetic, such as nitrous oxide. The barbiturate 
produces rapid, pleasant anaesthesia, which is then maintained with the volatile 
anaesthetic.
The barbiturates were the first group of drugs to be introduced for intravenous 
administration, followed by eugenols, of which propanidid is currently available, 
and is notable for its rapid recovery.
A somewhat different approach has been the development of steroids with 
anaesthetic potency. The first usable compound was hydroxydione, but this was 
not a satisfactory compound due to its slow onset of action, slow recovery and a 
high incidence of venous thrombosis. Many other steroids have been investigated. 
Althesin has been the most promising to date.
To date many drugs have been used, and many more tested. The ideal induction 
agent must meet a formidable list of requirements, including, e.g., smooth 
induction, predictable dosage, high safety (therapeutic index), minimal 
cardiovascular and respiratory disturbances, rapid and complete recovery, absence 
of pain or injury from injection, and stability in solution. The barbiturate 
thiopental, although it does not meet every requirement, has been used for 30 years 
and is still the standard against which any new drug is compared.
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1.41 Nonbarbiturate intravenous anaesthetics
Intravenous anaesthetic agents may be used for the induction of anaesthesia, as the 
sole agent for short operations, to supplement general anaesthesia or regional 
analgesia, or for sedation.
The introduction of thiopental into clinical practice in 1934 was the advent of 
intravenous anaesthesia. Thiopental and other barbiturates are not ideal 
intravenous anaesthetics primarily because they provide only hypnosis. The ideal 
intravenous anaesthetic would provide hypnosis, analgesia, and amnesia. The 
physical properties of an ideal intravenous anaesthetic include stability in solution, 
a long shelf-life, and water solubility. The drug should be a non-irritant and 
possess a low incidence of venous thrombosis. Excitatory effects on induction are 
undesirable, as are coughing, hiccup, and laryngospasm. An ideal agent should 
also have a very low incidence of hypersensitivity reaction and histamine release 
even in patients who show a sensitivity to other drugs. Exposure to the drug 
should not sensitise the patient to subsequent administration.
Many drugs have been used that offer some of these properties, but none has truly 
replaced thiopental as the most widely used intravenous anaesthetic drug. A great 
variety of intravenous drugs are available for use in the care of patients requiring 
general anaesthesia. The selection of a particular drug must be based on the 
individual patients need for hypnosis, amnesia and analgesia. Drug selection must 
match the physiology and/or the pathophysiology of the individual patient with the 
pharmacology of the particular drug. There is no single perfect drug for any 
particular patient, but rather it is the informed practitioner who wisely employs the 
appropriate drug or drugs in the practice of good anaesthesia care. The future of 
anaesthetic management probably involves the use of several drugs used together, 
including inhaled anaesthetics with intravenous drugs.
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Intravenous agents differ from inhalational anaesthetics in that, once injected, there 
is nothing that can be done to facilitate the removal of the drug, hence the adage 
"thiopental is fatally easy to give". The most important properties of existing 
agents rests on their ability to penetrate the tissues of the body, particularly the 
central nervous system, without delay. Their rapid course of action is explained by 
their high lipid solubility coupled with a rich cerebral blood flow which ensures 
rapid penetration into the brain. This being so, the intensity and duration of this 
action is critically influenced, not only by the dose, but also by the speed at which 
that dose in injected. This is the bolus effect. The drug should produce its action 
in one arm-brain circulation time.
Once admixture with the circulating blood volume has occurred, the drug effect 
declines predominantly in most instances with redistribution of the drug into less 
richly perfused areas of the body, muscle, skin and finally fat depots. This decline 
reflects a rapid fall in plasma drug concentration defined pharmocokinetically as 
the a-distributional phase, which is contrasted with the slower p-elimination 
phase. Only after exceptionally large or repeated doses can elimination, mainly by 
metabolic degradation in the liver, exert a critical influence. The pharmacokinetics 
of intravenous anaesthetics are discussed in a paper by Ghonesin and Korltila.20 
The ideal anaesthetic agent should produce a rapid recovery with little hangover 
effect. Redistribution to non-nervous tissue and rapid detoxification to inert 
metabolites is ideal.
Intravenous anaesthetics can of course, like all drugs, induce adverse reactions.
The subject has been extensively reviewed by Whitwam.28 Adverse reactions can 
usefully be described under four headings, namely:
1. Reactions associated with induction - muscle movements, cough,
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hiccup, respiratory and cardiovascular depression.
2. Tissue complications - local tissue damage, thrombophlebitis 
at the site of injection.
3. Reactions associated with recovery - psychic problems, 
motor disturbances, pain, nausea, prolonged somnolence.
4. Hypersensitivity - anaphylaxis, anaphylactoid reactions, 
skin rashes, bronchospasm.
The adverse reactions to the barbiturates thiopental and methohexitone are for the 
most part dose-related and they can therefore be avoided by care in the anaesthetic 
techniques.
Intravenous hypnotics
Propanidid, althesin, minaxolone, ketamine hydrochloride, etomidate, propofol, 
and gamma-aminobutyric acid (GABA) have all been used to induce anaesthesia. 
Propanidid is a eugenol derivative that is highly water insoluble. Cremophor EL is 
added to bring about solubility. Onset of anaesthesia and recovery is rapid. The 
rapid recovery is due to both redistribution and metabolism. The drug is 
metabolised by pseudocholinesterase in the liver and plasma, resulting in an 
elimination half-life of 10 minutes. The major disadvantage of propanidid is a 
high incidence of severe allergic reaction and occasional case of thrombophlebitis, 
which resulted in its withdrawal.
Propofol, 2,6-diisopropyl phenol, is formulated in lipid emulsion. It is a rapidly 
acting hypnotic agent with a short duration of action. Pain is experienced by some 
patients during intravenous injection and the blood pressure usually falls.
Recovery is rapid.
Etomidate, ^?-l-ethyl-l(a-methylbenzyl) imidazole-5-carboxylate, is a
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water-soluble induction agent, supplied as a solution containing propylene glycol, 
which gives a rapid onset of anaesthesia. On repeated administration there is little 
tendency to cummulation.23 Pain at the site of injection is common and there is a 
high incidence of involuntary movement24 which can be decreased with diazopam 
premedication. The drug is without analgesic action. Etomidate is rapidly 
metabolised and thus recovery is rapid, thus the drug is ideal for outpatient 
anaesthesia. However, the immediate post-anaesthetic period is frequently 
complicated by nausea and vomiting so that adjuvant anti-emetic medication is 
needed. Altogether the drug has no great advantage over other agents, it was 
recommended only if established agents are contraindicated.
Ketamine hydrochloride (ketalar), 2-(0-chlorophenyl)-2-(methylamino)cycl- 
ohexanone hydrochloride is a white crystalline solid, soluble in water with a pH 
between 3.5 and 5.5. It is stable at room temperature and benzethonium chloride is 
added as a preservative. Ketamine has unusual anaesthetic properties in that it 
produces unconsciousness with profound analgesia. It does not potentiate GABA 
(see mechanism of anaesthesia), but selectively blocks the ion channel activated by 
the selective excitatory amino acid N-methyl-D-aspartate (NMDA). Selective 
inhibition of the excitatory NMDA receptor in the central nervous system by 
ketamine also leads to CNS depression. The duration of anaesthesia brought about 
by ketamine is 5-10 minutes with a rise in blood pressure and heart rate. The drug 
also produces a high incidence of hallucinations, which are reduced by 
premedication with lorazepam.
GABA is a naturally occurring neuroinhibitor and is capable of producing 
anaesthesia. However it results in significant side effects, including prolonged 
recovery, emergence delirium, extra pyramidal muscle movement, and nervous 
irritation. Thus the drug was not approved for clinical practice.
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Althesin is a combination of two steroids, alphaxalone (primary active steroid) and 
alphadolone acetate (to increase solubility). It is presented as a clear colourless 
isotonic solution of neutral pH containing 9 mg alphaxalone and 3 mg alphadolone 
acetate in each ml, which also contains 20 percent cremophor EL. It is a brief 
acting intravenous anaesthetic agent which is usually non-irritant at the site of 
injection. Onset of action after administration is rapid, as is recovery.
Termination of its action is determined largely by rapid metabolism in the liver25 
rather than redistribution. It should therefore not be given to patients with liver 
disease. Althesin is also useful for the maintenance of anaesthesia and sedation 
when given by infusion. Like propanidid, a high incidence of hypersensitivity 
reactions has resulted in the total withdrawal of this intravenous anaesthetic. 
Althesin will be discussed further in the ‘review of steroidal anaesthetics’ (see 
Appendix).
Minaxolone is an attempt to provide a water-soluble steroid i.v. anaesthetic. It is 
1 la-dimethylamino-2p-ethoxy-3a-hydroxypregnan-20-one, a water-soluble 
derivative of althesin. In limited clinical trials it has been shown not to cause 
venous irritation and to have a rapid onset of action, though accompanied by a high 
incidence of muscle movements.26 By comparison with althesin, recovery from 
anaesthesia is slow27, presumably because of the high water solubility. Though 
initially promising in some ways, this agent has now been withdrawn because of 
adverse effects on long-term toxicity testing in animals.
1.5 Mechanism of anaesthesia
To understand the medicochemical aspects of anaesthetics it is necessary to have a 
working knowledge of neuroanatomy and neurophysiology.
The central nervous system (CNS) is made up of a brain and a spinal cord. This 
system is connected to all parts of the body by nerves, which are made up of
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Figure 9. Intravenous induction agents, 
thousands of long thin nerve fibres. Like all other organ systems the nervous
system consists of different types of cells. The cells which conduct the nerve
impulses are called neurones.
The cell body has cytoplasm which unlike other cells extends, from the cell body 
outwards forming long thin threads as thin as 0.005nm in diameter and up to 1 
metre in length. These threads are the nerve fibres along which travel the 
‘messages’ made up of nerve impulses to and from all parts of the body.
Nerve impulses pass along the nerve fibres in only one direction. They pass into 
the CNS along the fibres of sensory neurones, and out of the CNS along fibres 
called motor neurones.
1.51 Neuroanatomy28
The sensory, or input fibres course together in bundles with the motor, or output, 
fibres from the periphery to the spinal cord.
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Each nerve axon has its own membranous covering, often just called the nerve 
membrane, tightly surrounded by a myelin sheath called a Schwann cell covering. 
The myelin is not continuous along the fibre. The interruptions are the nodes o f 
Ranviery which are of great importance for nerve functioning.
The nerve fibres are collected in bundles similar to a telephone exchange. 
Conduction in these fibres would be slow if they were not insulated with the 
myelin coat. The interruptions in the myelin coat by the nodes of Ranvier, are 
where current enters and exits. Ionic fluxes occur at these nodes. The nerve 
impulse jumps along the fibre from node to node faster than in unmyelinated 
fibres.29
1.52 Neurochemistry30
The main inorganic constituents of nerve axons and cell bodies are sodium, 
potassium, calcium, magnesium, and chloride. The predominant intracellular 
cation is potassium and the predominant extracellular ions are sodium and 
chloride. Because there is not enough chloride within the cell for electroneutrality, 
at least half of the negative charges must be made up of fixed-charge lipid and 
protein complexes. Lipids and proteins are found free or in association with each 
other, forming lipoproteins, and also together with phosphorus, forming 
phospholipoproteins.
1.53 Neurophysiology31 
What is a nerve impulse?
Some nerve impulses originate inside the CNS, others come from the sense organs.
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The sole function of a sense organ is to change various forms of stimulus, such as 
light or sound, into nerve impulses which pass along sensory neurone fibres to the 
brain. Figure 10 illustrates a simple way of explaining what happens during the 
conduction of an impulse.
Figure 10. A simple analogy of a nerve impulse.
Imagine blocks of wood, such as dominoes, arranged in a row. The first domino is 
knocked over and falls against the next, which falls against the next,and so on to 
the end of the line. Note two important facts. Nothing, except a certain amount of 
energy, has moved along the line of dominoes, and this cannot happen again until 
the dominoes have been restored to their original positions. These events can be 
compared with a nerve impulse in the following way.
An impulse begins as a change in the arrangement of chemicals in a small area at 
one end of a nerve fibre, i.e. changes in permeability lead to depolarisation. Like 
one domino falling against the next and knocking it over, this changed area of 
nerve fibre excites an identical change in the area adjacent to it, which excites the 
next area, and so on to the end of the fibre. No material object has moved along 
the fibre, only a wave of chemical rearrangement. Just as the dominoes must be 
stood on end before they can be knocked down again, so a nerve fibre must recover 
before it can conduct another impulse. But this recovery period is only a few 
thousandths of a second.
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There is another similarity between falling dominoes and nerve impulses. If the 
first domino in the line is touched very lightly it may rock back and forth, but will 
not knock over the next and trigger off the impulse. The first domino must be 
pushed with a specific amount of force before it falls against the next. Similarly, 
there are stimuli that are so weak that they do not stimulate the nerve enough to 
trigger off impulses to the brain. Stimulation of a nerve fibre must reach what is 
called the threshold level before the fibre sends a nerve impulse to the brain.
Another feature of nerve impulses is that there is no such thing as a weak or strong 
impulse. They either occur or do not, all are exactly alike no matter where they 
originate. This is called the all-or-none principle. The only feature of an impulse 
which ever varies is the number of them which pass along a nerve fibre per second. 
The frequency of the impulse depends on the strength of the stimulus. Thus a 
strong stimulus results in hundreds of impulses per second being sent to the brain, 
whereas a weak stimulus produces only a few impulses per second and a stimulus 
below the threshold level produces none at all.
Neurones, are not continuous with one another. Nerve impulses must cross a 
synapse where the axon of one neurone meets the dendrites, or cell body, of 
another. The dendrites and cell body of a motor neurone have synapses with 
thousands of other neurones.
Synapses also have a threshold level. The threshold of a synapse is the number of 
impulses per second at which the synaptic gap is ‘bridged* and impulses begin to 
flow in the next neurone. The threshold level of a sense organ, plus the threshold 
of eveiy synapse in the chain of neurones connected to it, form a barrier to the 
movement of impulses between that sense organ and the brain. This barrier is only 
penetrated by the high frequency impulses which result from strong stimuli. The
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lOW  frequency impulses resulting from weaker stimuli are unable to cross the 
synapse, and so do not reach the brain. The velocity at which an impulse is 
conducted along the nerve is known as the conduction velocity and is proportional 
to the diameter of the fibre.
In summary, the nervous system is a mass of interconnected nerve fibres which 
conduct impulses from receptors to effectors throughout the whole body.
Nerve transmission
A  nerve impulse is a physico-chemical process in a nerve fibre. In a fibre in the 
resting state, there is a potential difference across the membrane of approximately 
60 to 90 mV, inside negative to outside.32 This is known as the resting membrane 
potential.
The origin of the resting potential is of great interest. The nerve cell contains a 
high concentration of potassium, which flows in and out of the cell with ease. The 
cell was believed to be impermeable to sodium because of the low sodium 
concentration in the excitable cell. Because the excitable cell appeared to be 
highly permeable to potassium and impermeable to sodium, it was treated by 
neurophysiologists as if it were an electrochemical, or Nernst, cell. Thus the 
resting potential was determined using the Nernst equation. However it was later 
shown that in the resting state the cell is slightly permeable to sodium but 
somehow able to extrude this ion. The mechanism for extrusion has been called a 
sodium pump. Thus the resting potential is intimately related to the ratio of 
potassium ions between the inside (Ki) and outside (Ko) of the cell membrane. At 
rest, a Ki:Ko ratio of approximately 30 to 1 exists.
During nervous activity, an action potential, the transmembrane potential goes 
from about -70 to about +40mV and promptly returns to the resting potential; the
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event lasts about 1 millisecond.
When a nerve is stimulated the cell becomes transiently highly permeable to 
sodium. The sodium pump is inactivated, sodium permeability increases, and 
sodium ions pass from the exterior to the interior of the nerve cell through the 
so-called sodium channels. This process is called depolarization. A relatively 
slow phase of depolarization occurs during which the electrical potential within the 
cell becomes progressively less negative, until it reaches the threshold potential, 
about -50mV. At this stage a massive change in sodium permeability occurs and a 
rapid phase of depolarization follows resulting in a reversal in the membrane 
potential to about +30mV. The total amplitude of the action potential is 
approximately lOOmV (Figure 11 A). As the cell approaches its peak action 
potential the sodium permeability is rapidly reduced (sodium inactivation) and 
potassium permeability increases until the normal resting membrane potential is 
re-established. Thus, after an action potential the cell is left with a very small 
sodium increase and potassium decrease.
















Figure 11. Intracellular nerve action potential prior to and following exposure
to an anaesthetic.
This subsequent process is known as repolarization. The electrical status of the 
cell is restored by potassium diffusing out of the cell. The movement of potassium
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speeds up the repolarization process which would be slower if it depended on the 
sodium permeability changes above.
The initial membrane electrical state has now been restored; however, the cell has 
gained sodium and lost potassium. With the reactivation of the sodium pump the 
normal intra- and extracellular cation ratios are restored. It has been suggested that 
by using the energy derived from splitting adenosine triphosphate (ATP), an 
ATPase system could serve this function and act as a sodium pump.33
The nerve impulse passes from the active area of depolarization to the adjacent 
inactive region, which is thereby depolarized. The area of activation are the nodes 
of Ranvier. No ions flow through the myelinated sheath, thus the spacing of the 
areas of activation increases the impulse transmission velocity.
Immediately after an impulse has been propagated, the area is absolutely 
refractory or completely inexcitable, and so stimulus, no matter how strong or 
long, cannot excite it. Shortly thereafter, the axon becomes relatively refractory; it 
responds with a propagated impulse only to stimulation that is greater than the 
normal threshold. The length of the refractory period is affected by the frequency 
of stimulation and by many drugs.
Anaesthetically active drugs, in someway, act on, or bring about changes to the 
nerve cell whereby depolarization is interfered with and the action potential fails to 
reach the threshold potential (Figure 1 IB). Therefore, the stimulus is unable to 
propagate any nerve impulses. This could be brought about by interaction of the 
anaesthetic agent with a receptor.
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1.54 Receptor theory
Living cells possess special sites of drug action, the properties of which are to react 
with drugs of a specific nature and to initiate a chain of events leading to the 
pharmacological effect. Such sites of action are receptors.
Receptor structure
The overall physical structure of a receptor determines the three-dimensional 
configuration of the specific area of receptor protein that will bind a drug. The 
pharmacological structure of a drug must match the three dimensional 
configuration of the binding area of a receptor. Hence, subtle changes in drug 
structure may dramatically alter its ability to bind to a specific receptor population. 
In addition, two drugs with seemingly unrelated two-dimensional chemical 
structures may bind to the same receptor if their three-dimensional structures and 
charged areas are similar.
Recent advances in molecular biology have enabled researchers to deduce the 
primary structure of many receptors. Common features of all membrane receptors 
appear to be hydrophobic transmembrane regions as well as intracellular and 
extracellular regions. The exact arrangements of the three regions varies according 
to receptor type.
Classic receptor theory
To mediate effects drugs must bind to receptors. Such drug-receptor interactions 
provide the basis for the classic receptor theory. Class receptor theory assumes 
the compound or drug binds reversibly with the specific receptor site to produce a 
drug-receptor complex. The generation of this drug-receptor complex represents 
an intermediate step in producing a specific effect. The effect may cease when 
there is dissociation of the drug-receptor complex. This process is analogous to the
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classic model of Michaelis-Menton enzyme kinetics. Mathematically, this may be 
expressed as
[D] + [R ]^ [D R ]
where [D] = the concentration of drug, [R] = the concentration of receptor, and 
[DR] represents the concentration of drug-receptor complex. At equilibrium, one 
can define a K<j as the dissociation constant for that given drug. Thus, 
mathematically
Kd= M R l
[DR]
It is assumed that the drug-receptor complex represents an intermediate step in the 
production of a specific effect. An effect can be any biochemical compound, an 
enzyme level, heart rate, or blood pressure.
The delivery of a drug to a given receptor will be time and dose dependent. If the 
receptor is located within the central compartment, where there may be 
instantaneous equilibrium after a intravenous injection, the peak effect may occur 
immediately. If the drug-receptor complex occurs in a peripheral compartment, 
pharmacokinetic alterations in drug absorption and distribution may further alter 
the time course of a given drug effect.
The binding of a hormone or drug to its receptor does not instantly produce clinical 
effects. Instead a series of rapid biochemical events couple receptor binding to the 
ultimate clinical effect. These biochemical events are called second messengers. 
Alterations in second messenger coupling can alter the effectiveness of a drug.
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Drug-receptor interactions
The attachment of drug to receptor involves physical bonding by a number of 
forces including ionic, van der Waals, and hydrogen bonding. The extent to which 
each of these contributes to the drug-receptor attraction varies from one drug to 
another and from one receptor to another. The number of bonds involved is 
usually multiple and their steric arrangement critical. Thus it is usual in the case of 
stereoisomers, for one isomer to be much more potent than the other. The 
relationship between receptor structure and bonding is the subject of a review.34
Drugs which stimulate receptors and induce a pharmacological effect are agonists; 
those which block them are antagonists. Agonist drugs induce an effect that 
mimics endogenous hormones or neurotransmitters when bound to a receptor.
This effect may be stimulatory or inhibitory. The term affinity as related to a given 
agonist is a measure of the attraction between the given drug and the receptor.
Antagonist drugs inhibit or prevent receptor-mediated agonist effects by competing 
for receptor occupancy. A competitive antagonist can generally be displaced from 
the receptor complex by the administration of a receptor agonist if given in a large 
enough concentration, thus permitting the agonist to produce the expected effect.
It is so called because the agonist and antagonist compete for the same receptor. A 
non-competitive antagonist, when bound to the receptor complex, will produce a 
loss of the expected effect that cannot be reproduced by the concurrent 
administration of a receptor agonist.
Drugs which possess both agonist and antagonist actions are referred to as partial 
agonists.
Clarke35 proposed that tissue response was proportional to the number of receptor 
sites occupied. Once occupied, the receptor is unavailable for further stimulation.
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On this theory the critical difference between agonists and antagonists lies in the 
rates of dissociation of the drug-receptor complexes. An agonist should dissociate 
rapidly, thus freeing the receptor for a fresh act of combination. An antagonist, on 
the other hand, should dissociate slowly, thus reducing the availability of receptors 
to agonist impacts. A partial agonist should lie between these extremes.
Drugs exert their effects on receptors according to their efficacy. Agonists are 
assumed to have variable degrees of efficacy and to induce changes in their 
receptors which, in turn, initiate pharmacological responses. By contrast, 
antagonists have zero efficacy and induce no changes in their receptors, but they 
prevent access of agonists and therefore inhibit the pharmacological responses.
For a more detailed study of drug receptors, refer to a review by Rang.36
In addition to receptors, pharmacological agents act on other excitable cell 
membrane proteins such as ion channels. It has been shown that these channels 
mediate neural signalling by modulating ion permeability of electrically excitable 
membranes. Both the nicotinic acetylcholine receptor and the GABAa receptor, 
described in detail later, are receptor-ion channel complexes. The combination of 
a classic receptor protein plus an ion channel gives ligand-gated ion channels the 
unique ability to have drugs directly alter membrane permeability to cations.
Finally, drug effects are evaluated using dose-response curves (correlation between 
drug dose and measured effect), efficacy, potency, 50 percent effective dose 
(ED50), 50 percent lethal dose (LD50) and therapeutic index after stimulating 
excitable cell membrane proteins.
1.6 Biology of steroidal anaesthetics
There is now considerable evidence to suggest that the anaesthetic steroids elicit
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their effect by binding allosterically and probably extracellularly to the cell 
membrane-bound GABAa receptor37^ 3
1.61 Gamma-amino-n-butyric acid (GABA)44
Gamma-amino-n-butyric acid (GABA) is a major inhibitory neurotransmitter in 
the vertebrate central nervous system and in invertebrate central and peripheral 
nervous systems. Inhibitory neurotransmitters cause increased chloride 
conductance of postsynaptic membranes and decreased neuronal firing rate.
GABA is formed in the CNS of vertebrate organisms by the decarboxylation of 
L-glutamic acid by the enzyme glutamic acid decarboxylase (GAD).
GABA is liberated from the terminals of specific inhibitory nerves in vertebrate 
and invertebrate species. GABA typically produces an increase in membrane 
permeability to chloride ions that can be measured as an increase in membrane 
conductance. It is in this way that this naturally occurring transmitter can 
counteract the depolarizing action of excitatory processes to maintain the 
polarization of a cell at an equilibrium level near that of its resting value, acting 
essentially as a chemical voltage clamp. GABA has been shown to exert a 
hyperpolarizing or inhibitory effect by this mechanism. However, if intracellular 
chloride concentrations should occur, GABA can produce a decrease in membrane 
potential or depolarization. The impression is that of looking at a highly restrained 
nervous system, the inhibitory neurons acting like reins that serve to keep the 
neuronal horses from running away.
Potentiation of the actions of GABA would, therefore, be expected to depress the 
CNS to produce anaesthesia. Organon Teknika Laboratories have shown that 
clinically relevant concentrations of the general anaesthetics alphaxalone,
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propofol, etomidate, propanidid, and pentobartbitone potentiate the actions of 
GABA on GABAa receptors of tissue cultured cells.
1.62 Gamma-aminobutyric acid (GABA) receptors45
The sites to which the inhibitory neurotransmitter, GABA, binds to exert its
inhibitory effect are the functional GABA receptors 45
In the vertebrate species, GABA receptors are found only in nerve cell membranes 
and are sufficiently widespread that most neurones in the CNS are believed to 
possess them. There are two major types of vertebrate GABA receptors. The 
GABAa receptor is distributed more widely than the GABAB receptor. The 
physiological importance of these receptors depends upon the availability of 
endogenous GABA to activate them. Activated GABAa receptors exert their most 
profound influence, (1) at cell bodies and dendrites to alternate excitatory 
postsynaptic potentials, thereby preventing initiation of an action potential, and (2) 
at nerve terminals to reduce transmitter release by an incoming action potential.
At some nerve terminals, activated GABAg receptors also reduce transmitter 
release.
The primary classification of the two types of GABA receptors is made according 
to the sensitivity of the receptor to drugs. Characteristically GABAa receptors are 
activated most potently by muscimol (GABA receptor agonist), and rather less 
potently by GABA. GABAg receptors are activated most potentently by GABA 
and (-) baclofen, the latter being inactive on GABAa receptors. Muscimol is much 
less potent on GABAg receptors.
Because of the limited range of drugs available to act specifically at the GABAg 
receptor, knowledge of its physiological importance is derived solely from the use
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of baclofen as a centrally acting muscle relaxant. The role of the GAB Aa receptor 
complex is much clearer. The GABAa receptors are hetero-oligomeric 
ligand-gated ion channel proteins,47 which also serve as the receptor target of a 
cation for several categories of important drugs and perhaps endogenous 
modulators; the picrotoxin-like convulsants, the benzodiazepines, barbiturates and 
steroid anaesthetics; inhalational anaesthetics and alcohols may also act, at least in 
part, on some GABAa receptors 48 It plays an essential part in the local control of 
neuronal excitability throughout the CNS.
At concentrations in the anaesthetic range alphaxalone, propofol, etomidate, 
propanidid, and pentobarbitone directly activate the GABAa receptor in addition 
to potentiating GABA. This secondary action may be important in contributing to 
anaesthesia. Demonstration of general anaesthesia being induced by GABAa 
agonists supports the notion that the GABAa receptor is a specific target for 
intravenous anaesthetics.
1.63 Mechanism of action
The enhancement of GABA-mediated inhibition of barbiturates involves 
prolongation of the GAB A-activated chloride channel lifetime49, direct opening of 
the chloride channel by barbiturates is also observed.50 This cellular action of 
barbiturates on GABA chloride channels is a good candidate for a molecular 
mechanism of anaesthesia,51 numerous nonbarbiturate anaesthetics share this 
action on GABA, including volatile anaesthetics,52 ethanol53 and alphaxalone and 
naturally occurring steroid analogs.54 The GABA mechanism is the most likely to 
explain the action of steroid anaesthetics, and possibly the other anaesthetics as 
well.55
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Modulation of chloride channel kinetics by steroids probably involves binding to 
the receptor-channel protein.56 Nevertheless, an interaction with the lipid 
membrane has not been ruled out, and a chemically specific interaction with lipids 
that increases membrane fluidity has been observed for all anaesthetics, including 
steroids 57 Fesik and Makriyannis58 proposed from their NMR studies with 
hypnotically active and inactive steroids that perturbation of membrane lipid 
structure by the steroids may be transmitted to GABAa receptors. However, 
membrane fluidisation has not been proven to be associated with alteration of any 
biological function that could result in anaesthesia. The observed biological 
activity of the anaesthetic steroids at nanomolar concentrations59 and their 
stringent SARs including stereospecificity favours the modulation of GABAa 
receptors via a specific binding site. Thus proteins, e.g., the GABA chloride 
channel, are excellent candidates for being receptors for anaesthetics. These 
actions seem to be selective (occurring at concentrations at which other 
receptor/channels are unaffected) and show a high affinity and stereoselectivity.
Majewska et a/54 reported that metabolites of progesterone and 
desoxycorticosterone (anaesthetically active steroids) alter radioligand binding to 
the GABA receptor-chloride ionophore complex in rat brain in a manner that 
closely resembles the action of hypnotic barbiturates. These steroids share the 
ability of barbiturates to enhance chloride-dependent responses to GABA or the 
GABA agonist muscimol.60
Harrison et al3S illustrated several similarities between the actions of the active 
steroids and those of the hypnotic barbiturates in parallel radioligand binding 
assays. First, barbiturates and steroids that enhance GABAa receptor function in 
the CNS displace or inhibit the binding of the convulsant chloride channel ligand 
[35S]-f-butyl bicyclophosphorothionate ([35S]-TBPS) with similar coefficients. 
Second, both barbiturates and steroids stimulate the binding of the benzodiazepine,
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flunitrazepam, as well as that of the GABA agonist muscimol.61 Furthermore, like 
barbiturates and benzodiazepines the steroids potentiate inhibitory synaptic 
transmission mediated by GABA.62 All of the findings suggested a common site 
or mechanism of interaction of steroids and barbiturates with the GABA receptor 
complex. The active steroids may act as an endogenous ‘barbiturate-like 
substances’ at the barbiturate receptor site on the GABAa receptor complex.54
SAR for activity and the nature o f the "steroid site "
There are exacting steric requirements for steroid activity at the GABAa receptor 
complex. All of the active compounds found to potentiate GABA-activated 
chloride conductance responses in the present experiments have a 3a-hydroxyl, a 
ketone moiety at C(20) and a reduced pregnane skeleton.38 In addition, all of these 
active compounds are active in displacing TBPS binding. Conversely, steroid 
structures inactive in modulating GABA-activated chloride conductance are 
inactive in TBPS binding assays. These observations suggested a high degree of 
structural discrimination at the steroid "binding sites".
Structure-activity studies showed a high degree of structural and stereochemical 
specificity for the interactions between steroids and the GABA receptor complex 
in neuronal membranes, such as might be expected for a membrane protein binding 
site.38 However, in the case of these highly lipophilic steroids other interpretations 
are also plausible.
It has also been demonstrated that anaesthetic steroids of the 3a-hydroxy type 
produce profound membrane disordering, whereas 3p-hydroxy compounds 
produced no such effect. Thus, there may be no "specific" binding sites for 
steroids as such binding is normally imagined, and the interaction between steroids 
and the GABA receptor complex may arise as a consequence of the interaction 
between the steroid molecules and the lipid membrane.
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Alphaxalone was found to be effective in potentiating responses to GABA,63 
whereas the (3-hydroxy isomer of alphaxalone (betaxalone) was ineffective in 
potentiating responses to GABA64 and at relatively high concentrations acted as an 
antagonist.63 The 5a- and 5(3-pregnane steroid nuclei of active parent steroids are 
both active. The 5a-analog of hydroxydihydroprogesterone was found to be quite 
active in enhancing GABA function and inhibiting binding of the chloride channel 
ligand, [35S]TBPS.34*54*65
Fesik and Makriyannis proposed58 that anaesthetic steroids are accomodated 
lengthwise between two fatty acyl chains of membrane phospholipids, like 
cholesterol. The presence of a polar 17-substituent (in addition to a 3a-hydroxyl) 
in anaesthetic steroids however, makes the cholesterol-like interaction with 
phospholipids very unfavourable. Rather the two polar groups of hypnotic steroids 
may interact with polar head groups of phospholipids or polypeptides, while their 
hydrophobic backbone interacts with the methylene residues of the fatty acyl 
chains near the membrane surface. On the strength of these considerations, it is 
reasonable to propose that anaesthetic steroids may have two points of contact 
(probably through hydrogen bonding) with GABAa receptors through the two 
polar functional groups and their hydrophobic moieties remaining in contact with 
the fatty acyl chains of phospholipids surrounding GABAa receptors. Such 
interactions could demand stringent structural requirements for the ligands, 
because their two polar groups have to be positioned in a particular spacial 
orientation. One may then observe the disappearance or reduction of anaesthetic 
actions with some chemical modifications of the steroids that lead to distortion of 
the relative spacial configurations of the two polar groups. Such modifications 
may include not only the residues near the functional groups but also introduction 
of hydrophilic groups in the hydrophobic backbone of the steroid, which cause 
destabilisation of their hydrophobic interactions and eventually lead to profound
changes in overall configuration of the compounds.
Despite the aforementioned similarities, studies evaluating the anaesthetic effect of 
binary mixtures of the synthetic steroid alphaxalone and hyponotic barbiturates 
suggest they do not act through a common site or mechanism.66 On [3H] muscimol 
binding40 the effects of pentobarbital and alphaxalone were similar and clearly 
additive, but they potentiated each others inhibitory effect on TBPS binding.39 In 
contrast the stimulatory effects of combinations of the barbiturates, pentobarbitone 
and secobarbitone or the hypnotic steroids, alphaxalone and 
5p-pregnan-3a-ol-20-one were not additive.40 On the chloride flux assay the 
barbiturate and steroid direct activations were clearly synergistic, giving very large 
responses together in the absence of muscimol, despite small direct effects on their 
own,39 i.e., alphaxalone potentiated barbiturates and/or vice versa. It has 
previously been demonstrated that the direct agonist action of alphaxalone, 
5p-pregnan-3a-ol-20-one or 5a-pregnan-3a-ol-20-one is potentiated by the 
barbiturate, phenobarbitone,63,67 and 5p-pregnan-3a-ol-20-one was found to 
enhance greatly the amplitude of membrane currents elicited by pentobarbitone.40 
This is consistent with different sites or mechanisms of action and suggests the 
existence of a unique binding site for the steroid in GABAa  receptors.
Evidence supporting separate sites of action for the barbiturates and steroids was 
obtained by Kirkness and Turner,68 who showed that the enhancement of 
benzodiazepine binding in vitro by the two types of compounds was differentially 
sensitive to inhibition by phenobarbital, picrotoxin, and avermectin, as well as 
additive.
Whatever the nature of the barbiturate/steroid binding site(s), the demonstration of 
the potent modulation of GABAa receptors by endogenous steroids offers the 
future prospect of the development of new steroidal general anaesthetics, and a
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better understanding of the influence of the endocrine system on central nervous 
system function.
1.7 Structural requirements of steroidal anaesthetics 
It must be noted that when more than one group is introduced into a parent 
structure, the overall effect of the groups on activity is not necessarily additive and 
may show a substantial reduction or increase in the "expected" activity. It was 
clear from the work of Pfizer,69 Glaxo7,10 and Syntex12 groups that for high 
anaesthetic activity within the steroidal series the 3a-hydroxyl and 17p-acetyl 
groups are essential moieties, with both the 5a- and 5p-compounds affording 
potent hypnotics.
Organon Teknika Laboratories backed this up by showing that in both the 5a- and 
5{3-series, 3a-hydroxypregnan-20-ones exhibit very good hypnotic activity, 
whereas the 3p-hydroxy analogues do not.7 If the shape of ring A, and more 
importantly the relative position of the 3-hydroxyl, is indeed so important, it is 
surprising that compounds of the 5a- and 5p-series show similar activity. The 
great difference in shape can be seen by comparing the 5a-compound with the 5p 
all-chair conformation (Figure 12). The 3a-hydroxyl group in both the 5a- and 
5P-series is on the underside of the steroid nucleus, although the 3a-hydroxyl 
group in the 5p-series is carried much lower than in the 5a-series.
However, a similar position of the 3a-hydroxyls in the 5a- and 5p-analogs is 
required for each isomer to possess similar activity. The only conformation in 
which the 5p-isomer carries the 3a-hydroxyl in roughly the same position as in the
5a-series, is the unfavoured one with both the A and B rings as boats (Figure 13),




Figure 12. a) The 5a-conformation, A\B trans, b) the 5p all-chair
conformation, A\B cis.
christened the catamaran by Phillips.70 To account for similar activity of the 5a- 
and 5p-series it is proposed that this is the likely conformation when it binds to the 
GABAa  receptor, or a conformation very close to it.
n
H
Figure 13. The A and B ring dispositions when both assume the 
boat conformation in the 5P-series. The "catamaran".
Similar to the catamaran conformation of the 5p-series, Organon Teknika 
suggested that the likely conformation of ring A in Org. 9843 (anaesthetically 
potent steroid) when it binds to the GABA^ receptors, is the a-boat form, or a 
conformation very close to it (Figure 14).
Figure 14. Possible conformation of ORG. 9843 at the GABAa receptor.
H OH H
ORG. 9843 Ring A; a  -  boat
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X-ray analysis of crystalline ORG. 9843 reveails that ring A is in the chair 
conformation, in which the 2|3-morpholinyl amd the 3a-hydroxyl groups are trans 
diaxial, whereas the infrared spectrum of the compounds in methylene chloride
bonding between the hydroxyl group and the nitrogen atom) - with the hydroxyl 
group nearly co-planar with the plane of the steroid (Figure 15). Neither of these 
conformations are likely to be present when Org. 9843 binds to the GABAa 
receptor, when it is probably in the a-boat form with the hydroxyl group below the 
plane of the steroid and nearly orthogonal to it.
Figure 15. a) X-ray of ORG. 9843, with ring A in chair conformation, 
b) ORG. 9843 in solution, with ring A in the p-boat form.
On the basis of the structure-activity data available the following modifications in 
structure were suggested.
Synthesis o f novel secosteroids
Two essential features for steroid actions at the GABAa receptor appear to be the 
presence of a 5a- or 5P-reduced tetracyclic steroid skeleton and a hydroxy group in 
the 3a-position .71 Although a number of studies have examined steroid 
structure-activity issues,38,41,71 there is little information regarding the necessity of 
the tetracyclic steroid nucleus.




In an effort to examine the importance of the tetracyclic structure, as well as to 
create potential steroid site ligands with greater molecular flexibility,
- 4 2 -
Rodgers-Neame et al72 synthesized a series of' substituted benz[e]indenes (Bis). 
The Bis are tricyclic molecules that can be enwisioned as steroid-like but that 
contain only a portion of the steroid A-ring. Rodgers-Neame et al examined the 
most effective of these compounds synthesized, BI-1 (Figure 16) and compared its 
action on GABA-gated chloride currents with responses produced by 




Figure 16. a) 3a-OH-DHP, b) the benz[e]indene, BI-1.
Both compounds were found to be effective potentiators of GABA responses, 
however, unlike 3oc-OH-DHP, BI-1 is much less effective at directly gating 
chloride channels in the absence of GABA. Similar actions were found of other 
Bis, suggesting that these effects are characteristic of this class of drugs.
The failure of benzodiazepine and picrotoxin site antagonists to block the BI-1 
effects, coupled with the inability of BI-1 to potentiate GABA currents in the 
presence of high concentrations of 3a-OH-DHP and vice versa, suggests that the 
BI acts at the steroid site on GABAa receptors. Clearly, removal of the steroid A 
ring does not eliminate GABA-potentiating ability but markedly alters the ability 
to gate chloride channels directly. It is possible that the GABA-potentiating and 
direct chloride channel-gating effects may be mediated by separate sites.
Org.9843 is a relatively rigid structure, diaxially substituted at C(2) and C(3). 
Subde conformational changes in ring-A (or any of the other rings for that matter)
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may be reflected in changes in (a) potentiation of GABA, or (b) activation of the 
GABAa receptor, and hence anaesthetic activity. Thus the synthesis of three 





Figure 17. Structures of proposed secosteroids.
This thesis involves the synthesis of the first of these families, the 
A,B-secosteroids (or 5,10-secosteroids). The initial target was the 3a-hydroxy 
A,B-seco system. If anaesthetic properties were detected, the prime target in a 
further project would be a 2p-morphilino-3oc-hydroxy variant to mimic Org. 9843 
and to further probe the conformational requirements at the receptor. Chapter 2 
will therefore describe approaches to the initial target.
RESULTS AND DISCUSSION
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PISCUSSIOIN
2.1 Aims and objectives
The objective of this project was the synthesis of new families of secosteroids 
designed to probe conformational requirements for inducing and maintaining 
general anaesthesia after intravenous administration.
The primary target was the ring A,B-secosteroid (107).
HO
107
. Intermediate targets included:











A key intermediate in the preparation of the final secosteroids, 60 and 65, and the 




The strategy employed in the preparation of the 5,10-secopregn-l(10)-en-5-one 
(39) would involve the oxidative P-ffagmentation of 5a-hydroxy pregnanes using 
eerie ammonium nitrate as the oxidising agent, or irradiating with a 500W tungsten 
lamp in the presence of mercury oxide-iodine.
In order to reduce both the A1,10 double bond and the 5-carbonyl moiety from the 
10-membered ring to give the C(3)-hydroxy-saturated macrocycle, as in 107, the 
double bond would have to be ‘protected* as the corresponding epoxide.
Structure-activity relationships reported in the literature (see Appendix, review of 
steroidal anaesthetics) have shown that the 3a-hydroxyl and 20-carbonyl moieties 
are necessary for anaesthetic potency. These stereospecific functional groups 
would be incorporated into the final synthetic products. Since all starting steroids 
possessed a 3p-hydroxyl group they would at some point, usually after ring 
opening, have to undergo a Mitsonubu reaction to invert the stereochemistry at 
C(3). The 20-carbonyl moiety would be achieved via a series of selective 
deprotections and protections at both ends of the steroid molecule.
It must also be noted that throughout this report all of the chemistry performed 
after AB-ring opening, to give steroids of the type 39, was carried out on the A1,10
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fra/tf-isomer of the 5,10-secosteroid, and at no> point was the c/s-isomer used. 
Hydrogenation of the A1,10 double bond would! be carried out at a later stage in the 
synthesis of 107.
2.2 Attempted preparation of 5,10-secopregnan-3a-ol-20-one (107)
Via G rob fragmentation
Initial attempts focussed on the Grob rearragement73, whereby the bonds of the 
substituents in the C(l) and C(6 ) positions were perfectly aligned geometrically for 
a fluoride-mediated ring-opening to give the macrocyclic diene (3) as the first 









It was proposed that the dienone (5) be converted to silyloxytrienolates (6 ). 
Formation of the conjugated dienone (4) via DDQ oxidation74 of progesterone 
allowed the selective protection of the 2 0 -carbonyl to give 2 0 -ethylenedioxypre- 
gna-l(2),4(5)-dien-3-one (5). However attempts to form the silyloxytrienolate (6 ) 
(R = Me3, lBu(Me)2), failed, presumably due to the stability of the conjugated
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Reagents and conditions: a. DDQ, PhCH3, A, 24 hr, b. HOCH2CH2OH, HC(OEt)3, 
p-TSA; c. R3SiCl, base.
Scheme 2
The conjugation was disrupted by the preferential addition of thiophenol at C(l) to 
give la-phenylthio-20-ethylenedioxypregn-4(5)-en-3-one (7) 75 (Scheme 3). 
Unfortunately reaction of the derivative (7) with base and silyl chloride (both 
trimethyl and ter/butyldimethylsilyl chloride) gave only the elimination product 
(5), and not the desired phenylthiosilyloxy dienolate.
PhSa
5 7 5
Reagents and conditions: a. PhSNa, Et3N, THF; b. R3SiCl, base.
Scheme 3
The 1-trimethylsilyl steroid (9) was prepared according to the method of Fleming
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et al76 by the conjugate addition of lithium bi§(trimethylsilyl)cuprate (8 ) to the 
dienone (5) (Scheme 4). The analogous reaction with lithium bis(ferrbutyldimeth- 
ylsilyl)cuprate failed due to the steric bulk of the silyl cuprate, and in this case only 
starting material was recovered.
3. bMe3SiSiMe3 ----------- ► Me3SiLi ----------- ► (M ^Si^CuLi
8
95
Reagents and conditions: a. MeLi, HMPA; b. CuCN, THF; c. 8 , THF.
Scheme 4
However, l-trimethylsilyl-20-ethylenedioxypregn-4(5)-en-3-one (9), a mixture of 
la -  and lp-isomers, was formed in a disappointing yield of 25%. This, coupled 
with the promising look of other routes led to the discontinuation of this approach.
Via ozonolysis o f 19-nor-3-ethylenedioxypregn-5(10)-en-20$-ol (20)
Deprotection of p-oestradiol diacetate (10) using potassium carbonate in methanol 
gave a quantitative yield of p-oestradiol (1 1 ), which was selectively methylated at 
the 3-hydroxyl, in a yield of 73%, using methyl iodide and sodium hydride 
(Scheme 5), to give 1 2 .
Reagents and conditions: a. K2C03, MeOH; b. Mel, NaH, THF.
Scheme 5
Selective protection of the 3-hydroxyl of 11 would allow the appropriate side chain 
to be attached at the 17-position. This would be achieved by a ‘Wittig’ type 
reaction. Before this could be achieved the 17-hydroxyl was oxidized. Carrying 
out the oxidation with PCC77 (pyridinium chlorochromate) or Jones’ reagent,78 
C1O 3/H2SO4 , gave poor yields of 40% and 20% respectively. This low yield could 
possibly be attributed to the formation of aryl-chromium complexes, which are 
quite common. However, this was not investigated any further as carrying out the 
reaction with 5 mol% tetrapropylammonium perruthenate (TPAP)79 and 1.5 equiv
4-methylmorpholine N-oxide (NMO) in methylene chloride gave a good yield of 
13,77%, and the reaction offered a convenient work-up (Scheme 6 ). The alkene 
(14) was formed via an efficient and very convenient Wittig reaction80 using 
(ethyl)triphenylphosphonium bromide, dimethyl sulphoxide (DMSO) and sodium 
hydride. The methylsulphinyl carbanion is first formed from dimethyl 
sulphoxide-sodium hydride at 75-80°C. The solution was cooled and treated with 
the phosphonium salt to give the alkylidene phosphorane, or Wittig reagent, almost 
instantaneously, as a dark red solution. Subsequent addition of the 17-ketone (13), 
and appropriate reaction time and temperature completed the process. 
Hydroboration of the alkene (14) yielded the 17-hydroxyl steroid (15).










Reagents and conditions: a. TPAP, NMO, CH2C12; b. CH3CH2PPh3Br, DMSO, NaH, 
A; c. i. B2H6 , THF; ii. NaOH, H20 2.
Scheme 6
Modification of the aromatic ring-A in 3-methoxyoestra-17p-ol (12) gave the A5,10 






Reagents and conditions: a. NH3, Li, EtOH, Et20; b. (COOH)2, MeOH.
Scheme 7
Similar chemistry was applied to 3-methoxy-17p-(l-hydroxyethane)-oestrane (15), 
with similar results. Birch reduction78,81 of the aromatic ring-A of 15 gave the 
diene (18), which underwent oxalic acid promoted deprotection78 to give the A5,10 
3-keto steroid (19). A small amount, 10%, of the conjugated product, the A4,5 
3-ketone (19A), was also isolated. Conventional ethylene acetal derivatization of
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the 3-carbonyl using ethylene glycol and catallytic p-TSA gave 20. Care was used 
in this reaction as over-refluxing resulted in the double bond shifting to give the 
A4,5 steroid. Hence the A5,10 steroid (20) was only isolated in a 50% yield (Scheme 
8 ). The next step was the ozonolysis82 of the A5,10 bond of 20 to give the dione 
(21). This was carried out with disappearance of starting material giving a streaky 
product by tic, suggesting the formation of an ozonide had been achieved. 
However, the attempted decomposition of the ozonide using powdered zinc and 
acetic acid failed. It may be the case that the zinc/acetic acid mixture was acidic 
enough to deprotect the 3-acetal, and thus give a complex reaction mixture. It was 
at this point that this approach was discontinued.
OH OHOH
MeO MeO
19 + 19A15 18
OHOH
20 21
Reagents and conditions: a. NH3, Li, EtOH, Et20 ; b. (COOH)2, MeOH, HO(CH2)2OH, 
p-TSA, PhCH3, A; d. i. 0 3, EtOAc, ii. Zn, HOAc.
Scheme 8
2.3 Preparation of 3a-hydroxy-5,10-secopregnen-20-ones
Synthesis o f 5 ,10-secopregnenes
It has been reported that 5a-(or5p)hydroxy pregnanes undergo oxidations resulting
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in the fragmentation of the C(5)-C(10) bond to give the A,B-secosteroid.83 This 
oxidation may be brought about by oxidising agents such as lead tetraacetate,84 
eerie ammonium nitrate85 or alternatively using photochemical methods.86
Protection of the 20-carbonyl of pregnenolone was best achieved in a 58% yield by 
co-distilling ethylene glycol and water from the reaction mixture.87 The poor yield 
of this ‘protection* was due to the relative insolubility of pregnenolone in the 
reaction solvent. Protection of the 3-hydroxyl as the acetate, to give the readily 
soluble 3p-acetoxypregn-4(5)-en-20-one (23), prior to ketalisation of the 
20-carbonyl afforded an overall yield of 93% for 24 (Scheme 9).
23 Pregnenolone 24
Reagents and conditions: a.HOCH2CH2OH, p-TSA, A ; b. Ac20 , DMAP, Et3N, 
CH2C12; c . HOCH2CH2OH, HC(OEt)3, p-TSA, A.
Scheme 9
Epoxidation of the A5,6 double bond86 of 23 gave the 5a,6a-epoxide (25), which 
upon treatment with lithium aluminium hydride was regioselectively opened to 
give the 5a-hydroxy steroid (27)86 in a quantitative yield. Similar epoxidation of 
the A5,6 double bond of 24, followed by regioselective ring-opening, and 
simultaneous deprotection of the 3-acetate of 26 gave the 5a-hydroxy steroid (27). 
Regiospecific acylation of the 3-hydroxyl of 27 gave the monoacetate 28, the 
tertiary 5a-hydroxyl being too hindered to react (Scheme 10).
Ring-A,B-opening of 28 was investigated. However, the 20-acetal proved to be
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23; R= H 
24; R= Ac




Reagents and conditions: a. m-CPBA, CH2C12; b. LiAlH4, THF; c. Ac20 , py.
Scheme 10
too labile thus resulting in, in most cases, a 5,20-dione. This was disappointing as 
selective deoxygenation of the 5-carbonyl in the presence of the 20-carbonyl would 
be virtually impossible as the carbonyls would be chemically indistinguishable. 
Also selective protection of either carbonyl in the presence of the other would hold 
out similar problems.
Tetravalent cerium (eerie ion) is a powerful oxidant, and has been shown to 
possess the ability to oxidize a wide variety of organic compounds.88 It has been 
reported that 6 p-hydroxy steroids undergo smooth oxidative cyclization to give the 
corresponding C(6p,19)-oxido compounds in fair to good yields, in addition to 
some ketone formation (Scheme 11), after reaction with eerie ammonium nitrate in 
aqueous acetonitrile or aqueous acetic acid at 80°C.
Under the same experimental conditions the tertiary, 5a-hydroxy steroid 
underwent smooth fragmentation to give the 5,10-secosteroid in high yield 
(Scheme 12). The reaction was almost instantaneous, occurring within 3 minutes,
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AcO
X = H, Cl, or Br
Scheme 11
and was accompanied by a colour change from dark red to colourless.
AcO AcOOH O
Scheme 12
The initial step in the eerie ion-induced reactions is probably an inner sphere 
process.89 The dark red alcohol-cerium complex formed initially may dissociate 
with transfer of one electron from the alcohol to the metal ion, and the resulting 
electron deficient oxygen may then abstract hydrogen from an adjacent 5-carbon 
atom. Water is required for a successful reaction, in the absence of water complex 
reaction mixtures result.
The reaction conditions were applied to 28 to give both the deprotected 20-ketone 
(29) and the E-isomer of the deprotected 20-keto secosteroid (30) in the yields 
shown (Scheme 13). Treatment of 30 with potassium carbonate in methanol gave 
the 3{i-hydroxy secosteroid (31), in a yield of 87%, after just 10 minutes at room 
temperature. Hydrolysis of the 20-ketal of 28 may also be achieved using an 
aqueous solution of sulphuric acid in acetone, to give the 20 keto steroid (29).
Mihailovic et al. reported83 that irradiating the 5a-hydroxy steroid with a 500W 
tungsten lamp in the presence of mercury oxide and iodine gave rise to a mixture










Reagents and conditions: a. (NH4)2Ce(N03)6, CH3CN, H20 , 80°C; b. K2C 03, 
MeOH.
Scheme 13
of (E)- and (Z)-A,B-secosteroids.90 In the case of the 5a-hydroxy steroid (28) a 
mixture of the (E)-secosteroid (32) and the (Z)-secosteroid (33) was formed in 
yields of 14% and 8 % respectively. Together with this, 8 % of starting material (28) 
was isolated as well as 26% of the C(20) deprotected (E)-secosteroid (30) (Scheme 
14).
AcOAcO AcOOH
28 (Z); 33(8%)(E); 32 (14%)
+ 28 (8 %) + 30 (26%)
Reagents and conditions: a. HgO, I2, CC14, to).
Scheme 14
Lead tetraacetate as oxidant,84 in the presence of calcium carbonate, gave a 
disappointingly low yield of 10% of the (Z)-secosteroid (33). No (E)-secosteroid
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Reagents and conditions: Pb(OAc)4, CaCC>3 , PhCH3, A, 48hr.
Scheme 15
In summary, employing eerie ammonium nitrate as oxidant gave rise to the 
E-isomer, irradiating in the presence of mercury (II) oxide and iodine gave a 
mixture of E- and Z-isomers, whereas lead tetraacetate as oxidant gave only the 
Z-isomer. Whilst reaction with lead tetraacetate gave the desired product it gave a 
poor yield. The conditions employed in the oxidation with eerie ammonium nitrate 
and the ring-opening with irradiation proved to be too acidic for the acid labile 
20-acetal. Hence, a more acid stable 20-hydroxyl protecting group was required.
The activity of eerie ammonium nitrate will be discussed further in chapter 2.5, 
which describes preparation of 3a-hydroxy-5(10—*lpH)a6 e0 pregnan-2 O-ones.
Providing it would be possible to selectively deprotect at C(3), the synthesis of a 
3,20-diacetoxy-secosteroid could provide an answer to the problem of the acid 
labile 20-acetal. The acetate protecting group is stable to acid and is hydrolysed 
readily by treatment with a base,91 such as potassium carbonate.
Epoxidation, as before, of the A5,6 double bond of pregnenolone gave the 
5a,6a-epoxide (34). It is known that 20-ketones may be reduced with sodium 
borohydride in methanol to give the 2 0 p- and 2 0 a-hydroxyderivatives in the high
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ratio of ca 92:8.92 Lithium aluminium hydridle has been shown to be much less 
stereoselective.93 However, reduction of simple pregnan-20-ones with sodium 
borohydride gives only ca 80% of 2 0 p-alcoholL94, whereas reduction with lithium 
aluminium hydride gave quantitative yields of the 20-alcohol. It was not important 
if a mixture of 2 0 a- and 2 0 p-alcohols was obtained, as both hydroxyls would be 
oxidized to the 20-carbonyl at a later stage. However, the 20p-hydroxy steroid 
could be isolated in an excellent yield, ca 97%, after recrystallisation. The 
2 0 a-isomer could be obtained as the major component by reduction of the 
20-carbonyl with lithium in liquid ammonia-THF.92 Simultaneous reduction of the 
20-carbonyl and regiospecific ring opening of the epoxide 34 gave the 
3p,5a,20p-triol (35) 92 after refluxing in the presence of lithium aluminium hydride 





Reagents and conditions: a. m-CPBA, CH2C12; b. LiAlH4, THF, A.
Scheme 16
To avoid using large amounts of lithium aluminium hydride an alternative 
synthesis was used to prepare the triol (35) in quantities in excess of lOOg. The 
20-carbonyl of pregnenolone was reduced to give the diol (36), prior to 
epoxidation. Epoxidation of the A5,6 double bond, followed by regiospecific 
epoxide-opening with lithium aluminium hydride was carried out as previously 
described to give the triol (35) (Scheme 17). The overall yield of 35 from 
pregnenolone was 75%.









Reagents and conditions: a. LiAlH4, THF; b. m-CPBA, CH2C12; c. LiAlH4, THF, A.
Scheme 17
Selective protection of the 3- and 20-hydroxyls as acetates was affected by stirring 
the triol (35), with acetic anhydride, in pyridine overnight. The tertiary 





Reagents and conditions: a. Ac20 , py., rt, 24 hr.
Scheme 18
Oxidation of the 5a-hydroxyl, again, brought about fragmentation of the 
C(5)-C(10) bond to give the secosteroid. Refluxing 38 in acetonitrile, with 2.5 
equivalents of eerie ammonium nitrate85 in water, for 3 minutes gave exclusively 
the (E)-A,B-secosteroid (39) in a yield of 82%. No Z-isomer was formed. 
Ring-opening of 38 by irradiating with a 500W tungsten lamp in the presence of
i
I
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mercury oxide and iodine83 gave a mixture of (E)- and (Z)-A,B-secosteroids, 39 
and 40 respectively, in respective yields of 48% and 11% (Scheme 19). Both 




AcOAcO AcO 0  
39 (a; 82%, b; 48%)
OH
38 40 (a; 0%, b; 11%)
Reagents and conditions: a. (NH4)2Ce(N03)6, CH3CN, H20 , 80°C; b. HgO, I2,
CC14, hx>.
Scheme 19
Further investigation of the 3- and 20-protecting groups revealed that it was possible to 
either mono-protect or di-protect the 3- and 20-hydroxyls as benzyl ethers. Reaction of 
the triol (35) with 1 .1  equivalents of benzyl bromide in the presence of sodium hydride95 
affected mono-benzylation at the 3-position, to give 41 in a yield of 73%. Selective 
protection, as previously described, of the 2 0 -hydroxyl as an acetate gave the 
3-benzyloxy-20-acetoxy steroid (42), which underwent A,B-ring opening to give 
(E)-3p-benzyloxy-20p-acetoxy-5,10-secopregn-l(10)-en-5-one (43), in a yield of 46%, as 
a white solid. This allowed selective deprotection of the 3-hydroxyl to give the alcohol 
(44) in a quantitative yield (Scheme 20).
- 6 0 -
OH OH OAc




Reagents and conditions: a. 1.1 eq., PhCH2Br, NaH, THF; b. Ac20 , py.; 
c.(NH4)2Ce(N03)6, CH3CN, H20 , 80°C; d. H2, Pd/C, EtOH.
Scheme 20
Dibenzylation of the 3- and 20-hydroxyls (the 5-hydroxyl being virtually inert to the 
reaction conditions) of 35 was achieved by using 2 equivalents of benzyl bromide in 
similar conditions to the mono-benzylation. A,B-ring opening of the dibenzyl protected 
steroid (45) was affected again using the eerie ammonium nitrate conditions to give 





Reagents and conditions: a. 2 eq. PhCH2Br, NaH, THF; b. (NH4)2Ce(N03)6, 
CH3CN, H20 , 80°C.
Scheme 2 1
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An insight into the conformation of the 10-membered ring of the E-isomer of the 
A,B-secosteroid could be gained from the relative rates of deprotection of the 3- 
and 20-protecting groups. The 3p-acetate of 39 was hydrolysed to the free alcohol 
after stirring a methanolic solution of 39 in the presence of potassium carbonate at 
room temperature for only 5 minutes. The 3p-hydroxy secosteroid (44) was 
formed in a quantitative yield. However deprotection of the 20-acetate required 
refluxing a methanolic solution of 39 for 24 hours, using potassium carbonate as 
base. The 3,20-diol (47) was formed in a yield of 81% (Scheme 22). This will be 





Reagents and conditions: a. K2C 03, MeOH, rt, 5min; b. K2C 0 3, MeOH, A, 24hr.
Scheme 22
Selective deprotection of the dibenzyl secosteroid (46) proved unsuccessful, with 





Reagents and conditions: a. H2, Pd/C, EtOH.
Scheme 23
Oxidative p- fragmentation to form 5,10-secosteroids
On treating 5-hydroxy steroids with the mercury oxide-iodine reagent and
i
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irradiating with a 500W tungsten lamp, they umdergo fragmentation of the 
C(5)-C(10) bond with formation of a new type of 10-membered ring containing 
5,10-secosteroidal compounds.
The mechanism for this conversion is unclear, although the Mihailovic group are 
close to understanding i t 83,84,86 It is thought that alkoxy radicals (50) obtained 
from 5-hydroxy steroids, such as 48 and 49, readily undergo p-fragmentation 
involving scission of the C(5)-C(10) bond to give as final products (via the carbon 
radical intermediate (51)) the diastereomeric Z- and E-l(10)-unsaturated-5,10-se- 
costeroid-5-ketones, 52 and 53, in high yield (Scheme 24).
AcO AcOOH
48; 5 a- OH 50
AcO O







Subsequent investigations have shown that, (1) oxidative C(5)-C(10) 
p-fragmentation is a general process which could be applied to various steroidal 
5a- and 5p-hydroxy derivatives independent of the substituent at the 17-position96 
(although it has been shown in this thesis that the reaction conditions are 
sufficiently acidic to hydrolyse a 2 0 -acetal, to a certain extent) or that the presence 
and orientation97 of the 3-acetoxy group (although 5-hydroxy substrates with 
modified98 or substituted99 ring B can give products other than 5,10-seco ketones); 
and (2 ) this type of fragmentation can be affected by various oxidative agents or 
methods (for example, with lead tetraacetate under thermal83,84 or U.V. photolytic
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conditions,96,97 with mercury oxide-iodine86 or lead tetraacetate-iodine83,100, or 
with eerie ammonium nitrate85).
Since, in general, the direction of p-fragmentation is unsymmetrical, alkoxy 
radicals can be rationalised in terms of the relative stability of the resulting 
C-centred free radical moiety and C-0 moiety, as well as of steric and/or 
stereo-electronic factors. 101 It appeared that in the case of the 5-hydroxy steroids, 
such as 48 and 49, the main factor controlling C(5)-C(10) bond cleavage is the 
stability of the tertiary C-10 radical intermediate (51), bearing the angular 19-Me 
group at the C-10 radical centre. Thus it may be assumed that in the 5-hydroxy 
steroid compounds the ease and direction of the fragmentation process should be 
strongly influenced by the presence, or absence, of a methyl substituent at position 
10.
It has since been found that this is the case. 102 Oxidations were carried out on 
19-Hor-5-hydroxy steroids by methods previously used to effect fragmentation of 
the C(5)-C(10) bond in the analogous 19-methyl-5-hydroxy steroids of type 48 and 
49, i.e. lead tetraacetate under thermal conditions (28h) or U.V. photolytic 
conditions (3h), with lead tetraacetate in the presence of iodine (6 h), and with the 
mercury oxide-iodine reagent (3h), the last two being irradiated with a 500W 
tungsten lamp. It was found that, in contrast to the 19-methyl containing steroid, 
the three procedures using lead tetraacetate were unsuccessful in inducing 
p-fragmentation of the 19-Aior-5a-hydroxy steroid. In all these cases only 
unchanged starting material was isolated. However in the reaction with the 
mercury oxide-iodine reagent the C(5)-C(10) bond of the 19-Aior-5-hydroxy steroid 
was readily broken, forming both the Z- and E-isomeric 5,10-secosteroids, 
although not as selectively or in as high a yield as in the 19-methyl series.
Hence it was deduced that the presence of the 19-methyl group in steroidal
- 6 4 -
5-alcohols enhanced cleavage of the C(5)-C(10) bond in p-fragmentation of the 
corresponding 5-alkoxy radicals, when compared to the analogous \9-nor 
compounds. Also, that various oxidative reagents, or methods, which are equally
19-methyl-5-hydroxy derivatives, become selective in inducing p-fragmentation in 
19-nor steroidal systems. The difference in reactivity between mercury 
oxide-iodine and lead tetraacetate (under various conditions) in the 19-nor steroids 
was probably due to factors dependent on the nature and mode of action of the 
oxidizing agents investigated. But there was no precise rationalistion for the 
results available at the moment.
The conformations of the 10-membered ring in the Z-isomers of the 19-methyl and 
19-nor 5,10-secosteroids in solution, and the solid state, were very similar and 
correspond to A97 (Figure 18). The conformation of the 10-membered ring in the 
E-isomeric 19-nor product in solution, and the solid state, also closely resembles 
the main conformation in solution, and in the solid state, of the 
19-methyl-5,10-secosteroid, both corresponding to B97 (Figure 18).
efficient (but not necessarily stereochemically equivalent96) when applied to
A (Z) B(E)
Figure 18
The similarity in the spatial arrangements of carbon atoms in both the
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Z-secosteroid and their E-isomers was substantiated by comparison of their 
corresponding similar 13C NMR spectra. It must be noted that the peak 
corresponding to the C(5) carbon for the (Z)-19-methyl isomer is absent, but is 
present in the corresponding (Z)-l9-nor secosteroid and the E-isomers. The 
stereochemistry of 39 was determined by NMR studies.
The E-isomer of the 5,10-secosteroid has a characteristic short wavelength 
adsorption in the U.V. spectrum, (293 nm) which is absent in the U.V. spectrum of 
the Z-isomer. There is also a difference in the proton NMR spectrum of the two 
isomers. The signal for the proton H-C(l) appears as an unresolvable multiplet for 
the Z-isomer at ca. 5.25 ppm, and those of the 4a-proton and the 4p-proton appear 
as a double doublet at ca. 2.4 and 3.1 ppm respectively. On the other hand, the 
resonance of H-C(l) for the E-isomer is, due to shielding by the 5-keto group, 
displaced upfield to ca. 4.8 ppm with a double doublet pattern. Also, in the 
spectrum of the E-isomer, there are no signals observed between 2.5 and 4.5 ppm 
(assuming no substituents on rings C and D possess a resonance in this range).
The E-isomer undergoes, more readily, transannular reactions83 with participation 
of the A1,10 double bond, because of the favourable position of the carbonyl group 
with respect to the olefinic bond. However in the Z-isomer the A1,10 double bond 
and 5-ketone are on opposite sides of the ring (Figure 18), and would need to 
change to a less stable conformation to favour intramolecular cyclisation.
In summary, the unsaturated Z- and E-isomeric secosteroids behave differently 
towards reagents which might effect or participate in reactions involving bond 
formation across the 10-membered ring, and that the E-isomer is more reactive in 
these transannular processes than the Z-isomer. But local reactions on substituents 
of the 10-membered ring occur as predicted, in a similar manner for both the E- 
and Z- isomers.
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Synthesis of(E)-3a-hydroxy-5,10-secopregn-l( 10)-ene-5,20-dione (60)
Selective deprotection of the 3p-acetate of 39 has been discussed previously, and 
gave the 3p-hydroxy secosteroid (44) in a quantitative yield. Inversion of the 
3p-hydroxyl of 44 was carried out according to the procedure described by 
Mitsonubu. 103 Conventional Mitsonubu reaction of the 3p-hydroxyl gave the 
3a-formate ester (54) in a yield of 67%, via an SN2 mechanism giving an inversion 
of configuration at C(3). Also formed was the cyclopropyl secosteroid (55), in a 









Reagents and conditions: a. DEAD, PPh3, THF, b. H C02H, THF.
Scheme 25
The formation of such cyclopropane ring containing compounds has previously 
been reported, 104 from the solvolysis of 3-tosylates of (E)- and (Z)-5,10-sec- 
osteroids. Compound 44A contains a homoallylic system, which participates in an 
i-steroid-type rearrangement.
The absolute stereochemistry of 55 was determined by NMR studies. The JH 
NMR spectra indicated an ABX2 system for the cyclopropyl protons [5 2.78 (1H,
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dddd, J34', 2.1, J3y  6.3, J32.. 12.4, J3 4.. 19.1 Hz, 3-H), 3.05 (1H, dd, J1>2' 5.7, Jlf2. 









Recrystallisation of 55 from ethyl acetate provided crystals suitable for an X-ray 
crystallographic determination, which duly confirmed that the proposed structure 
was indeed correct [(Figure 20) full details are in Appendix],
Figure 20. X-ray plot of 20p-acetoxy-1,3(10—>1 pH,5^3aH)aZ?eopregn-10(19)-e-
n-5-one (55), (ORTEP plot).
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The results of the X-ray analysis established the nature of the fusion of the three- 
and nine-membered rings in the bicyclo [7.1.0] decanone system. The transannular 
reaction of the 3p-phosphate (44A) occurs in an S^i fashion. Displacement of the 
3|3-phosphate afforded the cyclopropane ring p to the plane of the cyclononanone 
ring (Figure 19).
The 3-formyl ester was chosen ahead of, for example, the benzoate ester due to its 
relative ease of hydrolysis. Treatment of the 3oc-formate ester (54) with potassium 
carbonate gave the 3a-hydroxy steroid (56) in a quantitative yield. The yield of 
the 3a-hydroxy steroid from the 3p-hydroxy steroid was 6 6 %. The choice of 
3a-hydroxyl protecting group was the silyl ether due to stability to base, and its 
ease of attachment and hydrolysis. 105 Also hydrolysis, with acid, would not be 
vigorous enough to affect transannular reaction of the A1,10 double bond with the
5-ketone, as demonstrated in chapter 2.5. Preparation of 3a-hydroxy-5(10—HPH)- 
tffoopregnan-20-ones. Protection of the 3a-hydroxy group as the 
rerrbutyldimethylsilyl ether106 proceeded in 30 minutes at room temperature in the 






Reagents and conditions: a. K2C 03, MeOH, rt, 30 min; b. tBDMSiCl, Im, DMF.
Scheme 26
Manipulation of the 20-substituent would give the desired 20-carbonyl group.
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Relatively vigorous conditions were required to hydrolyse the 20-acetate group. A 
methanolic solution of 57 was refluxed in the presence of potassium carbonate for 
24 hours to give the 20-alcohol (58). Oxidation of the 20-hydroxyl using 
pyridinium chlorochromate (PCC) 107 gave the desired 20-keto functionality (59) in 




Reagents and conditions: a. K2C 03, MeOH, A, 24 hr; b. PCC, CH2C12, rt, 3 hr.
Scheme 27
Conventional deprotection of the 3a-silyl ether105 gave the target secosteroid, 
(E)-3a-hydroxy-5,10-secopregn-l(10)-ene-5,20-dione (60) (Scheme 28), in an 




Reagents and conditions: a. (CH3)4CN+F', THF, rt.
Scheme 28
Synthesis o f (E)-3a,5a-dihydroxy-5,10-secopregn-l(10)-en-20-one (65) 
Stereoselective reduction of the 5-carbonyl of 56 with sodium borohydride in
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ethanol (the rate of reduction being dramatically reduced in fso-propanol) gave a 
65% yield of the 3a,5a-diol (61) (Scheme 29). No 5(3-alcohol was formed, hence 
the 5-carbonyl was reduced from the (3-plane of the steroid. This can be explained 
by the steric environment of the 5-ketone, clearly visualised in Figure 18B, and 




Reagents and conditions: a. NaBH4, EtOH, 0 - 10°C.
Scheme 29
Trialkylsilyl triflates have been used for the silylation of hindered alcohols under 
mild conditions. 108 Also di-rerr-butylsilyl ditriflate has been shown to react with 
1,2-, 1,3- and 1,4-diols in the presence of 2,6-lutidine to provide the corresponding 
dialkylsilylene derivatives in high yield.109 Di-rm-butylsilyl ditriflate may be 
prepared as described by Corey and Hopkins, 109 or purchased from Aldrich. 110 The 
ease of formation, stability towards hydrolysis, and mild conditions for 
deprotection meant that the dialkylsilylene derivatives were ideal for the protection 
of the 1,3-diol (61). Reaction of 61 with di-rm-butylsilyl ditriflate in the presence 
of 2,6-lutidine (3 equiv) at rt for 10 minutes, after work-up, gave the 
di-rm-butylsilylene derivative (62) (Scheme 30). The six-membered ring 
derivative of the 1,3-diol, 61, was stable to chromatography on silica gel.





Reagents and conditions: a. ((CH3)3C)2Si(OTf)2, 2,6-lutidine, CH2C12, rt.
Scheme 30
Conversion of the 20-acetate to the 20-carbonyl was carried out as previously 
described. Hydrolysis of the acetate gave the alcohol (63), which upon oxidation 




Reagents and conditions: a. K2C 03, MeOH, A, 24 hr, b. PCC, CH2C12.
Scheme 31
Deprotection of the dialkylsilylene derivatives can be accomplished satisfactorily 
with aqueous hydrofluoric acid in acetonitrile111 or with pyridinium 
hydrofluoride. 112 Deprotection of 64 with HF-pyridine, for 1 hour at room 
temperature, afforded (E)-3a,5a-dihydroxy-5,10-secopregn-l(10)-en-20-one (65)
- 7 2 -






Reagents and conditions: a. HF - py, THF, rt. 
Scheme 32
Synthesis of(E)-3a,20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (72)
As has been discussed earlier, the 3a-hydroxyl group is necessary for anaesthetic 
activity. All the starting materials used possessed a 3p-hydroxyl group, thus in the 
previous preparations the 3(3-hydroxyl group was inverted after A,B-ring opening. 
However, inversion of the 3p-hydroxyl group was also investigated prior to ring 
opening.
Pregnenolone underwent the Mitsonubu reaction103 via two separate esters. 
Esterification of the 3p-hydroxyl as the benzoate, coupled with simultaneous 
inversion in configuration, gave the 3a-benzoate (6 6 ) in a yield of 6 8 %. Relatively 
vigorous conditions, of refluxing in the presence of a strong base, 113 were required 
for hydrolysis of the 3a-benzoate ester to give 3a-pregnenolone (67), in a yield of 
47% from 3p-pregnenolone (Scheme 33).
However, the preferred route of inversion of the 3p-hydroxyl group was via the 
formyl ester due to its ease of esterification and hydrolysis, and increased yields 
compared to the 3a-benzoate ester (6 6 ). The 3a-formyI ester114 (6 8 ) was formed





Reagents and conditions: a. DEAD, PPh3, PhC02H, THF; b. NaOH, MeOH, 
80°C, 1 hr.
Scheme 33
as per the benzoate ester (6 6 ) in an increased yield of 73%. Hydrolysis of the 
facile formyl ester occurred in 30 minutes at room temperature using potassium 
carbonate as base. 3a-Pregnenolone (67) was prepared in an overall yield of 63% 





Reagents and conditions: a. DEAD, PPh3, HC02H, THF; b. K2C 03, MeOH, 
rt, 30 min.
Scheme 34
Both 3a- and 3p-pregnenolone were isolated as white solids, but were inseparable 
by chromatography. 3a-Pregnenolone had a lower melting point than 
3p-pregnenolone (see experimental section) and a greatly increased solubility in 
corresponding organic solvents.
The NMR signal for the 3-proton is shifted considerably downfield in 
3a-pregnenolone with respect to 3p-pregnenolone. The 5 values are given in
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Table 1. Although the signals for both the steroids are multiplets, the couplings to 
adjacent protons for the 3-proton of 3a-pregnenolone are smaller than those for 
3p-pregnenolone, thus giving a narrower signal.
— 5H(ppm) H - C(3) multiplicity
3a - pregnenolone 4.05 - 3.98 m
3p - pregnenolone 3.58 - 3.48 m
Table 1
Epoxidation of the A5,6 double bond gave the 5a,6a-epoxide (69) in a yield of 
84%. Simultaneous epoxide ring-opening and 2 0 -carbonyl reduction, as previous, 
gave the triol (70) in a low yield of 38% (Scheme 35). The reason for the low 





Reagents and conditions: a. m-CPBA, CH2C12; b. LiAlH4, THF, A.
Scheme 35
Selective protection of the 3a- and 20P-hydroxyls was carried out, as previous, to 
give the diacetate (71) in a quantitative yield (Scheme 36).





Reagents and conditions: a. Ac20 , py., rt, 12 hr.
Scheme 36
A,B-Ring opening of the tertiary 5a-alcohol was affected using eerie ammonium 
nitrate in refluxing acetonitrile to give the 3a,20P-diacetoxy secosteroid (72) in a 





Reagents and conditions: a. (NH4)2Ce(N03)6, CH3CN, H20 , 80°C.
Scheme 37
The overall yield of the 5,10-secosteroid from 3a-pregnenolone was 12% 
compared to 65% from 3p-pregnenolone. Thus it was concluded that it would be 
more viable to invert the stereochemistry at C(3) to give the desired 3a-hydroxyl 
moiety, after A,B-ring opening.
Synthesis o f 3a,5a-dihydroxypregnan-20-one (75)
It was of interest to not only submit novel 3a-hydroxy-20-keto secosteroids for 
biological evaluation, but also any untested 3oc-hydroxy-20-keto pregnanes.
Mitsonubu reaction103 of 27 gave selective inversion of the 3p-hydroxyl to give the
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3a,5a-diol (74) via the 3a-benzoate ester (73) (Scheme 38). The 5a-hydroxyl 






Reagents and conditions: a. DEAD, Ph3P, PhC02H, THF; b. NaOH, MeOH.
Scheme 38
Deprotection of the 20-acetal was achieved, using sulphuric acid in refluxing 







Reagents and conditions: a. H2S04, MeOH, A, 30 min.
Scheme 39
i
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2.4 Preparation of 5,10-secopregnan-3a-ol-20-one (107)
In order to access the saturated 10-membered ring analogues it was necessary to 
deoxygenate the 5-carbonyl and reduce the A1,10 double bond of 39.
Attempted reduction o f A1’10 double bond
Unfortunately reduction of the A1,10 double bond prior to deoxygenation of the 
5-carbonyl failed. Hydrogenation was attempted using hydrogen gas with a 
palladium catalyst at atmospheric pressure and a pressure of 150 atmospheres, and 
also with a platinum catalyst at atmospheric pressure (Scheme 40). The attempted 





Reagents and conditions: a. H2, Pd/C, EtOH; b. H2, Pt/C, EtOH.
Scheme 40
The procedure and equipment were checked when a sample of pregnenolone was 
hydrogenated successfully at atmospheric pressure using a palladium catalyst (25% 
w/w) in a yield of 89% (Scheme 41).
Further attempts were made to reduce the A1,10 double bond using diimide. 115 It 
has been shown that the trans double bond was much easier to reduce than the cis 
form in the diimide reduction of 12-membered cyclic olefins. 115 The attempted 
reduction of 39 was carried out under three different modes of generating diimide.





Reagents and conditions: a. H2, Pd/C, EtOH, 2.5 hr.
Scheme 41
These methods were; (1) oxidation of hydrazine hydrate with 30% hydrogen 
peroxide in the presence of cupric salts, 116 (2 ) oxidation of hydrazine hydrate in the 
presence of selenium, 117 and (3) decomposition of potassium azodicarboxylate in 
the presence of base. 118 However, as with the attempted hydrogenations, the 
diimide reductions failed and only starting material was isolated.
Also, in a further attempt to reduce the A1,10 double bond of 39, transfer 
hydrogenations119 were used. Transfer hydrogenation is the process whereby 
hydrogen is formed in situ by, for example, the oxidation of cyclohexene to give 
cyclohexadiene or even benzene. Three different methods of transfer 
hydrogenation were used; (1) oxidation of cyclohexene with palladium (II) 
hydroxide as catalyst, 120 (2 ) oxidation of cyclohexene in the presence of 
Wilkinsons* catalyst121 and, (3) oxidation of ammonium formate in the presence of 
palladium catalyst. 122 All of the attempted ‘hydrogenations’ were carried out in 
refluxing ethanol or methanol for up to 1 week. Unfortunately the transfer 
hydrogenations also failed and only starting material was recovered.
From the failure of the attempted reductions of the A1,10 double bond of 39, 
together with the fact that no reduction occurred and only starting material was 
recovered, it was surmised that the A1,10 double bond of 39 was too sterically 
hindered by the 5-carbonyl moiety and the 19-methyl group to undergo 
hydrogenation. Thus it was decided that deoxygenation of the 5-carbonyl would 
be necessary prior to reduction of the A1,10 double bond.
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It was also found that carrying out the aforementioned hydrogenation in methylene 
chloride in place of ethanol gave a reaction, although not the desired one. The
5,10-secosteroid diacetate (39) underwent a rearrangement, together with 
elimination of the resulting 5-hydroxyl and the 3-acetate groups, and in situ 
reduction of the resulting A10,19 exocyclic double bond, when stirred in an 
atmosphere of hydrogen in methylene chloride in the presence of palladium on 
activated carbon for 72h to give the 5(10—3►lpH)fl6 eosteroid (78) (Scheme 42). 
Steroids of this type will be discussed in detail in chapter 2.5, Preparation o f 





Reagents and conditions: a. H2i Pd/C, CH2Cl2 , 72 hr.
Scheme 42
Treatment of the acetate (78) with potassium carbonate and refluxing for 96 hours gave 
the 20-hydroxy-5(10—5►lpH)aZ?£osteroid (79) in a quantitative yield (Scheme 43).
OHOAc
78 79
Reagents and conditions: a. K2C 03, MeOH, A, 96 hr. 
Scheme 43
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Attempted deoxygenation o f the C(5) carbonyl moiety 
Three methods were attempted for the deoxygenation of the 5-carbonyl; (1) 
Wolff-Kischner reduction, (2) formation of a C(5) dithiane followed by cleavage 
by Raney nickel, and (3) dehydration of the C(5) hydroxyl group by various 
methods following reduction the of C(5) carbonyl.
Wolff-Kischner reduction
Aldehydes and ketones may be reduced to the corresponding hydrocarbon by the 
Wolff-Kischner method123 which involves heating the corresponding hydrazone 
with base, usually potassium hydroxide (Scheme 44).
The mechanism of the Wolff-Kischner reduction may involve the initial formation 
of the mesomeric anion (I) by removal of a proton by the base from the hydrazone. 
A prototropic shift gives the anion (II) which loses nitrogen to form the carbanion 





Huang-Minlon demonstrated that a modified Wolff-Kischner reduction proceeded
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normally on keto groups at the steroidal positions 3,7,12,17 and 20 to give the 
normal methylenic compounds. 124 The keto group at position 11 remained 
unattacked due to steric hinderance. Moffett and Hunter125 have reported an 
alternative Wolff-Kischner procedure for the reduction of 11-oxo steroids, as have 
Djerassi and Thomas. 126
The Huang-Minlon modification has the following advantages: (1) the isolation of 
the hydrazone is unnecessary, (2) the reaction time is considerably reduced, (3) the 
reaction can be carried out at atmospheric pressure, and (4) the yields are usually 
higher. The hydrazone is first formed in situ by refluxing a solution of the 
carbonyl compound in diethylene glycol or triethylene glycol with the commercial 
hydrazine hydrate and about 3 equivalents of potassium hydroxide127 (or 
potassium carbonate may be used128) for 1 hour; the water and excess hydrazine 
are removed by distillation until a favourable temperature for the decomposition of 
the hydrazone is attained (170-190°C) and the solution refluxed for 3-5 hours 
longer.
Attempted reduction of the 5-carbonyl of 39 using the Huang-Minlon modification, 
with either potassium hydroxide or potassium carbonate as base, failed to give the 
desired product. In both cases a complex reaction mixture resulted. One problem 
could be that the 5,10-secosteroid is highly base sensitive. As has been previously 
shown in this report, treatment with potassium carbonate is sufficient to hydrolyse 
the 3p-acetate and, to some extent, the 20-acetate. Refluxing the 5,10-secosteroid 
(39) in diethylene glycol with potassium hydroxide gave the triol (80) and baseline 
material (Scheme 46).
A further problem was that of the previously mentioned transannular reaction. 
Mihailovid et al have reported on the transannular reaction of hydroxylamine






Reagents and conditions;aKOH, diethylene glycol, A, 2 hr.
Scheme 46
across the 10-membered ring.83 Since hydrazine was used to effect the reduction of 
the 5-carbonyl this could be relevant. Proton NMR of the crude reaction mixture 
of the attempted reduction of the 5-carbonyl of 39 showed no signal for the olefinic 
proton, and the IR showed no peak corresponding to a carbonyl. The mass spectra 
showed a mass ion in excess of the desired product. It may be that a transannular 








Chromatography showed the attempted reduction of the 5-carbonyl moiety via the 
Huang-Minlon modification of the Wolff-Kischner reaction to be very complex, 
and for this reason it was not purified any further.
- 8 3 -
Preparation o f C(5) dithioketal
An important method for accomplishing complete reduction of a carbonyl group 
involves dithioketal formation followed by hydrogenolysis of the carbon-sulphur 
bonds. The mild and relatively neutral conditions employed in this procedure help 
make it a useful companion to the Wolff-Kischner reduction.
Many studies of the reactions of steroid ketones have demonstrated that 
ethanedithiol will condense with carbonyl functions at various positions. 129 
Several efficient procedures for preparing ethylene thioketals have been devised by 
Fieser eta l . 130 In the simpliest and often most effective of these methods boron 
trifluoride etherate is added, with stirring, to a solution (or suspension) of the 
carbonyl compound in ethanedithiol. Selective thioacetal formation of diones was 
also reported. For example, it was found that the addition of acetic acid to the 
ethanedithiol and acid catalyst caused a milder reaction medium allowing the 
synthesis of the 3-dithioacetal of cholestane-3,6-dione. In the absence of acetic 
acid the 3,6-bis-dithioacetal was obtained.
It has also been reported that when acetic acid and p-toluenesulphonic acid, as 
catalyst, were used the selectivity of the 3-position over that of the 17 was greatly 
reduced. 131 It was also found that using methanol as solvent gave greater 
selectivity than acetic acid and also avoided the problem of acetate formation. 131 
Thus when methanol was used as the solvent, selective 3-thioacetal formation 
could be achieved in high yield in the presence of other groups such as the 
17-ketone and the 19-alcohol.
Desulphurisation of thioketals may be accomplished by refluxing an ethanol or 
dioxane solution of the sulphur compound with Raney nickel (W-2, W-4, or 
W-7) . 132 For best results, a large excess of the catalyst is required (i.e., weight ratio
- 8 4 -
of catalyst to substrate greater than 6 ). Freshly prepared catalyst may reduce other 
functional groups, 133 but this can be at least partly avoided if the Raney nickel is 
deactivated before use by refluxing for several hours in acetone.
The attempted condensation of the ketone (39) with ethanedithiol failed. The 
reaction was attempted for both the diacetate (39) and the diol (47) using 
ethanedithiol. It was attempted in neat dithiol, 1.5 equivalents of dithiol and 
methanol, and also 1.5 equivalents of dithiol and acetic acid. In all the above cases 
boron trifluoride etherate was used as catalyst. The reaction mixture, in all the 
cases, was very complex and for this reason was not purified in any way.
However, carrying out the reaction in acetic acid with propane-1,3-dithiol, using 
p-toluenesulphonic acid as catalyst, gave the corresponding dithioketal (81) of the 
ketone (39) (Scheme 48). Unfortunately the dithioketal was isolated in a low yield 
of 8 %, and the reaction could not be repeated using boron trifluoride etherate as 




Reagents and conditions: a. HS(CH2)3SH, p - TSA, AcOH, rt.
Scheme 48
As a trial reaction the ketone (83) gave the propane dithioketal (84), after 
condensation with propane-1,3-dithiol in methanol using boron trifluoride etherate 
as catalyst, in a good yield of 70%. Also as a comparison of the rate of hydrolysis 
of 3-acetates, the 3p-acetate of 82 was hydrolysed. Hydrolysis of 82 was affected 
by stirring a methanolic solution of 82 for 3  hours in the presence of potassium
- 8 5 -
carbonate (Scheme 49) compared to 5 minutes under the same conditions for the 






Reagents and conditions: a. K2C 03, MeOH, rt, 3 hr; b. HS(CH2)3SH, BF3 .OEt2, 
MeOH, rt, 30 min.
Scheme 49
Also condensation of the ketone (82) with ethane dithiol in acetic acid with boron 
trifluoride etherate as catalyst gave the ethane dithioketal (85), with simultaneous 








Reagents and conditions: a. HS(CH2)2SH, BF3 .OEt2, AcOH, rt, 2 hr.
Scheme 50
Desulphurisation of the thioketal (81) was affected by refluxing an ethanolic 
solution of 81 with a twenty-fold excess of W-2 Raney nickel, 134 prepared as 
described in the literature. 135 The C(5) methylene steroid (8 6 ) was formed in a 
good yield of 71% (Scheme 51). An overall yield of 6 % from the ketone (38).





Reagents and conditions: a. Raney Ni, EtOH, A.
Scheme 51
Dehydration!elimination o f the 5-hydroxyl moiety
The third attempted route to the deoxygenation of the 5-carbonyl was via the 
elimination of the 5-hydroxyl. Careful reduction of the 5-carbonyl of 39, with 
cooling and premature quenching to avoid hydrolysis of the 3-acetate, using 
sodium borohydride gave the stereospecific 5a-hydroxy steroid (87) (Scheme 52). 






Reagents and conditions: a. NaBH4, EtOH, 0°C -  rt.
Scheme 52
Elimination o f 5-tosylate
It was proposed that on formation of the 5-tosylate of 87, this tosylate group could 
undergo elimination using collidine136 to give the corresponding olefin, 137 or 
reaction with lithium aluminium hydride to give the C(5) methylene group. 138 
Attempted synthesis of the 5-tosylate involved reaction of the alcohol (87) with 
tosyl chloride in pyridine, which acts as solvent and base. Unfortunately though,
- 8 7 -
even at reduced temperatures, the 5-tosylate could not be isolated as transannular 
elimination of the tosylate occurred instantaneously to give the 5(10—>lpH)a^?- 
£osteroid (8 8 ) as a white solid (Scheme 53). Although the reaction almost 
certainly proceeds via the 5-tosylate, it was not detected via chromatography. The 
transannular elimination was repeated when the reaction proceeded via the 





R = Ts, Ms
Reagents and conditions: a. TsCl ( or M sCl), py., -78 - 25°C.
Scheme 53
Reductive removal o f the 5 -hydroxyl with chlorotrimethylsilane-sodium iodide 
It has been shown that chlorotrimethylsilane-sodium iodide (CTMS-Nal) effects 
reductive removal of hindered tertiary hydroxyls to give saturation. 139 Hence it 
was expected that treatment of the alcohol (87) with CTMS-Nal would give the 
C(5) methylene steroid (8 6 ). Unfortunately the reaction seems to proceed as in 
Scheme 53, as the only product was the 5(10—5►lpH^eosteroid (8 8 ), see 
experimental section.
Attempted radical deoxygenation o f 5 -alcohol
In the last decade there has been a marked increase in the use of radical reactions 
in organic synthesis. 140 The radical deoxygenation of secondary alcohols is one of 
the reactions of this kind. 141 The radical deoxygenation of secondary alcohols by 
tin hydride reduction of appropriate thiocarbonyl derivatives is a preparatively 
useful reaction, especially for complex molecules.
- 8 8 -
Barton et al suggested that a thioformate derivative would have a relative thermal 
stability and ease of reductive elimination. 142 They reported that the thioformates 
of tertiary alcohols were smoothly reduced by tributyltin hydride to the 
corresponding hydrocarbon in a radical chain reaction. 142
The reaction of Barton and McCombie, 141 the radical deoxygenation of secondary 
alcohols, was improved by the use of the reagents 2,4,6-trichlorophenoxythiocarb- 
onyl chloride and its congener pentafluorophenoxythiocarbonyl chloride. 
Deoxygenations with these derivatives were found to be fast and quantitative. 143 
Acylations were carried out in benzene or toluene. The deoxygenation reaction 
could then be performed in the same solvent with tributyltin hydride, this being a 
significant advantage over any previous procedure. Also when X was 
2,4,6-trichlorophenoxy, or especially pentafluorophenoxy, the reaction with 
tributyltin hydride was rapid (minutes rather than hours) and the yields were 
excellent (Scheme 54).
S
Reagents and conditions: a. C6F50C(S)C1 ( or 2,4,6 - C6H2Cl3 0 C(S)Cl), py, 
HOSu, PhCH3, 80°C.
Scheme 54
Attempted acylation of the 5-hydroxyl group of 87 using pentafluorophenoxythio­
carbonyl chloride in refluxing toluene unfortunately failed. The only product 
isolated was that of the 5(10—i>ipH)a&eosteroid (8 8 ). Thus it was probable that on 
forming the 5-pentafluorophenoxythioformate (89), again a rapid transannular 
cyclization occurred (Scheme 55), as in the case of the 5-tosylate. The reaction 
was repeated at a lower temperature, '78 - ‘40°C, in an attempt to isolate the
- 8 9 -
thioformate (89). However, even at such low temperatures 89 was not detected by 
chromatography, and after appropriate work-up the only product was the 
abeostzxoid (8 8 ) (Scheme 55).
OAcOAc OAc
a or b AcO AcOAcO OH
Reagents and conditions: a. C6F5OC(S)Cl, py., HOSu, PhCH3, 80°C; b. 
C6F5OC(S)Cl, py., HOSu, CH2C12, -78°C--40°C.
Scheme 55
In summary, it was not possible to reduce the A1,10 double bond of the
5,10-secosteroid whilst both the bulky 19-methyl and 5-carbonyl surrounded i t  
Unfortunately, attempts to deoxygenate the 5-carbonyl moiety also failed (with the 
exception of a low yield of the C(5) methylene steroid via the dithioketal) due to 
problems from transannular reactions brought about by the A1,10 double bond. It 
was not possible to eliminate the 5-hydroxyl moiety via ‘a good leaving group’ 
approach also, due to the aforementioned transannular reactions. Hence the A1,10 
double bond could not be reduced with the 5-carbonyl present, but the 5-carbonyl 
could not be deoxygenated whilst the A1,10 double bond was present. A possible 
way round this could be by protection of the olefinic moiety. Protection of the 
carbonyl moiety would have no advantage, as it would not lessen the steric bulk.
Synthesis o f 5 ,10-secopregnan-3a-ol-20-one (107) .
Epoxidation of the A1,10 double bond of 39 proceeded uneventfully144 to give the 
‘olefin protected’ epoxide (90) as a white solid in a yield of 93% (Scheme 56).
The conformation of the epoxide was proved by JH NMR spectroscopy. The
- 9 0 -
splitting pattern corresponding to the H-C(l) proton appeared as a doublet with a 
vicinal coupling constant of 9.2Hz. This suggested that the dihedral angle between 
this proton and one of the C(2) protons was very close to, if not, 90°, i.e. a coupling 
constant of 0Hz. The other C(l)-C(2) dihedral angle would thus be in the order of 
150°, to give the said coupling constant. This suggestion was verified by models, 
and may only be brought about by the stereochemistry of the C(l) proton being a  
to the plane of the steroid backbone. 145 The 19-methyl signal was unchanged and 





Reagents and conditions: a. m-CPBA, CH2C12, rt, 2 hr.
Scheme 56
Protection of the A1,10 double bond, as an epoxide, dramatically changed the 
character of the 5-carbonyl, suggesting that some intramolecular ‘bonding’ existed 
between the A1,10 double bond and the 5-carbonyl. This assumption explains the 
observed ease of transannular reaction, as was seen by the attempted isolation of 
derivatives of the 5-alcohol (87).
The 5-carbonyl of 90 behaved much more like a carbonyl is expected to, compared 
to that of 39. Also the adjacent protons became a great deal more acidic, than 
those of 39, thus adding to the suggestion of a "partial transannular bond" existing 
between the A1,10 olefinic bond and the 5-carbonyl. The acidity of the C(4) 
protons of 90 was demonstrated by treatment of 90 with potassium carbonate in 
methanol. It was expected that potassium carbonate would hydrolyse the 
3-acetate, as was the case with 39 (Scheme 22). But this was not the case. One of
- 9 1 -
the C(4) protons was extracted by the base leading to elimination of the 3-acetate 
to give the A3’4 olefin (91). Conjugate addition of the solvent methanol, to the 
double bond led to a transannular ring opening of the epoxide of 91 to give the 




90 92 (76%)91 (21%)
Reagents and conditions: a. K2C 03, MeOH, rt, 25 min.
Scheme 57
Another example of the ‘new found freedom’ of the 5-carbonyl was the much 
increased speed of reduction using sodium borohydride in ethanol. The 5-carbonyl 
of 90 underwent reduction in less than a tenth of the time taken to reduce the 





Reagents and conditions: a. NaBH4, EtOH, rt, 45 min.
Scheme 58
Now, with the A1,10 double bond protected it was possible to derivatize the 
5-hydroxyl moiety. The 5-tosylate (94) was isolated in a yield of 8 6 % after the 
reaction of 93 with tosyl chloride and pyridine (Scheme 59). The reaction was 
stirred for 72 hours, thus the 10-membered ring was now stable to transannular






Reagents and conditions: a. CH3C6H4S 0 2C1, py., CH2C12, rt, 72 hr.
Scheme 59
Hence, it should now be possible to either deoxygenate the 5-carbonyl of 90 or 
dehydrate/eliminate the 5-hydroxyl to give the corresponding C(5) hydrocarbon. It 
has been reported that the reduction of ketone tosylhydrazones with the mild 
reducing agent, sodium cyanoborohydride, in acidic 1:1 DMF-sulfolane provides a 
mild, convenient, and high yielding method for deoxygenation by either a direct 
hydride attack or a tautomerisation-then-reduction route. 146
In situ reduction of the hydrazone of 90 with sodium cyanoborohydride gave the 





Reagents and conditions: a. TsNHNH2, NaCNBH3, p-TSA, DMF, sulfolane, A .
Scheme 60
Alternatively the hydrazone (96) of 90 could be isolated by stirring a solution of 
the ketone (90) with tosyl hydrazine for 5 days. The hydrazone was isolated in a 
yield of 34%, as a white solid. Reduction of the hydrazone (96) with sodium
- 9 3 -






Reagents and conditions: a. TsNHNH2, CH2Cl2 , 5 day; b. NaCNBH3, p-TSA, DMF, 
sulfolane, A.
Scheme 61
Following the procedure of Barton and Jaszberenyi, for the radical deoxygenation 
of secondary alcohols, 143 the 5-hydroxyl group of 93 was deoxygenated in a yield 
of 65% (34% from the ketone (90)). The pentafluorophenoxythioformate 
derivative (97) of 93 was prepared as described earlier and isolated in a yield of 
6 8 %. Treatment of the xanthate (97) with tributyltin hydride147 in the presence of 
azobisisobutryonitrile (AEBN) gave the C(5) methylenic steroid (95) after 15 





Reagents and conditions: a. C6F50C(S)C1, py., HOSu, PhCH3, 80°C; b. Bu3SnH, 
AIBN, PhCH3, 110°C.
Scheme 62
Deoxygenation of the epoxide would give the A1,10 olefin, 148 which it would now, 
hopefully, be able to reduce as the bulky carbonyl was no longer present.
- 9 4 -
Deoxygenation of the epoxide of 95 was initially attempted using samarium (II) 
iodide in THF . 149 The most stable oxidation state of the lanthanide elements is +3. 
Thus, divalent lanthanide salts150 should behave as strong reducing agents. 151 
Samarium metal reacts smoothly with 1,2-diiodoethane in THF to give samarium 
diiodide (Scheme 63). Ytterbium may be used in place of samarium . 149
Sm + ICH2CH2I -------------► Sml2 + CH2 = CH2
Scheme 63
The reaction should be carried out at room temperature, under an inert atmosphere 
and anhydrous conditions, and yields are reported to be high. The resulting 
samarium diiodide-THF solution is coloured blue-green. Epoxides are 
deoxygenated to olefins by samarium diiodide, and to a lesser extent by ytterbium 
diiodide. Use of an excess of samarium diiodide in the presence of rm-butyl 
alcohol resulted in virtually quantitative conversion into olefin without by-products 
resulting from epoxide rearrangement152 or reduction into alcohol.
Unfortunately the deoxygenation of the epoxide of 95 with samarium diiodide 
proceeded very slowly; by tic only approx. 1 0 % of a mixture of trans- and 
m -olefins was formed after 5 days at 35-40°C.
It has long been known that bromohydrins give olefins on treatment with zinc. 153 
Reduction of an iodohydrin to an olefin has also been reported. 154 When an 
epoxide was added to sodium iodide in acetic acid, an iodohydrin was formed 
rapidly, and subsequent addition of zinc powder gave an olefin. 155 The yield was 
improved upon when the mixture of acetic acid, sodium iodide, and zinc was 
buffered by sodium acetate. In the process, protonation of the epoxide was 
presumably followed by nucleophilic addition of the iodide ion, and then reduction
- 9 5 -
of the iodohydrin before solvolytic processes can destroy much of it. Iodide ion 
consumed in the second stage was regenerated in the third, so that a catalytic 
amount of sodium iodide should suffice to promote olefin formation. 156 
Reduction of the epoxide was shown to give a mixture of roughly equal parts of 
trans- and cw-olefms. 154
On treatment of 95 with sodium iodide, zinc, sodium acetate, and acetic acid the 
A1,10 olefin (8 6 ), a mixture of E- and Z- isomers, was formed in a yield of 73%, 
corrected for recovered starting material. Also isolated was the la-hydroxysteroid 




95 E/Z; 8 6  (73%) 98(13%)
Reagents and conditions: a. Zn, Nal, NaOAc, AcOH, rt, 5 day.
Scheme 64
The fact that an isomeric mixture of olefin (8 6 ) was formed was immaterial, as the 
next step was the hydrogenation of the A1,10 double bond. Hydrogenation of the 
A1,10 double bond of 8 6  was very slow, 50% conversion in 2 weeks, but gave the 
fully saturated steroid (99) (Scheme 65). Hydrogenation of the A1,10 double bond 
was carried out prior to inversion of configuration at C(3) in order to eliminate the 
problem of side-products, of the type (55), formed in the Mitsonubu reaction, as a 
result of transannular reactions.
Selective hydrolysis of the 3p-acetate of 99 was less rapid than that of 38. The 
3p-hydroxy steroid (100) was formed by treatment of the 3p-acetate (99) with base




Reagents and conditions: a. H2, Pd/C, EtOH, 14 day.
Scheme 65




Reagents and conditions: a. K2C 0 3, MeOH, rt, 24 hr.
Scheme 6 6
The by-product of the deoxygenation of the epoxide (95), 98 may also be 
converted to the 19a-methyl isomer of the 3(3-hydroxy saturated steroid (100). 
Radical deoxygenation of the la-hydroxyl group of 98 was carried out, as 
described previously, using the method of Barton and Jaszberenji, 143 in one step to 
give the olefinic diacetate (101). Selective hydrolysis of the 3(3-acetate, over 24 
hours, followed by hydrogenation of the A10,19 double bond gave the 3(3-hydroxy 
steroid (100A) (Scheme 67).
Inversion of the configuration at C(3) using the Mitsonubu reaction103 was 
performed on 100 to give the 3a-hydroxy steroid (103) via the 3a-formyl ester 
(102). Hydrolysis of the 3a-formyl group took 24 hours at room temperature 
(Scheme 6 8 ), compared to 1 hour for the more facile 3 a-formyl ester of the 5-keto 
secosteroids. The 2H NMR signal for the 3(3-proton of 103 was shifted





Reagents and conditions: a. i. C6F50C(S)C1, py., HOSu, PhCH3, 80°C, ii. 
Bu3SnH, AIBN, PhCH3, 110°C; b. K2C 03, MeOH, rt, 24 hr; c. H2, Pd/C, EtOH.
Scheme 67
considerably upfield with respect to that of the 3a-proton of 100, proving an 
inversion in stereochemistry at this position had indeed occurred, giving rise to the 




Reagents and conditions: a. DEAD, PPh3, HC02H, THF; b. K2C 03, MeOH, rt, 24 hr.
Scheme 6 8
The following preparative steps were all carried out on 15 milligrammes of the 
3a-hydroxysteroid (103), and therefore limited spectral data is available (see 
experimental section).
Protection of the 3a-hydroxyl group was effected, as before, using rm-butyldim- 
ethylsilyl chloride and imidazole to give the 3a-silyl ether (104) in a quantitative 
yield (Scheme 69).
Manipulation of the C(20) substituent was then carried out to give the desired 
20-ketone. Hydrolysis of the 20-acetate, with potassium carbonate, took 24 hours







Reagents and conditions: a. tBDMSiCl, Im, DMF, rt, 24 hr.
Scheme 69
at reflux to give the 20-hydroxy steroid (105) which, upon treatment with PCC 





Reagents and conditions: a. K2CO3, MeOH, A, 24 hr, b. PCC, CH2C12, rt, 3 hr.
Scheme 70
Deprotection of the 3a-silyl ether of 106 was carried out using a THF solution of 






Reagents and conditions: a. TBAF, THF, rt, 24 hr.
Scheme 71
- 9 9 -
2.5 Preparation of 3a-hydroxy-5(10—5►lpH)a£eopregnan-20-ones
The Baldwin rules for ring closure
Baldwin has provided a specific set of rules for certain closings of 3- to 
7-membered rings. 157 These rules distinguish two types of ring closure, called exo 
and endo, and three kinds of atoms at the starred positions: Tet for sp3, Trig for sp2, 





Figure 21. Baldwin’s rules for ring closure.
The following are Baldwin’s rules for closing rings of 3 to 7 members. 
Rule 1. Tetrahedral systems
a. 3- to 1-Exo-Tet are all favoured processes,
b. 5- to 6-Endo-Tet are all disfavoured.
Rule 2. Trigonal systems
a. 3- to 1-Exo-Trig are favoured,
b. 3- to 5-Endo-Trig are disfavoured,
c. 6 - to 1-Endo-Trig are favoured.
- 1 0 0 -
Rule 3. Digonal systems
a. 3- to 4-Exo-Dig are disfavoured,
b. 5- to 1-Exo-Dig are favoured,
c. 3- to 1-Endo-Dig are favoured.
"Disfavoured" does not mean it cannot be done, only that it is more difficult than 
the favoured cases, due greatly to the disfavoured processes requiring severe 
distortion of bond angles and distances in the linking chain for reaction. These 
rules are empirical and have a stereochemical basis.
Synthesis o f 3a,5a-dihydroxy-5( 10~^l$H)abeopregnan-20-one (116)
Evidence exists for a transannular interaction between the carbon-carbon double 
bond and the carbonyl group, when these groups are located opposite each other in 
a ring of medium size. 158 Kosower et al159 reported the use of solvent effects to 
identify a transannular electronic transition involving the carbon-carbon double 
bond and the carbonyl group of 5-cyclodecenone. It was suggested that such a 
transition, which led to a bond in the excited state between atoms not bonded in the 
ground state, be called photodesmotic (Figure 22).
O O
-►
Figure 22. The photodesmotic transition of 5-cyclodecenone.
Leonard and Owens158 showed that the transannular interaction between the 
carbon-carbon double bond and the carbonyl group in 5-cyclodecenone was 
apparent in the excited state from the ultraviolet spectrum, but not detected in the
- 1 0 1 -
ground state by infrared, indicating that the transannular interaction was an excited 
state phenomenon. They suggested that, within a solvent cage, in the 10-membered 
ring the aforementioned groups were held close together in conformations 
possessing little strain.
Lange and Bosch160 have also reported on the ease of transannular reaction 
between the carbon-carbon double bond and the carbonyl group of 
rra/w-5-cyclodecenone. An example of a transannular Patemo-Buchi reaction, 
Figure 23, was demonstrated by the photochemistry of rra/ts-5-cyclodecenone.
ho
Paterno-Buchi
Figure 23. The transannular Patemo-Buchi reaction of fra/is-5-cyclodecenone.
IiTadiation of cw-5-cyclodecenone resulted in complete isomerisation to the 
trans-isomer, 160 which would then undergo the transannular Patemo-Buchi 
reaction.
It is known that (E)-cyclodecenones of similar type to the 5,10-secosteroid (39) 
easily undergo thermal and acid-catalysed cyclisations. 161 Acid-catalysed 
cyclisations of 39 afforded steroid compounds of the 5(10—>1 )abeo type, involving 
intramolecular C(l)-C(5) bond formation to give A- nor B-homo derivatives with 
the rr<ms-lp,5a-configuration (i.e., 5(10—>lpH)fl^<9-5 a-steroids) , 97,162 more 
details in chapter 2.6. Both the five(5 -Ex0 -7>/g)- and the
seven(7 -Ex0 -7 r/g)-membered ring formations are favoured by Baldwin’s rules for 
ring closure. 157
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The 5,10-secosteroid (39) was formed by oxidation of the 5 a-hydroxy steroid (38) 
using eerie ammonium nitrate in refluxing acetonitrile, the reaction mixture being 
quenched after 3 minutes. However if the reaction was allowed to proceed for a 
further 2  minutes, the 5(10—MpH)aZ?e0 steroid (108) is isolated (Scheme 72).
Reagents and conditions: i. eerie ammonium nitrate, CH3CN, 80°C, 3 min; 
ii. eerie ammonium nitrate, CH3CN, 80°C, 5 min; iii. 2N HC1,0 ^  4 hr.
Scheme 72
Reaction of the 5a-hydroxy pregnane (38) with eerie ammonium nitrate at 80°C 





AcO OH AcO OH
38 109
Reagents and conditions: a. CAN, CH3CN, H20 , 80°C, 5 min.
Scheme 73
Selective hydrolysis of the 3p-acetate again occurred rapidly at room temperature
- 1 0 3 -





Reagents and conditions: a. K2C 03, MeOH, rt, 30 min.
Scheme 74
Inversion of the 3p-hydroxyl of 110 occurred regioselectively, with the 
5a-hydroxyl group being too hindered to undergo any reaction. Thus the 
3a-formyl ester (111) was formed114 in a good yield of 80% (Scheme 75), and 
underwent hydrolysis to give the 3a-alcohol (112) in a quantitative yield.
OAcOAc OAc
97%80%i
HCOO'"’HO HO OHOH OH
110 112111
Reagents and conditions: a. DEAD, PPh3, HC02H, THF; b. K2C 03, MeOH, rt, 
30 min.
Scheme 75
It was possible to chemically distinguish between the 3a-hydroxyl and the 
5a-hydroxyl groups of 112 by using a sufficiently bulky protecting group, although 
at this stage in the synthesis di-protection would not be a problem. The 3a-silyl 
ether (113) was formed in the conventional manner (Scheme 76).
Hydrolysis of the 20-acetate of 113 gave the 20-alcohol (114) by refluxing in the 
presence of potassium carbonate for 24 hours. Oxidation of 114 using PCC was 
regioselective in giving the 20-keto steroid (115), i.e., the 5a-hydroxyl was inert to





Reagents and conditions: a. tBDMSiCl, Im, DMF, rt. 
Scheme 76
the reaction conditions (Scheme 77).
OAc OH
87% 94%
tBDMSiO tBDMSiO tBDMSiOOH OH OH
113 114 115
Reagents and conditions: a. K2CO3 , MeOH, A, 24 hr; b. PCC, CH2C12, rt, 3hr.
Scheme 77
Deprotection of the 3a-silyl ether was carried out using a THF solution of 






Reagents and conditions: a. TBAF, THF, rt.
Scheme 78
Finally, hydrogenation of the exocyclic A10,19 double bond of 116 occurred 
smoothly at atmospheric pressure, using palladium catalyst, to give the desired
- 1 0 5 -
compound, 3a,5a-dihydroxy-5(10—*ipH)afec<9pregnan-20-one (117) (Scheme 79) 
in an overall yield of 22% from pregnenolone, or 36% from the 5(10—*1(3H)abeo- 





Reagents and conditions: a. H2, Pd\C, EtOH, 15 hr.
Scheme 79
Recrystallisation of 117 from ethyl acetate provided crystals suitable for an X-ray 
crystallographic determination, which duly confirmed the structure as 
3a,5a-dihydroxy-5(10—>lpH)aZ?eopregnan-20-one [(Figure 24) for full details see 
Appendix].
Figure 24. X-ray plot of 3a,5a-dihydroxy-5(10—>lpH)aZ?eopregnan-20-one (117),
(ORTEP plot).
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As may be seen from the X-ray structure, hydrogenation of the A10,19 double bond 
of 116 gave rise to the a-methyl substituent at C(10). Also, examination of the 
solid state molecular packing revealed that the lattice was dominated by 
intermolecular hydrogen bonds through the hydroxyl groups. Throughout the 
lattice hydrogen bonds occur between the 3a-hydroxyl group of one steroid and the 
5a-hydroxyl of another steroid, and vice versa. The ultimate consequence of these 
intermolecular contacts is an array of infinite herringbone polymers parallel to the 
a axis. The backbone of each herringbone is composed of two one-dimensional 
polymers. These polymers are cross-linked by the hydrogen bonds [(Figure 25), 
full details are in Appendix]. This is, to the best of our knowledge, a new 
supermolecular structural type (for a relevant review see Bishop et a l 163).
Figure 25. Solid state molecular packing of 117.
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The target compound (117) may be synthesized by an alternative route. Attempted 
benzylation of the 3a-hydroxyl of 56 resulted in protection of the 3-hydroxyl 
together with transannular ring closure across the 1 0 -membered ring via 
coordination of the benzyl group to the 5-carbonyl (118). Thus the dibenzyl ether 
(119) was formed as a white solid in a 6 8 % yield (Scheme 80). From the NMR 
of 119, one of the exocyclic vinylic protons exists above the plane of the 
rearranged A,B rings, and one below, p- and a-protons respectively. The a-proton 
interacts, in some way, with the n system of the 5a-benzyl group. The NMR 
signal for this proton is thus shifted considerably downfield from approximately 5 







Reagents and conditions: a. PhCH2Br, NaH, THF, rt, 24 hr.
Scheme 80
Base hydrolysis of the 20-acetate of 119, followed by PCC oxidation of the 
resulting 20-hydroxyl (120) gave the desired 20-ketone substituent (121) (Scheme 
81).
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Reagents and conditions: a. K2CO3 , MeOH, A, 24 hr; b. PCC, CH2C12, rt, 3 hr.
Scheme 81
Hydrogenation of 121 achieved both deprotection of the benzyl ethers together 
with reduction of the A10,19 double bond to give the target compound 117, 
3a,5a-dihydroxy-5(10—>lpH)aZ?e<9pregnan-2 0 -one (Scheme 82), in an overall 





Reagents and conditions: a. H2, Pd\C, EtOH, 24 hr.
Scheme 82
Synthesis of5(10-+ipH)abeopregnan-3a-ol-20-one (128)
It has also been shown, in Chapter 2.4, that transannular ring closure across the 
10-membered ring of the 5,10-secosteroid may be promoted by base, as well as 
acid, via extraction of a 19-methyl proton (Scheme 83). Ring closure between 
C(l) and C(5) occurred stereoselectively, via olefination of the C(10)-C(19) bond 
to give the exocyclic A10,19 double bond (characterised by two singlets in the 
proton N M R  for the olefinic protons, around 5 ppm), and the lp-proton. It was 
usually not possible to isolate the 5-substituted secosteroid (122). Again, both the
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five(5-Exo-Tet)- and the seven(7-Exc>-7er)-rnembered ring formations are favoured 




122; R = Ts, Ms, or Xanthate 8 8
Scheme 83
The preparation of the 3a-silyloxy secosteroid (57) has been described previously 











Reagents and conditions: a. K2C 03, MeOH, rt; b. DEAD, PPh3, H C 02H, THF; c. 
K2C 0 3, MeOH, rt; d. tBDMSiCl, Im, DMF, rt.
Scheme 84
Stereoselective reduction of the 5-carbonyl of 57, using sodium borohydride gave 
the 5a-hydroxy secosteroid (123) as the only product (Scheme 85).
Advantage was taken of the fact that attempted elimination of the 5a-hydroxyl 
group of the 5,10-secosteroid resulted in transannular ring closure, as discussed 
previously. Reaction of the 5a-hydroxy steroid (123) with tosyl chloride and





Reagents and conditions: a. NaBH4, EtOH, rt, 48 hr.
Scheme 85
pyridine resulted in the in situ elimination of the resulting tosyl group to give to 





Reagents and conditions: a. TsCl, py., CH2C12.
Scheme 8 6
As before (Chapter 2.3), the 20-acetate (124) was hydrolyzed to give the 20-hydro­






Reagents and conditions: a. K2C 03, MeOH, A, 24 hr, b. PCC, CH2C12, rt,3 hr.
Scheme 87
Deprotection of the 3a-silyl ether of 126 was achieved using tetrabutylammonium
- i n -
fluoride to give a quantitative yield of the 3a-hydroxy steroid (127) as a colourless 





Reagents and conditions: a. TBAF, THF, rt.
Scheme 88
The target compound, 5(10—>lpH)a6e<?pregnan-3a-ol-20-one (128) was formed by 
hydrogenation of the A10,19 double bond of 127 at atmospheric pressure, using a 
palladium catalyst (Scheme 89). The 5 (lO-MpH)afo?0 Steroid was isolated as a 
white solid, and in an overall yield of 21% from pregnenolone, over 14 steps (or 





Reagents and conditions: a. H2, Pd\C, EtOH, 12 hr.
Scheme 89
The 3a-silyloxy-5(10—M pH^^osteroid (124) may be synthesized by an 
alternative route.
Reduction of the 5-ketone of 39 occurred stereoselectively, from the P face of the 
carbonyl, to give the 5a-alcohol (87). In situ elimination of the intermediate 
5a-tosylate, formed from the 5a-alcohol (87), via transannular reaction gave the
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Reagents and conditions: a. NaBH4, EtOH, 0°C - rt; b. TsCl, py.
Scheme 90
Regioselective hydrolysis of the 3|3-acetate of 8 8  was possible, although at a 
slower rate than that of 39. The 3p-alcohol (129) was formed after treatment of 8 8  





Reagents and conditions: a. K2C 03, MeOH, rt, 3.5 hr.
Scheme 91
Inversion of the configuration of the 3p-hydroxyl of 129 was carried out following 
the procedure of Mitsonubu, 103 generating the 3a-hydroxy steroid (131) via the 
3a-formyl ester (130) in an overall yield of 69% (Scheme 92).





Reagents and conditions: a. DEAD, PPh3, H C02H, THF; b. K2C 03, MeOH, rt, 1 hr.
Scheme 92
Protection of the 3a-hydroxyl group of 131 was performed as usual to give the 





Reagents and conditions: a. tBDMSiCl, Im, DMF, rt, 1 hr.
Scheme 93
The target compound 5(10^ipH)flftec>pregnan-3a-ol-20-one (128) may then be 
prepared as described earlier in this chapter. The overall yield of 128 via this 
second route, whereby ring closure was carried out prior to inversion of 
configuration at C(3), was 17% from pregnenolone, over 14 steps (or 26% from the 
5,10-secosteroid (39)).
2.6 Conformational analysis of A and B rings of 5 ,1 0 -secosteroids
It has been generally recognized that in studies on structure-activity relations it is 
very important to include the three-dimensional structure information. For that 
reason conformational analysis together with molecular graphics have now become
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key tools in computer-assisted drug design. 164
Chemical structures used in studies on biological activity are usually specified on 
different levels of precision and sophistication. The constitution of a molecule 
simply specifies its elemental composition and the atomic topology. The 
configuration gives the spacial attachment of the atoms, while the molecular 
conformation designates the arrangement of the atoms in a molecule with a given 
configuration in three-dimensional space. Of critical importance are the effects on 
attractive and non-attractive lipophilic, polar, hydrogen bonded and charged 
interactions with the receptor.
The borderline between configuration and conformation is usually defined by 
stating that configurational isomers can only be converted by breaking and 
mending chemical bonds, whereas conformational isomers (conformers) are 
interconverted solely by rotation about single bonds simultaneously with 
co-operative geometry deformations. The barrier height of the potential energy of 
a molecule that experiences a conformational conversion is relatively low. 
Therefore, in solution some of the interconversions may easily take place, even at 
room temperature, so that different conformers will co-exist in a dynamic manner. 
Moreover, a conformer which remains within a certain potential well may exhibit a 
considerable conformational flexibility.
X-ray diffraction in single crystals yields the molecular geometry, and the 
molecular packing and nuclear magnetic resonance (NMR) is used to give 
additional information about the conformation of molecules in solution. The X-ray 
structures can be used as starting geometries in molecular mechanics studies. This 
computational technique allows a relative energy to be associated with each 
conformation and it has the ability to minimize the energy with respect to 
variations of the molecular geometry. An indispensible reference on structural
- 1 1 5 -
data has been compiled in the "Atlas of Steroid Structure" . 165 Within the 
Bom-Oppenheimer approximation, the Schrodinger equation for a molecule can be 
separated into a part describing the motions of the nuclei. Molecular mechanics 
studies the latter set of motions, using empirical potential functions to describe the 
forces between nuclei due to the electrons.
Molecular mechanics makes it feasible to explore the multi-dimensional potential 
energy surface that describes the energy of the molecule instead of studying just a 
few selected geometries. Within its limit of applicability, the method is capable of 
satisfactorily reproducing experimentally determined geometries and relative 
potential energies.
The concepts behind molecular mechanics are conceived in plain terms with 
respect to covalent bonds, charge interactions and forces between non-bonded 
atoms. The molecular energy is obtained from the atomic coordinates as a simple 
sum of a series of classical potential energy functions. Required is a set of 
empirical functions, known as a force field. An algorithm is used for minimizing 
the potential energy by adjusting the atomic coordinates. Unfortunately, the 
success of the molecular mechanics method depends on experimental data, and the 
reliability can be no better than that of the data used for the initial parameterization 
of the force field.
The structural model is expressed mathematically in a set of coordinates. From 
such a model the potential (steric) energy can be calculated. The steric energy is 
then minimized by varying the coordinates in an iterative process. To compare the 
relative energies of different conformers, and to get an idea about the height of an 
interconversion barrier, geometry optimization with respect to energy 
minimization is a necessity. Several techniques have been developed to find the 
geometry for which the energy is simultaneously a minimum with respect to all
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coordinates. 166
Intermolecular interactions and molecular flexibility
Hydrogen bonds play a crucial role in intermolecular steroid-receptor interactions 
and they account partly for the packing forces in the solid state. The head-tail 
designation is used to describe hydrogen bonding in the crystal, which refers to the 
edges of the steroid molecular corresponding to C(3) and C(17) respectively or to 
substituents on these positions. For van der Waals interactions it is illustrative to 
consider the shape of the molecule.
The molecular flexibility of a steroid molecule may be simulated by molecular 
mechanics. The positions of certain atoms may be changed step-wise in such a 
way that the molecule may be bent towards the a- or P-side. Minimisation will 
then give the minimum energy conformation of the molecule.
The configuration of anaesthetically potent steroid molecules may mimic the 
actual situation at the receptor site, where presumably also very favourable 
hydrogen bond interactions occur.
Conformational analysis o f six- and ten-membered rings161 
Cyclic hydrocarbons have long been a major target of conformational analysis. 168 
Pseudorotation169 is the mode of interconversion between the different twist-boat 
forms of cyclohexane as well as between different symmetrical conformers of 
larger ring hydrocarbons. Pseudorotation usually surmounts low-energy barriers 
and is associated with a simultaneous change of all ring torsion angles without 
severe distortions in bond angles. Another mode of conformational 
interconversion, the symmetrical mode, usually crosses higher energy barriers than 
pseudorotation. Examples of the symmetrical mode are transitions from the 
cyclohexane chair form to the twist-boat form retaining an axis of symmetry, and
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to the boat form retaining a plane of symmetiy.170 
Six-membered rings
The twist-boat (TB) conformer interconverts to its enantiomer (via pseudorotation) 
through the boat conformation. The boat conformation exhibits a veiy low energy 
barrier. The chair to twist-boat (C-TB) interconversion (symmetrical mode) 
courses a fairly high energy barrier through a so-called half-chair conformation. 
Both interconversions exhibit the very same kind of coordinated atomic 
movement. This atomic movement has been termed kayaking, because it involves 
three ring bonds A-B-C-D following a moving pattern similar to the pattern 
exhibited by the movement of the kayaker’s arms and the paddle. Kayaking is 
associated with characteristic torsion angle differences. There is a significant 
change in the middle torsion angle (B-C) and a smaller change in both the other 
torsion angles (A-B and C-D) that is opposite to the change in the central torsion 
angle. The TB-TB interconversion exhibits two kayaking patterns. The C-TB 
interconversion exhibits one kayak pattern. This particular version of kayaking is 
coded "K3"
Ten-membered rings
Only a few low-energy cyclodecane conformations have been discussed in 
detail.170,171 The symmetrical boat-chair-boat (BCB) form has been found to be the 
minimum energy conformer, cyclodecane favouring the BCB form as much as 
cyclohexane favours the chair form.171 The BCB form pseudorotates with itself 
and has been found in the crystal structure of several cyclodecane derivatives. It 
may be that crystal packing effects gives rise to the crystals favouring the BCB 
form.
The five lowest energy conformers and their relative strain energies (in KJ/mol) 
are: BCB (0), TBCC (1.8), TBC (4.7), TCCC (4.8), and BCC (6.4). The TCCC
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conformer is the crown form of cyclodecane, whereas the CCC conformer is 
neither a minimum nor a saddle point.171
The higher energy interconversions are dominated by the K3-kayaking mode, but 
cyclodecane displays new versions of the basic kayaking and flapping motions; 
handle flapping and single comer flapping. Handle flapping almost rigidly flaps a 
ring torsion angle A-B-C-D about the hinge comprised of the line AD. The new 
mode of kayaking is termed K5-kayaking, and is different from K3-kayaking in 
that it involves five (A'-A-B-C-D-D'), rather than three ring bonds (A-B-C-D).
In summary, the different modes of conformational interconversion associated with 
the lowest barriers between minimum energy conformers display patterns of 
well-coordinated atomic movement. It was found that 97% of the 115 
conformational interconversions in cyclohexane to cyclodecane exhibit the same 
basic atomic movements.167 Each interconversion, no matter how complex, can be 
separated into a few basic modes; termed kayaking and flapping.
Conformations o f the ten-membered ring in 5 ,10-secosteroids 
X-ray analysis of the E-isomer of the 5,10-secosteroids (3P-epimer) showed the 
cyclodecenone ring to adopt an extended crown conformation, of type (Figure 
26), of approximate symmetry 2/m (C2h)-172 Similar shapes have been reported for 
the 10-membered ring in both the 1:1 silver nitrate adduct of germacatriene173 and 
elephantol p-bromobenzoate.174
The flexibility of the 10-membered ring makes its geometry very sensitive to even 
small perturbations, for example, substituent effects or crystal packing forces.
From and 13C NMR, in solution, the 10-membered ring exists in at least two 
distinct forms, the predominant one corresponding to the solid state conformation
- 1 1 9 -
of Aj, and the minor most likely to be B2 (Figure 26). Although the results show 
only the two most populated conformations, the actual time-dependent spatial 
arrangement is much more complicated. Conformations with relative populations 
of a few percent affect the NMR spectra only slightly but might be important in a 
particular chemical reaction.
Additional effects such as the transannular interaction of the double bond with the 
carbonyl group have been postulated to explain the unexpected thermodynamic 
stability of the ‘crown*-type conformation.
Four possibilities were assumed of orientating the olefinic methyl group and the 
C(5) carbonyl group above, or below, the plane of the 10-membered ring172 
(Figure 26). Other conformations distinctly different from the four proposed lead 
to stronger steric interactions. A discussion of conformations of medium sized 
monocyclic carbonyl compounds in solution has been published by Anet et a/.175
Figure 26. Conformations; i) A^ major conformation in solution and solid state 




Two classes of possible conformations may be distinguished according to the
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chemical shifts of the olefinic proton83 : in class A; H-C(l) is in the shielding 
region of the keto group, in class B; it is unaffected.
The four conformations of Figure 26 are characterized as follows:
A! (<crown conformation = solid state conformation). H-C(l) is in the shielding 
region of the keto group.
A2 (ground-state cyclodecane conformation). H-C(l) is in the shielding region of 
the keto group. However, the olefinic methyl group and C(6) are now in position 
a.
Bj (ground-state conformation o f (E)-cyclodecene-AgNOycomplex176). The 
olefinic methyl group at C(10) is in the shielding region of the keto group and 
H-C(l) is not influenced by the latter. The olefinic methyl group is above the 
plane of the ring.
B2 (conformation proposed in reference 161i). As in Bj the olefinic methyl group 
is in the shielding region of the ketone.
Conformation B2 has a slightly higher energy than conformation A ls of about 1 
Kcal/mol172 (or 4.18 KJ/mol). The conformation B2, postulated as the minor 
component in solution, represents according to calculations the least stable of the 
discussed set of four (Figure 26). The relative rigidity of the system and the 
transannular electronic interaction between the double bond and the carbonyl 
group could account for the higher than expected stability of B2.
Proton NMR experiments carried out on the 5,10-secosteroid (57) supported the 
existence of various conformations of the 10-membered ring in solution. Looking
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at the 360 MHz data, the signal from 3(3 looked different in CDCI3 to that in C6D6, 
presumably due to different couplings to neighbouring protons. Vicinal couplings 
are not expected to be solvent dependent, thus it was concluded that there was 
more than one conformation in solution. Two or more conformations are in fast 
exchange on the NMR timescale, and the equilibrium between different 
conformers is perturbed by solvation effects. Some of the results of the NMR 
studies are included in the Appendix.
The geometiy of the double bond deviates only slightly from planarity, in contrast 
to other (E)-cyclodecene structures. The geometrical prerequisite for this is the
short transnnular distance C (l) C(5) of only approximately 2.84A, considerably
less than the sum of the van der Waals radii. Apart from the absence of steric 
hinderance between the two sp2-carbon atoms C(l) and C(5), the short 
transannular interaction of the olefinic bond and the carbonyl double bond can be 
explained by the 71-interaction of the type reported for (E)-cyclodec-5-enone177 and 
analogous cases.178
The two deduced conformations can be correlated with the stereochemical course 
of different chemical transformations described for compounds of type 39;
1. Reduction of the C(5)-oxo group.179 In the two conformations, Aj and B2, a 
preferential attack at the C(5) carbonyl atom from the less hindered front side 
could be expected. Consequently the (5S)-alcohol is formed.
2. Acid catalysed cyclization.83 When treated with acid in aprotic solvents the 
(E)-5,10-seco-enone is cyclized to a 9:1 mixture of two isomeric compounds172 
(Figure 27). The trans-compound can be stereochemically correlated with B2 and 
the cw-isomer with Aj.










3. Thermal cyclization.161 An intramolecular synchronous (symmetry allowed) 
process can only be formulated if B2 is the involved conformation (Figure 28).
AcO
O J CH:
Figure 28. Transition state conformation for the thermal cyclization
The 7i-interaction between the olefinic bond and the ketone may be the reason for 
the unsuccessful attempts to reduce the C(l)-C(10) double bond by, for example, 
hydrogenation.
The increased rate of hydrolysis of the C(3) esters can be explained in terms of the 
relatively unhindered environment of the C(3) substituents in the ‘crown’ 
conformation, A l.
The six-membered ring, ring C, assumes the normal chair conformation, and the 
five-membered ring, ring D, is intermediate between a C(13) envelope and a C(16) 
half chair.
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The resonance signal, in the NMR spectrum, of the tra^s-isomer is shifted upfield 
by approximately 0.54 ppm with respect to the cis-isomer. This is due to the 
olefinic proton laying just above the carbonyl double bond of the keto group, i.e., 
in the region of positive shielding. It is assumed that the shielding influence of the 
C(5) carbonyl group causes a high field shift of the H-C(l) resonance in the main 
conformation. This influence is not operative for the minor conformation, where 
the keto group and the vinylic proton are anti-parallel to each other. Ring-flipping 
does not change the relative positions.
The olefinic hydrogen of the 5,10-seco-enone has a similar orientation as the 
olefinic hydrogen of fra/i.s-5-cyclodecenone. It is coupled to the C(19) methyl 
group, but the coupling is unresolvable on our NMR timescale.
The change in the configuration of the C(3) acetoxy group from a  to p leads to 
inversion of the OC(5) and H3C(19) moieties between a  and p positions for both 
conformations.97 This behaviour indicates that the energy difference between the 
two types of conformations is small compared to the energy difference between an 
axial and an equatorial acetoxy group.
Molecular mechanics techniques have been used to investigate the conformational 
space of a set of steroid analogues.
An initial conformation of the 5,10-secosteroid (39) was built from its internal 
coordinates (bond length, angle, and torsion) derived from X-ray deffaction 
reference using the Insight Biosym molecular modelling suite.180 This structure 
was then minimised (Figure 29) and the resultant structure used as a template for 
the building of the steroid analogues. All of these structures were minimised and 
their conformations compared. The final configurations corresponded quite well to 
the configurations found in the crystal structures.97,172 The structures were refined
- 1 2 4 -
with hydrogen atoms. Any differences in X-ray structures and models might well 
be sought in a transannular attraction of the olefinic and C(5) carbonyl moieties, 
which is not represented in the force field.
Figure 29. Minimised conformation of 39 (C(20) acetate replaced by C(20)
formate)
A molecular dynamics simulation was performed upon 39 in order to investigate 
the conformational space available to the 10-membered ring. The structure was 
given enough energy to initiate ring flipping at C(2)-C(3)-C(4) and then allowed to 
adopt its most stable conformation (Figure 29). The 10-membered ring assumed 
the now familiar crown-conformation with the C(3) acetoxy group in an equatorial 
position. The C(19) methyl and C(5) carbonyl are in a trans-arrangement, with the 
C(5) carbonyl moiety shielding the H-C(l) proton.
A molecular dynamics simulation was performed on compound 44 to investigate 
the possibility of intramolecular hydrogen bonding between the C(3) hydroxyl 
proton and the C(5) carbonyl oxygen, via a favourable six-membered ring.
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However, the crown conformation is of a lower energy and is the adopted one 
(Figure 30).
Figure 30. Minimised conformation of 44 (C(20) acetate replaced by C(20)
formate)
The results of the simulation were analysed using FOCUS181 and an atom-atom 
distance map was produced for the two hydrogen bonding atoms, shown in Figure 
31. These show that the hydroxyl proton is never within an excepted hydrogen 
bonding distance of the carbonyl oxygen, i.e., 2.5A.
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Hydroxyl proton - carbonyl distance
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time (ps)
Figure 31. C(3) hydroxyl proton - C(5) carbonyl oxygen distance for 44
Molecular mechanics techniques were also used to show the favoured 
(5S)-configuration of the C(5) hydroxyl, after reduction of the C(5) oxo group 
(Figure 32). The preferred conformations of rings C and D, discussed earlier, can 
also be seen clearly.
Figure 32. Minimised conformation of C(5) hydroxy-secosteroid
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T w o  more structures minimised were the anaesthetically potent 2-morpholiny- 
l-3a-hydroxy steroid (132) and the target secosteroid (107), in order to compare 
the relative positions of the important C(3a) hydroxyl groups (Figure 33). Both 
C(3) hydroxyls are in a similar position, with the secosteroid hydroxyl possessing a 
greater flexibility and thus more free to adopt a favoured conformation at the 
receptor site. Hence, the secosteroid, 107 looked promising for a new 
anaesthetically potent steroid. It has up to now not undergone biological 
evaluation.
132
Figure 33. Minimised conformation of the anaesthetically active steroid (132) and
the secosteroid (107)
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Transannular cyclisations
It has been noted that only the trans-secosteroid readily undergoes transannular 
cyclisations.83
In the stable conformation, the fra/w-seco-ketone would be expected to undergo 
transannular reactions with participation of the C(l)-C(10) double bond, because of 
the favourable position of the carbonyl group with respect to the olefinic bond. 
However, the c/s-isomer, with the double bond and carbonyl group on opposite 
sides of the ring (Figure 18), should not favour intramolecular cyclisations. In 
order to undergo transannular cyclisation the molecular of the cis-seco-ketone 
would first have to change to a less stable conformation.
In fact, the unsaturated cis- and trans-isomers were seen to behave differently 
towards reagents which effect or participate in reactions involving bond formation 
across the 10-membered ring, and that the trans-isomer is far more reactive than 
the c/s-isomer.83
It was found that both the C(3a) and C(3p) epimers underwent cyclisations, 
involving C(l)-C(5) bond formation to give A-nor-B-homo derivatives, of the type 
88,109, and 124, with the same configuration at C(l) and C(5), namely with the 
rr<z/tf-lp,5a-configuration,97and the seven-membered ring in a twist-chair 
conformation.1611 In all these internal ring closures the C(3p) acetate was 
considerably more reactive than the C(3a) epimer, suggesting that the cyclisations 
proceed via a conformation with the geometry of B2, shown in Figure 26, which 
resembles the ground state conformation of trans-cyclodecene (in its complex with 
silver nitrate).176
The trans- 1 p,5a-configuration was deduced by Akhtar and Marsh90 from the facts
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that analysis of the infrared spectra revealed, a) the C(5) alcohols containing a 
C(10) methylene group have a band corresponding to a hydrogen bonded C(5) 
hydroxy (this intramolecular hydrogen bond being formed with the 71-electrons of 
the exocyclic methylene C(10)-C(19) double bond, which disappears when the 
C(10) methylene group is reduced to a methyl group, b) that the 10-methylen- 
e-3p,5a-diol shows a free hydroxyl group, and c) that the stereoisomeric 
10-methylene-3a,5a-diol has no band corresponding to a free hydroxyl group. 
Moreover, the saturated 10-methyl-3a,5a-diol also forms an intramolecular 
hydrogen bond between the two (therefore cis) hydroxyl groups.
Our research has shown that, from the X-ray of 117, there exists intermolecular 
hydrogen bonding between the two hydroxyl groups in the solid state, giving a 
herringbone arrangement (Figure 25), discussed earlier.
Another cyclisation, involving C(l)-C(3) bond formation is the solvolysis of the 
epimeric C(3) tosylates.10411 Both compounds react in the same way, i.e. affording 
cyclopropane derivatives, but whereas the C(3p) tosylate was converted to the 
lp,3a-cyclo-5,10-secosteroid, of the type 44A, the C(3a) tosylate cyclizes to the 
lot,3p-cyclo-5,10-secosteroid with the opposite configuration at the junction 
carbon atoms C(l) and C(3). Thus, the two cyclisations proceed via similar, but 
different, intermediate geometries.97
2.7 Conclusion
The secosteroids, 60 and 65, and the abeosteroids, 117 and 128, all possess highly 
constrained modified ring AB portions, i.e., the ‘crown* conformation in the cases 
of 60 and 65. The overall conformation appears to be governed by the constraints 
imposed by the individual substituents present. As a result they all proved to be
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inactive as GABAa agonists, suggesting an unfavourable position, with respect to 
the receptor, adopted by the 3a-hydroxyl in the cases of the tested secosteroids and 
a&eosteroids.
Surprisingly, in the cases of 65 and 117, neither the 3a-hydroxyl nor the 5a-hydr- 
oxyl were in a favourable position for interaction with the GABAa receptor.
Sufficient quantities of the saturated secosteroid, 107, have thus far been 
unavailable for biological evaluation.
Future work should be directed towards synthesis of a sufficient amount of 107 to 
allow biological evaluation, with respect to the GABAa receptor, and also 
synthesis of the BC and CD secosteroids. Also synthesis of the Z-isomer of 39 
may lead to a shorter synthesis of 107, as protection of the A1,10 double bond may 
not be necessary due to its lower affinity for transannular reactions.
EXPERIMENTAL
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EXPERIMENTAL
3.1 Instrumentation and experimental techniques
All solvents were dried and distilled before use. Petrol refers to petroleum ether of 
60-80°C boiling range and ether to diethyl ether. Tetrahydrofuran was pre-dried over 
sodium wire and then refluxed over sodium benzophenone ketyl under a nitrogen 
atmosphere until anhydrous. This was redistilled immediately prior to use. All other 
solvents and reagents were purified using the procedures described in Purification o f 
Laboratory Chemicals}*1
Thin layer chromatography (tic) was used extensively as a qualitative guide during 
reactions and for assessing the purity of compounds. Merck DC-alufolien kieselgel 
60 F254 sheets, containing fluorescent indicator, were used for this purpose. 
Visualisation of compounds was achieved by illumination under short wavelength 
(254 nm) ultraviolet light, when possible. Plates were developed by treatment with 
either a 0.5% (w/v) aqueous solution of potassium permanganate or a 7% (w/v) 
methanolic solution of phosphomolybdic acid (PMA) or a 3% (w/v) solution of 
anisaldehyde in ethanol (Anis) or a solution of sulphuric acid in methanol, normally 
followed by warming of the tic plate.
Normal phase medium pressure flash chromatography was routinely employed using 
Amicon Matrex or Merck 9385 silica gel. Columns were packed as a slurry in the 
eluting solvent and the material to be chromatographed introduced directly as a 
solution in the eluting solvent or pre-absorbed onto silica and then applied as a thin 
layer to the top of the column. A pressure gradient was developed using a small hand 
bellow.
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Glassware used for moisture sensitive reactions was heated in an oven at 120°C 
overnight and then allowed to cool in a desicator over calcium chloride. Flasks and 
stirrer bars were additionally flame dried under a stream of dry nitrogen prior to use.
Solvents were evaporated with a Buchi rotary evaporator using a water aspirator or a 
vacuum pump as required, and a water bath temperature of <40°C to avoid 
unnecessary heating.
Melting points (m.p.) were determined on commercially available apparatus 
(electrothermal MKH or Gallenkamp) and are uncorrected. Elemental micro-analyses 
were carried out using a Carlo Erba 1106 Elemental Analyser. Optical rotations were 
measured using a Perkin-Elmer 141 polarimeter with concentrations expressed in 
g /1 0 0 cm3.
Infrared spectra were recorded in the range 4000-600cm'1 using a Perkin-Elmer 1310 
spectrophotometer with peaks reported (\)max) in wave numbers (cm'1), and the 
abbreviations br (broad), s (strong), vs (very strong), sh (sharp) used to describe the 
peaks. Samples were prepared as liquid films, nujol mulls or chloroform solutions as 
indicated.
Proton magnetic resonance spectra were recorded on a Jeol GX FT 270 (270 MHz) 
spectrometer, although where indicated a Jeol GX FT 400 (400 MHz) instrument was 
used, and some spectra were run at 200 MHz at the Organon laboratories, Newhouse. 
Carbon-13 magnetic resonance spectra were recorded on a Jeol GX FT 270 
spectrometer operating at 67.8 MHz and using 90 and 135 DEPT pulse sequences to 
aid multiplicity determination. Chemical shifts (5) are expressed in parts per million 
(ppm) downfield from the internal standard tetramethylsilane. The multiplicities of 
the resonances are denoted by s (singlet), d (doublet), dd (double doublet), t (triplet), q 
(quartet) and m (multiplet). The abbreviation br (broadened) is used to indicate
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signficant broadening, whether due to rapid exchange or unresolved fine coupling. 
Homonuclear decoupling experiments and 2D homonuclear shift correlated (COSY) 
spectra were used to confirm proton assignments when required.
Mass spectra were recorded using a VG Analytical 7070E instrument with a VG 2000 
data system. Electron ionisation (E.I.) spectra were produced using an ionising 
potential of 70ev. Chemical ionisation (C l.) was employed using f£0 -butane as the 
reagent gas.
3.2 Experimental procedure
Preparation o f pregna-1(2),4(5)-diene-3 20-dione (4)
2,3-Dichloro-5,6-dicyano-l,4-benzoquinone, DDQ, (4.54g, 19.2mM) was added to a 
stirred solution of progesterone (5.0g, 16mM) in toluene (150 cm3). The reaction 
mixture was refluxed under nitrogen for 24h. After cooling it was filtered and the 
filtrate washed with 1% potassium hydroxide solution (30 cm3), and water (2 x 30 
cm3). The organic layer was dried over magnesium sulphate, evaporated in vacuo, 
and purified by column chromatography on silica gel eluting with ethyl acetate-petrol 
(1:4) to give the diene (4) (2.72g, 55%) as an off-white solid, m.p. 140-141°C (Rf = 
0.54 ethyl acetate-petrol (1:1)); \)max (NUJOLVcm1 1692 s ((20)C=O), 1663 s 
((3)C=0), 1624 (C=C), 1602 (C=C); 5H (270 MHz, CDC13) 7.06 (1H, dd, J  2.8, J h2
10.3 Hz, H-C(l)), 6.25 (1H, dd, J1A 1.9, / 2,i 10.3 Hz, H-C(2)), 6.08 (1H, t, JA2 1.9 Hz, 
H-C(4)), 2.13 (3H, s, H3C(21), 1.25 (3H, s, H3C(19)), 0.71 (3H, s, H3C(18)); m/z 
(CL) 313 ([M+ + 1], 100%), 205 (11), 279 (1), 269 (4), 227 (2); Found: C, 80.2; H, 
8 .8 8 . C iiH ^C V /g H20  requires C, 80.2; H, 8.99%.
Data fo r  progesterone; m.p. 128-130°C (Rf = 0.57, ethyl acetate-petrol (1:1)); vmax 
(NUJOLVcm-1 1697 s (C=0), 1660 s (C=0), 1614 (C=C); 8 H (270 MHz, CDC13) 5.75 
(1H, s, H-C(4)), 2.13 (3H, s, H3C(21)), 1.20 (3H, s, H3C(19)), 0.68 (3H, s, H3C(18)).
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20-Ethylenedioxypregna-1(2),4(5)-dien-3-one (5)
To a stirred solution of the dione (4) (1.53g, 4.9mM) in triethyl orthoformate (8.5 
cm3, 51.0mM) was added ethylene glycol (3.8 cm3 ,7.5mM) and a catalytic amount of 
p-TSA (20mg). The reaction mixture was refluxed for 3h. After cooling it was 
diluted with ethyl acetate (50cm3) and washed with sodium bicarbonate solution 
(10cm3 o f IN) and water (2 x 15cm3). The organic layer was dried over magnesium 
sulphate, and concentrated in vacuo. Recrystallisation from methanol gave the acetal 
(5) (1.20g, 83%) as an off-white solid, m.p. 185-186°C (Rf = 0.66, ethyl acetate-petrol 
(1:1)); umax (NUJOLVcm1 1655 s (O O ), 1630 (C=C), 1610 (C=C), 1047 (C-O); SH 
(270 MHz, CDC13) 7.06 (1H, dd, J  3.0, J x2 10.1 Hz, H-C(l)), 6.23 (1H, dd, J  1.9, Jxx
10.1 Hz, H-C(2)) 6.07 (1H, t, J  1.6 Hz, H-C(4)), 4.04-3.85 (4H, m, 0C H 2CH20), 1.29 
(3H, s, H3C(21)), 1.23 (3H, s, H3C(19)), 0.84 (3H, s, H3C(18)); m/z (C.I.) 357 ([M+ + 
1], 36%), 341 (3), 313 (3), 295 (2), 271 (2), 255 (2); Found: C, 76.0; H, 9.05. 
C23H320 3 .2/5  H20  requires C, 76.0; H, 9.03%.
Ia-Phenylthio-20-ethylenedioxypregnan-4(5)-en-3-one (7)
20-Ethylenedioxypregna-l(2),4(5)-diene-3-one (5) (50mg, 0.14mM) was added to a 
stirred solution of thiophenol (0.15cm3, 0.14mM) and triethylamine (2|xl, 14 pM) in 
THF (2cm3). The reaction mixture was stirred at room temperature for 24h. This was 
then diluted with methylene chloride (1 0cm3), washed with aqueous sodium 
hydroxide (2 cm3 of IN) and water ( 2 x 4  cm3), dried over magnesium sulphate and 
concentrated in vacuo. Purification by column chromatography eluting with 
ether-petrol (4:1) gave the thiophenol (7) (53mg, 81%) as a yellow solid, m.p. 
143-145°C (Rf = 0.67, ether-petrol (7:3)); umax (NUJOL)/cm3 1673 s (C=0), 1580 
(C-C, At), 1470 (C-C, Ar), 950 (C-H, Ar); 5H (270 MHz, CDC13) 7.38-7.30 (5H, m, 
Ar), 5.85-5.78 (1H, m, H-C(4)), 3.98-3.82 (4H, m, 0CH 2CH20 ), 1.36 (3H, s, 
H3C(21», 1.31 (3H, s, H3C(19)), 0.83 (3H, s, H3C(18)); mfz (E.I.) 466 (M+, 2%), 456 
(2), 431 (3), 110 (10), 87 (100); Found : C, 74.2; H, 8.2. C29H38S 0 3 requires C, 74.6;
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H, 8.2%.
1 -trimethylsilyl-20-Ethylenedioxypregnan-4(5)-en-3-one (9)
To a stirred solution of hexamethylsilane (0.34cm3, 1.7mM) in HMPA (3cm3) at 0°C, 
under nitrogen, was added methyl lithium (1.2cm3, 1.7mM) to give a deep red 
solution, indicating the formation of the silyl lithium. After stirring at 0°C for 20 min 
the reaction mixture was diluted with THF (3cm3) and copper(I) cyanide (0.15g,
1.7mM) added to give a black solution which was stirred for a further 20 min at 0°C. 
The cuprate solution was then cooled to -78°C after which a solution of 
20-ethylenedioxypregna-l(2),4(5)-dien-3-one (5) (lOOmg, 0.2mM) in THF (2cm3) 
was added. The reaction mixture was stirred under nitrogen at -78°C for lh and at 
0°C for a further 3h. It was then stirred at room temperature for 96h after which it 
was quenched by the addition of saturated ammonium chloride solution (5cm3) and 
diluted with petrol (10cm3). After filtration through glass wool the filtrate was 
washed with water ( 3 x 5  cm3), dried over magnesium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel eluting with 
ethyl acetate-petrol (1:4) to give isomer A of 9 (20mg, 17%) as a colourless oil (Rf = 
0.81, ethyl acetate-petrol (1:1)); 8 H (270 MHz, CDC13) 5.70 (1H, s, H-C(4)), 
3.78-3.70 (4H, m, 0CH 2CH20), 1.34 (3H, s, H3C(19)), 0.70 (3H, s, H3C(18)), 0.05 
(9H, s, (CH3)3Si).
Further elution gave isomer B of (9) (lOmg, 8 %) as a colourless oil (Rf = 0.79, ethyl 
acetate-petrol (1:1)); 8 H (270 MHz, CDC13) 5.79 (1H, s, H-C(4)), 3.79-3.70 (4H, m, 
0C H 2CH20 ), 1.34 (3H, s, H3C(19), 0.71 (3H, s, H-C(18)), 0.05 (9H, s, (CH3)3Si).
P-Oestradiol (11)
P-Oestradiol diacetate (10) (15.0g, 42.1mM) and potassium carbonate (15.0g, 
108mM) were stined together in methanol (200cm3) at 70-75°C for 90 min. After 
this water,(500cm3) was added to the reaction mixture followed by sodium chloride to
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aid precipitation. The solid was filtered off, dissolved in methylene chloride 
(2 0 0 cm3), washed with water (2  x 50 cm3) and dried over anhydrous sodium sulphate. 
The solvent was removed under reduced pressure and recrystallisation from methanol 
gave f>-oestradiol (11) (1 1.4g, 99%) as a white solid, m.p. 179-180°C (lit 178-179°C) 
(Rf = 0.29, ethyl acetate-petrol (3:7)); \)max (NUJOLVcm1 3423 br (OH), 3180 br 
(OH), 1608 (C-C, Ar), 1586 (C-C, Ar), 873 (C-H, Ar), 819 (C-H, Ar); SH (270 MHz, 
CDC13) 7.07 (1H, d, Jxx 8.4 Hz,H-C (2)), 6.58 (1H, dd, J lA 2.7, / u  8.4 Hz, H-C(l)), 
6.52 (1H, d, J4A 2.6 Hz, H-C(4)); 3.64 (1H, t, / 17fl6 8.4 Hz, H-C(17)), 0.74 (3H, s, 
H3C(18)); m h  (E.I.) 272 (M+, 100%), 213 (33), 160 (29),133 (20); Found : C, 76.1, H, 
9.33. C18H2 4 0 2 .3/4H20  requires C, 76.1; H, 8.92%.
3-Methoxyoestra-17$-ol (12)
P-Oestradiol (11) (15.0g, 55.1mM) in THF (100cm3) was added dropwise to 80% 
sodium hydride (1.25g, 61.0mM), previously washed with petrol (3 x 20 cm3), in THF 
(50 cm3) and stirred under nitrogen. The reaction mixture was stirred at 0°C for 30 
min, until the evolution of hydrogen ceased, and then methyl iodide (3.8 cm3, 
60.5mM) was added dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred for 6 h. Saturated ammonium chloride solution (25 cm3) was 
added to quench, and the reaction mixture extracted with methylene chloride ( 1 0 0  
cm3), washed with water (2 x 50 cm3), dried over anhydrous sodium sulphate and 
concentrated in vacuo. Purification by column chromatography eluting with ethyl 
acetate-petrol (1:4) and recrystallisation from methanol gave the methyl ether (12)
(11.5g, 73%) as a white solid, m.p. 108-109°C (Rf = 0.53, ethyl acetate-petrol (3:7); 
Umax (NUJOLVcm1 3440 br (OH), 1609 (C-C, Ar), 1576 (C-C, Ar), 1250 (O-CH3), 
870 sh (C-H, Ar), 818 sh (C-H, Ar); 5H (270 MHz, CDC13) 7.20 (1H, d, / 2fi 8 .6  Hz, 
H-C(2)), 6.72 (1H, dd, J XA 3.0, J h2 8.3 Hz, H-C(l)), 6.64 (1H, d, / 4 ,2 2.7 Hz, H-C(4)),
3.77 (3H, s, OCH3), 3.72 (1H, t, / 7fl6 7.1 Hz, H-C(17)), 0.77 (3H, s, H3C(18)); m/z 
(E.I.) 286 (M+, 15%), 258 (1), 227 (3), 186 (5), 160 (4), 45 (49), 31 (100); Found : C, 
75.3; H, 9.04. C ^ H ^ O ^ H p  requires C, 75.0; H, 9.21%.
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3-Methoxyoestr-17-one (13)
Method 1
A solution of chromium trioxide (96 mg, 0.96mM) and sulphuric acid solution (0.2 
cm3 of 2N) in water (0.2 cm3) was added to a stirred solution of 3-methoxyoest- 
r-17$-ol (12) (250 mg, 0.87mM) in acetone (5 cm3). The reaction mixture was stirred 
at room temperature for 6 h. Water (10 cm3) was added and the reaction mixture 
extracted with methylene chloride (2 x 20 cm3). The organic extracts were dried over 
magnesium sulphate, concentrated in vacuo and purified by column chromatography 
eluting with ethyl acetate-petrol (1:9) to give the ketone (13) (50 mg, 20%) as a white 
solid, m.p. 176-177°C (Rf = 0.29, ethyl acetate-petrol (1:9)); \)max (NUJOLVcm1 
1736 s (C=0), 1608 s (C-C, Ar), 1579 s (C-C, Ar), 1503 s (C-C, Ar), 1245 (0-CH3), 
846 (C-H, Ar), 823 (C-H, Ar); 8 H (270 MHz, CDC13) 7.21 (1H, d, / 2,i 8 .6  Hz, 
H-C(2)), 6.72 (1H, dd, J lA 2.8, J ia 8 .6  Hz, H-C(l)), 6.65 (1H, d, 74fl 2.8 Hz, H-C(4)),
3.78 (3H, s, OCH3), 2.89 (2H, t, / 16>15 4.3 Hz Hr C(16)), 0.91 (3H, s, H3C(18)); 8 c 
(CDC13) 220.69 (C-17), 157.52 (C-3), 137.62 (C-10), 131.93 (C-5), 126.20 (C-l), 
113.80 (C-2), 111.48 (C-4); mlz (E.I.) 284 (M+, 100%), 256 (4), 227 (12), 199 (39), 
160 (38), 91 (22), 57 (40); Found : C, 80.7; H, 8.55, C19H240 2  requires C, 80.3; H, 
8.45%.
Method 2
Pyridinium chlorochromate, PCC, (207 mg, 0.96mM) was added to a stirred solution 
of 3-methoxyoestr-17$-ol (12) (250 mg, 0.87mM) in methylene chloride (5 cm3). The 
reaction mixture was stirred at room temperature under nitrogen for 4h. Water (5 
cm3) was added, the organic layer separated, and the aqueous layer extracted with 
diethyl ether ( 2 x 1 0  cm3). The combined organic extracts were dried over 
magnesium sulphate, evaporated in vacuo, and purified by column chromatography, 
eluting with ethyl acetate-petrol (1:4) to give the ketone (13) (97 mg, 39%) as a white
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solid, m.p. 176-177°C (Rf = 0.29, ethyl acetate-petrol (1:9)).
Method 3
3-Methoxyoestr-17$-ol (12) (300 mg, 1.05mM), TPAP (18 mg, 5 mol%) and NMO 
(184 mg, 1.57mM) were stirred together in methylene chloride (5 cm3), in the 
presence of ground molecular sieves, at room temperature for 12h. Silica gel was 
added to the reaction mixture and the solvent removed in vacuo. Column 
chromatography, eluting with ethyl acetate-petrol (1:4) gave the ketone (13) (231 mg, 
77%) as a white solid, m.p. 176-177°C (Rf = 0.29, ethyl acetate-petrol (1:9)).
3-Methoxy-17fi-ethyloestr-17(19)-ene (14)
Sodium hydride (3.00 g, 125mM) was added to dimethyl sulphoxide (150 cm3), 
freshly distilled and dried, and stirred for 45 min at 75°C, under nitrogen to give a 
light green solution. After cooling to room temperature ethyl triphenylphosphonium 
bromide (46.4g, 125mM) in dimethyl sulphoxide (100 cm3) was added to give a red 
solution, followed by 3-methoxyoestr-17-one (13) (9.60 g, 25.0mM) in dimethyl 
sulphoxide (50 cm3). The reaction mixture was warmed to 55-60°C and stirred under 
nitrogen for 2h. After cooling the reaction mixture was poured into saturated brine 
(500 cm3). The solid was filtered off, washed with water (400 cm3) and dissolved in 
methylene chloride (300 cm3). Water (100cm3) was added and the organic layer 
separated and washed with water ( 1 0 0  cm3), dried over magnesium sulphate and 
concentrated in vacuo. The solid was dissolved in methylene chloride (30 cm3) and 
applied to a silica column eluting with methylene chloride and the solvent evaporated 
in vacuo. Purification by recrystallisation from methanol gave the alkene (14) (8.12g, 
82%) as a white solid, m.p. 76-77°C (Rf = 0.84 ethyl acetate-petrol (1:9)); \)max 
(NUJOLVcm' 1 1676 (C=C), 1610 s (C-C, Ar), 1574 s (C-C, Ar), 1254 (O-CH3), 872 
(C-H, Ar), 812 (C-H, Ar); 5H (400 MHz, CDC13) 7.21 (1H, d, / 2fi 8.3 Hz, H-C(2)), 
6.71 (1H, dd, J lA 2.8, J ia  8.5 Hz, H-C(l)), 6.63 (1H, d, J4A 2.8 Hz, H-C(4)), 5.15 
(1H, qt, / 20.,6' 1.8, 20,16" 2.1,7 2o,2 i 7.0 Hz, H-C(20)), 3.78 (3H, s, OCH3), 1.69 (3H,
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dt, J2\,\6' 1*8, / 2U6" 2.1, / 21 2 0  7.0 Hz, H3C(21)), 0.91 (3H, s, H3C(18)); m/z (E.I.)
296 (M+, 6 %), 262 (24), 215 (5), 183 (22), 154 (100), 76 (18); Found : C, 84.9; H, 
9.60. C ^H ^O  requires C, 85.1; H, 9.46%.
3 -Methoxy-17$-(1-hydroxy ethyl)oestrane (15)
To a stirred solution of the alkene (14) (250 mg, 0.84mM) in THF (10 cm3) was added 
diborane in THF (1.70 cm3,0.90mM) under nitrogen. After stirring at room 
temperature, for lh, 10% sodium hydroxide solution (7 cm3) was added dropwise. 
After cooling to 0°C, 30% hydrogen peroxide (4.50 cm3) was added dropwise and the 
reaction mixture stirred for a further lh at 0°C under nitrogen. The reaction mixture 
was then allowed to separate and the THF layer treated with sodium metabisulphite 
solution (5 cm3), washed with water (2 x5  cm3) and dried over anhydrous sodium 
sulphate. The solvent was evaporated at reduced pressure and purification by column 
chromatography, eluting with ethyl acetate-petrol (3:7) gave the 20-hydroxyl (15)
(212 mg, 80%) as a white solid, m.p. 105-106°C (Rf = 0.32, ethyl acetate-petrol (3:7); 
uma* (NUJOLVcm1 3483 br (OH), 1602 s (C-C,Ar), 1578 s (C-C, Ar), 1226 (0-CH3), 
897 (C-H, Ar), 814 (C-H, Ar); 5H (270 MHz, CDC13) 7.21 (1H, d, J2A 8.4 Hz,
H-C(2)), 6.71 (1H, dd, J h 4  2.7, 8 .6  Hz, H-C(l)), 6.63 (1H, d, JA%X 2.7 Hz, H-C(4), 
3.80-3.68 (1H, m, H-C(20)), 3.78 (3H, s, OCH3), 1.26 (3H, d, J2h2Q 6.2 Hz, H3C(21)), 
0.70 (3H, s, H3C(18)); 5c (400 MHz, CDC13) 157.36 (C-3), 137.95 (C-10), 132 .74 
(C-5), 126.20 (C-l), 113.70 (C-2), 111.38 (C-4), 70.31 (C-20); m/z (E.I.) 314 (M+, 
100%), 296 (9), 286 (4), 227 (18), 119 (13), 173 (40), 57 (55); Found : C, 79.5; 9.78. 
C2 iH3o0 2.V6 H20  requires C, 79.5; H, 9.46%.
3-Methoxyoestra-2(3)J(10)-dien-17$-ol(16)
Distilled ether (20 cm3) and liquid ammonia (50 cm3) were stirred at room 
temperature using an overhead mechanical stirrer and a cold finger for 10 min. To 
this was added lithium shot (1.5 g) to give a blue solution which was stirred for 5 min 
after which 3-methoxyoestra-17$-ol (12) (1.0 g, 3.50mM) in ether (20 cm3) was added
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dropwise and the reaction mixture stirred for a further 90 min. Ethanol (15 cm3) was 
added dropwise, with extreme caution, followed by addition of water (40 cm3) 
dropwise to quench, after allowing half of the ammonia to evaporate off. The 
reaction mixture was extracted with methylene chloride (60 cm3) washed with water 
( 2 x 1 5  cm3), dried over magnesium sulphate and concentrated in vacuo. Purification 
by column chromatography, eluting with ethyl acetate-petrol (1:9) gave the diene (16) 
(630 mg, 63%) as a white solid, m.p. 96-97°C (Rf = 0.48, ethyl acetate-petrol (3:7)); 
\)max (NUJOLVcm1 3344 br (OH), 1696 (C=C), 1665 (C=C), 1225 (0-CH3); 6 H (270 
MHz, CDC13) 5.83 (1H, s, H-C(2)), 3.67 (1H, t, / 17>16 8.5 Hz, H-C(17)), 3.49 (3H, s, 
OCH3), 0.81 (3H, s, H3C(18)); mJz (E.I.) 288 (M+, 56%), 260 (4), 227 (3), 201 (5), 
122(100), 85 (33), 57 (81).
Oestr-5(10)~en-17$-ol-3-one (17)
The protected enol (16) (100 mg, 0.35mM) and oxalic acid (3 cm3 of 0 .1M solution) 
were stirred together in methanol (10 cm3) at 30°C for 40 min. Methylene chloride 
( 2 0  cm3) was added to the reaction mixture and the organic layer washed with 
saturated sodium bicarbonate solution ( 1 0  cm3) and water ( 2  x 1 0  cm3), dried over 
anhydrous sodium sulphate and concentrated in vacuo. Recrystallisation from ethyl 
acetate gave the C(3) ketone (17) (80 mg, 84%) as a white solid, m.p. 176-177°C 
(Rf = 0.26, ethyl acetate-petrol (3:7)); umax (NUJOLVcm1 3385 br (OH), 1675 s 
(0=0), 1640 (C=C); 5H (270 MHz, CDC13) 3.69 (1H, t, / 17tl6 8.3 Hz, H-C (17)), 0.77 
(3H, s, H3C (18)); m!z (Low eV E.I.) 274 (M+, 100%), 256 (16), 230 (18), 110 (6 ).
3-Methoxy-19-nor-pregna-2(3),5( 10)-dien-20$-ol (18)
Distilled ether (50 cm3) and liquid ammonia (100 ml, approx. 50 mol. equiv) were 
stirred at room temperature using a overhead mechanical stirrer. To this was added 
lithium shot (4.0 g) to give a blue solution. After stirring for 5 min 3-methox- 
y-17(3-(1 -hydroxyethyl)oestrane (15) (3.9 g, 12.4mM) in ether (50 cm3) was added 
dropwise and the reaction mixture stirred for a further 90 min. Then, ethanol (50 cm3)
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was added dropwise, with extreme caution, followed by water (50 cm3) to quench, 
after allowing half of the ammonia to evaporate off. The reaction mixture was 
extracted with methylene chloride (2 x 100 cm3), washed with water (2 x 40 cm3), 
dried over magnesium chloride and concentrated in vacuo. The product was isolated 
crude and used as thus in the next step, the synthesis of 19-nor-pregn-5( 10)-e- 
n-20$-ol-3-one (19).
Crude yield of 3-methoxy-19-nor-pregna-2(3)J(10)-dien-20$-ol (18) was 5.5g. (Rf = 
0.64 ethyl acetate-petrol (3:7)), 8 H (270 MHz, CDC13) 5.88-5.80 (1H, m, H-C(2)),
3.78 (3//, s, OCH3), 3.74-3.68 (1H, m, H-C(20)), 0.82 (3H, s, H3C(18)).
19-Nor-pregn-5(10)-en-20$-ol-3-one (19)
3-Methoxy-19-nor-pregna-2(3), 5(10)-dien-20$-ol (18) (100 mg, 0.32mM) and oxalic 
acid (3 cm3 of 0.1 M solution) were stirred in methanol (10 cm3) at 30°C for 45 min. 
Water (10 cm3) was added to the reaction mixture and it was extracted with 
methylene chloride ( 2x15  cm3). The organic extracts were combined and washed 
with sodium bicarbonate solution (10 cm3 of 2N), and water (2 x 10 cm3), dried over 
anhydrous sodium sulphate and concentrated in vacuo. The residue was purified by 
column chromatography, eluting with ethyl acetate-petrol (1:9) to give the A5,10 
alkene (19) (75 mg, 79%) as a white solid, m.p. 176-177°C (Rf = 0.32, ethyl 
acetate-petrol (3:7)); vmax (NUJOLVcm1 3426 br (OH), 1698 s (C=0), 1661 (C=C); 
SH (270 MHz, CDC13) 3.78-3.66 (1H, m, H-C(20)), 1.23 (3H, d, J2i,2o 6.4 Hz, 
H3C(21)), 0.69 (3H, s, H3C(18)); mlz (low eV E.I.) 302 (M+, 100%), 284 (6 ), 257 
(13), 243 (12), 215 (3), 119 (5); Found : C, 75.7; H, 9.78. C2oH3o02.5/6 H20  requires 
C, 75.7; H, 9.46%.
Further eluting with ethyl acetate-petrol (1:9) gave 19-nor-pregn-4(5)-e- 
n-20$-ol-3-one (19A) (10 mg, 10%) as a white solid, m.p. 95-97°C (Rf = 0.15, ethyl 
acetate-petrol (3:7)); \)max (NUJOLVcm1 3421 br (OH), 1656 s (C=0), 1611 (C=C); 
5h (270 MHz, CDC13) 5.83 (1H, s, H-C(4)), 3.78-3.66 (1H, m, H-C(20)), 1.25 (3H, d,
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y2i,20 6.2 Hz, H3C(21)), 0.73 (3H, s, H3C(18)); 8C (400 MHz, CDC13) 200.02 (C-3),
166.98 (C-5), 124.33 (C-4), 70.01 (C-20); m/z (E.I.) 302 (M+, 38%), 284 (50), 269 
(11), 217 (100), 110 (94), 57 (57); Found : C, 77.3; H, 10.0. C20H3o0 2 .V2  H20  
requires C, 77.2; H, 9.65%.
3-Ethylenedioxy-l9-nor-pregn-5( 10)-en-20f>-ol (20)
19-Nor-pregn-5(10)-en-20$-ol-3-one (19) (1.70 g, 5.63mM), ethylene glycol (3.14 
cm3,56.3mM) and a catalytic amount of p-TSA (20 mg) were stirred together in 
toluene (100 cm3) at 70°C for 2h with a Dean and Stark trap. After this the reaction 
mixture was diluted with methylene chloride (100 cm3), washed with water (2 x 50 
cm3) and dried over anhydrous sodium sulphate. The solvent was removed in vacuo 
and the residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (1:4) to give the acetal (20) (932 mg, 48%) as a white solid, m.p. 
124-125°C (Rf = 0.41, ethyl acetate-petrol (3:7)), \)max (NUJOLVcm1 3497 sh (OH), 
1672 (C=C), 1107 s (C-O); 5H (200 MHz, CDC13) 4.01-3.89 (4H, m, OCH2CH20), 
3.68 (1H, dq, 720f21 6.1, J20A1 10.3 Hz, H-C(20)), 1.25 (3H, d, y21>20 6.1 Hz, H3C(21)), 
0.68 (3H, s, H3C(18)); 5c (400 MHz, CDC13) 128.95 (C-10), 125.07 (C-5), 107.79 
(C-3), 69.83 (C-20), 63.92 (OCH2), 63.72 (OCH2); m/z (low eV E.I.) 346 (M+, 57%), 
284 (22), 115 (9), 99 (100), 63 (7), 55 (10); Found : C, 76.1; H, 10.2. C22H340 3 
requires C, 76.3; H, 9.83%.
20-Ethylenedioxypregnenolone (23)
Pregnenolone (2.0 g, 6.3mM), p-toluenesulphonic acid (60 mg, 0.3mM) and ethylene 
glycol (70 cm3) were placed in a rbf. Ethylene glycol and water were co-distilled 
from the reaction vessel at 60±2°C and 1 mmHg pressure over a two hour period. The 
reaction mixture was basified by the addition of saturated sodium hydrogen carbonate 
solution ( 2 0  cm3) and the white solid filtered off, washed with water ( 2  x 1 0 0  cm3) 
and dried under vacuum. Purification by recrystallisation from ethyl acetate-petrol 
gave the acetal (23) (1.32 g, 58%) as a white solid, m.p. 155-157°C (lit.87 156-158°c),
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(Rf = 0.38, ethyl acetate-petrol (1:2)); \)max (NUJOLVcm' 1 3460 br (OH), 1631 (C=C), 
1067 s (C-O); 5h (270 MHz, CDC13) 5.48 (1H, d, JeJ 5.0 Hz, H-C(6 )), 3.95-3.84 (4H, 
m, OCH2CH20), 3.54-3.46 (1H, m, ^ -0 (3 ) ) ,  1.29 (3H, s, H3C(21)), 1.03 (3H, s, 
H3C(19)), 0.65 (3H, s, H3C(18)); mlz (C.I.) 361 ([M+ + 1], 6 %), 343 (1), 317 (2), 299 
(4), 281 (1), 87(100).
3$-Acetoxy-20-ethlenedioxypregn-5(6)-ene (24)
To a stirred solution of pregnenolone (20 g, 63.3mM), triethylamine (10.6 cm3, 
76.2mM) and DMAP (770 mg, 6.3mM) in THF (500 cm3) was added acetic anhydride 
(60 cm3, 636mM). The reaction mixture was stirred at room temperature for 90 min. 
The mixture was poured in water, saturated with sodium chloride, (500 cm3), and the 
resulting white solid filtered off, washed with water ( 2 0 0  cm3) and dissolved in 
methylene chloride (500 cm3). The organic solution was washed with water (2 x 100 
cm3), dried over magnesium sulphate and concentrated in vacuo to give the 
3$-acetate (crude yield, 23.lg) as a white solid, (Rf = 0.65, ethyl acetate-toluene 
(1:2)). The 3$-acetate was used crude in the next step.
Crude 3$-acetoxypregn-5(6)-en-20-one (23.1 g, 64.5mM), ethylene glycol (35.9 cm3, 
645mM) and p-TSA (1.23 g, 6.45mM) were dissolved in triethylorthoformate (200 
cm3) and the mixture refluxed for 2 V2 h. After cooling the reaction mixture was 
poured into water, saturated with NaCl (500 cm3), and the resulting solid filtered off 
and dissolved in methylene chloride (500 cm3). The organic solution was washed 
with water ( 2  x 2 0 0  cm3), dried over magnesium sulphate and concentrated in vacuo. 
The residue was recrystallised from methanol to give the 20-acetal (24) (27.3 g, 93% 
overall) as a white solid, m.p. 123-124°C (Rf = 0.55, methanol-methylene 
chloride-hexane (2:3:13)); \)max (NUJOLVcm' 1 1727 s (C=0), 1645 (C=C), 1270 s 
(C-O); SH (270 MHz, CDC13) 5.24-5.13 (1H, m, Ha -C(3)), 4.01-3.89 (4H, m, 
0C H 2CH20), 3.88-3.82 (1H, m, H-C(6 )), 2.01 (3H, s, H3CCO), 1.26 (3H, s,
H3C(21)), 1.02 (3H, s, H3C(19)), 0.75 (3H, s, H3C(18)).
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20-Ethylenedioxy-5a.6(x-epoxypregnan-3$-ol (25)
To a stirred solution of 20-ethylenedioxypregnenolone (23) (1.89 g, 5.0mM) in 
methylene chloride (40 cm3) was added 80% m-chloroperoxybenzoic acid (1.89 g, 
6.0mM). The reaction mixture was stirred at room temperature under nitrogen for 45 
min. After which 25% sodium sulphite solution and 25% sodium bicarbonate 
solution were added cautiously, until the starch-iodide test gave a negative result.
The organic layer was separated and washed with sodium bicarbonate (10 cm3 of IN) 
and water ( 2  x 1 0  cm3), dried over anhydrous sodium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (1:2) to give the epoxide (25) (1.69 g, 90%) as a white solid, m.p. 
198-199°C (Rf = 0.21, ethyl acetate-petrol (3:10)); umax (NUJOLVcm' 1 3442 sh (OH), 
1254 (C-O); 5h (270 MHz, CDC13) 4.00-3.82 (5H, m, Ha -C(3) + OCH2CH20 ), 2.90 
(1H, d, J6J 4.4 Hz, Hp-C(6 )), 1.28 (3H, s, H3C(21)), 1.06 (3H, s, H3C 19)), 0.71 (3H, 
s, H3C(18)); m/z (CL) 377 ([M+ + 1], 8 %), 359 (7), 315 (3), 285 (3), 95 (4), 87 (100); 
Found : C, 73.2; H, 9.77. C23H360 4 requires C, 73.4; H, 9.57%.
3$-Acetoxy-20-ethylenedioxy-5a-6a-epoxypregnane (26)
To a stirred solution of 3$-acetoxy-20-ethylenedioxypregnen (24) (24.12 g, 0.06M) in 
methylene chloride (300 cm3) was added, portionwise, 80% m-chloroperoxybenzoic 
acid (15.5 g, 0.072M). The reaction mixture was stirred at room temperature for lh. 
After this 25% sodium sulphite solution and 25% sodium bicarbonate solution were 
added to the reaction mixture with stirring until the starch-iodide test gave a negative 
result. The organic layer was separated and washed with sodium bicarbonate solution 
(50 cm3 of IN) and water (2 x 50 cm3), dried over magnesium sulphate and 
concentrated in vacuo. Purification by recrystallisation from ethyl acetate-petrol gave 
the epoxide (26) (24.31 g, 97%) as a white solid, m.p. 184-186°C (Rf = 0.42, ethyl 
acetate-petrol (1:3)); t)max (NUJOLVcm1 1729 s (C=0), 1248 (C-O), 1047 (C-O); 5H 
(200 MHz, CDC13) 5.02-4.85 (1H, m, Ha -C(3)), 4.01-3.83 (4H, m, 0C H 2CH20 ), 2.90
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(1H, d, J llA6 4.76 Hz, H-C(17)), 1.29 (3H, s, H3C(21)), 1.09 (3H, s, H3C(19)), 0.71 
(3H, s, H3C(18)).
20-Ethylenedioxypregnan-3$,5a-diol (27)
To a stirred suspension of lithium aluminium hydride (6 .8  g, 0.18M) in THF (500 
cm3) was added the epoxide (26) (25.0 g, 0.06M), dropwise in THF (200 cm3). The 
reaction mixture was stirred with overhead mechanical stirring at room temperature, 
under nitrogen, for 24h. 1% Potassium hydroxide solution was added cautiously to 
quench, while stirring. The resulting white precipitate was filtered through celite. The 
filtrate was diluted with methylene chloride (500 cm3) and washed with water (2 x 
1 0 0  cm3), dried over anhydrous sodium sulphate and evaporated under reduced 
pressure. The residue was recrystallised from ethyl acetate-petrol to give the diol (27) 
(21.25 g, 94%) as a white solid, m.p. 203-205°C (Rf = 0.24, ethyl acetate); 
DmaxCNUJOLVcm- 1 3389 sh (OH), 3296 br (OH), 1047 (C-O); 6 H (270 MHz, CDC13)
4.04-3.80 (5H, m, H ^C O ) + OCH2CH20), 1.29 (3H, s, H3C(21)), 0.99 (3H, s, 
H3C(19)), 0.75 (3H, s, H3C(18)); m!z (Cl.) 379 ([M+ + 1], 6 %), 361 (7), 343 (1), 317
(1), 301 (4), 159 (1), 87 (100), 69 (10).
3$-Acetoxy-20-ethylenedioxypregnan-5a-ol (28)
The diol (27) (21.0 g, 56.0mM) was added to a stirred solution of acetic anhydride 
(8.4 cm3, 89.0mM) in pyridine (300 cm3). The reaction mixture was stirred at room 
temperature for 24h. After this it was poured into saturated brine (1000 cm3) and the 
white solid filtered off. The solid was washed with dil. HC1 and water and then 
dissolved in methylene chloride (200 cm3). Water (100 cm3) was added, the organic 
layer separated and washed with water ( 1 0 0  cm3), dried over anhydrous sodium 
sulphate and concentrated in vacuo. The residue was recrystallised from methanol to 
give 3$-acetoxy-20-ethylenedioxypregnan-5a-ol (28) (22.05 g, 94%) as a white solid, 
m.p. 200-201°C (Rf = 0.19, ethyl acetate-petrol (1:3)); [a]22^  = +4.1° (C = 0.462 in 
CH2Cl2); \)max (NUJOLVcm' 1 3465 br (OH), 1726 s (C=0), 1247 (C-O); SH (270
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MHz, CDC13) 5.28-5.14 (1H, m, H^CO)), 4.08-3.81 (4H, m, 0CH 2CH20), 2.02 (3H, 
s, H3CCO), 1.30 (3H, s, H3C(21)), 1.02 (3H, s, H3C(19)), 0.77 (3H, s, H3C(18)); 5C 
(CDC13) 170.61 (C=0), 111.92 (C-20), 74.94 (C-5), 70.84 (C-3), 65.15 + 63.15 
(0CH 2CH20); m h  (C.I.) 421 ([M+ + 1], 5%), 403 (2), 361 (5), 343 (3), 299 (4), 251
(2), 159 (1), 87 (100); Found : C, 69.2; H, 9.41. C ^H ^O s.3^  H20  requires C, 69.2;
H, 9.57%.
3$-Acetoxypregnan-5a-ol-20-one (29)
Aqueous sulphuric acid solution (10 ml of IN) was added dropwise to a stirred 
solution of the acetal (28) (3.0 g, 7.14mM) in acetone (200 cm3). The reaction 
mixture was stirred at room temperature for 30 mins. The mixture was concentrated 
at reduced pressure and water (50 cm3) was added. The solution was extracted with 
methylene chloride ( 1 0 0  cm3) and the organic layer washed with sodium carbonate 
solution (20 ml of IN) and water (2 x 30 cm3), dried over anhydrous sodium sulphate 
and concentrated in vacuo. The residue was recrystallised from ethyl acetate to give 
the ketone (29) (2.23 g, 83%) as white needles, m.p. 199-200°C (Rf = 0.17, ethyl 
acetate-petrol (1:3)); \)max (NUJOLVcm1 3419 br (OH), 1725 s (C=0), 1682 s 
((20)C=O), 1243 (C-O); 8 H (270 MHz, CDC13) 5.20-5.10 (1H, m, H^CO )), 2.55 (1H, 
t, / 17 il6  8.1 Hz, Ha -C(17)), 2.11 (3H, s, H3C(21)), 2.02 (3H, s, H3CCO), 1.00 (3H, s, 
H3C(19)), 0.60 (3H, s, H3C(18)); 5C (400 MHz, CDC13) 209.63 (C-20), 170.65 (C=0), 
74.81 (C-5), 70.75 (C-3); mlz (C.I.) 377 ([M+ + 1], 38%), 359 (32), 336 (10), 317 (25), 
299 (100), 281 (10); Found : C, 72.7; H, 9.68. H20  requires C, 72.5; H,
9.59%.
(E)-3&-Acetoxy-5,10-secopregn-l(10)-ene-5,20-dione (30)
Ceric ammonium nitrate (326 mg, 0.60mM) in water (1 cm3) was added to 
3$-acetoxy-20-ethylenedioxypregnan-5a-ol (28) (100 mg, 0.24mM) stirred at 80°C in 
acetonitrile (2 cm3), to give a bright red colour. The reaction mixture was stirred at 
80°C for 3 min, after which it had become decolourised. It was immediately poured
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into ice/25% sodium bicarbonate solution (10 cm3) and extracted with methylene 
chloride ( 3x 10  cm3), dried over anhydrous sodium sulphate, and evaporated in 
vacuo. The residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (1:5). The first elute gave 3$-acetoxypreg nan-5 ap-ol-20-one (29) (37 
mg, 37%) as a white solid, m.p. 199-200°C (Rf = 0.17, ethyl acetate-petrol (1:3)).
The next eluate gave (E)-3$-acetoxy-5,10-secopregn-l(10)-ene-5,20-dione (30) (22 
mg, 22%) as a white solid, m.p. 208-209°C (Rf = 0.36, ethyl acetate-petrol (1:4); 
[a]22,, = + 62.5° (C = 1 .1 2 , CH2C12); umax (NUJOLVcnV1 1732 s (C=0), 1714 s 
((20)C=O), 1698 ((5)C=0), 1645 (C=C), 1246 (C-O); S H (270 MHz, CDC13)
5.48-5.32 (1H, m, Ha -C(3)), 4.90-4.80 (1H, m, HE-C(1)), 2.12 (3H, s, H3C(21)), 2.04 
(3H, s, H3CCO), 1.75 (3H, s, H3C(19)), 0.66 (3 H, s, H3C(18)); m/z (C.I.) 375 ([M+ + 
1], 28%), 259 (10), 315 (6 8 ), 297 (100), 281 (10), 260 (12), 159 (10), 81 (15); Found: 
C, 74.1; H, 9.43. C23H340 4 requires C, 73.8; H, 9.09%.
(E)-3fi-Hydroxy-5,10-secopregn-l( 10)-ene-5,20-dione (31)
(E)-3$-Acetoxy-5,10-secopregn-l(10)-ene-5,20-dione (30) (500 mg, 1.20mM) was 
added to a stirred solution of potassium carbonate (500 mg, 3.62mM) in methanol (10 
cm3). The reaction mixture was stirred at room temperature for 30 min. Water (15 
cm3) was added and the reaction mixture extracted with methylene chloride ( 2  x 2 0  
cm3). The combined organic extracts were washed with dil. HC1 (10 cm3) and water 
( 1 0  cm3), dried over anhydrous sodium sulphate and concentrated in vacuo. 
Purification by column chromatography, eluting with ethyl acetate-petrol (1:1) gave 
the 3$-hydroxy dione (31) (449 mg, 87%) as a white solid, m.p. 168-169°C (Rf = 0.32, 
ethyl acetate-petrol (1:1)); [a]22D = + 40.0° (C=0.70, ethyl acetate); vmax 
(NUJOLVcm ' 1 3370 br (OH), 1694 s ((2 0 )0 0 ), 1679 s ((5)0=0), 1664 (C=C); 8 H 
(270 MHz, CDC13) 4.89-4.80 (1H, m, HE-C(1)), 4.48-4.34 (1H, m, ^ -0 (3 ) ) ,  2.12 
(3H, s, H3C(21)), 1.74 (3H, s, H3C(19)), 0.66 (3H, s, H3C(18)); m/z (C.I.) 333 ([M+ + 
1], 51%), 3.15 (100), 297 (99), 279 (11), 271 (18), 257 (18), 231 (5), 85 (30); Found :
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C, 75.5; H, 9.76. C21H32O3 requires C, 75.9; h, 9.64%. 
3$-Acetoxy-20-ethylenedioxy-5,10-secopregn-l(10)-en-5-one (32 and 33)
Method 1
A stirred suspension of 3$-acetoxy-20-ethylenedioxypregnan-5a-ol (28) (5.0 g,
11.9mM), yellow mercuric oxide (8.0 g, 37.0mM) and iodine (8.0 g, 31.5mM) in 
carbon tetrachloride (80 cm3) was irradiated for 2.5 h. at room temperature with a 
500W tungsten lamp. The solid was removed by filtration and the filtrate washed with 
aqueous sodium thiosulphate solution (30 cm3), aqueous sodium bicarbonate solution 
(30 cm3) and water (2 x 20 cm3), dried over magnesium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel, eluting 
with ethyl acetate-petrol (1:19). The first eluate gave
(Z)-3$-acetoxy-20-ethylenedioxy-5,10-secopregn-l(10)-en-5- one (33) (407 mg, 8 %) 
as a white solid, m.p. 138-139°C (Rf = 0.50, ethyl acetate-petrol (1:4)); \)max 
(NUJOLVcm' 1 1727 s (C=0), 1699 s ((5)C=0), 1647 (C=C), 1245 (C-O); 5H (270 
MHz, CDCI3) 5.46-5.33 (1H, m, Hz-C(l)), 5.32-5.21 (1H, m, Ha -C(3)), 4.06-3.84 
(4H, m, 0CH 2CH20 ), 2.02 (3H, s, H3CCO), 1.74 (3H, s, H3C(19)), 1.28 (3H, s, 
H3C(21)), 0.59 (3H, s, H3C(18)); mlz (C.I.) 419 ([M+ + 1], 7%), 403 (2), 375 (2), 360 
(10), 341 (5), 297 (10), 269 (5), 87 (100).
The next eluate afforded a mixture of products (2.05 g,) which upon recrystallisation 
from ethyl acetate-petrol gave (E)-3$-acetoxy-20-ethylenedioxy-5,10-secopreg- 
n-l(10)-en-5-one (32) (695 mg, 14%) as a white solid, m.p. 133-135°C (Rf = 0.38, 
ethyl acetate-petrol (1:4)); umax (NUJOLVcm 1 1729 s (C=0), 1702 s ((5)C=0), 1643 
(C=C), 1243 (C-O); 5H (270 MHz, CDC13) 5.48-5.32 ( 1H, m, Ha-C(3)), 4.92-4.80 
(1H, m, He-C(1)), 2.02 (3H, s, H3CCO), 1.75 (3H, s, H3C(19)), 1.30 (3H, s, H3C(21)), 
0.61 (3H, s, H3C(18)); mlz (C.I.) 419 ([M+ + 1] missing), 375 ([M+ + 1 - CH3CHO], 
30%), 359 (11), 341 (3), 315 (67), 299 (47), 297 (100), 279 (8 ), 122 (11), 81 (14);
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Found : C, 70.9; H, 9.25. C^BjgC^.1^  H20  requires C, 71.0; H, 9.11%; and starting 
material, 3$-acetoxy-20-ethylenedioxypregnan-5a-ol (28) (410 mg, 8 %).
Further eluates gave (E)-3$-acetoxy-5,10-secopregn-l(10)-ene-5,20-dione (30)(1.14 
g, 26%) as a white solid, m.p. 208-209°C (Rf = 0.36, ethyl acetate-petrol (1:4)); [a]22D 
= + 62.5° (C = 1.12, CH2C12); \)max (NUJOLVcm' 1 1732 s (0=0), 1714 s ((20)C=O), 
1698 ((5)C=0), 1645 (C=C), 1246 (C-O); 5H (270 MHz, CDC13) 5.48-5.32 (1H, m, 
4.90-4.80 (1H, m, HE-C(1)), 2.12 (3H, s, H3C(21)), 2.04 (3H, s, H3CCO), 
1.75 (3H, s, H3C(19)), 0.66 (3H, s, H3C(18)); m/z (C.I.) 375 ([M+ + 1], 28%), 359 
(10), 315 (6 8 ), 297 (100), 281 (10), 260 (12), 159 (10), 81 (15); Found : C, 74.1; H, 
9.43. requires C, 73.8; H, 9.09%.
Method 2
To a refluxing solution of lead tetraacetate (232 mg, 0.52mM), recrystallised from 
acetic acid and sucked dry under vacuum over phosphoric acid, in toluene (3 cm3) 
was added a solution of 3$-acetoxy-20-ethylenedioxypregnan-5a-ol (28) (200 mg, 
0.48mM) in toluene (2 cm3). Calcium carbonate (200 mg) was added and the reaction 
mixture was refluxed for 48 h after which starch-iodide paper indicated that there was 
no oxidant left. After cooling the reaction mixture was diluted with water (5 cm3) and 
extracted with ether (2x15 cm3). The combined organic extracts were dried over 
magnesium sulphate, concentrated in vacuo, and purified by column chromatography, 
eluting with ethyl acetate-petrol (1:9) to give (Z)-3$-acetoxy-20-ethylenediox- 
y-5,10-secopregn-l(10)-en-5-one (33) (19 mg, 10%) as a white solid, m.p. 138-140°C 
(Rf = 0.50, ethyl acetate-petrol (1:4)).
Preparation o f  5a,6a-epoxypregnan-3$-ol-20-one (34)
50% m-Chloroperoxybenzoic acid (13.1 g, 37.9mM) was slowly added to a stirred 
solution of pregnenolone (10 g, 31.6mM) in methylene chloride (200 cm3). The 
reaction mixture was stirred at room temperature under nitrogen for lh. 25% Sodium
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sulphite solution and 25% sodium bicarbonate solution were added cautiously, with 
stirring, until the starch-iodide test gave a negative result. The solution was then 
extracted with methylene chloride (2 x 150 cm3), and the organic extracts washed 
with water (2 x 50 cm3), dried over anhydrous sodium sulphate and concentrated in 
vacuo. Column chromatography on silica gel, eluting with ethyl acetate-petrol (1:2) 
gave the epoxide (34) (10.3 g, 98%) as a white solid, m.p. 177-178°C (Rf = 0.17, ethyl 
acetate-petrol (1:2)); t)max (NUJOLVcm"1 3438 br (OH), 1684 (C=0), 1230; 8 H (270 
MHz, CDC13) 4.01-3.82 (1H, m, Ha -C(3)), 2.94 (1H, d, J6J 5.0 Hz, Hp-C(6 )), 2.51 
(1H, t, J  8.4 Hz, H-C(17)), 2.11 (3H, s, H3C(21)), 1.06 (3H, s, H3C(19)), 0.55 (3H, s, 
H3C(18)); m/z (E.I.) 332 (M+, 20%), 314 (10), 299 (6 ), 156 (27), 71 (38), 43 (100); 
Found : C, 75.3; H, 9.63. C21H320 3 requires C, 75.9; H, 9.64%.
Data fo r  pregnenolone; m.p. 190-192°C (Rf = 0,33, ethyl acetate-petrol (1:2)); [cx]20d 
= + 33.3° (C = 1.17 in EtOH); vmax (NUJOLVcm*1 3507 br (OH), 1684 (C=0), 1643 
(C=C); 8 h (270 MHz, CDC13) 5.36-5.34 (1H, m, H-C(6 )), 3.58-3.48 (1H, m, 
Ha-CQ)), 2.54 (1H, t, J  8.9 Hz, H-C(17)), 2.12 (3H, s, H3C(21)), 1.01 (3H, s, 
H3C(19)), 0.63 (3H, s, H3C(18)); mlz (E.I.) 316 (M+, 41%), 298 (29), 283 (23), 213 
(17), 105 (30), 57 (54), 43 (100).
Pregna-3$-5a-20$-triol (35)
Method 1
To an overhead mechanically stirred solution of the epoxide (34) (10.5 g, 31.6mM) in 
THF (300 cm3) was added, cautiously, lithium aluminium hydride (5.8 g, 158mM). 
The reaction mixture was refluxed under nitrogen for 5h and stirred at room 
temperature for a further 3h. It was then quenched by the addition of 1% potassium 
hydroxide solution. The resulting white precipitate was filtered through celite. The 
filtrate was extracted with methylene chloride. The organic extracts were washed 
with water ( 2  x 50 cm3), dried over anhydrous sodium sulphate and concentrated in
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vacuo. Recrystallisation from ethyl acetate gave the triol (35) (8.7 g, 82%) as a white 
solid, m.p. 229-230°C (Rf = 0.48, methanol-CH2Cl2 (1:20)); [a]22D = + 1.0° (C=1.00 
in EtOH); o max (NUJOLVcm1 3406 (OH), 3384 (OH), 3316 (OH), 1240 (C-O); 6 H 
(270 MHz, CDC13) 4.12-3.98 (1H, m, Ha -C(3)), 3.76-3.63 (1H, m, H p-C(20)), 1.12 
(3H, d, 6.2 Hz, H3C(21)), 0.98 (3H, s, H3C(19)), 0.74 (3H, s, H3C(18)); 6 C 
(CDC13) 74.75 (C-5), 69.93 (C-3), 66.59 (C-20); m/z (E.I.) 336 (M+, 1%), 318 (59), 
300 (30), 285 (21), 283 (3), 264 (59), 232 (80), 41 (100); (C.I.) 337 ([M+ + 1], 2%), 
319 (39), 301 (100), 283 (32); Found: C, 67.8; H, 11.0. C21H360 3 .2H20  requires C, 
67.7; H, 10.8%.
Method 2
In a similar procedure 5a,6a-epoxypregna-3$,20$-diol (37) (10.0 g, 29.9mM) and 
lithium aluminium hydride (5.5 g, 149mM) were refluxed together in THF (400 cm3), 
with overhead mechanical stirring, for 5h. After cooling the reaction mixture was 
quenched by the addition of 1% potassium hydroxide solution. The resulting white 
precipitate was filtered through celite, and the filtrate diluted with methylene chloride 
(400 cm3). The organic solution was washed with water (2 x 250 cm3), dried over 
anhydrous sodium sulphate and concentrated in vacuo. The residue was recrystallised 
from ethyl acetate to give the 3$,5a,20$-triol (35) (9.36 g, 93%) as a white solid, m.p. 
228-230°C (Rf = 0.48, methanol-methylene chloride (1:20)).
Pregnen-3$,20$-diol (36)
Lithium aluminium hydride (18 g, 0.47M) was added portion wise to a solution of 
pregnenolone (100 g, 0.32M) in THF (1000 ml) with overhead mechanical stirring. 
Hydride was added with caution. The mixture was stirred at room temperature for 3h 
and then quenched with 1% potassium hydroxide solution whilst cooling in an ice 
bath. The white precipitate formed was filtered through celite and the filtrate was 
concentrated in vacuo. The residue was taken up in methylene chloride (700 cm3) 
and washed with water ( 2  x 1 0 0  cm3), dried over anhydrous sodium sulphate and
- 1 5 2 -
concentrated in vacuo. Purification by recrystallisation from ethyl acetate-petrol gave 
the diol (36) (99.6 g, 99%) as a white solid, m.p. 204-205°C (Rf = 0.15, ethyl 
acetate-petrol (1:2)); \)max (NUJOLVcm' 1 3409 (OH), 3272 (OH), 1643 (C=C); 6 H 
(270 MHz, CDC13) 5.38-5.31 (1H, m, H-C(6 )), 3.76-3.70 (1H, m, H ^C^O)), 
3.53-3.49 (1H, m, Ha-C(3)), 1.13 (3H, d, J21,20 6.1 Hz, H3C(21)), 1.01 (3H, s, 
H3C(19)), 0.75 (3H, s, H3C(18)); m/z (E.I.) 318 (M+, 100%), 300 (67), 285 (36), 267 
(45), 189 (92), 107 (87), 43 (96); Found : C, 77.7; H, 10.9. C21H340 2 .V3H20  requires 
C, 77.5; H, 10.7%.
5a,6a-Epoxypregna-3$,20$-diol (37)
60% m-Chloroperoxy benzoic acid (104.2 g, 0.30M) was added portion wise to a 
stirred solution of pregnendiol (36) (80 g, 0.25M) in methylene chloride (800 cm3). 
The reaction mixture was stirred at room temperature for 2h. 25% Sodium sulphite 
solution and 25% sodium bicarbonate solution were added cautiously, with stirring, 
until the starch-iodide test gave a negative result. The solution was then separated 
and the organic layer washed with sodium bicarbonate (2  x 2 0 0  cm3) and water ( 2  x 
100 cm3). The organic extracts were dried over anhydrous sodium sulphate and the 
solvent removed in vacuo. The residue was recrystallised from ethyl acetate-petrol to 
give the epoxide (37) (68.1 g, 81%) as a white solid, m.p. 198-199°C (Rf = 0.08, ethyl 
acetate-petrol (1:2)); umax (NUJOLVcm' 1 3483 br (OH), 3419 br (OH), 1279 (C-O);
5h (270 MHz, CDC13) 3.97-3.84 (1H, m, Ha-C(3)), 3.77-3.64 (1H, m, Ha-C(20)), 2.91 
(1H, d, J6%14.4 Hz, Hp-C(6 )), 1.12 (3H, d, 72i,20 6.1 Hz, H3C(21)), 1.07 (3H, s, 
H3C(19)), 0.70 (3H, s, H3C(18)); 5C (CDC13) 70.46 (C-3), 69.38 (C-6 ), 6 8 .6 6  (C-20), 
65.70 (C-5); m/z (Low eV E.I.) 334 (M+, 100%), 316 (74), 298 (47), 272 (28), 120 
(51), 91 (58); Found : C, 74.8; H, 10.4. C2 iH340 3 requires C, 75.4; H, 10.2%.
3$,20$-Diacetoxypregnan-5 a-ol (38)
Pregnan-3$,5a,20$-triol (35) (7.0 g, 20.8mM) and acetic anhydride (5.9 cm3, 
62.4mM) were stirred together in pyridine (150 cm3) at room temperature for 24h.
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The reaction mixture was then poured into water and salt added to aid precipitation. 
The resulting white solid was filtered off and washed with dil. HC1 and water. The 
solid was then dissolved in methylene chloride(150 cm3), washed with water (2 x 50 
cm3) and dried over anhydrous sodium sulphate. The solvent was removed in vacuo 
and purification by recrystallisation from methanol yielded the diacetate (38) (8 .6 6  g, 
99%) as a white solid, m.p. 207-208°C (Rf = 0.40, ethyl acetate-toluene (1:4)); umax 
(NUJOLVcm' 1 3544 br (OH), 1728 vs (0=0), 1244 (C-O); 8 H (270 MHz, CDC13) 
5.23-5.09 (1H, m, *^-0(3)), 4.89-4.81 (1H, m, Ha -C(20)), 2.02 (3H, s, COCH3), 2.01 
(3H, s, COCH3), 1.14 (3H, d, J2iao 6.0 Hz, H3C(21)), 0.99 (3H, s, H3C(19)), 0.62 
(3H, s, H3C(18)); 8c (CDC13) 170.61 (C=0), 170.45 (C=0), 74.96 (C-5), 72.82 (C-3), 
70.79 (C-20); m/z (E.I.) 402 ([M+ - H20], 9%), 360 (6 ), 342 (31), 306 (32), 282 (21), 
81 (29), 43 (100); (C.I.) 403 ([M+ + 1 - H20], 11%), 361 (15), 343 (77), 301 (33), 283 
(100); Found : C, 70.6; H, 9.52. C ^ H ^ O s .V ^ O  requires C, 70.7; H, 9.54%; [a]22D 
= -3.5° ( 0 1 .0  in CH2C12).
3$,20$-Diacetoxy-5,10-secopregn-l(10)-en-5-one (39 and 40)
Method 1
Ceric ammonium nitrate (11.42 g, 20.8mM) in water (20 cm3) was added to a stirred 
solution of 3$20$-diacetoxypregnan-5a-ol (38) (3.50 g, 8.3mM) in acetonitrile (50 
cm3) at 80°C. The reaction mixture was stirred at 80°C for 3 min after which it turned 
colourless from an initial deep red colour. The reaction mixture was immediately 
poured into ice/25% aq. sodium bicarbonate (200 cm3) and after cooling extracted 
with methylene chloride (3 x 100 cm3). The combined organic extracts were washed 
with water (2 x 50 cm3), dried over magnesium sulphate and concentrated in vacuo. 
The residue was purified by column chromatography, eluting with ethyl acetate-petrol 
(1:9) to give (E)-3$,20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (2.86 g, 82%) 
as a white solid, recrystallised from ethyl acetate-petrol, m.p. 155-156°C (Rf = 0.36, 
ethyl acetate-petrol (1:4)); \)max (NUJOLVcm1 1727 s (C=0), 1704 s ((5)C=0), 1631
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(C=C), 1240 (C-O); 5H (270 MHz, CDC13) 4.86-4.80 (2 H, m, HE-C(1) + H-C(20)),
4.49-4.33 (1H, m, Hp-C(3)), 2.03 (3H, s, H3CCO), 2.01 (3H, s, H3CCO), 1.73 (3H, s, 
H3C(19)), 1.14 (3H, d, J2h20 6.2 Hz, H3C(21)), 0.67 (3H, s, H3C(18)); 6 c (CDC13)
201.63 (C-5), 170.79 (C=0), 170.41 (C=0), 150.77 (C-10), 114.24 (C-l), 74.15 (C-3),
72.63 (C-20); m/z ((+) FAB in NBA) 419 ([M+ + 1], 24%), 403 (8 ), 359 (53), 341 
(85), 315 (6 ), 299 (39), 281 (100), 253 (9); Found : C, 72.2; H, 9.39. C ^H ^O s 
requires C, 71.8; H, 9.09%.
Method 2
A stirred suspension of 3$,20$-diacetoxypregnan-5a-ol (38) (26.0 g, 61.9mM), 
yellow mercuric oxide (41.6 g, 186mM) and iodine (42.0 g, 190mM) in carbon 
tetrachloride (600 cm3) was irradiated for 3h at room temperature with a 500W 
tungsten lamp. The solid was removed by filtration and the filtrate washed 
successively with sodium thiosulphate solution ( 2 0 0  cm3), sodium bicarbonate 
solution ( 2 0 0  cm3) and water ( 2  x 1 0 0  cm3), dried over magnesium sulphate and 
evaporated under reduced pressure. Purification of the residue by column 
chromatography, eluting with ethyl acetate-petrol (1:9) gave 
(Z)-3$20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (40) (2.81 g, 11%) as a white 
solid, m.p. 124-125°C (Rf = 0.44, ethyl acetate-petrol (1:4)); a)max (NUJOLVcm-1 
1729 s (C=0), 1702 s ((5)C=0), 1642 (C=C), 1242 (C-O); 5H (270 MHz, CDC13) 
5.36-5.26 (1H, m, Hz-C(l)), 4.84-4.76 (1H, m, H-C(20)), 4.40-4.29 (1H, m, H ^C tf)),
2.03 (3H, s, H3CCO), 2.00 (3H, s, H3COO), 1.76 (3H, s, H3C(19)), 1.14 (3H, d, 72i,20
6.1 Hz, H3C(21)), 0.71 (3H, s, H3C(18)); m/z (C.I.) 419 ([M+ + 1], 2%), 401 (3), 359 
(48), 341 (60), 299 (69), 281 (100), 271 (4), 149 (12), 89 (48).
Further elutes gave (E)-3$,20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (12.42 
g, 48%) as a white solid, m.p. 155-156°C (Rf = 0.36, ethyl acetate-petrol (1:4)).
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3$-Benzoxypregnan-5a20$-diol (41)
To a sitred suspension of sodium hydride (613 mg, 25.5mM), washed several times 
with petrol prior to use, in THF (50 cm3) was added the triol (35) (2.86 g, 8.5mM) in 
THF (10 cm3) dropwise, under nitrogen at 0°C. The reaction mixture was stirred for 
15 min, until frothing ceased, after which benzyl bromide (1.11 cm3, 9.4mM) was 
added dropwise. The reaction mixture was stirred for a further 6 h at 0°C and then 12h 
at room temperature. Water was added to quench and the THF removed in vacuo.
The residue was diluted with methylene chloride (100 cm3) and washed with water (2 
x 20 cm3). The organic layer was dried over anhydrous sodium sulphate, evaporated 
under reduced pressure, and purified by column chromatography, eluting with ethyl 
acetate-petrol (1:10) to give the monobenzyl ester (41) ((2.65 g, 73%) as a white solid, 
m.p. 175-176°C (Rf = 0.17, ethyl acetate-petrol (3:17)); v max (NUJOLVcm' 1 3423 br 
(OH), 3373 br (OH), 1497,1443 s (C-C, Ar), 739, 697 s (C-H, Ar); 5H (400 MHz, 
CDC13) 7.34-7.22 (5H, m, Ar), 4.54 (2H, q, J  11.8, J 16.9 Hz, PhCl^O), 3.88-3.80 
(1H, m, Ha-C(3)), 3.71 (1H, dq, / 20t21 5.8 / 2{U7 10.98 Hz, Ha -C(20)), 1.13 (3H, d, 
*21,20 6.0 Hz, H3C(21)), 1.00 (3H, s, H3C(19)), 0.74 (3H, s, H3C(18)); 5C (CDC13) 
139.18 (C-Ar), 128.18 (C-Ar), 127.86 (C-Ar), 127.60 (C-Ar), 127.53 (C-Ar), 127.31 
(C-Ar), 75.18 (C-5), 77.41 (ArCH20), 74.47 (C-3), 70.21 (C-20); m/z (C.I.) 409 ([M+ 
+ 1 - H20 ], 17%), 408 (30), 391 (70), 319 (48), 301 (100), 299 (8 8 ), 283 (81), 107 
(20); Found : C, 77.9; H, 9.82. C ^ H ^ . V ^ O  requires C, 78.0; H, 9.87%.
3$-Benzoxy-20$-acetoxypregnan-5a-ol (42)
The diol (41) (100 mg, 0.23mM) was added to a stirred solution of acetic anhydride 
(0.033 cm3 ,0.35mM) in pyridine (3 cm3). The reaction mixture was stirred at room 
temperature for 24h, after which it was poured into saturated brine (20 cm3). The 
resulting white solid was filtered off and washed with dil. HC1 and water. The solid 
was then dissolved in methylene chloride ( 2 0  cm3), washed with water (2 x 5  cm3) 
and dried over anhydrous sodium sulphate. The solvent was removed in vacuo and
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purification by column chromatography on silica gel, eluting with ethyl acetate-petrol 
(1:9) gave the acetate (42) (100 mg, 91%) as a white solid, m.p. 184-185°C (Rf = 
0.53, ethyl acetate-petrol (3:17)); umax (NUJOD/cm 1 3464 sh (OH), 1703 s (C=0), 
1265 s (C-O), 754,703 (C-H, Ar); 8 H (400 MHz, CDC13) 7.34-7.23 (5 H, m, Ar), 4.83 
(1H, dq, 72 021  6 .1 , 720.17 10.4 Hz, Ha -C(20)), 4.54 (2H, q, 7 11.8,7 16.8 Hz, 
PhCH20 ), 3.86-3.79 (1H, m, H^-CO)), 2.01 (3H, s, H3CCO), 1.14 (3H, d, 721,20 5.8 
Hz H3C(21)), 0.99 (3H, s, H3C(19)), 0.62 (3H, s, H3C(18)); 8 C (CDC13) 170.48 
(C=0), 139.14,128.33,127.58, 127.38 (all C-Ar), 7 5 .2 2  (C-5), 74.43 (PhCH20), 
72.86 (C-3), 70.23 (C-20); mlz (El.) 450 ([M+-H20], 5%), 432 (1), 408 (1), 390 (3), 
359 (5), 299 (47), 149 (59), 71 (59), 57 (100); Found : C, 76.0; H, 9.56.
C30II44O4 . V4H2O requires C, 76.2; H, 9.42%.
(E)-3$-Benzoxy-20$-acetoxy-5,10-seco-I(10)-pregnen-5-one (43)
To a stirred solution of 3$-benzoxy-20$-acetoxypregnan-5a-ol (42) (250 mg, 
0.53mM) in acetonitrile (10 cm3) at 80°C was added a solution of eerie ammonium 
nitrate (732 mg, 1.34mM) in water (3 cm3) to give a deep red colour. After 3 min the 
solution had decolourised and was immediately poured into ice/25% sodium 
carbonate solution (25 cm3). After cooling the solution was extracted with methylene 
chloride (3 x 30 cm3), dried over magnesium sulphate and concentrated in vacuo. The 
residue was purified by column chromatography, eluting with ethyl acetate-petrol 
(1:9) to give the secosteroid (43) (114 mg, 46%) as a white solid, m.p. 102-103°C (Rf 
= 0.52, ethyl acetate-petrol (3:17)); umaI (NUJOL)/cm'' 1730 s (0=0), 1702 s 
((5)C=0), 1662 (C-C, Ar), 1450 (C-C, Ar), 1246 (C-O), 740 (C-H, Ar), 696 (C-H, 
Ar); 8 h (400 MHz, CDC13) 7.35-7.25 (5H, m, Ar), 4.83 ( 1H, dq, 720.2i 6.1, 720,i7 10.4 
Hz, Ha-C(20)), 4.84-4.75 (1H, m, HE-C(1)), 4.57 (1H, d, 7 2.1 Hz, ArCH), 4.54 (1H, 
d, 7 4.6 Hz, ArCH), 4.16-4.08 (1H, m, Ha -C(3)), 2.01 (3H, s, H3CCO), 1.73 (3H, s, 
H3C(19)), 1.14 (3H, d, J2 I-2o 6.1 Hz, H3C(21)), 0.67 (3H, s, H3C(18)); 8 c  (CDC13)
207.98 (C-5), 170.43 (C=0), 139.84 (C, Ar), 138.32 (C-10), 128.37 (C, Ar), 128.28 
(C, Ar), 127.60 (C, Ar), 127.53 (C, Ar), 127.33 (C-l), 123.87 (C, Ar), 80.38 (C-3),
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(E)-3$20$-Diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (1.50 g, 3.59mM) and 
potassium carbonate (1.50 g, 10.9mM) were stirred together in methanol (25 cm3) at 
room temperature for 10 min. Water (25 cm3) was added and the solution extracted 
with methylene chloride (3 x 30 cm3). The combined organic extracts were washed 
with dil. HC1 (15 cm3) and water (2x15 cm3), dried over anhydrous sodium sulphate 
and concentrated in vacuo. Purification by column chromatography, eluting with ethyl 
acetate-petrol (3:7) gave the 3$-hydroxy acetate (44) (1.31 g, 97%) as a white solid, 
m.p. 131-132°C (Rf = 0.23, ethyl acetate-petrol (3:7)); [a]22D = +6 .6 ° (C = 1.00, ethyl 
acetate); umax (NUJOLVcm1 3484 sh (OH), 3205 br (OH), 1726 s (C=0), 1703 s 
((5)C=0), 1659 (C=C), 1239 (C-O); 5H (270 MHz, CDC13) 4.89-4.80 (1H, m, 
He-C(1)), 4.47-4.35 (1H, m, ^ -0 (3 )), 3.80-3.65 (1H, m, H-C(20)), 2.78-2.68 (1H, m, 
^ - 0 (4 ) ) ,  1.74 (3H, s, H3C(19)), 1.15 (3H, d, 72i,20 6-0 Hz, H3C(21)), 0.80 (3H, s, 
H3C(18)); m/z (C.I.) 377 ([M+ + 1], 5%), 359 (12), 341 (6 ), 332 (1), 317 (25), 299 
(75), 281 (24); Found C, 73.3; H, 9.88. C23H360 4 requires C, 73.4; H, 9.57%.
Method 2
A solution of 10% palladium on activated carbon (3 mg, 10% w/w) and 
3$-benzoxy-20$-acetoxy-5,10-secopregn-l(l0)-en-5-one (43) (30 mg, 0.6mM) in 
ethanol (3 cm3) was degassed under nitrogen for 15 min. The reaction mixture was 
stirred under an atmosphere of hydrogen at atmospheric pressure for 12h. The 
mixture was filtered and the filtrate concentrated under reduced pressure. The residue 
was dissolved in methylene chloride ( 1 0  cm3) and washed with water (2 x 4  cm3), 
dried over anhydrous sodium sulphate and concentrated in vacuo. The residue was
- 1 5 8 -
purified by column chromatography, eluting with ethyl acetate-petrol (2:3) to give the 
3$-alcohol (44) (23 mg, 95%) as a white solid, m.p. 131-132°C (Rf = 0.23, ethyl 
acetate-petrol (3:7)).
3$,20$-Dibenzoxypregnan-5a-ol (45)
To a stirred suspension of tetrabutylammonium iodide (22 mg, 0.06mM) and sodium 
hydride (36 mg, 1.5mM), washed several times with petrol prior to use, in THF ( 8  
cm3) was added the triol (35) (200 mg, 0.6mM) in THF (3 cm3) dropwise, under 
nitrogen at 0°C. The reaction mixture was stirred at 0°C for 15 min, until frothing 
ceased, after which benzyl bromide (0.15 cm3, 1.25mM) was added dropwise and 
then stirred at room temperature, under nitrogen, for 24h. Water was added to quench 
and the organic solvent removed in vacuo. The residue was diluted with methylene 
chloride ( 2 0  cm3) and washed with water (2 x 1 0  cm3), dried over anhydrous sodium 
sulphate and concentrated in vacuo. Purification by column chromatography, eluting 
with ethyl acetate-petrol (1:19) gave the dibenzyl ester (45) (162 mg, 47%) as a white 
solid, m.p. 109-110°C (Rf = 0.45, ethyl acetate-petrol (1:19)); omax (NUJOLVcm' 1 
3471 br (OH), 1604, 1496,1452 s (C-C, Ar), 733, 694 s (C-H, Ar); 6 H (270 MHz, 
CDC13) 7.33-7.25 (10H, m, Ar), 4.54 (2H, d, 7gem 2.4 Hz, PhCH20-C(3)), 4.47 (2H, 
dd, 7gcm 11.3, J 64.2 Hz, PhCH2O-C(20)), 3.91-3.80 (1H, m, Ha -C(3)), 3.50-3.38 (1H, 
m, Ha-C(20)), 1.14 (3H, d, /  6.1 Hz, H3C(21)), 0.99 (3H, s, H3C(19)), 0.65 (3H, s, 
H3C(18)); mlz (E.I.) 516 (M+ missing), 408 ([M+-PhCH2OH], 1%), 380 (1), 304 (5), 
279 (3), 149 (22), 105 (100), 77 (92); Found : C, 79.4; H, 9.27. C35H480 3. 3/4H20  
requires C, 79.3; H, 9.35%.
( E)-3$-20$-Dibenzoxy-5,10-seco-l(10)-pregnen-5-one (46)
Ceric ammonium nitrate (611 mg, 1.1 ImM) in water (2 cm3) was added to 
3$20$-dibenzoxypregnan-5a-ol (45) (230 mg, 0.45mM) in acetonitrile (10 cm3), 
stirred at 80°C. The reaction mixture was stirred at 80°C for 3 min, after which it had 
become clear, and was then poured immediately into ice/25% sodium bicarbonate
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solution (25 cm3). The solution was allowed to cool and then extracted with 
methylene chloride (3 x 25 cm3), dried over magnesium sulphate and concentrated in 
vacuo. Purification by column chromatography on silica gel, eluting with ethyl 
acetate-petrol (1:9) gave the dibenzyl protected secosteroid (46) (160 mg, 70%) as a 
white solid, m.p. 122-123°C (Rf = 0.38, ethyl acetate-petrol (1:9)); \)max 
(NUJOLVcm-1 1702 s (C=0), 1657 (C=C), 1494 (C-C, Ar), 1452 (C-C, Ar), 754 
(C-H, Ar), 732 (C-H, Ar), 697 (C-H, Ar); 6 H (400 MHz, CDC13) 7.35-7.24 (10H, m, 
Ar), 4.83-4.74 (1H, m, HE-C(1)), 4.63-4.33 (4H, m, PhCH2 x 2), 4.16-4.08 (1H, m, 
H ^C tf)), 3.43 (1H, d q ,/20,2 i 5.8,720, l7  9.8 Hz, Ha-C(20)), 1.73 (3H, s, H3C(19)), 
1.14 (3H, d, / 2 U 0  5.8 Hz, H3C(21)), 0.69 (3H, s, H3C(18)); 5C (CDC13) 208.01 (C-5), 
140.16 (C-10), 138.90 (C, Ar), 138.39 (C, Ar), 128.42 (C, Ar), 128.22 (C, Ar), 127.85 
(C, Ar), 127.65 (C, Ar), 127.60 (C, Ar), 127.28 (C, Ar), 123.65 (C-l), 80,49 (C-20), 
77.61 (C-3), 71.27 (PhCH20), 69.99 (PhCH20); m/z (C.I.) 515 ([M+ + 1], 3%), 497 
(2), 479 (1), 423 (5), 407 (16), 389 (15), 279 (25), 205 (32), 107(70), 91 (100); Found 
: C, 80.2; H, 9.30. C35H4 60 3 .V2H20  requires C, 80.3; H, 8.99%.
(E)-3$20$-Dihydroxy-5,10-secopregn-l( 10)-en-5-one (47)
Method 1
To a stirred solution of potassium carbonate (2.0 g, 14.5mM) in methanol (30 cm3) 
was added (E)-3$20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (950 mg, 
2.27mM). The reaction mixture was stirred at reflux for 24h, under nitrogen. Water 
(20 cm3) was added and the solution was extracted with methylene chloride (2 x 50 
cm3). The combined organic extracts were washed with dil. HC1 (20 cm3) and water 
( 2 0  cm3), dried over anhydrous sodium sulphate and evaporated under reduced 
pressure. The residue was purified by column chromatography eluting, with ethyl 
acetate-petrol (1:1) to give the (E)-3$20$-diol (47) (615 mg, 81%) as a white solid, 
m.p. 241-242°C (Rf = 0.24, ethyl acetate-petrol (1:1)); [oc]22D = -31.3° (C = 0.8, 
methanol); omax (NUJOLVcm1 3560 br (OH), 3395 br (OH), 1695 s (C=0), 1650
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(C=C); 5h (270 MHz, CDC13) 4.87-4.79 (1H, m, HE-C(1)), 4.46-4.32 (1H, m, 
H ^C tf)), 3.77-3.67 (1H, m, H-C(20)), 1.76 (3H, s, H3C(19)), 1.14 (3H, d, J2h20 6.1 
Hz, H3C(21)), 0.79 (3H, s, H3C(18)); 5C (CDC13) 206.51 (C-5), 137.99 (C-10), 122.93 
(C-l), 71.10 (C-3), 67.90 (C-20); m/z (low eV E.I.) 334 (M+, 100%), 316 (43), 298 
(15), 277 (37), 248 (51), 233 (29), 218 (19); Found : C, 75.2; H, 10.3. C21H340 3 
requires C, 75.4; H, 10.2%.
Method 2
A solution of 10% palladium on activated carbon ( 6  mg, 20% w/w) and 
(E)-3$20$-dibenzoxy~5,10-secopregn-l(l0)-en-5-one (46) (30 mg, 0.06mM) in 
ethanol (3 cm3) was degassed under nitrogen for 15 min. The reaction mixture was 
stirred under an atmosphere of hydrogen at atmospheric pressure for 12h. The 
mixture was filtered and the filtrate concentrated in vacuo. The residue was dissolved 
in methylene chloride (5 cm3) and washed with water ( 2 x 3  cm3), dried over 
anhydrous sodium sulphate and evaporated under reduced pressure. The residue was 
purified by column chromatography, eluting with ethyl acetate-petrol (1 :1 ) to give the 
3$,20$-diol (47) (18mg, 93%) as a white solid, m.p. 241-242°C (Rf = 0.24, ethyl 
acetate-petrol (1 :1)).
(E)-3a-Formoxy-20$-5,10-secopregn-l( 10)-en-5-one (54)
Diethylazodicarboxylate (0.63 cm3, 3.99mM) was added dropwise to a stirred 
solution of 20$-acetoxy-5,10-secopregn-l(10)-en-3$-ol-5-one (44) (l.Og, 2.66mM), 
triphenyl phosphine (2.09g, 7.98mM) and formic acid (0.15 cm3, 3.99mM) in THF 
(75 cm3) at 0°C. The reaction mixture was stirred at 0-10°C for 4h. Water (50 cm3) 
was added to the mixture and it was extracted with methylene chloride ( 2  x 1 0 0  cm3). 
The combined organic extracts were washed with aq. sodium bicarbonate (25 cm3) 
and water (2 x 50 cm3), dried over magnesium sulphate and concentrated in vacuo. 
The residue was purified by column chromatography, eluting with ethyl acetate-petrol 
(1:9) to give 20$-acetoxy-IJ(l0-*l$H, 5-*3cLH)abeopregn-10(19)-en-5-one (55)
- 1 6 1 -
(133mg, 14%), which was recrystallised from ethyl acetate to give colourless prisms, 
m.p. 135-137°C (Rf = 0.81, ethyl acetate-petrol (3:7)); omax (NUJOLVcm*1 3071 
(C-C, 3’ ring), 1736 s (C=0), 1698 s ((5)C=0), 1634 (C=C); SH (270 MHz, CDC13) 
4.84 (1H, dq, J20ai 6.1, / 2(U 7 10.3 Hz, H-C(20)), 4.61 (1H, s, H-C(19)), 4.52 (1H, s, 
H-C(19)), 3.05 (1H, dd, / u ' 5.7 Jh2"  15.4 Hz, H-C(l)), 2.78 (1H, dddd, J  2.1, J 6.3, J  
12.4, J  19.1 Hz, H-C(3)), 2.41-2.33 (1H, m, H ^C ^)), 2.01 (3H, s, H3CCO), 1.14 (3H, 
d, / 21f20 6.1 Hz, H3C(21)), 0.66 (3H, s, H3C(18)); m/z (E.I.) 358 (M+, 55%), 343 (10), 
329 (8 ), 298 (11), 283 (12), 265 (10), 159 (26), 147 (36); Found : C, 77.2; H, 9.61. 
C23H340 3 requires C, 77.1; H, 9.50%.
Further elutes gave (E)-3a-formoxy-20$-acetoxy-5,10-secopregn-l(10)-en-5-one (54) 
(721mg, 67%) as a white solid, m.p. 122-123°C (Rf = 0.71, ethyl acetate-petrol (3:7)); 
\)max (NUJOLVcm1 1729 s (C=0), 1710 s (HC=0), 1704 s ((5)C=0), 1635 (C=C), 
1242 (C-O); 5h (270 MHz, CDC13) 8.00 (1H, s, HCO), 5.55-5.45 (1H, m, Hp-C(3)), 
4.92-4.78 (2H, m, HE-C(1) + H-C(20)), 2.01 (3H, s, H3CCO), 1.75 (3H, s, H3C(19)),
1.13 (3H, d, y2 1 2 0  6.0 Hz, H3C(21)), 0.66 (3H, s, H3C(18)); m/z (C.I.) 405 ([M++l], 
6 %), 387 (5), 359 (6 8 ), 345 (43), 327 (95), 299 (69), 281 (100); Found : C, 71.1; H,
9.00. C^RjgOs requires C, 71.3; H, 8.91%.
(E)-20$-Acetoxy-5,10-secopregn-l(10)-en-3a-ol-5-one (56)
Potassium carbonate (3.0g, 21.7mM) was added to a stirred solution of 
(E)-3oL-formoxy-20fi-acetoxy-5,10-secoprepregn -l(10)-en-5-one (54) (3.0g, 7.43mM) 
in methanol (100 cm3). The reaction mixture was stirred at room temperature for lh. 
The mixture was diluted with water (50 cm3) and extracted with methylene chloride 
(2 x 100 cm3). The combined organic extracts were washed with dil. HC1 (30 cm3) 
and water (2 x 40 cm3), dried over anhydrous sodium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (3:7) to give the 3a-hydroxyl (56) (2.74g, 98%) as a white solid, m.p. 
149-150°C (Rf = 0.23, ethyl acetate-petrol (3:7)); [a]22p = + 6.0 (C=1.00, ethlyl
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acetate); \)max (NUJOL)cm1 3424 br (OH), 1726 s (0=0), 1704 s (0=0); 5H (270 
MHz, CDC13) 4.87-4.80 (2H, m, HE-C(1)+H-C(20)), 4.44-4.34 (1H, m, Hp-C(3)), 2.01 
(3H, s, H3CCO), 1.73 (3H, s, H3C(19)), 1.14 (3H, d, 721>20 5.9 Hz, H3C(21)), 0.67 
(3H, s, H3C(18)); 5h (CDC13) 207.64 (C-5), 170.21 (C=0), 139.83 (C-10), 123.77 
(C-l), 120.61 (C-20), 70.79 (C-3); m/z (CI.) 377 ([M++l], 10%), 359 (16), 341 (6 ), 
317 (31), 299 (100), 281 (33), 259 (4); Found : C, 71.2; H, 9.52. C23H360 4 .5/8H20  
requires C, 71.3; H, 9.62%.
(E)-3<x-Tertbutyldimethylsiloxy-20$-acetoxy-5,10-secopregn-l(10)-en-5-one (57) 
(E)-20$-acetoxy-5,10-secopregn-l(10)-en-3a.-ol-5-one (56) (lOOmg, 0.27mM) in 
DMF (1 cm3) was added dropwise to a stirred solution of rm-butyldimethylsilyl 
chloride (44mg, 0.29mM) and imidazole (20mg, 0.29mM) in DMF (2 cm3) under 
nitrogen. The reaction mixture was stirred at room temperature under nitrogen for 30 
min after which the DMF was removed in vacuo. Methylene chloride (20 cm3) was 
added to the residue, and it was washed with dil. HC1 (2 cm3) and water (2x 5  cm3), 
dried over magnesium sulphate and evaportated at reduced pressure. Purification by 
column chromatography, eluting with ethyl acetate-petrol (1:9) gave the C-3 silyl 
ether (57) (119mg, 92%) as a white solid, m.p. 113-114°C (Rf = 0.71, ethyl 
acetate-petrol (3:17)); \)max (NUJOLVcm1 1728 s (C=0), 1700 s ((5)C=0), 1658 
(C=C), 1069 (O-Si); SH (270 MHz, CDC13) 4.86-4.78 (2H, m, HE-C(1) + H-C(20)),
4.45-4.31 (1H, m, Hp-C(3)), 2.00 (3H, s, H3CCO), 1.72 (3H, s, H3C(19)), 1.14 (3H, d, 
y2 it20 6.1 Hz, H3C(21)), 0.89 (9H, s, (H3C)3CSi), 0.66 (3H, s, H3C(18)), 0.10 (6 H, s, 
(H3C)2Si); m/z (CI.) 491 ([M++l], 19%), 473 (11), 431 (46), 413 (70), 373 (21), 359 
(15), 341 (37), 281 (100); Found : C, 71.2; H, 10.5. C29H5oSi04  requires C, 71.0; H, 
10.2%.
(E)-3a-Tertbutyldimethylsiloxy-5,10-secopregn-l( 10)-en-20$ -ol-5-one (58) 
Potassium carbonate (lOOmg, 0.72mM) was added to a stirred solution of 
(E)-3a-terbutyldimethylsiloxy-20$-acetoxy-5,10-secopregn-l (10)-en-5-one (57)
- 1 6 3 -
(50mg, O.lOmM) in methanol (2 cm3) at room temperature. The reagents were heated 
to reflux for 24h. After cooling the reaction mixture was diluted with water (5 cm3) 
and extracted with methylene chloride (3x10 cm3). The combined organic extracts 
were washed with dil. HC1 (5 cm3) and water (2x10 cm3), dried over anhydrous 
sodium sulphate and concentrated in vacuo. The residue was purified by column 
chromatography, eluting with ethyl acetate-petrol (1:9) to give the 20$-hydroxyl silyl 
ether (58) (43mg, 94%) as a white solid, m.p. 163-164°C (Rf = 0.37 ethyl 
acetate-petrol (1:9)); umax (NUJOLVcm' 1 3405 br (OH), 1691 s (0=0), 1658 (C=C), 
1066 (O-Si); 5H (270 MHz, CDC13) 4.83-4.78 (1H, m, HE-C(1)), 4.40-4.33 (1H, m, 
Hp-C(3)), 3.70 (1H, d q ,/2o.2 i 6 .1 , / 2o,i7 9.8 Hz, H-C(20)), 1.74 (3H, s, H3C(19)), 1.13 
(3H, d, / 21f20 6.2 Hz, H3C(21)), 0.89 (9H, s, (H3C)3CSi), 0.79 (3H, s, H3C(18)), 0.10 
(6 H, s, (H3C)2Si); m il (C.I.) 449 ([M++l], 17%), 431 (46), 413 (31), 391 (19), 317 
(19), 299 (100); Found : C, 71.1; H, 10.8. C27H48Si0 3 .V2H20  requires C, 70.9; H, 
10.7%.
(E)-3oL-Tertbutyldimethylsiloxy-5,10-secopregn-l(10)-ene-5,20-dione (59)
Pyridinium chlorochromate, PCC, (310mg, 1.44mM) was added to a stirred solution 
of (E)-3a-tertbutyldimethylsiloxy-5,10-secopregn-l(10)-en-20$ -ol-5-one (58) 
(430mg, 0.96mM) in methylene chloride (20 cm3). The reaction mixture was stirred 
at room temperature under nitrogen for 3h. Silica gel was then added to the reaction 
mixture, the solvent evaporated in vacuo and purification by column chromatography, 
eluting with ethyl acetate-petrol (1:9) gave the 5,20-dione (59) (409mg, 96%) as a 
white solid, m.p. 142-143°C (Rf = 0.49, ethyl acetate-petrol (1:9)); umax 
(NUJOL)/cm3 1707 s (C=0), 1693 s (C=0), 1663 (C=C), 1078 (O-Si); 5H (270 MHz, 
CDC13) 4.92-4.75 (1H, m, HE-C(1)), 4.46-4.30 (1H, m, Hp-C(3)), 2.11 (3H, s, 
H3C(21)), 1.73 (3H, s, H3C(19)), 0.89 (9H, s, (H3C)3CSi), 0.65 (3H, s, H3C(18)), 0.10 
(6 H, s, (H3C)2CSi); m/z (C.I.) 447 ([M++l], 71%), 429 (25), 389 (13), 315 (19), 297 
(100); Found : C, 72.3; H, 10.4. C27H46Si03 requires C, 72.6; H, 10.3%.
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(E)-3a-Hydroxy-5,10-secopregn-l(10)-ene-5,20-dione (60)
1M TBAF in THF (0.92 cm3, 0.9ImM) was added dropwise to a stirred solution of 
(E)-3a-tertbutyldimethylsiloxy-5,10-secopregn-l(10)-ene-5, 20-dione (59) (340mg, 
0.76mM) in THF (10 cm3). The reaction mixture was stirred at room temperature for 
2h. Methylene chloride (30 cm3) was added and the solution washed with dil. HC1 (5 
cm3) and water (2 x 10 cm3). The organic layer was dried over anhydrous sodium 
sulphate, concentrated in vacuo, and purified by column chromatography eluting with 
ethyl acetate-petrol (3:7), followed by recrystallisation from ethyl acetate to give the 
3a-hydroxy dione (60) (212mg, 84%) as flat crystals, m.p. 182-184°C (Rf = 0.17, 
ethyl acetate-petrol (3:7)); [a]22D = +79.3° (C=1.04, CH2C12); Dmax (NUJOLVcm-1 
3370 br (OH), 1692 s (0=0), 1678 s (0=0), 1640 (C=C); 5H (270 MHz, CDC13) 
4.86-4.82 (1H, m, HE-C(1)), 4.60 (1H, d, J  7.7 Hz, HO-C(3)), 4.48-4.28 (1H, m, 
Hp-C(3)), 2.12 (3H, s, H3C(21)), 1.74 (3H, s, H3C(19)), 0.66 (3H, s, H3C(18)); m/z 
(low eV E.I.) 332 (M+, 100%), 314 (60), 246 (80), 233 (44), 149 (13), 99 (18); Found 
: C, 75.9; H, 9.84. C21H320 3 requires C, 75.9; H, 9.64%; UVmax = 293nm.
(E)-20$-Acetoxy-5,10-secopregn-l(10)-ene-3a-5a-diol (61)
Sodium borohydride (384mg, 10. ImM) was added portion wise to a stirred solution of 
(E)-20$-acetoxy-5f10-secopregn-l(10)-en-3o.-ol-5-one (56) (1.90g, 5.05mM) in 
ethanol (100 cm3). The reaction mixture was stirred at room temperature for 12h. 
Water (20 cm3) was added and the solution extracted with methylene chloride (2 x 
100 cm3). The combined organic extracts were dried over anhydrous sodium sulphate 
and evaporated in vacuo. The residue was purified by column chroamtography eluting 
with ethyl acetate-petrol (1:1) to give the 3a$<x-diol (61) (1.24g, 65%) as a white 
solid, m.p. 68-69°C (Rf = 0.23, ethyl acetate-petrol (1:1)); [oc]22D = -18.0° (C=0.64, 
ethyl acetate); omax (NUJOLVcm 1 3375 br (OH), 1729 (C=0), 1665 (C=C); 5H (270 
MHz, CDC13) 5.47-5.45 (1H, m, HE-C(1)), 4.88-4.81 (1H, m, H-C(20)), 4.29-4.22 
(1H, m, Hp-C(3)), 4.22-4.15 (1H, m, Hp-C(5)), 2.55-2.51 (1H, m, Ha-C(4)), 2.01 (3H, 
s, H3CCO),1.69 (3H, brs, H3C(19)), 1.15 (3H, d, / 21t20 6.4 Hz, H3C(21)), 0.66 (3H, s,
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H3C(18)); m/z (E.I.) 378 (M+ missing), 360 ([M+ - H20), 4%), 342 (4), 318 (4), 306
(6 ), 300 (5), 285 (7), 267 (4), 218 (10); Found ; C, 71.9; H, 10.1. GyHjgCVVjHjO 
requires C, 71.9; H, 10.1 %.
(E)-3aJa-(Ditertbutyl)siloxy-20$-acetoxy-5,10-secopregn-l(10)-ene (62) 
2,6-Lutidine (0.34 cm3, 2.94mM) was added dropwise to a stirred solution of 
(E)-20$-acetoxy-5,10-secopregn-l(10)-ene-3a£<x-diol (61) (370mg, 0.98mM) and 
di-rmbutylsilylbis(trifluoromethanesulphonate) (0.43 cm3, 1.17mM) in methylene 
chloride (10 cm3) at 0°C under nitrogen. The reaction mixture was stirred at 0°C for 
10 min after which silica gel was added. The solvent was removed under reduced 
pressure and the silica applied to a column. Column chromatography, eluting with 
ethyl acetate-petrol (1:9) gave the bissilyl ether (62) (390mg, 77%) as a colourless oil 
(Rf = 0.85, ethyl acetate-petrol (3:17)); \)max (FILM)/cm l 1733 s (C=0), 1658 (C=C), 
1059 (O-Si); 6 H (270 MHz, CDC13) 5.57-5.53 (1H, m, HE-C(1)), 4.87-4.80 (1H, m, 
H-C(20)), 4.53-4.50 (1H, m, Hp-C(3)), 4.31-4.25 (1H, m, Hp-C(5)), 2.48 (2H, dd, J
4.4,79.3 Hz, H2-C(4)), 2.02 (3H, s, H3CCO), 1.69 (3H, s, H3C(19)), 1.15 (3H, d, 
J2iao 6.4 Hz, H3C(21)), 1.02 (9H, s, (H3C)3CSi), 1.00 (9H, s, (H3C)3CSi), 0.65 (3H, s, 
H3C(18)); m/z (C.I.) 519 ([M++l], 4%), 459 (29), 401 (8 ), 343 (6 ), 283 (34), 239 (6 ), 
205 (100); Found : C, 68.0; H, 10.6. C31H54Si04 . l 2/3H20  requires C, 67.9; H, 10.5%.
(E)-3oLja-(Ditertbutyl)siloxy-5,10-secopregn-l(10)-en-20$-ol (63)
Potassium carbonate (500mg, 3.62mM) was added to a stirred solution of 
(E)-3a,5a-(ditertbutyl)siloxy-20$-acetoxy-5,10-secopregn-l (10)-ene (62) (370mg,
0.7ImM) in methanol (20 cm3) and the mixture refluxed for 24h. After cooling the 
mixture was diluted with water ( 1 0  cm3) and the solution extracted with methylene 
chloride (3 x 20 cm3). The combined organic extracts were washed with dil. HC1 (5 
cm3) and water ( 2  x 1 0  cm3), dried over anhydrous sodium sulphate and concentrated 
in vacuo. The residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (1:19) to give the 20$-hydroxyl bissilyl ether (63) (314mg, 92%) as a
- 1 6 6 -
colourless oil (Rf = 0.44, ethyl acetate-petrol (1:9)); vmax (FILMVcm' 1 3420 br (OH), 
1658 (C=C), 1059 (O-Si); 5H (270 MHz, CDC13) 5.60-5.50 (1H, m, HE-C(1)), 
4.60-4.50 (1H, m, Hp-C(3)), 4.35-4.25 (1H, m, Hp-C(5)), 3.80-3.70 (1H, m, H-C(20)),
2.55-2.45 (2H, m, H2-C(4)), 1.69 (3H, s, H3C(19)), 1.15 (3H, d, / 21>20 6.0 Hz, 
H3C(21)), 1.07 (9H, s, (H3C)3CSi), 1.03 (9H, s, (H3C)3CSi), 0.78 (3H, s, H3C(18)); 
m/z (C.I.) 477 ([M++l], 37%), 459 (80), 419 (90), 401 (11), 301 (69), 283 (100), 257 
(20).
(E)-3a£a-(Ditertbutyl)siloxy-5,10-secopregn-l( 10)-en-20-o ne (64)
Pyridinium chlorochromate (183mg, 0.85mM) was added to a stirred solution of 
(E)-3a,5oL-(ditertbutyl)siloxy-5,]0-secopregn-l(10)-en-20$- ol (63) (270mg, 0.57mM) 
in methylene chloride (15 cm3) and the mixture stirred at room temperature, under 
nitrogen, for 2.5h. The reaction mixture was preabsorbed onto silica gel and applied 
to a column. Column chromatography, eluting with ethyl acetate-petrol (1:19) gave 
the 20-ketone (64) (247mg, 92%) as a colourless oil (Rf = 0.52, ethyl acetate-petrol 
(1:9)); omax (FILMVcm-1 1706 s (C=0), 1657 (G=C), 1059 (O-Si); 5H (270 MHz, 
CDC13) 5.56 (1H, dd, /  6.0, J  10.2 Hz, HE-C(1)), 4.53-4.51 (1H, m, H p-C(3)), 
4.30-4.23 (1H, m, Hp-C(5)), 2.55-2.46 (2H, m, H2-C(4)), 2.12 (3H, s, H3C(21)), 1.70 
(3H, s, H3C(19)), 1.05 (9H, s, (H3C)3CSi), 1.03 (9H, s, (H3C)3CSi), 0.64 (3H, s, 
H3C(18)); mix (C.I.) 475 ([M++l], 100%), 457 (14), 417 (75), 391 (11), 281 (17), 255
(7), 239 (21).
(E)-3a,5a-Dihydroxy-5,10-secopregn-l(10)-en-20-one (65)
To a stirred solution of (E)-3aJa-(ditertbutyl)siloxy-5,10-secopregn-l(10)-en-20-o ne 
(64) (200mg, 0.42mM) in THF (10 cm3) was added hydrogen fluoride-pyridine (0.06 
cm3 , 0.5ImM). The reaction mixture was stirred at room temperature under nitrogen 
for lh. After this the reaction mixture was diluted with methylene chloride (30 cm3) 
and washed with aq. copper sulphate (2  x 1 0  cm3), aq. sodium bicarbonate ( 1 0  cm3) 
and water (2 x 10 cm3). The organic layer was dried over anhydrous sodium sulphate,
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evaporated under reduced pressure, and purified by column chromatography, eluting 
with ethyl acetate-petrol (3:1) to give the 3a,5a-diol (65) (80mg, 57%) as a white 
solid, m.p. 131-133°C (Rf = 0.36, ethyl acetate-petrol (3:1)); omax (NUJOLVcm*1 
3351 br (OH), 3222 br (OH), 1703 s (C=0), 1690 (C=C); 5H (270 MHz, CDC13)
5.46-5.40 (1H, m, HE-C(1)), 4.32-4.26 (1H, m, Hp-C(3)), 4.24-4.16 (1H, m, Hp-C(5)),
2.56-2.50 (2H, m, H2-C(4)), 2.12 (3H, s, H3C(21)), 1.70 (3H, s, H3C(19)), 0.70 (3H, s, 
H3C(18)); m/z (C.I.) 335 ([M++l], 7%), 317 (11), 299 (15), 281 (4), 255 (6 ) 245 (3); 
Found : C, 73.3; H, 9.95. C ^ H ^ C V /^ O  requires C, 73.4; H, 10.2%; UVmax = 
290nm.
3a-Benzoy/pregnenolone (6 6 )
To a stirred solution of pregnenolone (3g, 9.5mM), benzoic acid (1.27g, 10.4mM) and 
triphenylphosphine (5.47g, 20.9mM) in THF (100 cm3) was added diethyl 
azodicarboxylate, DEAD, (1.64 cm3,10.4mM) dropwise at 0°C under nitrogen. The 
reaction mixture was allowed to warm to room temperature and stirred under nitrogen 
for 6 h. Half of the THF was removed in vacuo and water (100 cm3) was added to the 
residue. Ethyl acetate (50 cm3) was added and the organic layer was separated, and 
the aqueous layer was extracted with diethyl ether (2 x 25 cm3). The combined 
organic extracts were dried over magnesium sulphate, concentrated in vacuo, and 
purified by column chromatography, eluting with ethyl acetate-petrol (1 :2 0 ) to give 
the benzoyl ester (66) (2.7g, 6 8 %) as a white solid, m.p. 191-192°C (Rf = 0.45, ethyl 
acetate-petrol (3:37)); omax (NUJOL)cm*1 1699 s (C=0), 1670 (C=C), 711 (C-H, Ar); 
5h (270 MHz, CDC13) 8.07-7.39 (5H, m, Ar), 5.32 (1H, t, J6J 2.7 Hz, H-C(6 )), 
5.26-5.24 (1H, m, HpC(3)), 2.13 (3H, s, H3C(21)), 1.06 (3H, s, H3C(19)), 0.65 (3H, s, 
H3C(18)); m/z (C.I.) 421 ([M++1], 41%), 403 (3), 299 (100), 281 (17), 257 (6 ); Found 
: C, 80.3; H, 8.73. C28H360 3 requires C, 80.0; H, 8.57%.
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3a-Pregnenolone (67)
Method 1
3a-Benzoylpregnenolone (6 6 ) (250mg, 0.60mM) in methylene chloride (1 cm3) was 
added to a stirred solution of sodium hydroxide (250mg, 6 . ImM) in methanol (5 cm3). 
The reaction mixture was stirred at 80°C for lh. After allowing the mixture to cool it 
was diluted with methylene chloride (20 cm3) and washed with dil. HC1 (2x15  cm3), 
with care, and water ( 2x10  cm3). The organic layer was dried over anhydrous 
sodium sulphate and evaporated under reduced pressure. The residue was purified by 
column chromatography, eluting with ethyl acetate-petrol (1:5) to give 
3a-pregnenolone (67) (130mg, 69%) as a white solid, m.p. 114-115°C (Rf = 0.33, 
ethyl acetate-petrol (1:2)); [a]22D = + 16.2° (C=1.05 in CH2C12); vmax (NUJOLVcm' 1 
3381 br (OH), 1703 s (0=0), 1665 (C=C); 5H (270 MHz, CDC13) 5.42-5.39 (1H, m, 
H-C(6 )), 4.05-3.98 (1H, m, Hp-C(3)), 2.13 (3H, s, H3C(21)), 1.01 (3H, s, H3C(19)), 
0.63 (3H, s, H3C(18)); 5c (CDC13) 209.40 (C-20), 138.58 (C-5), 123.27 (C-6 ), 71.44 
(C-3); m/z (E.I.) 316 (M+, 21%), 298 (38), 283 (22), 261 (15), 145 (22), 71 (59), 57 
(100); Found : C, 79.4; H, 10.3. C21H320 2 requires C, 79.7; H, 10.1%.
Method 2
3a-Pregnenolone formate (6 8 ) (lOg, 0.029M) in methylene chloride (50 cm3) was 
added to a stirred solution of potassium carbonate (lOg, 0.072M) in methanol (750 
cm3). The reaction mixture was stirred at room temperature for 30 min, after which 
water (200 cm3) was added. The mixture was then extracted with methylene chloride 
(2 x 500 cm3). The organic layer was washed with dil. HC1 (2 x 50 cm3) and water (2 
x 50 cm3), and dried over anhydrous sodium sulphate, evaporated under reduced 
pressure and purified by crystallisation from ethyl acetate-petrol to give 
3a~pregnenolone (67) (7.9g, 8 6 %) as a white solid, m.p. 114-115°C. (Rf = 0.33, ethyl 
acetate-petrol (1 :2 )).
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3a-Pregnenolone formate (6 8 )
To a stirred solution of pregnenolone (lOg, 32.0mM), formic acid (2.0 cm3, 51.0mM) 
and triphenylphosphine (18.25g, 70.0mM) in THF (250 cm3) was added diethyl 
azodicarboxylate (10.0 cm3, 64.0mM) dropwise at 0°C under nitrogen. The reaction 
mixture was allowed to warm to room temperature and stirred under nitrogen for 4h. 
It was then concentrated at reduced pressure and the residue dissolved in methylene 
chloride (150 cm3). Water (50 cm3) was added, the organic layer was separated, and 
the aqueous layer was extracted with diethyl ether (2 x 30 cm3). The combined 
organic extracts were washed with brine (50 cm3), dried over magnesium sulphate, 
and evaporated in vacuo. The residue was purified by column chromatography, 
eluting with ethyl acetate-petrol (1:10) to give thtform yl ester (6 8 ) (7.95g, 73%) as a 
white solid, recrystallised from ethyl acetate, m.p. 153-154°C (Rf = 0.68, ethyl 
acetate-petrol (3:7)); [<x]22D = +11.1 (C=1.14 in EtOH); \)max (NUJOLVcm' 1 1714 s 
(HC=0), 1699 s ((20)C=O), 1676 (C=C); 5H (200 MHz, CDC13) 8.06 (1H, s, HCOO), 
5.36-5.29 (1H, m, H-C(6 )), 5.21-5.12 (1H, m, Hp-C(3)), 2.13 (3H, s, H3C(21)), 1.04 
(3H, s, H3C(19)), 0.66 (3H, s, H3C(18)); mlz (C.I.) 345 ([M++l], 30%), 327 (11), 299 
(100), 281 (13), 255 (5), 147 (5), 85 (8 ); Found : C, 76.5; H, 9.45. C22H320 3 requires 
C, 76.7; H, 9.30%.
5a,6a-Epoxypregnan-3a-ol-20-one (69)
60% m-Chloroperoxybenzoic acid (1.6g, 7.2mM) was added to a stirred solution of 
3a-pregnenolone (67) (2.0g, 6.0mM) in methylene chloride (50 cm3). The reaction 
mixture was stirred at room temperature under nitrogen for 1 h. After this 25% 
sodium sulphite solution and 25% sodium bicarbonate solution were added 
cautiously, with stirring, until the starch-iodide test gave a negative result The 
solution was then extracted with methylene chloride (2 x 50 cm3). The organic 
extracts were combined and dried over anhydrous sodium sulphate, concentrated in 
vacuo and purified by column chromatography, eluting with ethyl acetate-toluene
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(1:2) to give the epoxide (69) (1 .7 7 g, 84%) as a white solid, m.p. 118-119°C (Rf = 
0.20, ethyl acetate-petrol (1:2)); \)max (NUJOLVcm1 3401 br (OH), 1696 s (C=0), 
1248 (C-O); 5h (200 MHz, CDC13) 4.15-4.05 (1H, m, Hp-C(3)), 2.90 (1H, d, J6J 5.1 
Hz, Hp-C(60), 2.12 (3H, s, H3C(21)), 1.07 (3H, s, H3C(19)), 0.58 (3H, s, H3C(18)); 5C 
(400 MHz, CDC13) 209.50 (C-20), 67.75 (C-3), 65.28 (C-5), 63.23 (C-6 ); m/z (E.I.) 
332 (M+, 13%), 314 (11), 301 (7), 281 (6 ), 211 (10), 71 (32), 43 (100); Found : C, 
73.6; H, 9.25. C21H320 3 + 72EtOAc requires C, 73.4; H, 9.57%.
Pregnan-3a£a20$-triol (70)
To a stirred suspension of lithium aluminium hydride (858mg, 22.6mM) in THF (25 
cm3) was added the epoxide (69) (1.5g, 4.5mM) in THF (25 cm3) dropwise. The 
reaction mixture was refluxed for 4h. After allowing the reaction mixture to cool to 
room temperature 1% potassium hydroxide solution was added to quench. The 
resulting white precipitate was filtered through celite and the filtrate concentrated in 
vacuo. The residue was dissolved in methylene chloride (50 cm3) and washed with 
water ( 2x15  cm3). The organic layer was dried over anhydrous sodium sulphate, 
evaporated under reduced pressure, and purified by column chromatography, eluting 
with ethyl acetate-petrol (2:1) to give the triol (70) (577mg, 38%) as a white solid, 
m.p. 261-262°C (Rf = 0.48, methanol-CH2Cl2 (1:19)); umax (NUJOLVcm ' 1 3436 sh 
(OH); 8 h (200 MHz, CDC13) 4.12-4.04 (1H, m, Hp-C(3)), 3.80-3.67 (1H, m, 
^ -0 (2 0 )) , 1.15 (3H, d, / 2Uo 6.0 Hz, H3C(21)), 0.95 (3H, s, H3C(19)), 0.74 (3H, s, 
H3C(18)); miz (C.I.) 337 ([M++l], 1%), 319 (24), 301 (100), 283 (29), 264 (13); 
Found : C, 75.2; H, 11.0. C21H360 3 requires C, 75.0; H, 10.7%.
3a,20$-Diacetoxypregnan-5a-ol (71)
Pregnan-3a£a20$-triol (70) (500mg, 1.5mM) and acetic anhydride (0.42 cm3, 
0.5mM) were stirred together in pyridine (5 cm3) at room temperature for 24h. The 
reaction mixture was then poured into saturated brine (25 cm3) and the resulting white 
solid filtered off. The solid was washed with dil. HC1 and water, and then dissolved
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in methylene chloride(20 cm3). Water (5 cm3) was then added, the organic layer was 
separated, and the aqueous layer was extracted with ethyl acetate ( 2 x 15  cm3). The 
combined organic extracts were dried over anhydrous sodium sulphate, concentrated 
in vacuo, and purified by column chromatography, eluting with ethyl acetate-petrol 
(1:5) to give the diacetate (71) (606mg, 97%) as a white solid, m.p. 172-173°C (Rf = 
0.40, ethyl acetate-petrol (1:4)); \)max (NUJOLVcm' 1 3577 sh (OH), 1728 s (C=0), 
1246 (C-O); 5h (270 MHz, CDC13) 5.23-5.18 (1H, m, Hp-C(3)), 4.84 (1H, dq,720,2i 
6 .1 ,/20,i7 10-3 Hz, ^ -0 (2 0 )), 2.07 (3H, s, H3CCO), 2.02 (3H, s, H3CCO), 1.14 (3H, 
d, J2h2o 6.1 Hz, H3C(21)), 0.95 (3H, s, H3C(19)), 0.63 (3H, s, H3C(18»; m/z (E.I.)
420 (M+ missing), 402 ([M+ - H20], 10%), 358 (6 ), 342 (54), 306 (60), 282 (26); 
Found : C, 71.7; H, 9.91. C^H ^O s requires C, 71.4; H, 9.52%.
(E)-3a20$-Diacetoxy-5,10-secopregn-l( 10)-en-5-one (72)
Ceric ammonium nitrate (754mg, 1.38mM) in water (3 cm3) was added to a stirred 
solution of 3a20$-diacetoxypregnan-5a.-ol (71) (230mg, 0.55mM) in acetonitrile (10 
cm3) at 80°C. After 3 min at 80°C the mixture was immediately poured into ice/25% 
sodium bicarbonate solution (50 cm3) and the solution extracted with methylene 
chloride (2 x 50 cm3). The combined organic extracts were washed with water (2 x 
25 cm3), dried over anhydrous sodium sulphate and concentrated in vacuo. The 
residue was purified by column chromatography, eluting with ethyl acetate-petrol 
(3:17) to give (E)-3a,20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (72) (85mg,
37%) as a white solid, m.p. 138-139°C (Rf = 0.36, ethyl acetate-petrol (1 :4)); \)max 
(NUJOLVcm' 1 1731 s (C=0), 1702 s (C=0), 1643 (C=C), 1246 (C-O); 5H (270 MHz, 
CDC13) 5.27-5.22 (1H, m, Hp-C(3)), 4.93-4.79 (2H, m, HE-C(1) + H-C(20)), 2.05 (3H, 
s, H3CCO), 2.03 (3H, s, H3CCO), 1.74 (3H, s, H3C(19)), 1.14 (3H, d, / 2 U 0  6.1 Hz, 
H3C(21)), 0.71 (3H, s, H3C(18)); m/z (E.I.) 418 (M+, missing), 358 (M+ - AcOH, 
39%), 340 (7), 298 (8 ), 280 (14), 147 (16), 121 (18), 43 (100).
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3a-Benzoyl-20-ethylenedioxypregnan-5a-ol (73)
To a stirred solution of benzoic acid (360mg, 3.20mM), triphenylphosphine (840mg, 
3.20mM) and 20-ethylenedioxypregnan-3$£a-diol (27) (l.Og, 2.66mM) in THF (100 
cm3) under nitrogen was added diethylazodicarboxylate (0.5 cm3, 3.20mM) in THF 
(50 cm3) dropwise. The initial orange solution became colourless and the reaction 
mixture was stirred at room temperature for 1 2 h, after which it was concentrated in 
vacuo, diluted with ether (50 cm3) and washed successively with ammonium chloride 
solution ( 2 0  cm3), saturated sodium bicarbonate solution ( 2 0  cm3), and water ( 2  x 2 0  
cm3). The organic extract was dried over anhydrous sodium sulphate and 
concentrated under reduced pressure. The residue was recrystallised from petrol to 
give the 3a~benzoate (73) (500mg, 40%) as a white solid, m.p. 192-193°C (Rf = 0.62, 
ethyl acetate-petrol (1:4)); \)max (NUJOLVcm' 1 3590 br (OH), 1710 s (C=0), 1635 s 
(C-C, Ar), 1251 (C-O), 907 (C-H, Ar); 5H (270 MHz, CDC13) 8.00-7.45 (5H, m, Ar),
5.47-5.43 (1H, m, Hp-C(3)), 3.98-3.82 (4H, m, OCH2CH20), 3.20 (1H, brs, HO-C(5)), 
1.28 (3H, s, H3C(21)), 1.06 (3H, s, H3C(19)), 0.67 (3H, s, H3C(18)); m/z (C.I.) 483 
([M++ l], 3%), 465 (2), 87 (100).
20-Ethylenedioxypregna-3a,5a-diol (74)
3a-Benzoyl-20-ethylenedioxypregnan’5a-ol (73) (70mg, 0.15mM) was added to a 
stirred solution of sodium hydroxide (24mg, 0.58mM) in 1:1 mixture of methanol and 
methylene chloride (10 cm3). The reaction mixture was stirred vigorously at room 
temperature for 3h, after which it was diluted with methylene chloride (10 cm3) and 
washed with saturated sodium bicarbonate solution ( 2 x 5  cm3) and water ( 2 x 5  cm3). 
The organic extract was dried over anhydrous sodium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (1:2) to give the 3a£a-diol (74) (41 mg, 76%) as a white solid, m.p. 
182-184°C (Rf = 0.24, ethyl acetate); \>max (CHC13 sol.Vcm1 3390 br (OH), 1254 S 
(C-O); 6 h (270 MHz, CDC13) 4.14-4.06 (1H, m, Hp-C(3)), 3.98-3.83 (4H, m, 
0C H 2CH20 ), 1.29 (3H, s, H3C(21)), 1.02 (3H, s, H3C(19)), 0.74 (3H, s, H3C(18));
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mlz (CL) 379 ([M++l], 5%), 87 (100).
3a£a-Dihydroxypregnan-20-one (75)
20-Ethylenedioxypregnan-3aJa-diol (74) (300mg, 0.8mM) and aq. sulphuric acid 
solution (2 cm3 of IN) were refluxed in methanol (30 cm3) for 30 min. After cooling 
the reaction mixture was diluted with water ( 2 0  cm3) and extracted with methylene 
chloride (30 cm3). The organic layer was washed with sodium bicarbonate solution 
( 2 0  cm3) and water ( 2  x 1 0  cm3), dried over anhydrous sodium sulphate and 
concentrated in vacuo. The residue was recrystallised from ethyl acetate-petrol to 
give the diol (75) (130mg, 50%) as white needles, m.p. 182-183°C (Rf = 0.39, ethyl 
acetate-petrol (1:1)); [a]22D = + 105.6° (C=0.973 in CHC13); vmax (NUJOLVcm"1 
3319 sh (OH), 3207 sh (OH), 1697 s (0=0); 6 H (200 MHz, CDC13) 4.14-4.06 (1H, m, 
Hp-C(3)), 2.90-2.76 (1H, brs, O-H), 2.55 (1H, t, J llA6 8.4 Hz, H-C(17)), 2.12 (3H, s, 
H3C(21)), 0.92 (3H, s, H3C(19)), 0.60 (3H, s, H3C(18)); 6 C (400 MHz, CDC13) 209.76 
(C-20), 74.82 (C-5), 67.78 (C-3); m/z (C.I.) 335 ([M++l], 42%), 317 (100), 299 (8 8 ), 
281 (11), 262 (18); Found : C, 75.3; H, 10.1. Q i H ^  requires C, 75.4; H, 10.2%.
Attempted hydrogenation of(E)-3$,20$-diacetoxy-5,10-secopregn-l( 10)-en-5-one 
(39)
Method 1
A  solution of (E)-3$,20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (250mg, 
0.60mM) and 10% palladium on activated carbon (25mg, 10% w/w) in ethanol (20 
cm3) was degassed under nitrogen for 15 min. The reaction mixture was stirred under 
an atmosphere of hydrogen at atmospheric pressure for 1 week. After filtration, the 
solution was worked up as normal. No saturated product was isolated, just unreacted 
starting material (245mg, 98%).
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Method 2
30% Hydrogen peroxide (0.045 cm3 ,0.45mM) was added to a stirred solution of 
(E)-3$,20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (60mg, 0.14mM), 
hydrazine (0.023 cm3,0.74mM) and a trace of copper (II) sulphate in ethanol (5 cm3). 
The reaction mixture was stirred at 0°C for 2h and a further 24h at room temperature, 
under nitrogen. Water (10 cm3) was added to quench and the mixture extracted with 
methylene chloride (2x15  cm3). After normal work up, no saturated product was 
isolated, just unreacted starting material (47mg, 78%).
Method 3
A stirred solution of (E)-3$-20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) 
(lOOmg, 0.24mM), palladium (II) hydroxide (25mg, 25% w/w) and freshly distilled 
cyclohexene (1 cm3) in ethanol (5 cm3) was refluxed for 24h. After cooling the 
mixture was filtered, and the filtrate concentrated in vacuo. The residue was dissolved 
in methylene chloride ( 1 0  cm3), and the solution washed with water ( 2 x 5  cm3), dried 
over magnesium sulphate and evaporated under reduced pressure. The residue was 
purified by column chromatography, eluting with ethyl acetate-petrol (1:4) to give no 
saturated product, just unreacted starting material (97mg, 97%).
Preparation o f pregnanolone (77)
10% Palladium on activated carbon (250mgs, 25% w/w) was added under nitrogen to 
pregnenolone (lg, 3.16mM) in ethanol (50 cm3). After degassing the mixture for 15 
min it was stirred under an atmosphere of hydrogen at atmophseric pressure for 2.5h. 
The catalyst was removed via filtration through celite, and the filtrate concentrated in 
vacuo. The resulting colourless oil was diluted using ethyl acetate (50 cm3), washed 
with water (2 x 1 0  cm3), and the organic extract dried over anhydrous sodium 
sulphate. The solvent was removed in vacuo and the residue was purified by column 
chromatography on silica gel, eluting with ethyl acetate-petrol (1:4) to give
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pregnanolone (77) (894mg, 89%) as a white solid, m.p. 204-205°C (Rf = 0.51, ethyl 
acetate-petrol (3:7)); omax (NUJOLVcm 1 3389 br (OH), 1678 (C=0); 5H (270 MHz, 
CDC13) 3.66-3.54 (1H, m, H^Ctf)), 2.52 (1H, t, J  9.0 Hz, H-C(17)), 2.11 (3H, s, 
H3C(21)), 0.71 (3H, s, H3C(19)), 0.60 (3H, s, H3C(18)); m/z (E.I.) 318 (M+, 34%), 
300 (22), 285 (10), 215 (28), 107 (31), 43 (100); Found : C, 79.1; H, 11.0. C2 iH340 2 
requires C, 79.2; H, 10.7%.
20$-Acetoxy-5( 10—*l$H)abeopregnane (78)
A solution of 3$20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (l.Og, 2.39mM) 
and 10% palladium on carbon (lOOmg, 10% w/w) in methylene chloride (100 cm3) 
was degassed under nitrogen for 15 min. The reaction mixture was then stirred under 
an atmosphere of hydrogen at atmospheric pressure for 72h. The mixture was filtered 
and the filtrate washed with water (2 x 30 cm3), dried over magnesium sulphate, and 
purified by column chromatography, eluting with ethyl acetate-petrol (1:49) to give 
20$-acetoxy-5( 10^>l$H)abeopregnane (78) (529mg, 64%) as a white solid, m.p. 
73-74°C (Rf = 0.82, ethyl acetate-petrol (1:9)); \)max (NUJOLVcm-1 1734 s (C=0), 
1244 (C-O); 5h (270 MHz, CDC13) 4.88-4.78 (1H, m, H-C(20)), 2.02 (3H, s, H3CCO),
1.14 (3H, d, / 2 U 0 6.0 Hz, H3C(21)), 0.94 (3H, d, J l9 10 7.5 Hz, H3C(19)), 0.65 (3H, s, 
H3C(18)); 5c (CDC13) 170.51 (C=0), 72.96 (C-20); m/z (E.I.) 346 (M+, 6 %), 286 (70), 
271 (13), 257 (15), 232 (15), 218 (35), 43 (100); Found : C, 79.4; H, 11.1. C ^ H ^  
requires C, 79.7; H, 11.0%.
5(10—*l$H)Abeopregnan-20$-ol (79)
A solution of 20$-acetoxy-5(10~*l$H)abeopregnane (78) (300mg, 0.87mM) and 
potassium carbonate (300mg, 2.17mM) in methanol (15 cm3) was stirred at room 
temperature for 96h. Water (5 cm3) was added, and the mixture extracted with 
methylene chloride (2 x 30 cm3), dried over anhydrous sodium sulphate and 
concentrated in vacuo. The residue was purified by column chromatography, eluting 
with ethyl acetate-petrol (1:19) to give 5(10~*l$H)abeopregnan-20$-ol (79) (253mg,
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96%) as a white solid, m.p. 73-74°C (Rf = 0.52, ethyl acetate-petrol (1:9)); \)max 
(NUJOLVcm ' 1 3385 br (OH), 1246 (C-O); 8 H (270 MHz, CDC13) 3.73 (1H, dq, / 20>21
6.0, y20t 17 9.7 Hz, H-C(20)), 1.13 (3H, d, J212q 6-2 Hz, H3C(21)), 0.94 (3H, d, / 19tl0
7.3 Hz, H3C(19)), 0.77 (3H, s, H3C(18)); m/z (C.I.) 305 ([M++l], 1%), 287 (100), 271
(5), 259 (7), 218 (61), 151 (30), 123 (23), 95 (20); Found : C, 82.1; H, 12.2. 
C21H360.V 6H20  requires C, 82.1; H, 11.8%.
Attempted preparation of3$,20$-dihydroxy-5,10-secopregn-l(10)-en-5-one (47) 
3$,20$-Diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (l.Og, 2.39mM) and potassium 
hydroxide (147mg, 2.63mM) were refluxed together in diethylene glycol (20 cm3) for 
2h. After cooling, water (20 cm3) was added and the reaction mixture extracted with 
methylene chloride (3 x 25 cm3). The combined organic extracts were washed with 
dil. HC1 (20 cm3) and water (2 x 20 cm3), dried over anhydrous sodium sulphate, and 
concentrated in vacuo. The residue was purified by column chromatography, eluting 
with ethyl acetate-petrol (1:1) to give 5(10-*l$H)abeopregn-10(19)-ene-3$,5a20$-t- 
riol (80) (199mg, 25%) as a colourless oil, (Rf = 0.20, ethyl acetate-petrol (1:1)); \)max 
(FILMVcm-1 3410 br (OH), 1628 (C=C); 5H (270 MHz, CDC13) 5.14 (1H, s,
H-C(19)), 4.99 (1H, s, H-C(19)), 4.52-4.42 (1H, m, Ha-C(3)), 3.79-3.68 (1H, m, 
H-C(20)), 3.22-3.12 (1H, m, H-C(l)), 1.13 (3H, d,y21t20 6.1 Hz, H3C(21)), 0.80 (3H, 
s, H3C(18)); m/z (E.I.) 334 (M+, 75%), 316 (100), 298 (29), 272 (18), 248 (34), 233 
(14), 165 (21), 155 (13), 147(10).
3$,20$-Acetoxy-5-(propyl dithiane)-5,10-secopregn-l( 10)-ene (81)
1,3-Propane dithiol (0.48 cm3,4.79mM) was added to a stirred solution of 
3$,20$-diacetoxy-5,10-secopregn-l (10)-en-5-one (39) (2.0g, 4.79mM) and p-TSA 
(LOg, 5.8mM), recrystallised from water, in acetic acid (20 cm3). The reaction 
mixture was stirred at room temperature for 12h. Water (10 cm3) was added and the 
solution extracted with methylene chloride (3 x 25 cm3), dried over magnesium 
sulphate and evaporated under reduced pressure. Purification by column
- 1 7 7 -
chromatography, eluting with ethyl acetate-petrol (1 :9) gave the dithiane (81)
(192mg, 8 %) as a yellow/brown solid, m.p. 92-93°C (Rf = 0.58, ethyl acetate-petrol 
0:4)); Umax (NUJOLVcm1 1730 s (C=0), 1641 (C=C); 5H (270 MHz, CDC13) 
5.69-5.50 (1H, m, ^ - 0 (3 ) ) ,  4.83-4.64 (2H, m, HE-C(1) + H-C(20)), 2.62-2.15 (6 H, 
m, SCH2CH2CH2S), 1.99 (3H, s, H3CCO), 1.96 (3H, s, H3CCO), 1.76 (3H, s, 
H3C(19)), 1.08 (3H, d, 721t20 6.0 Hz, H3C(21», 0.57 (3H, s, H3C(18)); 6 C (CDC13) 
171.21 (C=0), 170.70 (C=0), 141.52 (C-10), 123.97 (C-l), 72.11 (C-20), 72.06 (C-3); 
mlz ((+)FAB in NBA) 508 (M+, 13%), 449 (19), 401 (16), 341 (91), 281 (100), 253
(6 ); ((-)FAB in NBA) 507 ([M+-l], 100%), 470 (9), 433 (36), 391 (17), 373 (15), 322 
(24), 302 (21), 273 (17); Found : C, 61.3; H, 8.25. Q g H ^ O ^ V ^ O  requires C, 
61.3; H, 8.84%.
9-Dihydroxyandrost-5(6)-en-17-one (83)
Potassium carbonate (5.0g, 36.2mM) was added to a stirred solution of 
3$-acetoxyandrost-5(6)-en-19-ol-17-one (82) (5.0g, 14.5mM) in methanol (100 cm3). 
The reaction mixture was stirred at room temperature for 3h. Water (50 cm3) was 
added and the solution was extracted with methylene chloride (100 cm3). The organic 
layer was washed with dil. HC1 (20 cm3) and water (2  x 25 cm3), dried over 
anhydrous sodium sulphate and concentrated at reduced pressure. The residue was 
purified by column chromatography eluting, with ethyl acetate-petrol (3:2) to give the 
diol (83) (3.8g, 87%) as a white solid, which on recrystallisation from ethyl acetate 
gave needles, m.p. 229-231°C (Rf = 0.25, ethyl acetate-petrol (3:2)); \)max 
(NUJOLVcm1 3342 br (OH), 1732 s (C=0), 1666 (C=C); 5H (270 MHz, DMSO-d*) 
5.48 (1H, brs, H-C(6 )), 4.61 (1H, d, J 4.6 Hz, H-OC(3)), 4.37 (1H, t , /4 .7  Hz, 
H-OC(19)), 3.68 ( lH ,d d ,/4 .5 ,/gem 11.3 Hz, H-C(19)), 3.40 ( 1H, d d , / 5 .3 ,/ gem 11.3 
Hz, H-C(19)), 3.34-3.22 (1H, m, ^ -0 (3 ) ) ,  0.83 (3H, s, H3C(18)); 6 C (DMSO-d6) 
219.91 (C-17), 138.20 (C-5), 122.99 (C-6 ), 70.09 (C-3), 61.80 (C-19); m/z (C.I.) 305 
([M++l], 23%), 287 (100), 269 (64), 256 (94), 223 (10), 145 (12), 69 (15); Found : C, 
74.9; H, 9.43. C19H280 3 requires C, 75.0; H, 9.21%.
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3p, 19-Dihydroxy-17-( 1,3-propane dithiane)-androst-5(6)-ene (84)
To a stirred solution of 3$,19-dihydroxyandrost-5(6)-en-17-one (83) (l.Og, 3.29mM) 
and 1,3-propanedithiol (0.36 cm3, 3.62mM) in methanol (5 cm3) was added boron 
trifluoride etherate (1.0 cm3, 8.13mM). The reaction mixture was stirred at room 
temperature for 30 min and then the resulting white precipitate was filtered off and 
washed with water (15 cm3) and methanol (10 cm3). The white solid was dried under 
vacuum and then recrystallised from ethyl acetate to give the propanedithiane (84) 
(912mg, 70%) as a white solid, m.p. 189-191°C (Rf = 0.28, ethyl acetate-petrol 1:1)); 
Umax (NUJOLVcm’1 3355 br (OH), 1666 (C=C), 1365 (C-5); 5H (270 MHz, CDC13) 
5.78-5.72 (1H, m, H-C(6 )), 3.87 (1H, d , / gem 11.7 Hz, H-C(19)), 3.63 (1H, d , / gem
11.7 Hz, H-C(19)), 3.03-2.34 (6 H, m, SCH2CH2CH2S), 1.06 (3H, s, H3C(18)); 8 C 
(CDC13) 135.59 (C-5), 126.89 (C-6 ), 71.23 (C-3), 63.20 (C-17), 62.75 (C-19), 42.17 
(S-CH^, 39.62 (S-CH^; m/z (C.I.) 395 ([M++l], 60%), 377 (35), 365 (20), 347 (19), 
289 (22), 271 (100), 241 (39), 149 (33), 107 (40); Found : C, 64.1; H, 8.92. 
C22H34S20 2 .H20  requires C, 64.1; H, 8.74%.
3fi,19-Diacetoxy-17-ethanedithianeandrost-5(6)-ene (85)
To a stirred solution of 3$-acetoxyandrost-5(6)-en-19-ol-17-one (82) (890mg, 
2.58mM) and ethane dithiol (0.23 cm3, 2.84mM) in acetic acid (15 cm3) was added 
boron trifluoride etherate (1.0 cm3, 8.13mM). The reaction mixture was stirred at 
room temperature for 2h. Diethyl ether (25 cm3) was added, together with water (10 
cm3). The organic layer was separated and washed with water ( 2 x 1 0  cm3), dried 
over magnesium sulphate and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel, eluting with ethyl acetate-petrol (1:19) to give 
the dithiane (85) (492mg, 41%) as a white solid, m.p. 93-94°C (Rf = 0.52, ethyl 
acetate-petrol (1:19)); omax (NUJOLVcm1 1729 s (C=0), 1722 s (C=0), 1666 (C=C), 
1244 (C-O); 5h (270 MHz, CDC13) 5.64-5.60 (1H, m, H-C(6)), 4.68-4.56 (1H, m, 
H ^CQ )), 4.50 (1H, d, / gem 11.8 Hz, H-C(19)), 3.96 (1H, d, / gcm 11.8 Hz, H-C(19)),
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3.33-3.07 (4H, s, SCH2CH2S), 2.04 (3H, s, H3CCO), 2.02 (3H, s, H3CCO), 0.95 (3H, 
s, H3C(18)); m/z (C.I.) 465 ([M++l], 25%), 436 (4), 421 (1), 405 (100), 371 (5), 345 
(31), 251 (16), 237 (10); Found : C, 63.7; H, 7.87. C ^ H ^ S ^ . V ^ O  requires C, 
63.8; H, 7.80%.
3$,20$-Diacetoxy-5,10-secopregn-l(I0)-ene (8 6 )
Method 1
Sodium iodide (3.50g, 23.2mM) and sodium acetate (400mg, 4.82mM) were stirred in 
acetic acid (20 cm3). After cooling in an ice-bath zinc dust (5.0g, 76.9mM) was 
added to the reaction mixture followed by the dropwise addition of 
l$,10a-epoxy-3f>20$-diacetoxy-5,10-secopregnane (95) (460mg, 1.1 OmM) in acetic 
acid (15 cm3). The reaction mixture was allowed to warm to room temperature and 
stirred for 5 days. The reaction mixture was diluted with water (50 cm3) and 
extracted with methylene chloride (3 x 50 cm3). The combined organic extracts were 
washed with water (2 x 30 cm3), dried over magnesium sulphate and concentrated 
under reduced pressure. The residue was purified by column chromatography, eluting 
with ethyl acetate-petrol (1:39) to give 3$,20$-diacetoxy-5,10-secopregn-l(10)-ene 
(86) (182mg, 73% corrected recovered for starting material) as a colourless oil, (Rf = 
0.65, ethyl acetate-petrol (1:9)); \)max (FILMVcm1 1733 s (C=0), 1654 (C=C), 1241 
(C-O); 5h (270 MHz, CDC13) 5.42-5.35 (1H, m, Hz-C(l)), 5.09-4.98 (1H, m, 
^ - 0 (3 ) ) ,  4.84 (1H, dq, y20,2i 6.1 J20A110.3 Hz, H-C(20)), 4.81 ( 1H, m, HE-C(1)),
2.03 (3H, s, H3CCO), 2.02 (3H, s, H3CCO), 1.65 (3H, s, H3C(19)), 1.15 (3H, d , / 21t20
6.1 Hz, H3C(21)), 0.64 (3H, s, H3C(18)). m/z (C.I.) 405 ([M++l], 1%), 363 (38), 345 
(17), 303 (100), 285 (95), 273 (6 ).
The next elutes gave l$,10a-epoxy-3$,20§-diacetoxy-5,10-secopregnane (95) 
(204mg, 43%). Further elutes gave 3$,20$-diacetoxy-5,10-secopregn-10( 19)-e- 
n-la-ol (98) (58mg, 13%) as a colourless oil, (Rf = 0.09, ethyl acetate-petrol (1:9));
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\>max (FILMVcm ' 1 3386 br (OH), 1728 s (C=0), 1646 (C=Q, 1243 (C-O); 5H (270 
MHz, CDC13) 5.40 (1H, s, H-C(19)), 5.06 (1H, s, H-C(19)), 4.89-4.76 (2H, m,
Ha-C(3) + H-C(20)), 4.13 (1H, dd, JlX  7.1 J l T  14.3 Hz, H-C(l)), 2.08 (3H, s, 
H3CCO), 2.04 (3H, s, H3CCO), 1.16 (3H, d, / 2U20 6.0 Hz, H3C(21)), 0.70 (3H, s, 
H3C(18)); m/z (C.I.) 421 {M++l], 1%), 403 (5), 361 (30), 343 (22), 301 (90), 283 
(100), 271 (7).
Method 2 (Scheme 51)
A suspension of (E)-3$,20$-diacetoxy-5(propyl dithiane)-5,10-secopregn-l(10)-ene 
(81) (73mg, 0.14mM) and W-2 raney nickel (1.74g, 29.5mM) in ethanol (20 cm3) was 
refluxed for lh. After cooling,the reaction mixture was filtered overcelite and the 
filtrate concentrated under reduced pressure. The residue was dissolved in methylene 
chloride ( 2 0  cm3) and washed with water (2 x 1 0  cm3), dried over magnesium 
sulphate and concentrated in vacuo. Purification by column chromatography, eluting 
with ethyl acetate-petrol (1:49) gave (E)-3f>,20$-diacetoxy-5,10-secopregn-l(10)-ene
(8 6 ) (43mg, 71%) as a colourless oil (Rf = 0.65, ethyl acetate-petrol (1:9)).
(E)-3$20$-Diacetoxy-5,10-secopregn-l(10)-en-5a.-ol (87)
3fi,20$-Diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (l.Og, 2.39mM) in ethanol (10 
cm3) was added dropwise to a stirred solution of sodium borohydride (109mg, 
2.87mM) in ethanol (15 cm3) at 0°C. The reaction mixture was stirred at 0°C for 2h 
and then allowed to warm to room temperature and stirred for a further 7h. Water (10 
cm3) was added to quench and the reaction mixture extracted with methylene chloride 
(3 x 25 cm3). The combined organic extracts were dried over anhydrous sodium 
sulphate, evaporated under reduced pressure, and purified by column 
chromatography, eluting with ethyl acetate-petrol (1:3) to give the 5a-hydroxyl (87) 
(770mg, 77%) as a white solid, m.p. 123-124°C (Rf = 0.32, ethyl acetate-toluene 
(1:2)); [a)n D = -3.8° (C=1.30, CH2C12); \>max (NUJOLVcnr1 3510 br (OH), 1724 s 
(C=0), 1664 (C=C); 5H (400 MHz, CDC13) 5.38-5.30 (1H, m, Ha-C(3)), 5.16-5.07
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(1H, m, HE-C(1)), 4.85 (1H, dq, / 20,21 6 . 3 , 1 0 . 5  Hz, Ha-C(20)), 4.12-4.05 (1H, 
m, Hp-C(5)), 2.07 (3H, s, H3CCO), 2.02 (3H, s, H3CCO), 1.76 (3H, s, H3C(19)), 1.15 
(3H, s, J2h 20 5.9 Hz, H3C(21)), 0.66 (3H, s, H3C(18)); 5C (270 MHz, CDC13) 170.53 
(C=0), 170.40 (C=0), 123.78 (C-10), 117.48 (C-l), 72.70 (C-3), 71.03 (C-20), 
67.08(C-5); mlz (C.I.) 421 ([M++l], 1%), 403 (1), 361 (5), 343 (9), 301 (22), 283 (25); 
Found C, 70.3; H, 9.53. C ^ H ^ C V ^ O  requires C, 70.4; H, 9.55%.
Attempted elimination ofC-5 hydroxyl o f (E)-3$,20$-diacetoxy-5,10-secopreg- 
n-l(10)-en-5a-ol (87)
Method 1
A  solution of (E)-3$,20$-diacetoxy-5,10-secopregn-l(10)-en-5a-ol (87) (lOOmg, 
0.24mM) and tosyl chloride (55mg, 0.29mM) in pyridine (5 cm3) was stirred at 0°C 
for 2h and a further 48h at room temperature under nitrogen. Water (10 cm3) was 
added and the resulting white solid filtered and washed with dil. HC1 (5 cm3), 
followed by water ( 2  x 2 0  cm3) and then dissolved in methylene chloride (15 cm3). 
The organic solution was washed with water ( 2 x 5  cm3), dried over magnesium 
sulphate, and concentrated in vacuo. Purification by column chromatography, eluting 
with ethyl acetate-petrol (1:19) gave
3$,20$-diacetoxy-5(10-+lf>H)abeopregn-l0(19)-ene (8 8 ) (95mg, 92%) as a 
colourless oil, (Rf = 0.75, ethyl acetate-petrol (3:7)); umax (FILM)/cm 1 1732 s (C=0), 
1727 s (C=0), 1632 (C=C), 1243 (C-O); SH (270 MHz, CDC13) 5.19-5.10 (1H, m, 
IV C tf)), 4.92-4.75 (1H, m, H-C(20)), 4.82 (1H, s, H-C(19)), 4.65 ( 1H, s, H-C(19)),
2.02 (3H, s, H3CCO), 1.98 (3H, s, H3CCO), 1.08 (3H, d, 721f20 6.0 Hz, H3C(21)), 0.64 
(3H, s, H3C(18)); mlz (C.I.) 403 ([M++l], 1%), 342 (22), 325 (2), 299 (1), 283 (100), 
267 (3), 253 (2); Found : C, 74.4; H, 9.64. C^HjgC^ requires C, 74.6; H, 9.45%.
Method 2
In the same way, (E)-3$20$-diacetoxy-5,10-secopregn-l(10)-en-5a-ol (87) (50mg,
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0 .12mM) and mesyl chloride (0.01 cm3, 0.14mM) in a 1:1 mixture of DMF : pyridine 
(2 cm3) gave 3$,20$-diacetoxy-5(10-*l$H)abeopregn-10(19)-ene (8 8 ) (38mg, 79%), 
purified by column chromatography, eluting with ethyl acetate-petrol (1:19), as a 
colourless oil, (Rf = 0.75, ethyl acetate-petrol (3:7)).
Method 3
A solution of (E)-3$,20$-diacetoxy-5,10-secopregnan-5a-ol (87) (20mg, 0.05mM) 
sodium iodide (29mg, 0.19mM), and trimethylsilyl chloride (0.012 cm3, 0.09mM) in 
acetonitrile (5 cm3) and stirred at 0-10°C under nitrogen for lh. After warming to 
room temperature, water (5 cm3) was added and the mixture extracted with methylene 
chloride ( 2 x 1 0  cm3). The combined organic extracts were dried over magnesium 
sulphate, evaporated under reduced pressure, and purified by column 
chromatography, eluting with ethyl acetate-petrol (1:19) to give 3$,20$-diacetox- 
y-5(10^>l$H)abeopregn-10(19)-ene (8 8 ) (lOmg, 52%) as a colourless oil, (Rf = 0.75, 
ethyl acetate-petrol (3:7)).
Attempted deoxygenation o f (E)-3$,20$-diacetoxy-5,10-secopregn-l(10)-en-5a-ol
(87)
Method 1
Pentafluorophenyl chlorothionoformate (0.046 cm3, 0.29mM) was added to a stirred 
solution of (E)-3$,20p-diacetoxy-5,10-secopregn-l(10)-en-5a-ol (87) (lOOmg, 
0.24mM), 3N-hydroxysuccinimide (6 mg, 0.05mM) and pyridine (0.02 cm3, 0.25mM) 
in toluene (10 cm3). The reaction mixture was refluxed for 1 h, and after cooling 
diluted with water (10 cm3). The mixture was extracted with methylene chloride (2 x 
10 cm3). The combined organic extracts were dried over magnesium sulphate, 
concentrated in vacuo, and purified by column chromatography, eluting with ethyl 
acetate-petrol (1:19) to give3$,20$-diacetoxy-5(10—*l$H)abeopregn-10(19)-ene (8 8 ) 
(81mg, 85%) as a colourless oil, (Rf = 0.75, ethyl acetate-petrol (3:7)).
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Method2
In a similar way, the above reaction mixture was stirred at '78 - "40°C for 4h. Water 
(5 cm3) was added and the mixture allowed to warm to room temperature. The 
solution was extracted with methylene chloride (2 x 1 0  cm3), and the combined 
organic extracts dried over magnesium sulphate, and concentrated in vacuo. 
Purification by column chromatography, eluting with ethyl acetate-petrol (1:19) gave 
3§,20$-diacetoxy-5(10-*l$H)abeopregn-10(19)-ene (8 8 ) (76mg, 79%) as a 
colourless oil, (Rf = 0.75, ethyl acetate-petrol (3:7)).
1 $,10a-Epoxy-3$,20$-diacetoxy-5,10-secopregnan-5-one (90)
60% m-Chloroperoxybenzoic acid (690mg, 2.39mM) was added to a stirred solution 
of (E)-3$20$-diacetoxy-5,10-secopregn-l(10)-en-5-one (39) (l.Og, 2.39mM) in 
methylene chloride (40 cm3). The reaction mixture was stirred at room temperature 
for 2h. Then 25% sodium sulphite solution and 25% sodium bicarbonate solution 
were added to quench, until the starch-iodide test gave a negative result. The layers 
were separated and the organic layer washed with aq. sodium bicarbonate ( 2  x 2 0  
cm3) and water ( 2  x 2 0  cm3), dried over magnesium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel, eluting with 
ethyl acetate-petrol (3:17) to give the l$,10a.-epoxide (90) (966mg, 93%) as a white 
solid, m.p. 172-173°C (Rf = 0.42, ethyl acetate-petrol (3:7)); umax (NUJOL)/cm'x 
1732 s (C=0), 1708 s (C=0), 1241 (C-O); 6 H (270 MHz, CDC13) 5.41-5.33 (1H, m, 
I^-C O )), 4.86-4.80 (1H, m, H-C(20)), 2.71 (2H, d, 74>3 8.1 Hz, H-C(4)), 2.50 (1H, d, 
J h2 9.2 Hz Ha-CO)), 2.04 (3H, s, H3CCO), 2.01 (3H, s, H3CCO), 1.35 (3H, s, 
H3C(19)) 1.14 (3H, d, y2 1 2 0  6.0 Hz, H3C(21)), 0.67 (3H, s, H3C(18)); mlz (C.I.) 435 
([M++l], 6 %), 417 (4) 391 (10), 375 (100), 357 (16), 331 (3), 315 (71), 297 (42), 279 
(10); Found: C, 68.0; H, 9.04. requires C, 68.2; H, 8.79%.
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3(x-Methoxy-20$-acetoxy-l( 10—*1$H), 4(5—*4$H)-abeopregnan-10a-ol-5-one (92) 
Potassium carbonate (4.0g, 29.0mM) was added to a stirred solution of 
l$,10a-epoxy-3$20$-diacetoxy-5,10-secopregnan-5-one (90) (4.0g, 9.22mM) in 
methanol (200 cm3). The reaction mixture was stirred at room temperature for 25 
min, after which water (50 cm3) was added. The mixture was extracted with 
methylene chloride ( 2  x 1 0 0 cm3), and the combined organic extracts were washed 
with dil. HC1 (40 cm3) and water (2 x 40 cm3). The organic layer was dried over 
anhydrous sodium sulphate, concentrated in vacuo, and purified by column 
chromatography, eluting with ethyl acetate-petrol (2:3) to give 
l$,10oL-epoxy-20f>-acetoxy-5,10-secopregn-3(4)-en-5-one (91) (732mg, 21%) as a 
white solid, m.p. 213-214°C (Rf = 0.46, ethyl acetate-petrol (1:1)); umax 
(NUJOLVcm' 1 1732 s (C=0), 1655 s (C=0), 1632 (C=C), 1245 (C-O); SH (270 MHz, 
CDC13) 7.04 (1H, qd, Jx r  2.2, JXT  10.0 Hz, H-C(3)), 6.00 (1H, dd, J  2.5, / 4>3 10.0 
Hz, H-C(4)), 4.84 (1H, dq, / 20,21 6.1, J2o,n 10.3 Hz, H-C(20)), 2.66 (1H, dt, J  5.2, J
18.5 Hz, H-C(l)), 2.02 (3H, s, H3CCO), 1.15 (3H, d, / 2 U 0  6.1 Hz, H3C(21)), 1.14 
(3H, s, H3C(19)), 0.65 (3H, s, H3C(18)); m/z (C.I.) 375 ([M++ l], 100%), 357 (11), 315 
(72), 297 (42), 279 (3), 247 (3), 205 (4); Found : C, 73.5; H, 9.39. C23H34O4 requires 
C, 73.8; H, 9.09%.
Further elutes gave 3cL-methoxy-20$-acetoxy-l(10—*lf>H),4(5—*4f>H)-abeopregn- 
an-10a- ol-5-one (92) (2.84g, 76%) as a white solid, m.p. 179-180°C (Rf = 0.33, ethyl 
acetate-petrol (1:1)); [a]22D = + 4.7° (C = 1.07, CH2C12); umax (NUJOLVcm1 3522 br 
(OH), 1733 s (0=0), 1698 s (0=0), 1247 (C-O); 5H (270 MHz, CDC13) 4.83 (1H, dq, 
•*2021 6 1 > -*20.17 10.3 Hz, H-C(20)), 4.01-3.95 ( 1H, m, Hp-C(3)), 3.29 (3H, s, H3CO),
2.02 (3H, s, H3CCO), 1.15 (3H, d , / 21>20 6.1 H z,H 3C(2 1 )), 1.12 (3H,s, H3C(19)), 
0.63 (3H, s, H3C(18)); m/z (CL) 407 ([M+ + 1], 5%), 389 (1 1 ), 375 (50), 347 (71),
329 (94), 315 (100), 297 (32), 279 (6 ); Found : C, 70.5; H, 9.62. C24H380 5. V8H20  
requires C, 70.5; H, 9.37%.
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1 $,10a-Epoxy-3$20$-diacetoxy-5,10-secopregnan-5a-ol (93)
Sodium borohydride (20mg, 0.53mM) was added to a stirred solution of 
l$,10a-epoxy-3$20$-diacetoxy-5,10-secopregnan-5-one (90) (200mg, 0.46mM) in 
ethanol (10 cm3) at 0°C under nitrogen. The reaction mixture was stirred at 0-10°C for 
lh  and room temperature for further 45 min. Water (5 cm3) was added to quench and 
the mixture extracted with methylene chloride ( 2x15  cm3). The combined organic 
extracts were dried over anhydrous sodium sulphate, concentrated in vacuo, and 
purified by column chromatography, eluting with ethyl acetate-petrol (3:7) to give the 
5a-hydroxy epoxide (93) (104mg, 52%) as a white solid, m.p. 195-196°C (Rf = 0.17, 
ethyl acetate-petrol (3:7)); Dmax (NUJOLVcm' 1 3455 br (OH), 1727 s (0=0), 1246 
(C-O); 6 h (270 MHz, CDC13) 5.11-5.00 (1H, m, Ha-C(3), 4.91-4.78 (1H, m,
H-C(20)), 3.88-3.78 (1H, m, Hp-C(5)), 3.48-3.40 (1H, m, H-OC(5)), 2.80 (1H, d, Jh2
10.1 Hz, H-C(l)), 2.22 (1H, dd, J  3.8, J  13.5 Hz, Ha-C(4)), 2.08 (3H, s, H3CCO), 2.02 
(3H, s, H3CCO), 1.25 (3H, s, H3C(19)), 1.14 (3H, d, J2h20 6.2 Hz, H3C(21)), 0.67 
(3H, s, H3C(18)); mlz (C.I.) 437 ([M++l], 10%), 419 (10), 391 (14), 377 (47), 359 
(71), 317 (53), 299 (100), 281 (43), 271 (10); Found : C, 67.9; H, 9.25. 
C25H4o06.V3H20  requires, C, 67.9; H, 9.20%.
l$,10a-Epoxy-3$20$-diacetoxy-5a-tosyl-5,10~secopregnane (94)
To a stirred solution of tosyl chloride (29mg, 0.15mM) and pyridine (0.01 cm3, 
0.14mM) in methylene chloride (2 cm3), at 0°C, was added the 5a-hydroxy epoxide 
(93) (60mg, 0.14mM) in methylene chloride (1 cm3). The reaction mixture was 
stirred at room temperature for 72h. Dil. HC1 (1 cm3) was added dropwise and the 
mixture extracted with methylene chloride ( 2 x 5  cm3). The combined organic 
extracts were washed with water ( 2 x 5  cm3), dried over magnesium sulphate, and 
concentrated in vacuo. The residue was purified by column chromatography, eluting 
with ethyl acetate-petrol (1:4) to give the 5a-tosylate (94) (70mg, 8 6 %) as a white 
solid, m.p. 125-126°C (Rf = 0.37, ethyl acetate-petrol (3:7)); \)max (NUJOLVcm1 
1729 s (C=0), 1244 (C-O), 1180 (S=0), 1176 (S=0), 907 (C-H, Ar); 5H (270 MHz,
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CDC13) 7.79 (2H, d, J  8.2 Hz, Ar-Horlho), 7.35 (2H, d, J 8.3 Hz, Ar-Hmcta), 5.25-5.14 
(1H, m, IVCC3)), 4.90-4.74 (2H, m, Hp-C(5)) + H-C(20)), 2.72 ( 1H, d, J x2 9.0 Hz, 
H-C(l)), 2.45 (3H, s, BjCPh), 2.02 (3H, s, H3CCO), 1.97 (3H, s, H3CCO), 1.20 (3H, 
s, H3C(19)), 1.14 (3H,d, J2h20 6.1 Hz, H3C(21)), 0.65 (3H, s, H3C(18)). m/z ((+)FAB 
in NBA), 591 ([M++l], 1%), 580 (44), 568 (39), 549 (49), 531 (80), 516 (47), 505 
(56), 493 (55), 359 ([M++l-AiOH-TsOH], 13%), 341 (4), 331 (4), 317 (11), 299 (39), 




Tributyl tin hydride (0.92 cm3, 3.17mM) was added dropwise, under nitrogen to a 
stirred solution of the 5a-thionoformate (97) (1.40g, 2.1 ImM) and 
azobisisobutyronitrile (410mg, 2.50mM) in toluene (50 cm3). The reaction mixture 
was stirred at 110°C for 15 min under nitrogen. After cooling water (20 cm3) was 
added, the organic layer separated, and the aqueous layer was extracted with diethyl 
ether (2 x 20 cm3). The combined organic extracts were washed with water (2 x 20 
cm3), dried over magnesium sulphate and concentrated in vacuo. The residue was 
purified by column chromatography on silcia gel, eluting with ethyl acetate-petrol 
(1:39) to give l$,10a-epoxy-3$,20$-diacetoxy-5,10-secopregnane (95) (844mg, 95%) 
as a white solid, m.p. 117-119°C (Rf = 0.69, ethyl acetate-petrol (3:17)); omax 
(NUJOLVcm' 1 1730 s (C=0), 1244 s (C-O); 5H (400 MHz, CDC13) 5.02-4.95 (1H, m, 
^ -0 (3 ) ) ,  4.84 (1H, dq, / 20>2j 6.1, / 2(U 7 12.2 Hz, H-C(20)), 2.87 (lH,d, J lt2 9.2 Hz, 
H-C(l)), 2.04 (3H, s, H3CCO), 2.02 (3H, s, H3CCO), 1.26 (3H, s, H3C(19)), 1.14 (3H, 
72Uo 6.1 Hz, H3C(21)), 0.67 (3H, s, H3C(18)); m/z (C.I.) 421 ([M++l], 2%), 401
(2), 377 (1), 361 (100), 343 (6 ), 301 (100), 283 (61), 271 (5), 243 (3), 215 (5), 177 
(12).
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Method 2
l$,10a-Epoxy-3$20$-diacetoxy-5,10-secopregnan-5-one (90) (250mg, 0.58mM) in 
DMF (2 cm3) was added to a stirred solution of p-tosyl hydrazide (130mg, 0.70mM), 
p-TSA (25mg, 10% w/w) and sodium cyanoborohydride (145mg, 2.30mM) in 
sulpholane (2 cm3). The reaction mixture was refluxed for 2.5h under nitrogen. After 
cooling the reaction mixture was poured into saturated brine (15 cm3) and the 
resulting precipitate filtered off. The white solid was washed with water (30 cm3) and 
dissolved in methylene chloride (20 cm3). The organic solution was washed with 
water ( 2 x 5  cm3), dried over magnesium sulphate and concentrated in vacuo. The 
residue was purified by column chromatography, eluting with ethyl acetate-petrol 
(1:39) to give lp,10a-epoxy-3$,20f>-diacetoxy-5,10-secopregnane (95) (34mg, 14%) 
as a white solid, m.p. 117-119°C (Rf = 0.69, ethyl acetate-petrol (3:17)).
Method 3
A solution of l$,10a-epoxy-3$20f>-diacetoxy-5-tosylhydrazone-5,10-secopregnane 
(96) (150mg, 0.25mM), sodium cyanborohydride (63mg, l.OOmM) and p-TSA (15mg, 
10% w/w) in a 1:1 mixture of DMF and sulfolane (4 cm3) was refluxed for 2h. After 
cooling, water (10 cm3) was added and the resulting white solid Filtered off. The solid 
was washed with water (20 cm3) and dissolved in methylene chloride (20 cm3). The 
organic solution was washed with water ( 2  x 1 0  cm3), dried over magnesium sulphate 
and concentrated in vacuo. Purification by column chromatography, eluting with 
ethyl acetate-petrol (1:39) to give l$,10a-epox-
y-3$,20$-diacetoxy-5,10-secopregnane (95) (28mg, 27%) as a white solid, m.p.
117-119°C (Rf = 0.69, ethyl acetate-petrol (3:17)).
1 $,10a-Epoxy-3$,20$-diacetoxy-5-tosylhydrazone-5,10-secopregnane (96) 
loL,10a-Epoxy-3$20§-diacetoxy-5,10-secopregnan-5-one (90) (l.Og,. 2.30mM) was 
added to a stirred solution of p-tosylhydrazide (472mg, 2.54 mM) in methylene 
chloride (20 cm3). The reaction mixture was stirred at room temperature under
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nitrogen for 5 days. The mixture was diluted with methylene chloride (20 cm3) and 
washed with water (2 x 1 0  cm3), dried over magnesium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (1:4) to give the 5-tosyl hydrazone (96) (472mg, 34%) as a white solid, 
m.p. 103-104°C (Rf = 0.44, ethyl acetate-petrol (2:3)); vmax (NUJOLVcm' 1 3180 br 
(NH), 1723 s (0=0), 1631 (O N ), 1597 s (C-C, Ar), 1376 s (S=0), 1244 (C-O), 1167 
(S=0), 815 (C-H, Ar); 8 H (270 MHz, CDC13) 9.27 (1H, s, NH), 7.85 (1H, d, J  8.3 Hz, 
Ar-H), 7.77 (1H, d, J  8.1 Hz, Ar-H), 7.33-7.26 (2H, s, Ar), 5.52-5.41 (1H, m, 
^ -0 (3 ) ) ,  4.85 (1H, dq, J1Q2i 6.1, J20 tl7 9.7 Hz, H-C(20)), 2.72 ( 1H, d, J l 2 13.2 Hz, 
H-C(l)), 2.43 (3H, s, ^ C P h ), 2.03 (3H, s, H3CCO), 2.01 (3H, s, H3CCO), 1.25 (3H, 
s, H3C(19)), 1.16 (3H, d , / 21t20 6.0 Hz, H3C(21)), 0.66 (3H, s, H3C(18)); m/z (C.I.) 
603 ([M+ + 1] missing), 391 ([M+-TsNHNCCH3], 8 %), 377 (1), 359 (4), 299 (4), 279
(3), 227 (4), 187 (8 ), 172 (4), 157 (29); Found : C, 62.6; H, 7.62; N, 5.03. 
C32H4 6SN20 7 .2/3H20  requires C, 62.5; H, 7.71; N, 4.56%.
1 p, 10a-Epoxy-3$20&-diacetoxy-5a-pentqfluorophenylthionoformoxy-5,10-secopregn 
ane (97)
Pentaflurorophenyl chlorothionoformate (1.3 cm3, 8.08mM) was added dropwise to a 
solution of l$,10a-epoxy-3$,20$-diacetoxy-5,10-secopregnan-5a-ol (93) (2.30g, 
5.28mM), N-hydroxysuccinimide (152mg, 1.32mM) and pyridine (0.64 cm3, 
7.92mM) in toluene (50 cm3), and the mixture refluxed at 80°C for 90 min under 
nitrogen. After cooling, water (20 cm3) was added and the mixture extracted with 
methylene chloride (2 x 100 cm3). The combined organic layers were washed with 
water ( 2  x 2 0  cm3), dried over anhydrous sodium sulphate and evaporated under 
reduced pressure. The residue was purified by column chromatography on silica gel, 
eluting with ethyl acetate-petrol (1:19) to give the 5a-thionoformate (97) (2.37g,
6 8 %) as a colourless oil, (Rf = 0.44, ethyl acetate-petrol (3:17)); \>max (FILM)/cm_1 
1727 s (C=0), 1651 (C=S), 1523 s (C-C, Ar), 1300 (C-F, Ar), 1240 (C-O); 5H (400 
MHz, CDC13) 5.44-5.30 (2H, m, Ha-C(3) + Hp-C(5)), 4.85 (1H, dq, / 20,21 6.1, / 20fi7
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10.4 Hz, H-C(20)), 2.85 (1H, d, J u2 9.2 Hz, H-C(l)), 2.07 (3H, s, H3CCO), 2.03 (3H, 
s, H3CCO), 1.31 (3H, s, H3C(19)), 1.15 (3H, d , / 2 1 2 0  6.1 Hz, H3C(21)), 0.69 (3H, s, 
H3C(18)); 5f (CDC13) - 152.74 (2F, d, J  17.3 Hz, Fonho), -157.11 (2F, t, J  22.0 Hz, 
Fmeta). -162.44 (IF, q, J  17.9, J 21.4 Hz, Fpara); m/z ((+) FAB in NBA) 622 (M+, 2%), 
603 (6 ), 543 (4), 525 (2), 419 (33), 359 (100), 299 (61), 281 (37), 121 (61), 93 (78).
3$,20$-Diacetoxy-5,10-secopregnane (99)
A solution of 3$20$-diacetoxy-5,10-secopregn-l( 10)-ene (8 6 ) (147mg, 0.36mM) and 
1 0 % palladium on activated carbon (15mg, 1 0 % w/w) in ethanol ( 2 0  cm3) was 
degassed under nitrogen for 15 min. The reaction mixture was stirred under an 
atmosphere of hydrogen, at atmospheric pressure for 2 weeks. The mixture was 
filtered, the filtrate concentrated under reduced pressure and the residue dissolved in 
methylene chloride (15 cm3). The organic solution was washed with water ( 2 x 5  
cm3), dried over magnesium sulphate and concentrated in vacuo. Purification by 
column chromatography, eluting with ethyl acetate-petrol (1:39) gave 
3$,20$-diacetoxy-5,10-secopregnane (99) (51 mg, 35%) as a colourless oil, (Rf = 0.59, 
ethyl acetate-petrol (1:9)); \)max (FILMVcm1 1732 s (C=0), 1244 s (C-O); SH (270 
MHz, CDC13) 5.24-5.16 (1H, m, H^Ctf)), 4.84 (1H, dq, / 20,2i 6.1, J20,n 10.3 Hz, 
H-C(20)), 2.03 (3H, s, H3CCO), 2.02 (3H, s, H3CCO), 1.14 (3H, d, J2U20 6 .1 Hz, 
H3C(21)), 0.86 (3H, d, / 19fl0 7.0 Hz, H3C(19)), 0.66 (3H, s, H3C(18)).
20$-Acetoxy-5,10-secopregnan-3$-ol (100)
Method 1
Potassium carbonate (20mg, 0.14mM) was added to a stirred solution of 
3$,20$-diacetoxy-5,10-secopregnane (99) (13mg, 0.03mM) in methanol (1 cm3). The 
reaction mixture was stirred at room tempterature for 24h, after which water (3 cm3) 
was added. The mixture was extracted with methylene chloride ( 2 x 5  cm3), and the 
combined organic extracts washed with dil. HC1 (2 cm3) and water ( 2 x 3  cm3). The
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organic layer was dried over anhydrous sodium sulphate, concentrated in vacuoy and 
purified by column chromatography, eluting with ethyl acetate-petrol (1:4) to give 
20$-acetoxy-5,10-secopregnan-3$-ol (100) (7mg, 60%) as a colourless oil, (Rf = 0.12, 
ethyl acetate-petrol (1:9)); \)max (FILMVcm*1 3378 br (OH), 1731 s (C=0), 1243 
(C-O); 5h (270 MHz, CDC13) 4.83 (1H, dq, J20,2i 6 .2 , 720 17 10.1 Hz, H-C(20)), 
4.14-4.03 (1H, m, H ^C tf)), 2.02 (3H, s, H3CCO), 1.14 (3H, d, J2U20 6.1 Hz, 
H3C(21)), 0.87 (3H, d, J m o  7.0 Hz, H3C(19)), 0.65 (3H, s, H3C(18)).
Method 2
A solution of 20$-acetoxy-5,10-secopregn-10(19)-en-3$-ol (101) (50g, 0.14mM) and 
10% palladium on activated carbon (5mg, 10% w/w) in ethanol (10 cm3) was 
degassed under nitrogen for 15 min. The reaction mixture was stirred under an 
atmosphere of hydrogen at atmospheric pressure for 24h. After filtration, the filtrate 
was concentrated under reduced pressure and dissolved in methylene chloride ( 1 0  
cm3), washed with water ( 2 x 5  cm3) and concentrated in vacuo. Purification by 
column chromatography, eluting with ethyl acetate-petrol (1:4) gave 
20$-acetoxy-5,10-secopregnan-3$-ol (100) (36mg, 72%) as a colourless oil, (Rf = 
0.12, ethyl acetate-petrol (1:9)).
20$-Acetoxy-5,10-secopregn-10(19)-en-3$-ol (101)
Pentafluorophenyl chlorothionoformate (0.11 cm3 ,0.68mM) was added to a stirred 
solution of N-hydroxysuccinimide (14mg, 0.12mM), pyridine (0.04 cm3,0.50mM) 
and 3fi,20fi-diacetoxy-5,10-secopregn-10(19)-en-la-ol (98) (200mg, 0.48mM) in 
toluene (5 cm3). The reaction mixture was refluxed for 2h. After cooling, the mixture 
was filtered to remove the pyridine hydrochloride. To the filtrate was added 
azobisisobutyronitrile (60mg, 0.37mM) and tributyltin hydride (0.15 cm3,0.56mM), 
and the mixture was refluxed at 110°C for 30 min, under nitrogen. After cooling 
water (5 cm3) was added and the mixutre extracted with methylene chloride (2 x 10 
cm3). The combined organic extracts were dried over magnesium sulphate and
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concentrated in vacuo to give crude 3$,20$-diacetoxy-5,10-secopregn-10(19)-ene 
(182mg). The crude 3$/20$-diacetate (182mg) was dissolved in ethanol (5 cm3) and 
potassium carbonate (200mg, 1.45mM) added. The reaction mixture was stirred at 
room temperature for 24h, after which it was diluted with water (5 cm3). The mixture 
was extracted with methylene chloride (2x15 cm3). The combined organic extracts 
were washed with dil. HC1 (5 cm3) and water ( 2x 5  cm3), dried over anhydrous 
sodium sulphate and evaprated at reduced pressure. The residue was purified by 
column chromatography, eluting with ethyl acetate-petrol ( 1 :9) to give 
20$-acetoxy-5,10-secopregn~10(19)-en-3$-ol (101) (67mg, 39%) as a colourless oil, 
(Rf = 0.23, ethyl acetate-petrol (1:9)); omax (FILMVcm*1 3430 br (OH), 1723 s (0=0), 
1628 (C=C), 1242 s (C-O); 8 H (270 MHz, CDC13) 5.12 (1H, s, H-C(19)), 5.03 (1H, s, 
H-C(19)), 4.86 (1H, dq, / 20,2 1 6.2, J20A110.3 Hz, H-C(20)), 3.88-3.79 (1H, m, 
H ^C tf)), 2.02 (3H, s, H3CCO), 1.15 (3H, d, / 2120  6.1 Hz, H3C(21)), 0.68 (3H, s, 
H3C(18)); m/z (C.I.) 363 ([M++l], 4%), 345 (2), 303 (53), 285 (100), 245 (4), 217 (6 ), 
206 (18), 12 1  (16).
20$-Acetoxy-5,10-secopregnan-3oL-ol (103)
To a stirred solution of 20§-acetoxy-5,10-secopregnan-3$-ol (100) (60mg, 0.16mM), 
triphenyl phosphine (8 6 mg, 0.33mM) and formic acid (0.01 cm3,0.27mM) in THF ( 6  
cm3) was added diethylazodicarboxylate (0.04 cm3, 0.25mM). The reaction mixture 
was stirred at room temperature for 4h, after which half of the solvent was removed in 
vacuo. Water (5 cm3) was added and the mixture extracted with methylene chloride 
(2 x 10 cm3). The combined organic extracts were dried over magnesium sulphate, 
concentrated under reduced pressure, and purified by column chromatography, eluting 
with ethyl acetate-petrol (1:39) to give the 3<x-formyl ester (1 0 2 ) (40mg, 62%) as a 
colourless oil, (Rf = 0.62, ethyl acetate-petrol (3:17). Potassium carbonate (40mg, 
0.29mM) was added to a stirred solution of 3a-formoxy-20$-acetoxy-5,10-secopr- 
egnarte (102) (40mg, O.lOmM) in a 1:1 mixture of methanol and methylene chloride 
(4 cm3). The reaction mixture was stirred at room temperature for 24h, after which
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the solvent was removed under reduced pressure. The residue was dissolved in 
methylene chloride (10 cm3), washed with dil. HC1 (2 cm3) and water ( 2 x 3  cm3), 
dried over anhydrous sodium sulphate and concentrated in vacuo. The residue was 
purified by column chromtography, eluting with ethyl acetate-petrol (1:4) to give 
20$-acetoxy-5,10-secopregnan-3a-ol (103) (16mg, 43%) as a colourless oil,(Rf = 
0.20, ethyl acetate-petiol (3:17)), \)max (FILMVcm1 3366 br (OH), 1728 s (C=0),
1243 s (C-O); 5H (270 MHz, CDC13) 4.84 (1H, dq, y20t21 6 .1, y2 (U 7 10.3 Hz, H-C(20)), 
3.72-3.63 (1H, m, Hp-C(3)), 2.02 (3H, s, H3CCO), 1.14 (3H, d, y21>20 6.1 Hz, 
H3C(21)), 0.86 (3H, d, y19>10 7.0 Hz, H3C(19)), 0.68 (3H, s, H3C(18)).
Preparation o f 5,10-secopregnan-3a-ol-20-one (107)
3a-Tertbutyldimethylsiloxy-20$-acetoxy-5,10-secopregnane (104)
A solution of 20fi-acetoxy-5,10-secopregnan-3a-ol (103) (15mg, 41.pM), 
tertbutyldimethylsilyl chloride (lOmg, 66.2pM) and imidazole (5mg, 74pM) in DMF 
(1 cm3) was stirred at room temperature under nitrogen for 24h. Silica was added, the 
solvent removed in vacuo, and purification by column chromatography, eluting with 
ethyl acetate-petrol (1:49) gave the 3a-silyl ether (104) (19mg, 96%) as a colourless 
oil, (Rf = 0.87, ethyl acetate-petrol (1:9)); omax (FILMVcm 1 1733 s (C=0), 1247 s 
(C-O), 1073 (O-Si).
3a-Tertbutyldimethylsiloxy-5,10-secopregnan-20$-ol (105)
Potassium carbonate (20mg, 145 jiM) was added to a stirred solution of 
3oL-tertbutyldimethylsiloxy-20$-acetoxy-5,10-secopregnane (104) (19mg, 39.6pM) in 
methanol (2 cm3). The reaction mixture was refluxed for 48h. After cooling the 
mixture was diluted with water (2  cm3) and extracted with methylene chloride ( 2x 5  
cm3). The combined organic extracts were washed with dil. HC1 (2 cm3) and water (2 
x 3 cm3), dried over anhydrous sodium sulphate and concentrated in vacuo. The 
residue was purified by column chromatography, eluting with ethyl acetate-petrol
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(1:19) to give the 20$-hydroxy silyl ether (105) (9 mg, 52%) as a colourless oil, (Rf = 
0.49, ethyl acetate-petrol (1:9)); omax (FILMVcm 1 3389 br (OH), 1243 (C-O), 1073 
(O-Si).
3a-Tertbutyldimethylsiloxy-5,10-secopregnan-20-one (106)
A solution of 3a-tertbutyldimethylsiloxy-5,l0-secopregnan-20$-ol (105) (8 mg, 
18.3pM) and pyridinium chlorochromate (6 mg, 27.8pM) in methylene chloride (1 
cm3) was stirred at room temperature for 2 h. Silica gel was added, the solvent 
removed under reduced pressure, and purification by column chromatography, eluting 
with ethyl acetate-petrol (1:39) gave
3a-tertbutyldimethylsiloxy-5,10-secopregnan-20-one (106) (3mg, 38%) as a 
colourless oil, (Rf = 0.66, ethyl acetate-petrol (1:9)); umax (FILMVcm' 1 1701 s (C=0), 
1279 (C-O), 1073 (O-Si); 5H (270 MHz, CDC13) 4.34-4.25 ( 1H, m, Hp-C(3)), 2.18 
(3H, s, H3CCO), 0.89 (9H, s, (H3C)3CSi), 0.87 (3H, d, / l9 f l0  6 .8  Hz, H3C(19)), 0.70 
(3H, s, H3C(18)), 0.05 (6 H, s, (H3C)2Si).
5.10-Secopregnan-3cL-ol-20-one (107)
1M TBAF in THF (3.0|il, 10.3|iM) was added to a stirred solution of 
3a-tertbutyldimethylsiloxy-5,10-secopregnan-20-one (106) (2mg, 4.5jiM) in THF (0.5 
cm3). The reaction mixture was stirred at room temperature for 24h. The solvent was 
removed in vacuo, and the residue dissolved in methylene chloride (3 cm3), washed 
with dil. HC1 (1 cm3) and water (2x1 cm3). The organic layer was dried over 
anhydrous sodium sulphate, concentrated in vacuo and purified by column 
chromatography, eluting with ethyl acetate-petrol (1:4) to give
5.10-secopregnan-3a-ol-20-one (107) (0.5mg, 35%) as a colourless oil, (Rf = 0.11, 
ethyl acetate-petrol (3:17)); vmax (FILMVcm1 3321 br (OH), 1699 s (C=0), 1244 
(C-O); mlz (C l.) 321 ([M++1], 3%), 303 (2), 275 (6 ), 257 (100).
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3p,20$-Diacetoxy-5(10—*l$H)abeopregn-10(19)-en-5a-ol (109)
Ceric ammonium nitrate (16.3g, 29.7mM) in water (15 cm3) was added to a stirred 
solution o f 3$20$-diacetoxypregnan-5a-ol (38) (5.0g, 11.9mM) in acetonitrile (50 
cm3) at 80°C. The reaction mixture was stirred at 80°C for 5 min. Then the mixture 
was poured into ice/water (200 cm3) and extracted with methylene chloride (3 x 100 
cm3). The combined organic extracts were dried over anhydrous sodium sulphate, 
concentrated in vacuo, and purified by column chromatography eluting with ethyl 
acetate-petrol (1:4) to give3$t20$-diacetoxy-5(10—*lp>H)abeopregn-10(9)-en-5a-ol 
(109) (3.88g, 78%) as a white solid, m.p. 94-95°C (Rf = 0.32, ethyl acetate-petrol 
(1:4)); [a]22!) = + 43.9° (C=0.66, CH2C12); \)max (NUJOLVcm1 3509 sh (OH), 1727 s 
(C=0), 1628 (C=C), 1240 (C-O); 8 H (270 MHz, CDC13) 5.27-5.19 ( 1H, m, H ^Ctf)),
5.16 (1H, s, H-C(19)), 5.03 (1H, s, H-C(19)), 4.92-4.80 (1H, m, H-C(20)), 2.05 (3H, s, 
H3CCO), 2.02 (3H, s, H3CCO), 1.15 (3H, d, / 21f20 6.0 Hz, H3C(21)), 0.70 (3H, s, 
H3C(18)); m/z (C.I.) 419 ([M++l], 2%), 401 (3), 358 (31), 341 (49), 299 (100), 281 
(85), 271 (5), 253 (3), 149 (18); Found : C, 72.1; H, 9.61. C25H380 5 requires C, 71.8; 
H, 9.09%.
20fi-Acetoxy-5( 10—>lfiH)abeopregn-I0(J9)-ene-3pr5a-diol (110)
Potassium carbonate (lO.Og, 72.4mM) was added to a stirred solution of 
3p,20$-diacetoxy-5(10^1$H)abeopregn-10(19)en-5a-ol (109) (lO.Og, 23.8mM) in 
methanol (200 cm3). The reaction mixture was stirred at room temperature for 30 
min. Water (50 cm3) was added and the mixture extracted with methylene chloride (2 
x 200 cm3). The combined organic extracts were washed with dil. HC1 (50 cm3) and 
water (2 x 50 cm3), dried over anhydrous sodium sulphate and concentrated in vacuo. 
Purification by column chromatography, eluting with ethyl acetate-petrol (3:7) gave 
the 3p,5a diol (110) (8.21g, 92%) as a colourless oil (Rf = 0.31, ethyl acetate-petrol 
(2:3)); IaP p  = +38.4° (C=1.25, C H ^lj); \>max (FILMVcm1 3519 br (OH), 3447 br 
(OH), 1731 s (C=0), 1628 (C=C), 1243 (C-O); 5H (400 MHz, CDC13) 5.13 (1H, s, 
H-C(19)), 4.99 (1H, s, H-C(19)), 4.85 (1H, dq, / 20t21 6.4, J20>17 10.3 Hz, H-C(20)),
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4.47-4.42 (1H, m, H^-Ctf)), 2.44 (1H, dd, J x2f 6 .8  J x r  14.7 Hz, H-C(l)), 2.05 (3H, 
s, H3CCO), 1.15 (3H, d, / 21f20 6.4 Hz, H3C(21)), 0.68 (3H, s, H3C(18)); 5c (CDC13)
170.36 (C=0), 151.36 (C-10), 113.76 (C-19), 78.50 (C-5), 72.63 (C-20), 70.40 (C-3); 
mlz (C.I.) 377 ([M++1], 4%), 359 (8 ), 341 (6 ), 317 (11), 299 (100), 281 (21), 271 (4), 
255 (2), 230 (2); Found : C, 71.3; H, 10.1. C23H360 4. 2/3H20  requires C, 71.1; H, 
9.6%.
3a-Formoxy-20$-acetoxy-5( 10—>1 $H)abeopregn-l0(19)-en-5a-ol (111) 
Diethylazodicarboxylate (3.0 cm3, 19.1mM) was added drop wise to a stirred solution 
of 20$-acetoxy-5(10-+l$H)abeopregn-10(19)-ene-3$-5a-diol (110) (4.80g, 12.8mM), 
triphenyl phosphine (6.65g, 25.4mM) and formic acid (0.6 cm3, 15.9mM) in THF 
(150 cm3) under nitrogen at 0°C. The reaction mixture was stirred under nitrogen at 
0°C for 2h and at room temperature for a further 2h. The solvent was removed in 
vacuo and the residue was diluted with methylene chloride (100 cm3). The organic 
solution was washed with water (2 x 30 cm3), dried over anhydrous sodium sulphate, 
and purified by column chromatography, eluting with ethyl acetate-petrol (1:9) to 
give the 3a-formate (111) (4.1 lg,80%) as a colourless oil, (Rf = 0.80, ethyl 
acetate-petrol (2:3)); \>max (FILMVcm’1 3531 sh (OH), 1725 br (C=0), 1630 (C=C), 
1245 (C-O), 1185 (C-O); 5H (270 MHz, CDC13) 8.04 ( 1H, s, HCOO), 5.34-5.23 (1H, 
m, Hp-C(3)), 5.19 (1H, s, H-C(19)), 5.07 (1H, s, H-C(19)), 4.91-4.79 (1H, m, 
H-C(20)), 2.74 (1H, dd, J hr  8 .6 , J h r  11.0 Hz, H-C(l)), 2.02 (3H, s, H3CCO), 1.15 
(3H, d, / 21i20 6.0 Hz, H3C(21)), 0.68 (3H, s, H3C(18)); m/z (C.I.) 405 ([M++l], 20%), 
287 (4), 358 (26), 345 (59), 327 (51), 299 (78), 281 (100), 272 (8 ), 233 (5); Found : C, 
70.6; H, 9.26. C24U360 5}/4U20  requires C, 70.5; H, 8.94%.
20$-Acetoxy-5( 10—*1 $H)abeopregn-10(19)-ene-3a-5a-diol (112)
Potassium carbonate (4.0g, 29.0mM) was added to a stirred solution of 
3a-formoxy-20$-acetoxy-5( 10-^>l$H)abeopregn-10(19)-en-5a-ol (111) (3.50g, 
8 .6 6 mM) in methanol (150 cm3). The reaction mixture was stirred at room
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temperature for 30 min, after which water (50 cm3) was added and the mixture 
extracted with methylene chloride (2 x 150 cm3). The combined organic extracts 
were washed with dil. HC1 (50 cm3) and water (2 x 50 cm3), dried over anhydrous 
sodium sulphate and concentrated in vacuo. The residue was purified by column 
chromatography, eluting with ethyl acetate-petrol (3:7) to give the 3a,5a diol (112) 
(3.17g, 97%) as a colourless oil, (Rf = 0.31, ethyl acetate-petrol (2:3); [a]22D = +44.4° 
(C=1.42, CH2C12); \)max (FILMVcm*1 3512 br (OH), 3438 br (OH), 1729 s (C=0), 
1630 (C=C), 1245 (C-O); 8 H (270 MHz, CDC13) 5.21 ( 1H, s, H-C(19)), 5.15 (1H, s, 
H-C(19)), 4.91-4.79 (1H, m, H-C(20)), 4.29-4.17 (1H, m, Hr C(3)), 3.17 (1H, d ,/9 .3  
Hz, H-COC(3)), 2.81 (1H, t, J l2 9.7 Hz, H-C(l)), 2.55 (1H, s, H-OC(5)), 2.02 (3H, s, 
H3CCO), 1.15 (3H, d , / 2 U 0  6.1 Hz, H3C(21)), 0.67 (3H, s, H3C(18)); 8 C (CDC13)
170.37 (C=0), 151.67 (C-10), 114.04 (C-19), 79.42 (C-5), 72.56 (C-20), 71.86 (C-3); 
m/z (C.I.) ([M++l], 28%), 359 (13), 341 (10), 317 (36), 299 (100), 281 (57), 269 (3), 
255 (2); Found : C, 72.6; H, 10.0. C ^ H ^ .V 4H20  requires C, 72.5; H, 9.59%.
3a-Tertbutyldimethylsiloxy-20$ -acetoxy-5 (10—► 1 $H)abeopregn- 10(l9)-en-5a-ol 
(113)
To a stirred solution of tertbutyldimethylsilyl chloride (1.33g, 8 .8 ImM) and imidazole 
(600mg, 8.82mM) in DMF (50 cm3) was added 20p-aceioxy-5( 10~^l$H)abeopre- 
gn-10(19)-ene-3a£a-diol (112) (3.0g, 7.98mM). The reaction mixture was stirred at 
room temperature under nitrogen for lh. DMF was removed in vacuo and the residue 
diluted with methylene chloride (50 cm3). The solution was filtered and the filtrate 
washed with water ( 2  x 2 0  cm3), dried over anhydrous sodium sulphate and 
concentrated in vacuo. Purification by column chromatography, eluting with ethyl 
acetate-petrol (1:39) gave the 3a~silyl ether (113) (3.19g, 82%) as a colourless oil, (Rf 
= 0.56, ethyl acetate-petrol (1:19)); \)max (FILMVcm*1 3532 sh (OH), 1730 s (C=0), 
1629 (C=C), 1244 (C-O), 1097 (O-Si); 8 H (270 MHz, CDC13) 5.10 (1H, s, H-C(19)), 
5.03 (1H, s, H-C(19)), 4.90-4.78 (1H, m, H-C(20)), 4.38-4.30 ( 1H, m, Hp-C(3)), 2.71 
(1H, s, H-OC(5)), 2.56 (1H, dd, J UT 7.5, J XT 11.9 Hz, H-C(l)), 2.01 (3H, s, H3CCO),
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1.14 (3H, d, J2l 2Q 6.2 Hz, H3C(21)), 0.88 (9H, s, (H3C)3CSi), 0.66 (3H, s, H3C(18)), 
0.05 (3H, s, H3CSi), 0.04 (3H, s, H3CSi); 8C (CDC13) 175.22 ((C=0), 156.10(C-10),
118.41 (C-19), 83.15 (C-5), 77.42 (C-3), 76.68 (C-20); mlz (C.I.) 491 ([M++l], 22%), 
473 (8 ), 431 (39), 413 (28), 373 (13), 341 (21), 323 (2), 281 (100), 159 (13); Found : 
C, 70.4; H, 10.3. C ^ H s q S K V /^ O  requires C, 70.4; H, 10.1%.
3a-Tertbutyldimethylsiloxy’5(10—*lf>H)abeopregn-10(19)-ene-5 a,20$-diol (114)
A stirred solution of potassium carbonate (3.0g, 21.7mM) and 3a-tertbutyldimeth- 
ylsiloxy-20$-acetoxy-5(10-^>l$H)abeopregn- 10(19)-en-5a-ol (113) (3.0g, 6.12mM) 
in methanol (100 cm3) was refluxed for 24h. After cooling water (40 cm3) was added 
and the mixture extracted with methylene chloride (2 x 100 cm3). The combined 
organic extracts were washed with dil.HCl (30 cm3) and water ( 2  x 30 cm3), dried 
over anhydrous sodium sulphate and concentrated in vacuo. The residue was purified 
by column chromatography, eluting with ethyl acetate-petrol (1:19) to give the 
5a,20a-diol (114) (2.39g, 87%) as a colourless oil, (Rf = 0.23, ethyl acetate-petrol 
(1:19)); [a]22!) = + 18.5° (C=0.92, CH2C12); omax (FILMVcm1 3524 br (OH), 3470 br 
(OH), 1628 (C=C), 1251 (C-O), 1097 (O-Si); 5H (400 MHz, CDC13) 5.12 (1H, s, 
H-C(19)), 5.04 (1H, s, H-C(19)), 4.35-4.27 (1H, m, Hp-C(3)), 3.73 (1H, d q ,/20,2i 6.1, 
/ 2o,17 9.8 Hz, H-C(20)), 2.68 (1H, dd, J hr 7.0, J hT  11.6 Hz, H-C(l)), 1.14(3H,d, 
J2U20 6.1 Hz, H3C(21)), 0.89 (9H, s, (H3C)3CSi), 0.79 (3H, s, H3C(18)), 0.06 (3H, s, 
H3CSi), 0.05 (3H, s, H3CSi); 5c (CDC13) 151.33 (C-10), 113.64 (C-19), 78.33 (C-5), 
71.86 (C-20), 70.45 (C-3); m/z (C.I.) 499 ([M++l], 4%), 431 (50), 413 (21), 391 (11), 
373 (10), 281 (100), 255 (40), 159 (20); Found : C, 71.3; H, 10.9. C27H4 8Si03.l/3H20  
requires C, 71.4; H, 10.7%.
3a-Tertbutyldimethylsiloxy-5(10—*l$H)abeopregn-10( 19)-en-5a. -ol-20-one (115) 
Pyridinium chlorochromate (900mg, 4.18mM) was added to a stirred solution of 
3a-tertbutyldimethylsiloxy-5(10^>l$H)abeopregn-10( 19)ene-5a 2 0 fi-diol (114) 
(1.25g, 2.79mM) in methylene chloride (40 cm3). The reaction mixture was stirred at
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room temperature under nitrogen for 3h. Silica gel was added directly to the reaction 
mixture and the solvent removed in vacuo. Purification by column chromatography, 
eluting with ethyl acetate-petrol (1:9) gave the 20-ketone (115) (1.17g, 94%) as a 
colourless oil, (Rf = 0.27 ethyl acetate-petrol (1:9)); [a]22D = + 73.5° (C=1.13, 
CH2Cl2); vmax (FILMVcm' 1 3527 sh (OH), 1703 s (0=0), 1628 (C=C), 1252 (C-O), 
1097 (O-Si); 8 H (400 MHz, CDC13) 5.13 (1H, s, H-C(19)), 5.06 (1H, s, H-C(19)), 
4.35-4.27 (1H, m, Hp-C(3)), 2.76 (1H, s, H-OC(5)), 2.67 ( 1H, dd, Ju r 7.3, J x x  11.3 
Hz, H-C(l)), 2.56 (1H, t, J 11A6 9.2 Hz, H-C(17)), 2.12 (3H, s, H3C(21)), 0.88 (9H, s, 
(H3C)3CSi), 0.66 (3H, s, H3C(18)), 0.06 (3H, s, H3CSi), 0.05 (3H, s, H3CSi); m/z 
(CL) 447 ([M++l], 46%), 429 (22), 411 (3), 389 (7), 371 (2 ), 315 (6 ), 297 (100), 279 
(11), 253 (5); Found : C, 70.7; H, 10.8. C27H46Si0 3 .2/3H20  requires C, 70.7; H, 
10.3%.
3a,5a-Dihydroxy-5(10^>lf>H)abeopregn-10(19)-en-20-one (116)
1M Tetrabutylammonium fluoride in THF (1.1 cm3, 1.08mM) was added dropwise to 
a stirred solution of the 3a-silyl ether (115) (400mg, 0.90mM) in THF (20 cm3). The 
reaction mixture was stirred at room temperature for 4h, after which it was diluted 
with methylene chloride (50 cm3) and washed with dil. HC1 (20 cm3) and water (2 x 
20 cm3). The organic layer was dried over anhydrous sodium sulphate, concentrated 
in vacuo, and purified by column chromatography, eluting with ethyl acetate-petrol 
(1:1) to give the 3 a £ a  diol (116) (260mg, 87%) as a white solid, m.p. 159-160°C (Rf 
= 0.18, ethyl acetate-petrol (3:7)); [a]22D = + 84.0° (C=l .00, CH2C12); umax 
(NUJOLVcm1 3519 br (OH), 3393 br (OH), 1700 s (C=0), 1635 (C=C); 5H (400 
MHz, CDC13) 5.23 (1H, s, H-C(19)), 5.18 (1H, s, H-C(19)), 4.28-4.20 ( 1H, m, 
Hp-C(3)), 2.80 (1H, t, J h2 9.8 Hz, H-C(l))), 2.57 (1H, t, J X116 9.2 Hz, H-C(17)), 2.12 
(3H, s, H3C(21)), 0.66 (3H, s, H3C(18)); 5C (CDC13) 209.38 (C=0), 151.33 (C-10),
114.41 (C-19), 79.52 (C-5), 71.95 (C-3); m/z (C.I.) 333 ([M++l], 48%), 315 (50), 297 
(100), 279 (11), 253 (5), 215 (4), 177 (4); Found : C, 74.1; H, 9.86. C21H320 3.1/2H20  
requires C, 73.9; H, 9.94%.
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3a,5a-Dihydroxy-5( 10-+l$H)abeopregnan-20-one (117)
Method 1
A stirred solution of 10% palladium on activated carbon (19mg, 10% w/w) and 
3a£a-dihydroxy-5(10-+l$H)abeopregn-10(19)-en-20-one (116) (190 mg, 0.57mM) 
in ethanol (15 cm3) was degassed under nitrogen for 15 min. The reaction mixture 
was stirred under an atmosphere of hydrogen at atmospheric pressure for 15h. The 
mixture was filtered and the filtrate concentrated in vacuo. The residue was dissolved 
in methylene chloride (25 cm3), washed with water (2x10  cm3), dried over 
anhydrous sodium sulphate and evaporated under reduced pressure. Purification by 
column chromatography, eluting with ethyl acetate-petrol (2:3) gave
3a.J5o.-dihydroxy-5{10^>l$H)abeopregnan-20-one (117) (166mg, 87%) as a white 
solid, m.p. 152-153°C (Rf = 0.38, ethyl acetate-petrol (1:1)); [a]22D = + 12.8° 
(C=1.02, CH2C12); \)max (NUJOLVcm’1 3296 br (OH), 3237 br (OH), 1700 s (C=0); 
5h (400 MHz, CDC13) 4.33-4.27 (1H, m, Hp-C(3)), 2.57-2.53 ( 1H, m, H-C(l)), 2.12 
(3H, s, H3C(21)), 1.24 (3H, d, y1910 7.3 Hz, H3C(19)), 0.63 (3H, s, H3C(18)); 6 c 
(CDC13) 209.72 (C-20), 84.46 (C-5), 72.57 (C-3); mlz (low eV E.I.) 334 (M+, 69%), 
316 (100), 298 (62), 246 (27), 232 (42), 128 (44), 111 (34), 71 (28); Found : C, 74.9; 
H, 10.5. C21H340 3 .1/8H20  requires C, 74.9; H, 10.2%.
Method 2
A solution of 3a£a.-dibenzoxy-5(10-+l$H)abeopregn-10(19)-en-20-one (121) 
(lOOmg, 0.20mM) and 10% palladium on activated carbon (20mg, 20% w/w) in 
ethanol (20 cm3) was degassed under nitrogen for 15 min. The reaction mixture was 
stirred under an atmosphere of hydrogen at atmospheric pressure for 24h. The 
mixture was filtered and the filtrate evaporated under reduced pressure. The residue 
was dissolved in methylene chloride (30 cm3), washed with water ( 2 x 1 0  cm3), dried 
over anhydrous sodium sulphate and concentrated in vacuo. The residue was purified
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by column chromatography, eluting with ethyl acetate-petrol (2:3) to give 
3cL£a-dihydroxy-5(10-^>l$H)abeopregnan-20-one (117) (25mg, 39%) as a white 
solid, m.p. 152-153°C (Rf = 0.38, ethyl acetate-petrol (1:1)).
3a£<x-Dibenzoxy-20$-acetoxy-5(10^>l$H)abeopregn-10(19)-ene (119) 
20$-Acetoxy-5,10-secopregn-l(10)-en-3a-ol-5-one (56) (1.50g, 3.99mM) in THF (10 
cm3) was added dropwise to a stirred suspension of sodium hydride (300 mg, 
12.5mM), previously washed with petrol, in THF (40 cm3) at room temperature. The 
mixture was stirred for 15 min after which the evolution of hydrogen ceased and it 
was cooled to 0°C. Benzyl bromide (0.95 cm3, 7.97mM) was added dropwise and the 
reaction mixture stirred at 0°C under nitrogen for 4h, and a further 24h at room 
temperature. Water (10 cm3) was added to quench and the mixture was extracted 
with methylene chloride (2 x 50 cm3). The combined organic extracts were dried 
over magnesium sulphate, evaporated under reduced pressure, and purified by column 
chromatography, eluting with ethyl acetate-petrol (1:19) to give the dibenzyl ether 
(119) (1.26g, 6 8 %) as a white solid, m.p. 135-137°C (Rf = 0.67, ethyl acetate-petrol 
(3:7)); \)max (NUJOLVcm1 1725 s (C=0), 1651 (C=C), 1629 s (C-C, Ar), 1602 s 
(C-C, Ar), 1244 (C-O), 754 (C-H, Ar), 732 (C-H, Ar), 701 (C-H, Ar); 5H (270 MHz, 
CDC13) 9.52 (1H, s, H-C(19)), 7.34-7.11 (10H, m, Ar), 5.27 (1H, s, H-C(19)),
4.89-4.75 (1H, m, H-C(20)), 3.48-3.40 (1H, m, Hp-C(3)), 3.23-2.81 (4H, m, PhCH20  
x 2), 2.05 (3H, s, H3CCO), 1.14 (3H, d, / 21t20 6.0 Hz, H3C(21)), 0.65 (3H, s,
H3C(18)); m/z (C.I.) 557 ([M++l], 2%), 539 (2 ), 497 (3), 479 (4), 405 (1), 357 (11), 
211 (51), 123 (6 6 ), 107 (100); Found : C, 79.6; H, 8.70. C37H480 4  requires C, 79.8; H, 
8.63%.
3a£a-Dibenzoxy-5( 10^>l$H)abeopregn-10(19)-en-20$-ol (120)
Potassium carbonate (l.Og, 7.25mM) was added to a stirred solution of 
3a£a-dibenzoxy-20$-acetoxy-5( 10^>l$H)abeopregn-10( 19)-ene (119) (l.Og, 
1.80mM) in methanol (50 cm3). The reaction mixture was refluxed for 24h. After
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cooling the mixture was diluted with water (30 cm3) and extracted with methylene 
chloride (2 x 50 cm3). The combined organic extracts were washed with dil. HC1 (20 
cm3) and water ( 2  x 2 0  cm3), dried over anhydrous sodium sulphate and concentrated 
in vacuo. The residue was purified by column chromatography, eluting with ethyl 
acetate-petrol (1:4) to give the 20§-hydroxyl (120) (665mg, 72%) as a white solid, 
m.p. 121-122°C (Rf = 0.40, ethyl acetate-petrol (3:7)); oniux (NUJOLVcm' 1 3483 br 
(OH), 1635 (C=C), 1611 s (C-C, Ar), 1596 s (C-C, Ar), 732 (C-H, Ar), 697 (C-H, Ar); 
5h (270 MHz, CDC13) 9.51 (1H, s, H-C(19)), 7.32-7.14 (10H, m, Ar), 5.28 (1H, s, 
H-C(19)), 3.77-3.65 (1H, m, H-C(20)), 3.48-3.40 (1H, m, Hp-C(3)), 3.23-2.83 (4H, m, 
PhCHzO x 2), 1.14 (3H, d , / 2 U 0  6.0 Hz, H3C(21)), 0.75 (3H, s, H3C(18)); mlz (C.I.) 
515 ([M++1], 18%), 497 (25), 479 (17), 453 (16), 423 (21), 395 (16), 211 (42), 123 
(58), 107 (78), 89 (100); Found : C, 81.7; H, 9.07. C35H460 3 requires C, 81.7; H, 
8.95%.
3a£a-Dibenzoxy-5(10-+l$H)abeopregn-10(19)-en-20-one (121)
Pyridinium chlorochromate, PCC, (90mg, 0.42mM) was added to a stirred solution of 
3a£a-dibenzoxy-5(10-J>lQH)abeopregn-10(19)-en-20$-ol (120) (140mg, 0.27mM) in 
methylene chloride (3 cm3). The reaction mixture was stirred at room temperature for 
3h, after which silica gel was added and the reaction mixture evaporated in vacuo. 
Purification by column chromatography, eluting with ethyl acetate-petrol (1:9) gave 
the 20-ketone (121) (138mg, 99%) as a white solid, m.p. 80-81°C (Rf = 0.47, ethyl 
acetate-petrol (1:4)); omax (NUJOLVcm' 1 1700 s (C=0), 1643 (C=C), 1621 (C-C, Ar), 
1597 s (C-C, Ar), 1165 (C-O), 752 (C-H, Ar), 701 (C-H, Ar); 5H (270 MHz, CDC13)
7.34-7.13 (10H, m, Ar), 5.13 (1H, s, H-C(19)), 4.98 (1H, s, H-C(19)), 3.72-3.66 (4H, 
m, P hO ^O  x 2), 2.13 (3H, s, H3C(21)), 0.68 (3H, s, H3C(18)); m/z (C.I.) 512 
([M++l] missing), 421 ([M+ - PhCH3], 1%), 409 (1), 391 (1), 333 (2), 307 (4), 293 
(10), 275 (10), 211 (100), 123 (80), 107 (19); Found : C, 81.4; H, 8.87. 
C35H44O3.V4H2O requires C, 81.3; H, 8.62%.
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(E)-3a-Tertbutyldimethylsiloxy-20$-acetoxy-5,10-secopregn-l(I0)-en-5a-ol (123) 
Sodium borohyride (lOOmg, 2.63mM) was added portion wise to a stirred solution of 
the siloxy ketone (57) (l.Og, 2.04mM) in ethanol (50 cm3). The reaction mixture was 
stirred at room temperature under nitrogen for 48h. Water (20 cm3) was added to 
quench and the solution extracted with methylene chloride ( 2  x 50 cm3). The 
combined organic extracts were dried over anhydrous sodium sulphate and 
concentrated in vacuo. The residue was purified by column chromatography to give 
the siloxy-5a-ol (123) (773mg, 77%) as a colourless oil (Rf = 0.16, ethyl 
acetate-petrol (1:9)); vmax (FILMVcm1 3441 br (OH), 1733 s (0=0), 1661 (C=C), 
1242 (C-O), 1073 (O-Si); SH (270 MHz, CDC13) 5.44-5.41 ( 1H, m, HE-C(1)),
4.90-4.80 (1H, m, H-C(20)), 4.28-4.10 (2H, m, Hp-C(3) + Hp-C(5)), 2.02 (3H, s, 
H3CCO), 1.67 (3H, s, H3C(19)), 1.15 (3H, d, J 2 i.20 6.1 Hz, H3C(21)), 0.92 (9H, s, 
(CH3)3Si), 0.72 (3H, s, H3C(18)), 0.12 (3H, s, H3CSi), 0.10 (3H, s, H3CSi); mlz (C.I.) 
493 ([M++l], 4%), 475 (3), 433 (14), 415 (30), 343 (22), 283 (100), 257 (5); Found : 
C, 70.5; H, 10.7. C29H52Si0 4 requires C, 70.7; H, 10.6%.
3a-Tertbutyldimethylsiloxy-20$-acetoxy-5( 1 0 ^ IfiH)abeopregn-10( 19)-ene (124)
Method I
20$-Acetoxy-5(10-+l$H)abeopregn-10(19)-en-3a-ol (131) (90mg, 0.,25mM) was 
added to a stirred solution of fmbutyldimethylsilyl chloride (45mg, 0.30mM) and 
imidazole (21mg, 0.30mM) in DMF (1 cm3). The reaction mixture was stirred at 
room temperature for lh. The mixture was preabsorbed onto silica gel and 
purification by column chromatography, eluting with ethyl acetate-petrol (1:49) gave 
the 3a.-silyl ether (124) (115mg, 97%) as a white solid, m.p. 76-77°C (Rf -  0.86, ethyl 
acetate-petrol (1:9)); \)max (NUJOLVcm*1 1733 s (C=0), 1634 (C=C), 1244 (C-O), 
1061 (O-Si); bH (270 MHz, CDC13) 4.92-4.78 (1H, m, H-C(20)), 4.82 (1H, s, 
H-C(19)), 4.15-4.03 (1H, m, Hp-C(3)), 2.82 ( 1H, q, 7, r  10.9, J x x  18.4 Hz, H-C(l)),
2.02 (3H, s, BjCCO), 1.14 (3H, d, / 2 U 0  6.0 Hz, H3C(2 1 )), 0.90 (9H, s, (H3C)3CSi),
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0.66 (3H, s, H3C(18)), 0.06 (6 H, s, (H3C)2Si); m/z (C.I.) 475 ([M++l], 3%), 459 (4), 
415 (42), 357 (18), 343 (8 ), 283 (100), 149 (20); Found : C, 73.0; H, 10.8. C29H50SiO3 
requires C, 73.4; H, 10.5%.
Method 2
To a stirred solution of tosyl chloride (407mg, 2.13mM) and pyridine (1.15 cm3, 
14.2mM) in methylene chloride (10 cm3) was added a solution of 
(E)-3a-tertbutyldimethylsiloxy-20f>-acetoxy-5,10-secopregn- l(10)-en-5a-ol (123) 
(700mg, 1.42mM) in methylene chloride (10 cm3). The reaction mixture was stirred 
at 50°C for 48h. Water (10 cm3) was added, the organic layer was separated, and the 
aqueous layer extracted with methylene chloride (2x15  cm3). The combined organic 
extracts were dried over magnesium sulphate, concentrated in vacuo, and purified by 
column chromatography, eluting with ethyl acetate-petrol (1:49) to give 
3a-tertbutyldimethylsiloxy-20$-acetoxy-5( 10~*-l$H)abeopregn -10(19)-ene (124) 
(647mg, 96%) as a white solid, m.p. 76-77°C (Rf = 0.86, ethyl acetate-petrol (1:9)).
3a-Tertbutyldimethylsiloxy-5(10^>l$H)abeopregn-10( 19)-en-20 (3-ol (125)
Potassium carbonate (200mg, 1.45mM) and the 20$-acetate (124) (200mg, 0.42mM) 
were refluxed together in methanol (10 cm3) for 24h. After cooling water (5 cm3) 
was added and the mixture extracted with methylene chloride (2 x 20 cm3). The 
combined organic extracts were washed with dil. HC1 (5 cm3) and water (2 x 10 cm3), 
dried over anhydrous sodium sulphate, and concentrated in vacuo. The residue was 
purified by column chromatography, eluting with ethyl acetate-petrol (1:19) to give 
the 20$-hydroxyl silyl ether (125) (166mg, 91%) as a colourless oil, (Rf = 0.60, ethyl 
acetate-petrol (1:9); \>max (FILMVcm1 3384 br (OH), 1632 (C=C), 1068 (O-Si); 5H 
(270 MHz, CDC13) 4.79 (1H, s, H-C(19)), 4.63 (1H, s, H-C(19)), 4.27-4.22 (1H, m, 
Hp-C(3)), 3.74-3.63 (1H, m, H-C(20)), 3.06 ( 1H, q, 8 .8 , J IX  18.0 Hz, H-C(l)),
1.16 (3H, d , / 21t20 6.1 Hz, H3C(21)), 0.84 (9H, s, (H3C)3CSi), 0.83 (3H, s, H3C(18)), 
0.05 (6 H, s, (H3C)2Si); mlz (CL) 433 ([M++l], 4%), 415 (2 1 ), 375 (26), 357 (13), 283
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(100), 260 (10); Found : C, 74.8; H, 11.4. C27H4 8Si0 2  requires C, 75.0; H, 11.1%.
3a-Tertbutyldimethylsiloxy-5( 10^>1$H)abeopregn-10( 19)-en-20-one (126)
To a stirred solution of 3a-tertbutyldimethylsiloxy-5(10—*I$H)abeopregn-10(19)-e- 
n-20 $-ol (125) (150mg, 0.35mM) in methylene chloride (10 cm3) was added 
pyridinium chlorochromate (112mg, 0.52mM). The reaction mixture was stirred at 
room temperature under nitrogen for 3h. Silica gel was added to the reaction mixture 
and the solvent removed in vacuo. Purification by column chromatography, eluting 
with ethyl acetate-petrol (1:49) gave the 20-ketone (126) (142mg, 95%) as a 
colourless oil, (Rf = 0.74, ethyl acetate-petrol (1:9)); \)max (FILMVcm' 1 1706 s (C=0), 
1635 (C=C), 1061 (O-Si); SH (270 MHz, CDC13) 4.80 (1 H, s, H-C(19)), 4.65 (1H, s, 
H-C(19)), 6.78-6.72 (1H, m, Hp-C(3)), 3.05 (1H, q, J x r  9.0, / 1<2"  17.6 Hz, H-C(l)), 
2.07 (3H, s, H3C(21)), 0.84 (9H, s, (H3C)3CSi), 0.60 (3H, s, H3C(19)), 0.05 (6 H, s, 
(H3C)2Si); mlz (C.I.) 430 (M+, 2%), 373 (19), 297 (26), 281 (5), 258 (4), 149 (16), 75 
(100); Found : M+, 430.32671. C27H4$Si0 2 requires M, 430.32434, 5%.
5( 10-*lfiH)Abeopregn-10(I9)-en-3a-ol-20-one (127)
1M TBAF in THF (0.28 cm3,0.28mM) was added dropwise to a stirred solution of 
3a-tertbutyldimethylsiloxy-5(10^>lfiH)abeopregn-10(19)-en-20 -one (126) (lOOmg, 
0.23mM) in THF (5 cm3). The reaction mixture was stirred at room temperature for 
2h. Methylene chloride (15 cm3) was added and the solution was washed with dil. 
HC1 (5 cm3) and water (2x10  cm3). The combined organic extracts were dried over 
anhydrous sodium sulphate, concentrated in vacuo, and purified by column 
chromatography, eluting with ethyl acetate-petrol (1:9) to give 5(70—1yl$H)abeopre- 
gn-10(19)-en-3a-ol-20-one (127) (72mg, 98%) as a colourless oil, (Rf = 0.33, ethyl 
acetate-petrol (3:7)); omax (FILMVcm1 3392 br (OH), 1704 s (0=0), 1634 (C=C); 5H 
(270 MHz, CDC13) 4.89 (1H, s, H-C(19)), 4.73 (1H, s, H-C(19)), 4.42-4.37 (1H, m, 
Hp-C(3)), 3.17 (1H, q , / 1>r 8 .8 , J l T  18.1 Hz, H-C(l)), 2.12 (3H, s, H3C(21)), 0.67 
(3H, s, H3C(18»; m/z (C.I.) 317 ([M++l], 92%), 299 (100), 281 (28), 271 (4), 232 (5),
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161 (9), 99 (22), 85 (53); (E.I.) Found : M+, 316.24023. C2 ,H320 2  requires M, 
316.24125,77%.
5( 10-^>-l$H)Abeopregnan-3a-ol-20-one (128)
A solution of 5(10-*l$H)abeopregn-10(19)-en-3<x-ol-20-one (127) (200mg, 0.63mM) 
and 1 0 % palladium on activated carbon (2 0 mg, 1 0 % w/w) in ethanol ( 2 0  cm3) was 
degassed under nitrogen for 15 min. The reaction mixture was stirred under an 
atmosphere of hydrogen at atmospheric pressure for 12h. After this the mixture was 
filtered and the filtrated washed with water ( 2  x 1 0  cm3), after diluting with 
methylene chloride (30 cm3). The organic layer was dried over anhydrous sodium 
sulphate and purified by column chromatography, eluting with ethyl acetate-petrol 
(3:17) to give 5( 10—*lfiH)abeopregnan-3(x-ol-20-one (128) (178mg, 8 8 %) as a white 
solid, recrystallised from petrol, m.p. 113-114°C (Rf = 0.36, ethyl acetate-petrol 
(3:7)); omax (NUJOLVcm*1 3388 br (OH), 1703 s (C=0); §H (270 MHz, CDC13)
4.34-4.31 (1H, m, Hp-C(3)), 2.53 (2H, t, J u2 9.2 Hz, H-C( 1)), 2 .1 1  (3H, s, H3C(21)), 
0.99 (3H, d , / 19107 3  Hz, H3C(19)), 0.64 (3H, s, H3C(18)); m/z (C.I.) 319 ([M++l], 
85%), 301 (100), 283 (37), 257 (8 ), 233 (4), 215 (5), 149 (8 ); Found : C, 78.7; H, 10.9. 
C21H34O2. % H20  requires C, 78.8; H, 10.7%.
20$-Acetoxy-5(10-+l$H)abeopregn-10(19)-en-3$-ol (129)
Potassium carbonate (500mg, 3.62mM) was added to a stirred solution of 
3$,20$-diacetoxy-5(10^>l$H)abeopregn-10(19)-ene (8 8 ) (350mg, 0.87mM) in 
methanol (20 cm3). The reaction mixture was stirred at room temeprature for 2.5h. 
Water (10 cm3) was added and the mixture extracted with methylene chloride (2 x 25 
cm3). The combined organic extracts were washed with dil. HC1 (10 cm3) and water 
( 2  x 1 0  cm3), dried over anhydrous sodium sulphate, and concentrated under reduced 
pressure. Purification by column chromatography, eluting with ethyl acetate-petrol 
(3:17) gave the 3$-hydroxyl-20$-acetate (129) (262mg, 84%) as a colourless ol, (Rf = 
0.11 ethyl acetate-petrol (1:9)); vmax (FILMVcm*1 3394 br (OH), 1732 s (C=0), 1633
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(C=C), 1243 (C-O); 5H (270 MHz, CDC13) 4.86 (1H, s, H-C(19)), 4.82-4.78 (1H, m, 
H-C(20)), 4.70 (1H, s, H-C(19)), 4.42-4.36 (1H, m, Ha-C(3)), 3.17 (1H, q, J l2  9.3 Hz, 
H-C(l)), 2.02 (3H, s, H3CCO), 1.14 (3H, d, J2h20 6.1 Hz, H3C(21)), 0.68 (3H, s, 
H3C(18)); mlz (E.I.) 360 (M, 5%), 342 (10), 300 (6 ), 285 (5), 243 (7), 163 (12), 84 
(42); (Found : M+, 360.26645. requires M, 360.26952, 41%.)
3a-Formoxy-20$-acetoxy-5(10-^l$H)abeopregn-10(19)-ene (130) 
Diethylazodicarboxylate (0.16ml, 1.04mM) was added dropwise to a stirred solution 
of 20$-acetoxy-5( 10-*l$H)abeopregn-10( 19)-en-3fi-ol (129) (250mg, 0.69mM), 
triphenylphosphine (364mg, 1.39mM) and formic acid (0.05 cm3, 1.39mM) in THF 
(20 cm3) under nitrogen. The reaction mixture was stirred at room temperature under 
nitrogen for 7h. Water (20 cm3) was added and the mixture extracted with methylene 
chloride (2 x 30 cm3). The combined organic extracts were dried over anhydrous 
sodium sulphate, concentrated in vacuo, and purified by column chromatography, 
eluting with ethyl acetate-petrol (1:19) to give the 3a-formate (130) (197mg, 73%) as 
a colourless oil, (Rf = 0.56, ethyl acetate-petrol (1:9)); uniax (FILM)/cm_1 1727 s 
(C=0), 1711 s (C=0), 1636 (C=C), 1245 (C-O); 8 H (270 MHz, CDC13) 8.05 (1H, s, 
HCO), 5.17-5.08 (1H, m, Hp-C(3)), 4.91 (1H, s, H-C(19)), 4.87-4.80 (1H, m, 
H-C(20)), 4.80 (1H, s, H-C(19)), 2.92 (1H, q, J IX  9.9, J x x  18.1 Hz, H-C(l)), 2.02 
(3H, s, H3CCO), 1.15 (3H, d ,J 2u o  6.0 Hz, H3C(21)), 0.68 (3H, s, H3C(18)); mlz 
(E.I.) 388 (M+, 2%), 342 (13), 328 (8 ), 313 (4), 282 (7), 149 (17), 59 (38); (Found : 
M+, 388.26136. C24H360 4 requires M, 388.26125, 8 %).
20$-Acetoxy-5( 10-+1 p //)abeopregn-10( 19)-en-3a-ol (131)
Potassium carbonate(l lOmg, 0.80mM) and the 3a-formate (130) (1 lOmg, 0.28mM) 
were stirred together in methanol (10 cm3) at room temperature for lh. Water (5 cm3) 
was added to the reaction mixture and then it was extracted with methylene chloride 
(2 x 20 cm3), dried over anhydrous sodium sulphate, and concentrated in vacuo. The 
residue was purified by column chromatography, eluting with ethyl acetate-petrol
- 2 0 7 -
(1:9) to give the 3a-hydroxyl (131) (96mg, 94%) as a colourless oil, (Rf = 0.11, ethyl 
acetate-petrol (1:9)); umax (FILM)/cnr' 3364 br (OH), 1730 s (0=0), 1633 (C=C), 
1244 (C-O); 6 h (270 MHz, CDC13) 4.92-4.78 ( 1H, m, H-C(20)), 4.86 (1H, s, 
H-C(19)), 4.70 (1H, s, H-C(19)), 4.42-4.37 (1H, m, Hr C(3)), 3.17 (1H, q, 7 i r  9.0,
18.6 Hz, H-C(l)), 2.02 (3H, s, H3CCO), 1.14 (3H, d, 72 i.20 5.9 Hz, H3C(21)),
0.68 (3H, s, H3C(19)); mlz (E l.) 360 (M+, 7%), 342 (26), 300 (16), 285 (15), 267 (15), 
243 (28), 173 (16), 121 (39), 43 (100).
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Appendix 1 Review of steroidal anaesthetics
In 1927, Cashin and Moravek1 reported that high doses of cholesterol induced 
‘anaesthesia’. Cholesterol was found to potentiate the action of anaesthetic agents 
such as ether, chloroform or sodium pentobarbitone in the rabbit2 and other 
animals.3
In 1941, Hans Selye4 was the first to report the finding of reversible 
unconsciousness in rats, following the intraperitoneal injection of large quantities 
of several steroidal hormones. Selye noted that it was difficult to produce acute 
overdosage phenomena, even when giving enormous doses, whilst looking at the 
physiology of steroidal hormones. He discovered that various steroid hormones, 
especially desoxycorticosterone acetate (DCA) and progesterone (Figure 1) 
produced deep anaesthesia in rats and mice if injected into the peritoneum, where 
they could be rapidly absorbed. After recovery from the anaesthesia such animals 
showed no ill effects. Partially hepatectomized rats were found to be much more 
sensitive to the anaesthetic effect of the steroids than intact controls and also 
nephrectomized rats. Thus Selye concluded that the liver played an important role 
in the detoxification of these compounds, and also that males are less sensitive 




Figure I. The first reported steroidal anaesthetics, a) progesterone, b) DCA.
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Both progesterone and DCA were added to the iratts in peanut oil, as they were 
practically insoluble in water. The anaesthesia produced was found to be so deep 
that Selye was able to perform prolonged abdonninal operations in rats 
anaesthetized with DCA or progesterone. If letlhal doses were administered, death 
was apparently due to anaesthesia of the respiratory centres.
Selye4 attempted to obtain some information concerning the correlation between 
chemical structure and anaesthetic effect. His report included a table comparing 
the chemical structure of some fourteen steroids with their anaesthetic action. 
However, it was noted that only hormonally active steroids showed any anaesthetic 
effect, even though the activity was not limited to compounds with any one 
specific type of hormonal action.
Shortly after this publication, Selye published a paper on the acquired adaptation to 
the anaesthetic effect of steroid hormones.5 Selye reported that steroid hormones 
caused deep anaesthesia in various experimental animals, such as rats, if they were 
administered intraabdominally or intravenously in sufficiently large doses.6 This 
type of anaesthesia was similar to that obtained with other injected anaesthetics.7
It was also found that the anaesthesia produced by progesterone and DCA was 
usually not complicated by any untoward overdosage symptoms. On the other 
hand, anaesthetic doses of testosterone often caused convulsions and sometimes 
fatal pulmonary edema.
In the case of daily intraabdominal injections, a high degree of immunity to the 
anaesthetic action of such steroids was rapidly acquired. Of the two most active 
anaesthetic steroids, adaptation to progesterone was much more rapidly acquired 
than to DCA.
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The prolonged treatment with hormones leads tco t;he development of a resistance to 
their actions. This resistance is the result of the formation of hormone-inhibiting 
substances termed antihormones, which can be seen in the blood of the resistant 
animal.
Rats rendered resistant to the anaesthetic action of a certain steroid usually 
exhibited a high degree of resistance to other steroids as well, hence, the resistance 
was not strictly specific to the hormone with which the animal had been pretreated. 
Cholesterol, a steroid compound which does not produce anaesthesia, was unable 
to impart such resistance to anaesthetic steroids. The high degree of resistance to 
the anaesthetic action of steroid hormones (produced by prolonged pretreatment) 
was not accompanied by the appearance of demonstrable antihormones in the 
blood. Selye concluded that he had induced a resistance to a certain 
pharmacological action rather than to a certain chemical substance.8 Experimental 
evidence was presented in the paper, involving various steroids. This furnished 
another example of an acquired hormone resistance without antihormone 
formation.
Also, in 1941, Selye published a more detailed paper on the anaesthetic action of 
steroid hormones,9 where, based upon his observations, he came up with the 
"fundamental law o f steroid anaesthesia’, namely that "all compounds having a 
steroid hormone action are capable o f producing anaesthesia, while no compound 
devoid o f hormone action possesses this power’ .4,5,1°
This was true even though the anaesthetic effect was not dependent upon any 
particular type of hormone activity. Progesterone and DCA were seen to be much 
more potent anaesthetics than the androgens, which in turn were more potent than 
the estrogens, but all these compounds possessed some measure of anaesthetic 
action, while even their closest chemical derivatives, if hormonally inactive, were
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devoid of it.
Selye had also previously discovered that the amaesthetic effect of all steroid 
hormones was more marked in female than in male animals.4 Spaying did not alter 
the sensitivity of females, but castration raised the responsiveness of males to the 
female level.11
In the aforementioned report,9 Selye conducted experiments on rats, designed to 
test the validity of the ‘fundamental law of steroid hormone anaesthesia’ with a 
series of compounds which had not been studied so far from this point of view.
Two adrenal steroids were examined for possible anaesthetic effect; Reichstein’s 
compound "J" (17-ethylandrostane-3,17,20-triol)12, which was used in the form of 
its 3,20-diacetate, and Kendall’s compound "A" (17-ethyl-A4-androstene-21-o- 
1-3,11,20-trione or dehydrocorticosterone)12. Also the vitamin ascorbic acid was 
tested, as Israel and Meranze claimed that this compound had ‘progesterone-like’ 
actions.13
The diacetate of Reichstein’s compound "J", which was hormonally inactive, had 
no anaesthetic effect. Kendall’s compound "A", which was an active cortical 
hormone, exhibited marked anaesthetic potency. Vitamin activity was found not to 
confer an anaesthetic action upon a compound, since even large doses of ascorbic 
acid, <i/-a-tocopherol, and calciferol proved completely devoid of this effect.
The next compound to be tested was A5-acetoxy pregnenolone. It was readily 
available via partial synthesis as it represents an intermediary step in the 
commercial manufacture of DCA. Selye observed that this compound had an 
anaesthetic action.9 This appeared to, at first, represent an exception to the 
‘fundamental law of steroid hormone anaesthesia’, since it was not known to
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possess any hormonal action. However, on cairrying out tests for other 
physiological effects, Selye found that it possessed definite adrenal cortical 
hormone activity.9 Since this compound was not known to occur naturally, Selye 
reported that this may well be the first instance of an "artificial cortical hormone". 
Up to now ‘the fundamental law of steroid anaesthesia’ had been adhered to and, 
unless further research would reveal important exceptions, it appeared that a test of 
anaesthetic potency would represent a valuable short cut in the detection of 
hormonal activity. The only apparent exception was 17-ethinyl testosterone, a 
hormonally active compound with which Selye was unable to produce 
anaesthesia.9 However the compound was so insoluble that its inactivity as an 
anaesthetic was most probably due to the fact that sufficient quantities could not be 
rapidly administered in solution.
In many instances simultaneous administration of two anaesthetic drugs elicits a 
more pronounced anaesthesia than could be expected by mere summation of their 
effect. However, combined simultaneous treatment with two anaesthetic steroids 
led to a summation, but not a potentiation, of their actions.9 Selye showed this by 
experiments in which DCA and progesterone were given at the same time.9 Selye 
also noted that in these experiments, progesterone was definitely more potent than 
DCA, while in previous experiments4 the latter was found to be more active.
It became evident that in animals heavier than about 80 grams DCA produced 
more marked anaesthesia than progesterone. This difference became more evident 
as the weight of the animals rose. On the other hand small rats weighing 80 grams 
or less were definitely more sensitive to progesterone.
There appeared, however, to be a true potentiation of the actions of volatile 
anaesthetics, such as ether or chloroform, when administered simultaneously with 
a steroid anaesthetic, for instance progesterone.9
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Adrenalectomy was seen to sensitize the orgamismi to the anaesthetic action of 
DCA, estradiol, testosterone, and progesterone although it did not influence the 
anaesthesia caused by chloroform, ether, or magnesium chloride.9 
Hypophysectomy sensitized the organism to the anaesthetic action of DCA and 
progesterone in a similar fashion to adrenalectomy.9 Thyroidectomy did not 
influence the course of the anaesthesia produced by progesterone or DCA 
administration.9 Bilateral nephrectomy also did not change the course of 
anaesthesia caused by DCA and progesterone.9 Thus Selye was able to draw 
certain conclusions with regards the mechanism of the steroid anaesthetics and 
their overdosage.9 He concluded that the pituitary, adrenals, and the liver, were, in 
the same way involved in the ‘detoxification of the steroids’, and that in the 
absence of one of the aforementioned glands, the sensitivity to the anaesthetic 
effect increased, because the anaesthetic remained in an active form in the 
organism for a longer period of time.
During the course of Selye’s studies9 he found that shortly after an atropine 
injection the resistance of animals towards the anaesthetic effect of steroids 
increased, but prolonged pretreatment with atropine decreased resistance to the 
anaesthetic action of progesterone. This could be due to the well-known fact that, 
while the organism acquires adaptation to a certain stimulus, its resistance to other 
agents decreases. This was supported by experiments showing that rats which 
acquired a great deal of specific adaptation to toxic doses of formaldehyde, or 
forced muscular exercise, also became particularly sensitive to progesterone 
anaesthesia.9
Acetylcholine did not influence progesterone anaesthesia in any way.9 Selye drew 
no notable conclusions regarding this.
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It was known that steroid hormones produced amaiesthesia when injected 
intraperitoneally or intravenously. However, if' thiey were injected subcutaneously 
they did not exhibit any anaesthesia, probably because the rate of absorption was 
comparitively slow.5
Winter11 reaffirmed that female rats were more sensitive to the anaesthetic effect 
of progesterone than males, but this sex difference only became apparent after 
maturity. Winter suspected that the endocrine secretion of the gonad influenced 
hormone sensitivity, as the relative resistance of the male developed only after 
puberty. A number of experiments were carried out to elucidate this 
phenomenon.11
Progesterone was administered to normal males and females, castrated males and 
females, and both males and females castrated and treated with the artificial testoid 
substance methyl testosterone. After carrying out the experiments Winter 
concluded that the normal endocrine activity of the testis was largely, if not 
entirely, responsible for the comparitive resistance of the males, since castration 
increased sensitivity in males, but was without effect in female rats.11 Conversely, 
the resistance of castrated males and females was raised by the administration of 
methyl testosterone. Secretion of luteoids in the female did not confer some 
resistance towards progesterone anaesthesia, as while the secretion of testoids in 
the male is continuous, luteoid secretion in the female is intermittent and of 
relatively short duration.
Treatment with glucose and adrenalin tended to increase, while treatment with 
insulin or exposure to excessive heat or cold tended to decrease, the resistance of 
the rat to the anaesthetic effect of progesterone.11
In 1942 Selye investigated the antagonism between anaesthetic steroid hormones
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and pentamethylenetetrazol (metrazol), using IDCA  ^and progesterone as 
examples.14 Beecher has published a review115 rcep>orting that analeptic, convulsive 
drugs such as picrotoxin or metrazol, counteract ithe narcotic effect of certain 
anaesthetics, especially the barbiturates and tribnomoethanol (avertin).
Steroid anaesthesia was suitable when long-lasting narcosis was required, but 
cannot be used satisfactorily in cases in which a deep anaesthesia of short duration 
was required, because a dose sufficient to produce deep anaesthesia, usually 
maintained the state of narcosis for several hours. Hence, Selye thought it would 
be of interest to establish whether metrazol could arouse animals from the hormone 
anaesthesia whenever desired.14
Selye performed experiments on albino rats,14 which indicated that the anaesthesia 
produced by the intraperitoneal administration of steroid hormones, DCA or 
progesterone, could be interrupted at will by the administration of metrazol. It 
should be noted that this was not merely a prevention, but an actual interruption of 
the anaesthesia. Selye found that on administration of metrazol to the 
anaesthetized rats, they were on their feet after five minutes and showed only 
slight traces of narcosis. In this respect the anaesthesia produced by DCA and 
progesterone resembled that elicited by the barbiturates or tribromoethanol. Selye 
also discovered that fatal doses of metrazol were readily tolerated, without causing 
convulsions or lung edema, by rats receiving suitable doses of anaesthetic steroid 
hormones. Also, in this respect, the steroids again resembled the barbiturates. 
Thus, Selye concluded that the antagonism between DCA or progesterone and 
metrazole was mutual.
All of Selye’s published results14 are shown in Table 1.
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Treatment Number off animals
Average degree 
of anaesthesia Deaths
DCA 7 +++ 0
Metrazole and DCA 7 trace 1
Metrazole 7 0 7
Progesterone 10 +++ 0
Metrazole and Progesterone 12 0 0
Metrazole 10 0 10
Table 1. Antagonism between DCA/progesterone and metrazole, +++ indicates a
100 percent result.
In order to measure the anaesthetic effect of steroids with some degree of accuracy, 
a sensitive bioassay method was designed using immature female, partially 
hepatectomized rats.16 However, the applicability of this bioassay method was 
somewhat limited by the fact that steroids were only very sparingly soluble in 
non-toxic solvents, whilst it was required to administer them in veiy high 
concentrations.
Steroids, unlike most other anaesthetics, appeared to be most active in animals 
whose central nervous system was least developed. Selye reported that a few 
preliminary experiments in fish17 proved this to be correct. He found that 
anaesthesia was readily produced if the steroids were added to the water in which 
the fish were swimming. However, the invertebrates examined proved completely 
resistant to the anaesthetic effect of steroids. It was evident that the most 
important factor for the production of steroid anaesthesia in fish, was to achieve an 
adequate concentration of the anaesthetic in the water. Although the size and sex 
of the fish played some role, they were comparatively less important. For various 
reasons, Selye devised a bioassay method using immature specimens of the redfin 
minnow Notropis CornutusP
This test had the advantage over the previously used rat assay in that it was simpler
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and more sensitive.
Selye assayed forty-seven steroid derivatives usiing the fish and rat tests.17 In 
general, it was found that the steroids most active in the rat were also most active 
in the fish. The rat bioassay is detailed in a previous report.16
In the fish assay, the steroids were taken up in a few drops of alcohol (ethanol) and 
injected directly into the water. The anaesthetic effect of the alcohol played no part 
in the narcosis obtained as it was not used in sufficient amounts.
Selyes’ results were in agreement with ‘the fundamental law of steroid hormone 
anaesthesia*. The fish assay further validated the view that intense anaesthetic 
activity was largely dependent upon the solubility of the compound in the solvent 
in which they were administered.
The five most active steroid anaesthetics are shown in Table 2. Note, that the 
previously untested steroid, pregnanedione, showed the most anaesthetic potency 
and was ten times as active as DCA and five times as active as progesterone in the 
fish assay.
A.F.U. is the anaesthetic fish unit, which is defined as the minimum amount of a 
compound (expressed in mg.), which must be added, per minnow and per 200 cc. 
of tap water in order to produce deep anaesthesia.
The following conclusions were drawn by Selye,17 with regards the comparison 






Progesterone 21 -  Ethylprogesterone






A16 -  Pregnenedione
A.F.U. 0.50 0.50
Table 2. Active steroid anaesthetics in Selye’s fish assay.17
of compounds examined. No compound having a long C(17) side-chain possessed 
anaesthetic activity. A side chain, of 7 or more carbon atoms, was not compatible 
with anaesthetic activity, but at least 4 carbon atom side chains were compatible 
with marked anaesthetic potency.
Oxygenation at the two extreme poles of the molecule, i.e. C(3) and C(17) in the 
case of compounds possessing no side chain, and C(3) and C(20) or C(21) among 
those having a C(17) alkyl side chain, possessed the greatest anaesthetic activity. 
Further oxygenation was detrimental to anaesthetic potency. This was illustrated 
by the example of progesterone, which was more active than 6-hydroxyproge- 
sterone, or the most active anaesthetic steroid, pregnanedione, which became 
practically inert upon further oxygenation, as shown by pregnanedionediol and 
pregnanetrionol. However, the presence of oxygen was indispensable for any type 
of hormonal or anaesthetic activity among the steroids.
The degree of unsaturation was also found to be important in determining
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anaesthetic potency.17 "One double bond does, not appear to interfere seriously, 
with the anaesthetic effect, if it is situated in ring A or B, but two or more double 
bonds in these two rings, or one double bond in ring D are detrimental".17 
16-Dehydro-progesterone was less active than progesterone, A5,6-pregnadienolone 
was inert, whereas pregnenolone exhibited a moderate narcotic potency, and the 
same decrease in activity was noted in pregnanedione following the introduction of 
a A16-double bond.
It was also noted that, at least in an animal with such a primitive type of nervous 
system as that of the fish, the steroids compared favourably, in narcotic potency, 
with some of the most active anaesthetics known to pharmacologists, such as ether, 
alcohol, chloroform, morphine sulphate or magnesium chloride.17
Selye, as it has previously been stated, has shown that for the production of general 
anaesthesia in mammals, it was essential that the steroid should rapidly achieve a 
high concentration in the blood.9 Selye18 noted that a variety of steroid compounds 
(DCA, progesterone, and pregnane-3,17-dione) were absorbed into the 
gastrointestinal tract with sufficient speed to induce general anaesthesia in the rat, 
when administered orally. Under the conditions of Selye’s experiments it appeared 
that the alkaline reaction, and the digestive enzymes of the intestinal secretions 
were unable to destroy any significant amount of the steroids during the 
comparatively short time required for their absorption. It must be noted that this 
was in the rat, and conditions vary from the rat to the human gastointestinal tract 
It was also contradictory with respect to steroid hormones.
A factor which decreased the anaesthetic activity of orally administered steroids, 
with respect to intraperitoneally, subcutaneously, and intramuscularly administered 
steroids, was that their primary route is through the liver, which is known to take 
an active part in their detoxification.10,19 Introduction of an ethyl or methyl group
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at C(17) increased anaesthetic activity as it appeared that these compounds were 
less readily destroyed by the liver than their pairent compounds.
This oral activity was achieved by the administration of finely ground steroid 
crystals in distilled water through a fine rubber tube introduced into the stomach. 
The comparative inactivity of orally administered hormones, as well as their 
‘great’ anaesthetic activity when given via this route, was explained by a greater 
speed of absorption.
Selye10,19 also confirmed the fact that, steroid sensitivity of the central nervous 
system is common to a large variety of animals, by use of the bird. He showed that 
intraperitoneal administration of progesterone in oil, caused deep and prolonged 
anaesthesia in young pigeons.19
In 1944 Selye and Stone20 used their knowledge, that detoxification of steroid 
anaesthetics occurred in the liver, to gauge the speed with which the steroid was 
absorbed. In this manner it was possible to estimate the degree of hepatic 
detoxification by the decrease in the anaesthetically-effective dose condition by 
partial ablation of the liver. They also found that some steroid compounds had 
definite anaesthetic properties although they possessed no hormonal activity, 
contradictory to ‘the fundamental law of steroid hormone anaesthesia’.
A report by Farson et al,21 and also by Cashin and Moravek,1 questioned the 
suitability of the word ‘anaesthesia’, when looking at the effects of the steroid 
hormones. Etymologically ‘anaesthesia’ means without sensation, but usage 
confined it to a description of a reversible process, unless accidently it became 
terminal. On studying ‘Selye’s generalisations’, Farson et al initially used 
cholesterol21 After finding a high degree of fatality, occurring after loss of 
consciousness, various hormonal steroids were investigated, including
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progesterone. Farson discovered that, neither itfi animals which died nor with those 
that recovered after administration of progesterone, was there a period in which the 
animal did not respond promptly to pain stimuli. He, thus, concluded that this 
syndrome cannot directly be referred to as anaesthesia, when the sensory pathways 
were not blocked. This was contradictory to earlier reports by Selye, outlined in 
this report. A better term would be the ‘central depressant action’ of the steroidal 
hormones.
Nearly ten years passed before the next communication on steroidal anaesthetics. 
Fourteen years after Selye first reported on the existence of steroidal anaesthetics, 
Laubach et al22 reported on the first intravenous anaesthetic in man. 
Hydroxydione, 21-hydroxypregnane-3,20-dione sodium succinate (introduced by 
Pfizer as ‘Viadrir, and later by Schering as ‘Presuren’), Figure 2, was found to be 
the most promising of a number of water-soluble steroids.
HoCOCCHoCHpCO" Na
O
Figure 2. Viadril, the first successful intravenous anaesthetic in man.
Hydroxydione resembled pregnanedione, except that a sodium succinate group 
replaced a hydrogen atom in the 21-position of pregnanedione. This was therefore 
the sodium salt of a weak acid and, as such, the pH of its aqueous solution was 
well above neutral (8.5-9.8). It was studied in a number of patients, and was found 
to be a safe, convenient, and practical basal anaesthetic for surgical procedures in 
man.22
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It must be noted that around this time a report appeared23 in which it was claimed 
that sleep was induced in man by intravenous administration of progesterone.
In the mouse and rat, hydroxydione was found to have an anaesthetic potency 
equal to that of thiopental sodium, a known barbiturate anaesthetic, and a 
therapeutic index in excess of that of the thiobarbiturate. However, in cats, dogs, 
and monkeys hydroxydine was not as active (milligram for milligram) as 
thiopental sodium was, but was much less toxic than thiopental sodium. The 
advantages of the anaesthesia produced by hydroxydione were the relatively low 
degree of respiratory depression and rapid uncomplicated recovery with minimum 
post-anaesthetic depression 22 Little or no endocrine activity was demonstrated.22
In England, Lerman (1956),24 Taylor and Shearer (1956)25 and Galley and Rooms 
(1956)26 published reports of their work with hydroxydione.
Gordon et al27 studied the effects of Viadril on the cerebral metabolism of humans 
and reported metabolic changes identical with those of barbiturate anaesthesia. 
These studies culminated in the successful trial of Viadril with nitrous oxide 
supplement, as the anaesthetic for a prefrontal lobotomy.27 Encouraged by this, 
DeBon et al28 gave Viadril a clinical trial as a basal anaesthetic for surgery at the 
University of California, School of Medicine. The technique is detailed in the 
report, with the appropriate doses of meperidene (Demerol) hydrochloride, and 
scopolamine or atropine used as premedication.
Viadril was used in 125 patients for basal anaesthesia in a variety of surgical 
procedures, and in 3 patients for sedation during regional anaesthesia. It was given 
by intravenous injection as a 2.5 percent solution, which was freshly prepared by 
means of a previously set dextrose drip infusion. The anaesthetic solution was 
injected into the tubing, connecting the drip with the patient, so that mixing and
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dilution occurred before the solution reached tth(e vein. In the lightly premedicated 
patient, Viadril produced sleep in 5 to 10 minutes after adminsitration, and lasted 
for a maximum period of approximately two ho urs, after which more Viadril, in 
smaller doses, could be added to prolong anaesthesia. The anaesthesia was a 
smooth, quiet process devoid of any excitement phase, and it was noted that 
Viadril had the ability to obtund reflexes, particularly those of the pharynx and the 
larynx, i.e., coughing. Viadril was seen to produce a definite analgesic state far 
greater than that produced by the barbiturates. The amounts of relaxant drugs used 
were considerably smaller than those found necessary when employing thiopental 
sodium and nitrous oxide anaesthesia, Table 3.
Compound
Animal
species Route of administration




m in i S.E.
Duration 
min ±S.E. T.I.
Hydroxy - mice I.V. 10 / 0 3.2±0.1 34.9-3.5 11.6
dione rats I.V. 10/1 3.9 ±0.3 37.3-2.0 7.8
mice oral 10 /2 3.1±0.2 174.2123.2 12.0
Thiopental mice I.V. 10 /0 immediate 4.5 ±0.8 4.6
sodium rats I.V. 10/5 immediate 163.0±12.1 2.5
rats oral 10/9 1.6
Table 3. Comparative anaesthetic effect of Viadril and thiopental sodium in mice 
and rats. From Postgrad. Med. J. SuppL, 1972,48, p.9, J. Sutton. *Dose employed
was twice the AD50.
The various characteristics associated with the anaesthesia produced by Viadril, 
namely control of pain and reflexes, and production of relaxation, classified it as a 
true anaesthetic agent best compared with tribromoethanol. It had a pleasing lack 
of postoperative depression, with the majority of patients being responsive at the 
end of the procedures. Bouts of coughing and straining, sometimes observed 
during light thiopental sodium-nitrous oxide-oxygen anaesthesia did not occur with
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Viadril. Galley and Rooms26 noted that whille irecovery was prolonged it was a 
relatively pleasant experience.
DeBon et al28 noted no complications after the use of Viadril, except on three 
occasions when the administration of the drug was followed by thrombophlebitis in 
the injected vein. Some patients also complained of nausea and vomiting after 
operative procedures in which the drug was used. Hypotension was also noted in a 
number of cases soon after administration of Viadril, but this hypotension was 
easily controlled by the use of small doses of a vasopressor in the cases where the 
pressure dropped lower than was considered safe or where it failed to return 
spontaneously within a few minutes. DeBon concluded that Viadril was a true 
anaesthetic agent and that the more satisfactory results were obtained when 
administering the drug together with nitrous oxide (75%) and oxygen (25%). The 
administration of Viadril was reasonably safe, and it possessed a high therapeutic 
index.28
Further studies29 revealed that, on injection of hydroxydione cases of 
post-anaesthetic thrombophlebitis were so common, that this was a severe 
drawback. The delayed onset of not only anaesthesia, but also any side-effects was 
a second drawback. These two disadvantages meant that hydroxydione (Viadril) 
was unsuitable for clinical use. Several possible ways of overcoming the problem 
of venous thrombosis were discussed by Robertson and Wynn-Williams,29 but 
none were satisfactory. Thus the problem was never overcome and, as inhalation 
anaesthetics improved, so hydroxydione ( Viadril) became obsolete.
Robertson and Wynn-Williams29 suspected that some metabolites of hydroxydione 
could be responsible for much of its anaesthetic activity. There was particular 
interest in those which had a hydroxyl group at either end of the molecule in place 
of the ketone group and the succinate moiety of hydroxydione. Though they were
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potent anaesthetics they were not water-soluble;. Ilf clinically, such hydrogenation 
and hydrolysis were necessary before an active ccDmpound appeared, this would 
explain the delayed onset of action of Viadril It would also explain the relatively 
low potency of Viadril compared with later steroid anaesthetics, because it was 
unlikely that such hydrolysis would produce a 100 percent yield of active steroid.
After hydroxydione anaesthesia two pregnandiol-like metabolites (allopregnan- 
e-diol and pregnanediol) were seen in the urine. Pregnanediol was known to be the 
most important excretion product of progesterone in urine. Ylinen30 examined the 
excretion of urinary pregnanediol in a series of climacteric and postclimacteric 
gynaecological patients before and after operations performed under steroid 
anaesthesia. The conditions of anaesthesia used were as reported by DeBon et 
a l Urinary pregnanediol was determined in a series of gynaecological 
operations performed with one gram of hydroxydione as basal anaesthetic, 
according to Jensen’s method.31
Twenty-four hour collections of urine were made before the operation, and similar 
collections were performed after the operation.
According to Klopper et al,32 the average daily output of pregnanediol in males 
was 1.1 lmg, and post-menopausal women excreted an average of 0.60mg/24 
hours. After intravenous administration of hydroxydione there was a marked rise 
in the urinary pregnanediol (approx. 20-85mg/24 hours). This increase was most 
prominent during the first four hours of the anaesthesia. After the second 
postoperative day, the pregnanediol excretion was not seen to increase as an effect 
of hydroxydione.
The pronounced rise in the excretion of pregnanediol after administration of 
hydroxydione was connected with the metabolism of the steroid. Considering the
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central role which was known to be played by {progesterone in the biosynthesis of 
the steroids, it was apparent that the increase ini the pregnanediol excretion after 
administration of hydroxydione was connected with the increase of progesterone at 
some stage in the metabolism of hydroxydione. Klopper et al stated "all the 
biosynthetic pathways lead through progesterone".32
In corresponding control cases with other forms of anaesthesia, no such rise in 
urinary pregnanediol was present.32
Pauling33 divided general anaesthetics into two classes; those capable of hydrogen 
bond formation, such as barbiturates, steroids and aliphatic alcohols, were regarded 
as specifically inhibiting the processes supplying energy for the maintenance of 
cerebral electrical activity. Whilst those incapable of hydrogen bonding, for 
example the simple gaseous anaesthetics, were postulated to depress the electrical 
oscillations of the brain through hydrated microcrystal formation.
Ahmad et al34 reported that there was an absence of anaesthesia in alcohols (eg. 
terpenoid hemisuccinates) possessing molecular weights between those of simple 
aliphatic alcohols and those of the anaesthetically active steroids. The results 
supported the conclusions of Figdor et al,35 that the steroidal general anaesthetics 
displayed a high degree of structural specificity.
Coupled with Pauling’s observations,33 these results suggested that anaesthetics 
capable of hydrogen bonding acted via a specific mechanism and that anaesthetic 
activity was a result of retention of affinity for the receptors, i.e. from a direct 
stimulant action.
In 1963, Brown and Sarett36 prepared a number of functional derivatives of the 
anaesthetic steroids, pregnan-3a-ol-20-one and pregnan-3a-ol-ll,20-dione. The
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synthesis of two of the more interesting compounds, namely the 3-phosphate ester 
of pregnan-3ot-ol-20-one and 21-carboxypregnain-3a-ol-ll,20-dione is described.36 
It was thought these could conceivably be hydrolysed to the parent sterol in vivo, 
since phosphate esters of 21-oxy steroids were known to possess the antiinfl­
ammatory activity of the parent steroid,37 and the solubilizing carboxy group 
would be removed in vivo.
The phosphate ester of pregnanolone was prepared by the addition of pregnanolone 
to phosphorous oxychloride, followed by hydrolysis in dilute acid. The 
21-carboxy derivative of 11-ketopregnanolone was obtained via the oxalyl 
derivative.36
Intravenous administration of the 3-phosphate ester of pregnanolone to dogs at a 
dose of lOmg/kg, produced no anaesthesia. Similarly, administration of the 
sodium salt of 21-carboxy-11-ketopregnanolone, at a dose of lOmg/kg 
(11-ketopregnanolone equivalent) resulted in only a transient sedation with no 
measurable anaesthesia.
Grassi and Raimondi38 reported that steroid anaestheia had no effect on the vaginal 
cytology of the newborn female child after operative delivery. This was confirmed 
by the detection of the urinary 17-ketosteroids, which also remained normal.
In 1964, Atkinson et al39 reported on the results of studies on mice of the hypnotic 
(and other) effects on the central nervous system of 168 steroids (142 pregnane 
derivatives and 26 other steroids), 149 of .which had not previously been tested in 
this way. Earlier Witzel had summarized similar results of 124 steroids.40 The 
term ‘hypnotic* was preferred to ‘anaesthetic’, because some steroids induced light 
sleep in mice, without reaching surgical anaesthesia.
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Atkinson used male mice, which were injected iintxavenously with the steroids at 1 
percent concentration either dissolved in water cor suspended in saline.39 When 
hypnosis resulted the times between the injection and loss of the righting reflex 
‘the induction time’, and between the loss and recovery of the righting reflex ‘the 
sleep time’, were recorded. For some steroids the intravenous LD50 values were 
determined. It was also usual to determine the AD50 i.e. the dose which caused 
half the mice to lose their righting reflex. However Atkinson determined the dose 
that induced sleep for 25 minutes for the anaesthetically active steroids.39
The steroids mentioned within the report of Atksinson et al39 were synthesized 
according to Cocker et al.41
Ten of the 63 5a-pregnanes and 52 of the 76 5p-pregnanes produced hypnosis.
The three 5-unsaturated pregnane derivatives tested were inactive. Thirteen 
5-epimeric pairs of pregnane derivatives were tested, but no hypnotic 5a-steroid 
was encountered with an inactive 5p-epimer.
The results of Atkinson et fl/39 were as follows:
3-Hydroxypregnanone derivatives. The 3-hydroxy-5-pregnan-20-one series and 
their 11-oxo derivatives were tested. 3a-Hydroxy-5p-pregnan-20-one was found 
to be as potent as the most active steroid tested thus far, its 11-oxo derivative was 
only half as potent as the parent steroid. The high hypnotic activity of 
3a-hydroxy-5p-pregnan-20-one has previously been reported by Witzel.40 The 
3-esters of hypnotic steroids were seen to be in general, less potent than the free 
alcohols, as previously stated by Figdor et al.35 The 3a-hydroxyl steroids had 
short induction times, while esterification was seen to lengthen induction times. It 
was concluded that the most potent and rapidly acting compounds of this group 
were those with a free 3a-hydroxyl, whatever the configuration at C(5).
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Substituents on the steroid nucleus found to resiult in a loss of hypnotic activity 
were 16-methyl, 12a-acetoxyl, 17a-hydroxyl oir-acetoxyl, 17a-hydroperoxyl, 
16a-hydroxyl, and the 16a,17a-epoxide.
The 20-ethylene ketal was almost as potent a hypnotic as its parent, although it had 
an increased induction time and was almost twice as toxic. A 9(1 l)-ethylenic bond 
appeared to introduce weak hypnotic activity, whilst 16,17-unsaturation abolished 
any hypnotic activity present in the parent steroid. Halogenation at C(21) either 
decreased or abolished hypnotic activity.
Pregnanedione derivatives. 5(3-Pregnane-3,20-dione was a potent hypnotic, but it 
had a long induction time. Its 11-oxo and 1 l(12)-unsaturated derivatives were less 
potent. 6a-Methylation abolished any hypnotic activity.
5a-Pregnane-3,20-dione and its 11-oxo derivative caused convulsions, whilst its 
6a-methyl and l(2)-unsaturated derivatives were inactive.
21-Hydroxypregnanedione derivatives. 21 -Hydroxy-5p-pregnane-3,20-dione had 
the same hypnotic activity as the most potent of the series, 3a-hydroxy-5(3-pregn- 
an-20-one. Its induction time was lengthy. Although an unesterified 3-hydroxyl 
usually conferred rapid induction, this property was not shared by the 21-hydroxyl 
or 3-oxo derivatives.
Some of the hypnotic activity of 3-oxo steroids was thought to result from their 
metabolic transformation to active 3-hydroxy steroids.35 It was shown that 
hydroxydione was metabolised in human subjects to 3a-hydroxy steroids, while 
3p-hydroxy steroids were not found.
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The phosphate ester of 21-hydroxy-5p-pregn;an*-3,20-dione was found to be almost 
as active and about half as toxic as hydroxydiome. The 11-oxo derivative of 
21-hydroxy-5p-pregnan-3,20-dione was found tto be inactive, as was the 
21-acetate, although the 21-succinate had a moderate potency.39
The succinate esters of the 17a-hydroxy derivatives of 21-hydroxypregnanedione 
and the analogous trione were found to be inactive.
3,21-Dihydroxypregnanone derivatives. Isomerism at C(3) and C(5) gives four 
possible structures for 3,21-dihydroxypregnan-20-one. Some of these and some of 
their 11-oxo derivatives, as both free alcohols and esters, were examined.39
3a,21-Dihydroxy-5p-pregnan-20-one was almost as active as the corresponding 
3-oxo and 21-deoxy compounds, 21-hydroxy-5P-pregnan-3,20-dione and 
3a-hydroxy-5p-pregnan-20-one. Its induction time was between theirs. The 
21-acetate was only half as potent as the parent steroid, but its induction time was 
halved. The 3p-isomer was less hypnotic than the corresponding 3a-isomer.39
The 11-oxo derivative of 3ot,21-dihydroxy-5P-pregnan-20-one was inactive, like its
3-oxo counterpart, whereas the 3-acetate was weakly active with a long induction 
time.39 The 21-acetate of the 11-oxo series had a short induction time and was 
more potent than its 3-oxo analogue, but not as potent as its 11-deoxy derivative. 
The 3,21-diacetate of the 11-oxo series was too toxic for adequate testing, although 
it was clearly hypnotic. The 21-succinate and 21-phosphate were weakly hypnotic 
with long induction times. The more potent, water-soluble, 21-ester had a short 
induction time, indicating that it dissolved rapidly in the bloodstream. It was 
possible that the 11-oxo derivative was too polar to pass readily into the brain, and 
that its 21-succinate and -phosphate had little hypnotic activity because they too 
were too polar, or because they were readily hydrolysed in the bloodstream. The
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less polar, less readily hydrolysed 21-esters may pass as such into the brain, there 
to act by virtue of their unesterified 3a-hydro>xy/l groups.39
11-Substitution. O f 26 pairs of steroids tested, in only three had the 11-oxo steroid 
a greater hypnotic activity than the 11-unsubstituted steroid. Induction times 
tended to be shorter with the 11-oxo steroids. The therapeutic indices (LD5(/25 
min. sleep times) of 11-oxo steroids tended to be higher than their 11-deoxy 
analogues.39
11-Hydroxy or -acetoxy and 9,11- or 11,12-epoxy substitution diminished or 
abolished any hypnotic activity of the parent steroids. Water-soluble 11-hydroxy 
steroids were less toxic than their 11-deoxy counterparts.39
From the studies,39 3oc-hydroxy-5(l-pregnan-ll,20-dione 3-phosphate disodium 
was considered promising as an intravenous anaesthetic, as it formed stable 
aqueous solutions, had a high therapeutic index and did not produce 
thrombophlebitis in experimental animals, as hydroxydione did. It was used in 
man as an intravenous anaesthetic, but produced an unpleasant paraesthesia in the 
neck and spinal area. Although this symptom ceased spontaneously after a few 
minutes, and did not recur with subsequent doses, it was considered sufficiently 
serious to preclude further use of the steroid.
Of the 26 other steroids that were tested some produced convulsions, but none had 
hypnotic activity.
It was well known that the activity of the enzyme systems located in liver 
microsomes, which oxidize drugs, is influenced by such factors as sex, age, 
species, and the administration of drugs and other foreign compounds.42 It was 
also known that hepatic microsomal hydroxylation of steroid hormones is also
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influenced in an identical manner by these faictcors 43 The chronic administration of 
several drugs and insecticides, stimulated the acctivity of steroid hydroxylases in 
liver microsomes.
Kuntzman et al44 showed that the chronic administration of drugs and insecticides 
which induced the synthesis of oxidative enzymes in liver microsomes, decreased 
the anaesthetic action of steroids by increasing the in vitro hydroxylation of 
steroids by liver microsomal enzymes.
Male rats were treated with drugs or insecticides such as phenobarbital, 
chlorcyclizine, phenylbutazone, chlordane or DDT (which had been shown to 
markedly stimulate liver microsomal enzyme activity42,45) for 4 days.44 On the 
fifth day the rats received an intraperitoneal injection of the steroid (progesterone, 
androsterone, A4-androstene-3,17-dione, and deoxycorticosterone were used) and 
the duration of the anaesthetic effect was determined, using the loss of righting 
reflex as a measure of anaesthetic action. None of the steroids caused a loss of 
righting reflex in animals pretreated with a drug or insecticide.
Kuntzman suggested that the decrease in effect of the administered anaesthetic 
steroid may have been due to its increased rate of metabolism in vivo, which 
would have resulted in lower steroid levels in the brains of the chronically treated 
rats.44
In 1967, Heuser46 discovered that in high doses, some steroids caused convulsive 
activity in animals, which may cause behavioural abnormalities such as sedation, 
hallucination, and tranquillisation. Heuser looked closely at the sleep induced by 
the steroids progesterone and hydroxydione, and the barbiturate pentobarbital.
One stage of normal sleep that could not be distinguished from wakefulness is 
named paradoxical. Features of paradoxical sleep in cats include; twitching of
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whiskers, ears, paws, and tail; irregular respinaticon; irregular heart rate; REM; and 
an increase in brain temperature. Pentobarbital \was found to significantly reduce, 
if not eliminate, paradoxical sleep. Oswald discovered that in man, upon 
withdrawl of the barbiturate, a ‘rebound’ occurred during which the subjects spent 
an excessive percentage of sleep in the paradoxical stage, which often led to 
nightmares.47 This might be one explanation for the fact that patients resist 
withdrawal of barbiturates.
Heuser reported46 that progesterone induced natural sleep with no complete 
reduction in the paradoxical phase, and with no ‘rebound’ after withdrawal. When 
administered in sub-anaesthetic doses, progesterone was found to facilitate the 
occurrence of natural sleep. Heuser suggested the term "hypnaesthetic" for 
progesterone, as it referred to both the hypnotic and anaesthetic activities of the 
steroid.46
Hydroxydione was also found to reduce the occurrence of paradoxical sleep, but 
was less striking than that seen after pentobarbital, when administered in water 
intraperitoneally and intravenously. When anaesthetic doses were given 
paradoxical sleep was eliminated altogether.46
Heuser suggested that a steroid which induced natural sleep (without reduction of 
paradoxical sleep during, and without ‘rebound’ after treatment) would be a 
therapeutic agent in all situations of uncomplicated sleeplessness 46
Spironolactone48 and norbolethone 49 an anabolic steroid, have been shown to 
possess antianaesthetic properties in inhibiting the anaesthetic and sedative effects 
of pentobarbital, methylprylon and various steroid hormones or hormone 
derivatives.
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In 1970, Selye50 carried out comparative experiiments with many steroids to 
determine their influence upon anaesthesia prodiuced by progesterone or 
pentobarbital. Rats were pretreated with various s teroids (detailed in the paper50) 
twice daily for four days prior to, and on the day of the anaesthesia test. 
Pretreatment with various steroids was seen to protect the rat against the induction 
of anaesthesia by progesterone or pentobarbital.
There was no manifest relationship between the chemical structure and the 
antianaesthetic effects of the steroids tested. Among the active compounds were 
anabolic androgens, androstane, pregnane, gonane, and estrane derivatives, with or 
without ring unsaturation. There was also no clear-cut relationship between the 
antianaesthetic and other pharmacological actions of the compounds tested.50
Many of the compounds given as a pretreatment to inhibit anaesthesia were 
themselves anaesthetics, if administered for the first time. Thus it appeared that 
the anti-anaesthetic effect was an independent action of steroids, not referable to 
any of their other known hormonal actions 50
The mechanism of the antianaesthetic action was unclear. Almost thirty years ago 
Selye discovered that the anaesthetic effect of progesterone was more pronounced 
in female than male rats.4 These findings suggested that even the physiological 
amounts of anabolic androgens secreted by the testis, could significantly influence 
resistance to steroid anaesthesia. Hence, Selye showed that the resistance of 
females could be raised by a variety of anabolic steroids.51 Several days of 
pretreatment was necessary to obtain any of the antianaesthetic effects. Recent 
work performed by Selye51 showed that pretreatment in vivo with the steroids 
increased the oxidation of pentobarbital by isolated hepatic microsomes in vitro. 
Hence, it was thought that at least some protective effects of steroids were due to 
activation of hepatic microsomal enzymes.
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After the demise of hydroxydione and its analogue, 3a-hydroxy-5p-pregna- 
n-ll,20-dione 3-phosphate disodium, Glaxo lefit the topic of steroidal anaesthetics 
for several years. They returned to it late in 1965, with the objectives of finding a 
water-soluble steroid with the wide margin of safety, and pleasant induction and 
recovery, found with hydroxydione. Such an anaesthetic should combine the 
advantages of hydroxydione and the barbiturates, without their disadvantages. The 
screening programme centred on steroids with a free 3a-hydroxy group present.
Of the many compounds tested by intravenous injection into mice, the most potent 
was 3a-hydroxy-5a-pregnan-l 1,20-dione, alphaxalone. The anaesthetic potency 
of alphaxalone was high and induction rapid.55 Mice receiving a dose as low as 1 
to 2mg/kg lost their righting reflex within a few seconds of injection. The safety 
margin was wide and there was no evidence of thrombophlebitis. Alphaxalone, 
being insoluble in water, was best administered in the biologically-acceptable 
media, cremophor EL (polyoxyethylated castor oil), the non-ionic surfactant 
previously employed in the non-steroid intravenous anaesthetic, propanidid. The 
solubility of alphaxalone in 20 percent cremophor EL, though one hundred times 
its solubility in water, was still only 3mg/kg, and this was not considered 
sufficient. Fortunately, the addition of a small amount of 21-acetoxy-3a-hydrox- 
y-5a-pregnan-l 1,20-dione, alphadolone acetate, increased the solubility of 
alphaxalone in cremophor EL more than threefold. Alphadolone acetate had 
anaesthetic properties similar to alphaxalone, although it was only half as potent, 
and simply additive with alphaxalone.55
Althesin was formulated by Glaxo as a 3:1 mixture of alphaxalone and alphadolone 
acetate respectively, dissolved in 20 percent cremophor EL and made isotonic with 
blood using sodium chloride.
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The pharmacological properties of althesim ini amimals were reported by Child et 
al57 in 1971.
Davis and Pearce carried out experiments to show the similarities and differences 
between althesin, hydroxydione, thiopentone, methohexitone, propanidid and 
ketamine in animals.53
The anaesthetic dose 50 (AD50) and lethal dose 50 (LD50) for althesin and other 
intravenous anaesthetics were determined and shown in Table 4.
Anaesthetic agent AD50 m g/kg LD50 mg /k g Therapeutic index(LD50 /  a d 50)
Thiopentone sodium 13.2 90.5 6.9
Methohexitone sodium 5.4 39.4 7.4
Propanidid 22.9 185.0 8.1
Ketamine hydrochloride 12.7 108.0 8.5
Hydroxydione 18.0 311.0 17.3
Althesin 1.8 54.7 30.4
Table 4. Anaesthetic activity and lethal dose of intravenous anaesthetics in mice. 
From Postgrad. Med. J. Suppl., 1972, 48, p. 13, Davis and Pearce.
The safety margin with steroidal anaesthetics was found to be much wider than 
with other intravenous anaesthetics, as was confirmed by althesin and 
hydroxydione.53
After studying the effects of repeated doses it was discovered that althesin had a 
desirable freedom from a cumulative effect, whereas thiopentone was very 
cumulative and ketamine moderately so. This was confirmed using cats, in which 
althesin was infused at a constant rate for several hours to maintain stable 
anaesthesia.53
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The effects of acute liver damage on anaesthesia! were studied after dosing with 
thioacetamide.53 The duration of althesin anaestthesia was slightly increased by 
pretreatment with thioacetamide. The metabolism of normal doses of althesin was 
well within the capacity of the liver enzymes and was little affected by liver 
damage.
Local vascular effects were also studied via the appearance of mice tail veins.53 
Twenty-four hours after injection the tails of mice given hydroxydione were 
swollen and blue-black over their entire length. The tails of mice given althesin 
were indistinguishable from those given saline. They appeared normal except for
slight bruising at the site of injection. Hence, Althesin was free of
/
thrombophlebitis and paraesthesia.
Any problems encountered with the use of althesin were most likely due to 
cremophor EL. Cremophor EL was unsuitable for use in dogs as it caused the 
release of histamine or histamine-like substances in this species.54
Surgical procedures were performed in the cat under althesin anaesthesia alone.10 
Althesin could also be used as an induction anaesthetic followed by conventional 
inhalational anaesthetics, and used in conjunction with pre- and post-operative 
medicaments. Clinical trials in man and other animals confirmed the authors 
optimism in althesin.53 However, althesin was found to be highly toxic to newborn 
animals 54
A conference on the ‘Steroid Anaesthesia of Althesin’ covered its pharmacology, 
clinical pharmacology, and clinical assessment (Postgraduate Medical Journal,
June 1972, Supplement 2, Volume 48). Sutton55 described a brief history of steroid 
anaesthesia before althesin, in 1972.
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At the beginning of the 1970’s Glaxo intensiffiecd their research in the area of novel 
steroidal anaesthetics. They set about identif'yimg steroids more active, less toxic, 
and giving even better quality of anaesthesia than althesin. More than a thousand 
steroids were prepared and tested, via the intravenous route, in male mice, given as 
solutions or suspensions in 20 percent cremophor EL, unless they were 
water-soluble.
The findings were described by Phillipps,56 in 1974, in an excellent report on the 
structure-activity relationship (SAR) in steroidal anaesthetics. Phillipps reported 
on analogues of 3a-hydroxy-5a-pregnan-l 1,20-dione (alphaxalone). His findings 
are briefly reported hereafter.
Unlike the 5p-series, the 3-keto-5a-steroids were generally inactive. Introduction 
of a 3p-methyl group into alphaxalone converted the compound from a secondary 
into a tertiary alcohol; thus preventing oxidation to the 3-ketone in vitro and also 
slowing the rate of formation of conjugates of the 3a-hydroxy group and therefore, 
inactivation. However, the activity and duration were virtually unaffected.56
Introduction of extra hydroxyl groups at the 2a, 4p, 7P, 9a, 16a, 16p, or 
17a-positions produced inactive compounds, and at the 2p- or 21-positions less 
active compounds. Compounds lacking the 3a-hydroxyl, but with a 2a, 2p, or 
3P-hydroxyl were inactive, and introduction of extra oxo groups at the 7 or 
16-positions also destroyed activity.56
11-Desoxy compounds were in general, poorer in activity than the 11-ketones. 
Introduction of oxo groups at the 6- and 12-positions removed activity completely, 
and at the 7-position considerably reduced it. Potency was also lessened by 1 la , 
l ip ,  or 21-hydroxyl groups and eliminated by a 19-hydroxyl.56
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Phillipps included tables showing the relative activities of the steroids tested.56
It was thought that the effect of substitution at tlhe 2-position was of particular 
interest because in the rat, alphaxalone was metabolized in part to the inactive 
2a-hydroxy analogue57. However, a 2a-methyl group which may block 
2a-hydroxylation did not affect activity, but the introduction of a 2a-bromine atom 
reduced activity. The 2(3-morpholino compound, previously described by workers 
at the Organon Laboratories,58 was considerably less active than alphaxalone with 
about the same toxicity. A fluorine substituent also had a detrimental effect on 
activity, although the larger halogens, chlorine, bromine, and iodine, or a 
thiocyanato group, all gave products with good activity. The chloro compound 
being active at lower concentrations than alphaxalone. Although substitution with 
a 2p-hydroxyl gave a weakly active-compound, esterification of the 2p-hydroxyl as 
the acetate or propionate, almost completely regenerated the activity, indicating 
that the esters were acting as esters and were not readily hydrolysed. The 
2p-ethers were particularly active, and gave longer sleep times at 3.1 mg/kg than 
alphaxalone. The best compounds were the ethoxy and /z-butoxy derivatives. The 
i-propoxy compound was less toxic than the /z-propoxy compound and activity was 
even retained in the presence of the bulky r-butoxy substituent. The 2P-methyl 
derivative was twice as active as alphaxalone, and the 2p-zz-butyl derivative gave 
even longer sleep times, but was more toxic.
Substitution at the 4p-position with a wide variety of groups, gave compounds 
almost devoid of activity.56
Introduction of double bonds into ring A reduced toxicity and gave useful activity 
with 3a-hydroxy steroids. The introduction of a 5,6-double bond was less 
satisfactory, an 8,9-double bond reduced activity somewhat, a 14,15-double bond 
more so and a 16,17-double bond completely.56
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Phillipps speculated that the conformation, that iis ishape, of ring A may be of 
importance.56 In particular, the shape of the ring would determine the manner in 
which the 3-hydroxyl group, with its essential oxygen atom, projected from the 
molecule. Phillipps surmized that ring A in the ‘a-boat’ conformation was an 
active conformation, and when it is in the ‘p-boat’ conformation it is inactive. He 
included an excellent discussion on the various possible conformations of ring A. 
The 2(5,19-oxide was prepared, in order to hold ring A in the chair form. As he 
forecasted, this compound was inactive.56
Removal of the angular methyl group from C(10) in alphaxalone gave the 
corresponding 19-nor compound, which was just as active as alphaxalone but less 
toxic. Therefore, Phillipps prepared the 2P-ethoxy- 19-nor steroid,56 in which there 
could be no 1,3-diaxial repulsion between the substituent on C(2) in the absence of 
the angular methyl on C(10). As predicted there was no gain in activity, instead 
there was a loss. The 2a,5a-oxide in the 11 -desoxy series was inactive,56 perhaps 
because the oxide bridge projected on the a-face of the molecule, thus blocking it.
Turning to the other end of the molecule, substitution at the 21-position was 
rewarding 56 The 21-hydroxy compound and its acetate (alphadolone acetate) both 
retained moderate activity. The 21-thiol was only active at toxic doses, whereas 
the acetylthio derivative was more active than alphaxalone, and no more toxic. 
21-Alkoxy compounds showed reasonable activity, as did compounds with an 
extended alkyl side chain. The 21,21-ethylidene derivative was as active as 
alphaxalone, but less toxic. Fluorination at the 21-position had little effect on 
activity, but did enhance solubility in 20 percent cremophor EL.
A 21-cyano substituent reduced the activity and the compound was weakly acidic. 
However, it was sufficiently acidic to give a sodium enolate, soluble in water with
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fair stability. The aqueous solution of the sodliuim salt had virtually the same 
activity as did the parent compound in 20 percemt cremophor EL.56
A series of compounds with a basic nitrogen atom, to give water-soluble salts 
within the 2p- or 21-substituent were prepared.56 The 2P-piperidinoacetate 
compound showed instantaneous induction of anaesthesia but was much less active 
than the corresponding 2p-acetoxy compound.56 Its citrate was water-soluble and 
showed similar potency. The 2p-morpholinoethoxy compound was less active 
than the 2P-ethoxy analogue. The 21-morpholinoacetylthio derivative proved to be 
the first potentially water-soluble compound with activity comparable to that of 
alphaxalone. It showed similar activity in aqueous solution as its hydrochloride.56
Direct substitution at the 21-position with various amines gave a more stable group 
of compounds.56 Those with a free NH group were inactive. The most promising 
compounds were those substituted by heterocyclic amines, for example, 
morpholine or thiomorpholine.56 Substitution with a 2p-ethoxy group on the 
morpholino compound doubled the activity.
All the compounds thus far had been pregnan-20-ones, i.e. they had a 17p-acetyl 
side chain. Compounds with a 17a-acetyl side chain showed, at best, weak 
activity.56 Reduction of the 20-carbonyl to a 20a or 20p-hydroxyl group destroyed 
activity, and complete reduction to give the 17p-ethyl compound resulted in only 
weak activity.56
Insertion of an oxygen, atom between C(17) and C(20) gave the inactive 
17p-acetoxy compound, but insertion of an oxygen atom between C(20) and C(21) 
reduced potency only slightly.56 This compound was the methyl ester of the 
17p-carboxylic acid, the acid itself was inactive. Other esters and thiols also 
showed activity.56 The dialkylamides of C(17) were active but monoalkylamides
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were less so, and the amide was inactive. Delhydrjation of the amide group gave the 
nitrile, which was very close in activity to alphatxalone.56 The esters of the 
carboxylic acid at C(17) also provided water-soiluble derivatives with good 
stability in aqueous solutions. The morpholino-ethyl ester showed fair activity 
which was maintained in compounds with larger alkyl chains in the ester group. 
Further introduction of a 2p-ethoxy group improved the activity. This was retained 
in aqueous solution of the citrate and other salts, such as the hydrochloride lactate, 
methanesulphate, ascorbate, or phosphate. The ester of morpholino-ethanethiol 
also gave an improved activity.56
Phillipps56 confirmed the essential nature of an oxygen at the 3a-position, and also 
the importance of the exact manner it projected from ring A. He also concluded 
that it was still difficult to forecast activity with any accuracy even after testing 
many combinations of groups. The effects of the substituents on the steroid 
nucleus were not simply additive.56 For example, a substituent in the 2P-position, 
which was normally favourable, produced a very poor activity in the presence of a 
particular side chain in the 17-position. Hence, Phillipps was unable to predict 
activity from structure, outside small groups of related compounds.
All of the previous work was carried out without much knowledge of the 
mechanism of steroidal anaesthesia. Thus, various research groups attempted to 
explain this particular action of anaesthesia.
It was generally accepted that liposomes provided realistic and valuable models for 
biological membranes. Connor et al demonstrated the membrane disordering effect 
of a series of anaesthetics related to, and including alphaxalone, by measuring the 
increases in the release rate of sequestered sodium ions from sonicated egg lecithin 
liposomes.59 Flame photometry was used to measure the release rates of sodium. 
Steroid was added both as a solid and in ethanolic solution, in the sodium release
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experiments.
Connor et al showed that steroids which possessed high anaesthetic activity, as 
measured intravenously in mice, generally showed the largest effect on the 
liposomes in terms of increased sodium release (20-35% enhancement).59 Little or 
no effect was shown by anaesthetically inactive steroids or steroids of low activity, 
whilst steroids of intermediate anaesthetic potency had corresponding intermediate 
effects on the liposomes. The steroid 5a-pregnan-3,l 1,20-trione, which was not an 
anaesthetic but a convulsant, showed inhibition (2-3%) rather than enhancement of 
sodium release.59
Thus Connor et al concluded that membrane labilization was an essential step in 
the operations of steroidal anaesthetics.59
The introduction of althesin in England prompted a review of steroidal anaesthetics 
by Gyermek and Soyka,60 in which pregnanolone and althesin were discussed in 
detail.
Steroid anaesthetics and short-acting barbiturates appeared to have the same or 
very similar electrical effects in the central nervous system, although 
electrophysiologic and neuropharmacologic evaluations of steroid anaesthetics had 
been far less extensive than those of the barbiturates or inhalational anaesthetics. 
Rosner and Clark summarized the neurophysiological effect of anaesthetics.61
A unique side effect of 5(3-steroid hypnotics in contrast to the 5a-analogues, was 
thermogenesis, with the effect only being apparent in man. This was a major 
obstacle to the clinical use of many potent 5p-steroids.61
Althesin had been found to have no adverse effects in cats premedicated with a
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variety of drugs frequently given to patients, imclluding parasympathetic blocking 
agents, opiates, tranquilizers, and neuromuscuilair blocking agents.62 But it was 
found to be highly toxic to the foetus, when give;n to pregnant mice in labor, and 
also caused increased toxicity to newborn rats.621 Small doses (1-2 mg/kg) 
produced minor changes in the blood pressure of animals, followed by a moderate 
pressor effect on emergence from anaesthesia.
The metabolism of alphaxalone, the major active ingredient of althesin, was 
investigated in rats.57 The compound had a very short half-life in plasma 
following intravenous administration. About 60-70 % of an injected dose was 
excreted within five days, mostly in the form of metabolites in the faeces. Urinary 
excretion accounted for the remainder. Glucuronidation was an important step in 
the metabolism of alphaxalone. Radioautographic studies in the rat indicated that 
alphaxalone was widely distributed in the tissues one minute after intravenous 
injection.63 No selective uptake in the brain occurred. Soon after administration 
radioactivity was present predominantly in the excretory organs, eg. liver, and after 
an hour the bulk of the steroid (or its metabolites) was found in the gut and 
bladder. In pregnant rats relatively small amounts reached the foetus.57
When studied in the horse and sheep althesin was shown to elicit excitatory 
symptoms.64 Althesin anaesthesia in Landrace pigs, which were susceptible to 
hyperthermia under general anaesthesia, gave no hyperthermic effect and was seen 
to prevent muscle rigidity and hyperthermia.64 Thus the author suggested that 
althesin might be a useful anaesthetic for patients known to be liable to develop 
hyperthermic reactions.64
Gyermek and Soyka60 also discussed the results of studies of althesin in man. The 
minimal effective dose was 0.6-0.7 mg/kg of the two active ingredients, which was 
equivalent to 4 mg/kg thiopental, and produced sleep in less than 60 seconds with a
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duration of 1.5 to 13 minutes.65 The cardiovaiscmlar effects of althesin in man 
usually consisted of a moderate increase in piulste rate and a decrease in systolic 
and diastolic pressure.66 Cardiac output was eicher slightly increased or remained 
unchanged.67
Prys-Roberts et al68 did not consider althesin advantageous for hypertensive 
patients. DeCailar69 reported that althesin produced smaller decreases of blood 
pressure than other intravenous anaesthetics. An additional advantage of this agent 
for the cardiovascular system was its antiarrhythmic effect, which was 
demonstrated in man.70
Althesin has since been used successfully for neurosurgical procedures.71 
Following intravenous administration, althesin usually produced brief respiratory 
depression.65,72 Additional potential advantages of althesin in clinical anaesthesia 
included a transient decrease of intraocular pressure in man following its 
administration,73 which made it suitable for intraocular procedures. Althesin had 
no analgesic potency and was thought to share the same type of antianalgesic 
action as the barbiturates.65,74
Other side effects of althesin could be placed in two categories; those that occur on 
first administration and those that usually manifest following previous 
administration, and are of an allergic nature. The common clinical side-effects 
were involuntary muscle movements, twitchings and tremors, hiccupping, and 
respiratory and circulatory depression with large doses.75 Hypotension, 
erythematous rash, anaphylactoid reactions with bronchospasm and sometimes 
severe cardiorespiratory collapse may occur in sensitized patients.76 Studies 
indicated that cremophor EL was the offending sensitizing agent.
In general, althesin compared favourably with other inducing agents with respect
-25<9~
to such side-effects as nausea, vomiting, and ewein local irritation.
The advantages of althesin-like steroidal anaesthetics were deemed to be; 1) minor 
cardiovascular and respiratory depression, 2) wide therapeutic index, 3) laryngeal 
relaxation, 4) minimal cumulative effect on repeated or continuous administration, 
5) less chance of serious occlusive phenomena in the case of accidental 
intraarterial administration and, 6) the different metabolic handling of steroidal 
anaesthetics suggested that their use might be applicable in the presence of agents 
that can interact adversely with barbiturates, or in diseases where abnormal 
sensitivity to barbiturates may exist.
As previously stated, in rats male sex hormones or chronic treatment with massive 
doses of steroids, conferred resistance to the anaesthetic actions of steroids.8,9 In 
1975 Tache et al11 examined the influence upon steroidal anaesthesia of various 
catatoxic steroids. Catatoxic steroids were characterized by their ability to protect 
against numerous intoxications independently of their specific hormonal actions.78
Tachd et al found77 that in rats, the sleeping time induced by overdosage with any 
of the eight steroid anaesthetics; althesin, 3-(3-oxo-17(3-hydroxy-19-nor-4-andros- 
ten- 17a-yl)-propioinic acid-lactone, 21 -hydroxy-5cx-pregnan-3,20-dione,
4-pregnan-3,11,20-trione, 17-hydroxy-3-oxo-4-androstene- 17a-propionic 
acid-5-lactone, 3a-hydroxy-5(3-pregnan-l 1,20-dione, 5p-pregnan-3,l 1,20-trione 
and hydroxydione; was abolished or considerably reduced by a variety of catatoxic 
compounds, particularly 3p-hydroxy-20-oxo-5a-pregnan-16a-carbonitrile (PCN), 
9a-fluoro-l lp,17-dihydroxy-3-oxo-4-androstene-17ot-propio nic acid potassium 
salt, prednisolone, ethylestrenol, and spironolactone. The non-steroidal 
microsomal enzyme inducers, phenobarbital and diphenylhydantoin, were also 
eminently efficacious. Of the two glucocorticoids trested, prednisolone unlike 
triamcinolone significantly reduced steroid anaesthesia. A possible explanation for
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this could be that prednisolone, unlike triamcinolone, also exerted some catatoxic 
effects.78 In contrast, estradiol, progesterone, desoxycorticosterone, and 
hydroxydione, which exerted little or no catatoxic activity, were devoid of 
antianaesthetic activity, and in some cases, even prolonged sleep times.
The above tests were carried out on female rats. To obtain an optimal catatoxic 
effect it was important to allow four days of pretreatment. The catatoxic 
compounds were administered twice daily at a dose level of 10 mg in 1 ml water 
and the sleeping times were calculated in minutes, as the period between the loss 
and return of the righting reflex.
Increased biliary flow79 and hepatic microsomal drug-metabolizing enzyme 
induction80 by catatoxic compounds was thought to accelerate the destruction and 
elimination of steroidal anaesthetics and probably accounted entirely, or at least 
predominantly, for the absence, or short duration of their action.
In the New Zealand Veterinary Journal, Evans81 quoted "saffan" (Glaxo trade 
name for althesin) as a good anaesthetic for cats. An appropriate dose of saffan, 
administered intravenously, produced relaxation in about 9 seconds, and surgical 
anaesthesia in about 25 seconds, lasting for about 10 minutes. The anaesthesia 
could be deepened or lengthened, as requested, by supplementary doses of saffan, 
or by the use of inhalational anaesthetics. There was a good relaxation of 
abdominal muscles and respiration was well maintained. There were no lapses to 
deeper unconsciousness during recovery and, once recovered, the cat was alert and 
would usually eat shordy afterwards.
Results varied when saffan was given via intramuscular routes, but this could be 
minimized by ensuring that the drug was given by deep intramuscular injection, 
after which the anaesthetic was effective. Trials and extensive usage of saffan are
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discussed in the literature.64,82
The side-effects encountered under clinical conditions were listed by Stock83 as 
urination, defecation, muscle tremor, and salivation. These effects only occurred 
infrequently and were not considered to be of practical importance. Another 
side-effect observed, was hyperaesthesia, or edema, of the paws, ears and muzzle, 
in some cats following intravenous administration. It lasted for less than 2 hours 
usually, and was of no clinical significance nor cause for concern. Evans reported 
that the incidence of this effect could be dramatically reduced by the 
administration of an antihistamine 15 minutes before induction.81 An appropriate 
dose of an antihistamine could also be used to shorten the duration of edema once 
it had occurred.
The use of premedicants such as the phenothiazine derivatives, slightly lengthened 
the duration of anaesthesia and recovery time.81 Evans also stated that saffan must 
not be given after the administration of barbiturates.81
Holzbauer reported84 on the possibility that several steroids secreted by the ovary 
which possessed strong anaesthetic potencies, fulfilled a physiological role as 
modulators of the activity of certain brain regions. When injected intravenously 
these steroids entered the brain rapidly. Pregnanolone, the most potent among 
them and a metabolite of progesterone, caused immediate anaesthesia, and reached 
its peak concentrations in the brain after 3 minutes. Thirty minutes later, at a time 
when anaesthesia was still deep, the brain concentrations were only about 2% of 
the peak concentrations. It appeared that on entering the brain some process was 
triggered off, which maintained the state of anaesthesia long after the steroid had 
been metabolized and removed.84
The effect of steroids on the electrical activity of the brain has been studied on
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many occasions.85 When pregnanedione was injected intravenously, into cats, an 
inhibition of the electrocortical arousal reaction, elicited by stimulating the 
mid-brain reticular formation, occurred. The actions of progesterone on the brain 
have been reviewed by Kramer, Damrosch, and Klink.86 It was suggested that 
progesterone exerted its effect on neuronal activity indirectly through an increase 
in blood pressure.
The translocation, into the rat brain, of intravenously injected progesterone, 
pregnanolone, and pregnanedione in propylene glycol was studied by Raisinghani 
et a lP  It appeared that the depth of sleep was not directly related to the 
concentration of pregnanolone, a metabolite of the injected progesterone 
responsible for its hypnotic effect, in the brain. The possibility of an interaction 
between the steroid originally injected and the pregnanolone formed was 
considered.87
The presence of endogenously secreted steroids in the central nervous system was 
first demonstrated by Henkin et a lP
The translocation of a steroid from the blood into the brain could be influenced by 
a number of factors. Bidder89 found that oestradiol or phenobarbitone, when 
infused into one carotoid artery of the ether anaesthetized rat, significantly 
decreased the entry into the brain of simultaneously infused progesterone. It was 
difficult to assess the potency of a given steroid when it was secreted 
endogenously into the blood stream, as the vehicle was seen to affect the hypnotic 
potency of the steroids considerably. For example, after the intravenous injection 
of a suspension of 3oc-hydroxy-5a-pregnan-20-one in 0.5% Tween 80 at a dose of 
24 mg/kg, a mean sleeping time of 20 minutes was obtained.89 When the steroid 
was dissolved in cremophor EL, the same sleeping time was obtained with a dose 
of only 6 mg/kg.89
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Metabolism of steroid hormones in the liver to ring A reduced compounds which 
did not possess any conventional hormonal activities has long been known.90 
However, in the liver the metabolites were also esterified, which decreased their 
ability to penetrate the brain.89 Hence it was unlikely that the steroid metabolites 
formed in the liver would effect the activity of the central nervous system 
considerably, unless they were present in large quantities. There are at least two 
other sites in the body in which ring A reduced pregnane derivatives, with oxygen 
functions at carbons 3 and 20, were formed and secreted, and from where they 
could reach the brain before being esterified in the liver, namely the ovaries and 
the adrenal glands.89
The effect of different pituitary hormones on the concentrations of pregnane 
derivatives in the ovarian venous blood of rats, has been studied.91 Luteinising 
hormone (LH) caused a linear rise in the secretion of progesterone and 
allopregnanedione. No significant responses to LH were shown by any steroid 
with a 20a-hydroxyl group 91 Human chorionic gonadotrophin (HCG) and 
pregnant mare serum (PMS) caused a considerable rise in the secretion of the 
20-keto pregnane derivatives and also an increase of 20-dihydroprogesterone 
secretion 91 Mason observed that ovaries from rats stimulated with PMS formed 
allopregnanediol as the major product from [14C] progesterone 92 The activity of 
the enzyme 5a-reductase was high in ovaries in the follicular phase and low in 
ovaries in the luteal phase 92
From observations made,92 the secretion of allopregnanolone and 
allopregnanedione, like that of progesterone, is under the control of the pitiutary 
gland. The fact that the secretion of allopregnanedione and allopregnanolone fell, 
during pregnancy,92 was probably due to the decreased production of LH at this 
time. The ovary, like the adrenal gland, does not store any appreciable quantities
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of its secretion product.
As described,84 Holzbauer showed that the ov ary o f the rat secreted considerable 
amounts of several steroids (which were known to possess high anaesthetic 
potencies) during the oestrous cycle, which may contribute to variations in 
behaviour. In the metoestrus, the quantities of anaesthetic steroids secreted within 
24 hours was large enough to cause deep anaesthesia if injected intravenously, as a 
single dose, to a rat. Whether steroids with anaesthetic properties are secreted by 
the human ovary has yet to be investigated.
The enzyme 5a-steroid reductase, was also found in the adrenal gland of the rat,93 
the chick, and the guinea-pig.94 It was observed that in in vitro experiments [14C] 
pregnenolone, [14C] progesterone, and [14C] deoxycorticosterone when added to 
the incubation medium of rat adrenal section, were not only converted to 
corticosterone, 18-hydroxycorticosterone and aldosterone respectively but also to 
allotertrahydrocorticosterone, a ring A reduced metabolite of corticosterone 93 The 
anaesthetic dose of the 5a-reduced metabolite of deoxycorticosterone was equal to 
that of thiopentone sodium, the 5p-metabolite was three times more active than the 
barbiturate.93
The occurrence of a 5a-steroid reductase, in the rat hypothalamus,95 and the in 
vitro conversion of progesterone to pregnanolone by this tissue,96 and the anterior 
pituitary gland97 have been reported.
It is purely of interest that some water beetles (the German water-beetle and the 
Indian water-beetle) make use of the anaesthetic effect of steroids in their defence 
reactions. These beetles when attacked by fish release a milky fluid from their 
postoracic glands, which contains various steroids possessing anaesthetic potency. 
When added to water these steroids cause a reversible paralysis in goldfish.98
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In 1976, L ee" presented a model for the mode of operation of local anaesthetics." 
It was postulated that the sodium channel of the nerve was surrounded by lipid in a 
rigid state, with the rigidity keeping the sodium channel open." Addition of local 
anaesthetics to the membrane, after binding to the lipid component of the 
membrane, lowered the transition temperature for the annular lipid, thus 
transforming it into a fluid state. When the lipid was in this fluid state, the sodium 
channel could collapse inwards, closing the pore and reducing the sodium ion 
conductance, and producing anaesthesia."
Hydrophobic interactions between local anaesthetics and their sites of action were 
reported to be sterically undemanding.100 The interaction was also reported to be 
undemanding with respect to charge, since neutral, positively and negatively 
charged molecules were all known to act as local anaesthetics.100
The model presented by Lee" sought a correlation between the concentrations of 
compound that produced a significant drop (3-4°C) in lipid transition temperature 
and the concentration that blocked the sodium conductance in the nerve. The 
compounds tested included alcohols, amines, barbiturates, chlorpromazine, 
p-blockers, trihexylphenidyl, and benztropine."
In 1979, Lee extended his studies to the steroid molecules hydroxydione sodium 
succinate, conessine, alphaxalone, and the amino steroids, Org. NA13 and Org. 
6001 (Figure 3) of which some showed local anaesthetic activity.101
Samples were prepared by dissolving lipid plus chlorophyll A and anaesthetic in 
chloroform (if water insoluble). The samples were evaporated to dryness, buffer




Conessine ORG. NA13 ORG. 6001
Figure 3. Some steroidal local anaesthetics.
added (plus steroid if water soluble) and then shaken. Fluorescence measurements 
were made and temperature continuously monitored. A theoretical model 
involving Langmuir adsoiption isotherms for the binding of the drug were used to 
find the effect of the drugs on phase transition temperatures.101
It has been shown102 that changes in the fluorescence of chlorophyll A 
incorporated into liposomes could be used to measure the temperature of lipid 
phase transitions.
The results showed that the amino steroids, Org. NA13 and Org. 6001, interacted 
with the lipid, dipalmitoyl phosphatidylcholine, and produced a decrease in the 
phase transition temperature.101 A build-up of positive charge on the liposomes 
tended to limit the binding of the drug, and incorporation of negatively charged 
lipid increased the effect of the drugs, contrary to the suggestion of Ueda et a/.103 
Org. 6001 caused a large decrease in transition temperature, at pH values at which 
it is predominantly in the charged form, thus both charged and uncharged forms of 
a drug were able to bind to a membrane.104 In the cases of both the amino steroids, 
the concentration required to produce a 3 degree drop in transition temperature was 
about ImM. These results fitted the annular transition model for local 
anaesthesia."
Alphaxalone had no effect on the transition temperature of dipalmitoyl 
phosphatidylcholine,101 in contrast with the results of Conner et al.59 This lack of 
effect suggested that either alphaxalone was not a local anaesthetic, or that if it was
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then its mechanism of action must be different to that of other local 
anaesthetics.101 In fact, Rao and Wang reported105 that alphaxalone showed no 
local anaesthetic action.
The general anaesthetic action of alphaxalone remained unexplained, but could be 
due to either a decrease in the amount of transmitter released by a nerve impulse at 
a synapse, or due to a decrease in the sensitivity of the post-synaptic membrane to 
the transmitter. Alphaxalone seemed to have some effect on membranes 
containing cholesterol and brought about a decrease in the upper transition 
temperature in this system, whereas A16-alphaxalone had no general anaesthetic 
effect and no effect on the bilayers containing cholesterol.101
Lee101 also showed that hydrocortisone had no effect on the phase transition 
temperature of dipalmitoyl phosphatidylcholine. Munck106 suggested that 
hydrocortisone lies "on edge" at a water-heptane interface, in order to permit entry 
into the water phase of all its polar groups, including the C (ll)  hydroxyl.
Adopting a similar orientation in the lipid-water interface would mean little 
interaction with the lipid fatty acyl chains, and thus have little effect on the phase 
transition temperature, as was observed.101 A similar orientation could be 
expected for alphaxalone since the hydrophobic oxygen containing groups are 
spaced along one side/edge of the molecule.
Of the other steroids tested101 pregnanedione and pregnenolone, also had no effect 
on the temperature of lipid phase transitions. Although these compounds have 
been reported to possess general anaesthetic properties4 no studies have been made 
of any local anaesthetic activity. The lack of effect of these steroids on phase 
transition temperatures was not due to a failure to incorporate into the bilayers 
since they abolished the lipid pre-transition.101
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Hempelmann and Schaps reported on yet further observations on althesin.107 
Since, in man the liver is the major site for the metabolism and the kidneys for the 
excretion of althesin, reduced doses were necessary in patients with severe liver 
damage and impaired renal function.108 Althesin proved highly toxic when given 
to pregnant mice during labour,60 however Hollmen et al109 could not find any 
significant difference in the clinical condition of newborns delivered from mothers 
receiving either thiopentone or althesin for caesarian section.
Althesin should also be handled with caution in patients suffering from thrombotic 
disease and hypercoagulability, as Gaszynski et aln0 found that althesin brought 
about a selective action of platelet release from systemic stores.
Carbohydrate and fat metabolism in man was not significantly influenced by 
althesin and Mehta and Burton111 suggested that it may be a useful alternative in 
diabetic subjects. Also Duval and Gaudy112 reported that althesin was probably 
not the drug of choice in patients with a history of allergy and in those with 
asthma.
The effects of the steroid anaesthetic on cerebral circulation have been investigated 
by Pickerodt et al.113 In man there was a fall in intracranial pressure, which was 
interpreted as a result of a reduction in cerebral blood flow and cerebral blood 
volume.114
Hempelmann and Schaps107 reported on the effects of althesin on the 
cardiovascular system. Child and co-workers115 reported on a non-dose related 
transient fall in blood pressure and a slight tachycardia in cats following injection 
with althesin. According to the results of Kettler and Sonntag116 the 
haemodynamic effects of althesin were characterized by a peripheral vasodilation 
and a moderate fall in blood pressure. A subsequent increase in heart rate was
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interpreted as a reflectory mechanism, causing am increase in cardiac index. 
Althesin, as well as propanidid and thiopental, imduced severe haemodynamic 
changes in patients with cardiac disease. From tthe haemodynamic point of view, 
methohexital seemed to be the drug of choice for the induction of anaesthesia.117
Hempelmann and Schaps also briefly discussed107 the administration and dosage 
of althesin as well as the side-effects.
Al-Khawashki et al studied the effects of althesin and its steroidal components on 
neuromuscular transmission and skeletal muscle of three different species of 
laboratory animals (cat, toad, and rat).118 Certain well defined discrepancies and 
differences in the pattern of neuromuscular responses to althesin were revealed, 
largely determined by the nature of the components of althesin and their possible 
metabolic products in the body, besides the species of experimental animal. 
Reference, in this respect, was made to the depressant effect of the intravenous 
anaesthetic dose of althesin on the monosynaptic spinal knee jerk reflex in 
chloralosed cats, an action which was exhibited predominantly by alphaxalone but 
not by the other two components in the mixture, alphadolone acetate and 
cremophor EL.118 This type of activity was attributed to a possible depolarizing 
influence of alphaxalone.119 Such a depolarizing effect by alphaxalone could 
account for the motor excitatory manifestations, evidenced by jerky movements 
and muscular twitches of the limbs occurring during the induction phase of 
intrvenous althesin anaesthesia.
The isolated rats phrenic nerve diaphragm preparation seemed peculiar for its lack 
of neuromuscular responses to althesin and the two steroidal components.119
Bowman indicated120 that among common laboratory animals, cats closely 
resembled human beings in their sensitivity to a variety of drugs causing
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neuromuscular block by acting on the motor endl plate. This conformed with the 
lack of any appreciable influence by the two steiroidal althesin components on the 
tone of the isolated toad rectus abdominis muscle, and its contraction responses to 
acetylcholine.
In 1979, Phillipps et al reviewed water-soluble steroidal anaesthetics, 121 with 
special reference to minaxolone citrate, Figure 4.
•H 02CCH2CH(0H)CH2C 0 2H
H
Figure 4. Minaxolone citrate.
In 1980, Fukada and Fukada published a review on althesin as an intravenous 
anaesthetic. 122
General anaesthesia can be induced by such a wide variety of molecules that 
attempts to formulate on all-embracing hypothesis concerning their mode of action 
was unlikely to be successful.
The potency of anaesthetics has been correlated with some of their general 
physical properties, primarily their lipid solubility. 123 However, this did not hold 
true for steroid anaesthetics. As seen earlier, small changes in steroid structure led 
to large differences in anaesthetic activity.39
In 1983, Makriyannis and Fesik postulated124 that the considerable difference in 
activity exhibited by alphaxalone and A16-alphaxalone may be due to differences in 
their interactions with cellular membranes. Makriyannis and Fesik investigated the
- 271 -
actions of those two steroids with phosphatidylcholine bilayer vesicles, used as 
model membranes, using NMR experiments ( 13(C, and 2H) . 125 The results 
obtained suggested that alphaxalone was considerably more mobile in the 
phospholipid bilayer than A16-alphaxalone. The data also suggested that the acetyl 
group moved faster than the steroid nucleus. 124
The observed differences in mobility between the two steroids in the bilayer was 
explained by assuming that the variation in steroid geometiy led to different 
phospholipid-steroid interactions. 124 Thus it was postulated that the inactive 
A16-alphaxalone interacted with the fatty acid chains of phosphatidylcholine 
bilayer in such a manner that the most stable bilayer geometry was maintained, 
while the interacting steroid was partially immobilized. 124 This interaction may be 
similar to the interaction of cholesterol with phospholipids. 124 In contrast the 
biologically active alphaxalone, because of its slightly different stereochemical 
features, interacted with the bilayer differently. This interaction was thought to 
result in a disruption of the bilayer geometry, which was evidenced by the higher 
mobility of the incorporated steroid. 124 The perturbation produced by the 
anaesthetic molecule in the lipid region of the membrane could be transmitted to 
the membrane-associated proteins, resulting in a modification of their functions. 126 
The mobility of alphaxalone in the bilayer decreased at lower temperatures. 124
The results could be used to explain the different biological activities of 
alphaxalone and its A16 analog as anaesthetics. Makriyannis and Fesik tested the 
phospholipid system on a number of steroids structurally related to alphaxalone, 
possessing widely differing anaesthetic activities. 124 The results were consistent 
with the hypothesis that steroid anaesthetic activity depended on the ability of the 
drug to perturb the membrane lipids.
Harrison and Simmonds127 offered another explanation for the mechanism of
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action of steroid anaesthetics; modulation of tlhe GABA receptor complex. It was 
postulated127 that the remarkable potency of alplhaxalone, together with the 
inactivity of the corresponding p-hydroxy isomer, suggested receptor sites may be 
involved in its actions. The possibility of a molecular interaction between 
alphaxalone and the GABA receptor-ionophore complex was investigated using 
electrophysiological and radioligand binding techniques.
The results of the experiments suggested that alphaxalone was a potent modulator 
of the GABA receptor complex. 127 This action appeared to be specific for the 
GABA system. Furthermore, the enhancing effect of the steroid anaesthetic on 
GABAa  receptor binding was not reproduced when radioligands for other brain 
receptors were substituted for [3H] muscimol. 127
There were considerable similarities between the actions of pentobarbitone, a 
barbiturate anaesthetic, and alphaxalone at the GABA receptor complex. 127 Like 
pentobarbitone, alphaxalone enhanced [3H] GABA128 and [3H] muscimol binding 
in the presence of chloride ions. Treatment with the detergent Triton abolished the 
enhancing effect of alphaxalone on [3H] muscimol binding, possibily by altering 
the conformation of the membrane protein(s) which constitute the GABA receptor 
complex, and "uncoupling" the site at which alphaxalone acted from the muscimol 
binding site, as was suggested for the Triton-sensitivity of the pentobarbitone 
effect. 129 All these observations suggested that pentobarbitone and alphaxalone 
potentiated the actions of GABA via a common site or mechanism. Since 
pentobarbitone prolonged the average open-channel lifetime of the chloride 
channels operated by GABA, 130,131 it was of interest to know whether alphaxalone 
shared this property.
The actions of alphaxalone described occurred independently o f "classical" 
intracellular steroid receptors, as shown by the radioligand binding experiments. 127
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The concentrations of alphaxalone arising in t:he brain during surgical anaesthesia, 
in man, was likely to be in the low micromolar range. 132 This supported the 
hypothesis of Scholfield133 that alphaxalone may produce anaesthesia by 
enhancement of inhibition. The modulation of the GABA receptor complex 
provided a molecular basis for the prolongation by alphaxalone of inhibitory events 
in the mammalian CNS. This lent further support to the idea that the 
neurotransmitter receptors may be important in the mechanism of action of some 
general anaesthetics. 134
Banks and Peace demonstrated that a group of naturally occurring steroids, formed 
by the reduction of progesterone, differed in their ability to inhibit a soluble 
enzyme with a hydrophobic substrate-binding site and also investigated their 
anaesthetic potencies. 135 It was shown that the potent anaesthetic, 
5p-prengn-3a-ol-20-one, was able to inhibit bacterial luciferase competitively, 
whilst the corresponding, non-anaesthetic, diol (5p-pregna-3oc-20a-diol) did not. It 
was also demonstrated that 5a-pregnan derivatives, which were anaesthetics, failed 
to inhibit luciferase, whilst the anaesthetic 5p-derivatives were inhibitors. 135 The 
diols, which were inactive as anaesthetics, also failed to inhibit the enzyme. 135 
The activity of the compounds was measured by inhibition of the light production 
by bacterial luciferase. Thus some anaesthetic steroids were able to act as 
inhibitors of luciferase, others were not, and some closely related molecules were 
inactive in both respects. 135
As stated earlier, 124 attention has been focussed on interactions between 
anaesthetics and the lipid components of membranes. However, experiments on 
cell-free extracts and purified luciferase showed that the ability of simple 
anaesthetics to extinguish the light produced by cultures of luminous bacteria136 
could not be ascribed to an interaction with the cell membrane, but resulted from a
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direct effect on the enzyme concerned. 137 Due t<0 the fact that relatively small 
changes in structure caused marked changes in amaesthetic potency, Banks and 
Peace suggested that such molecules could engage in specific interactions with 
proteins and that by inference, suitable steroids could bind specifically to 
membrane-bound enzymes, receptors or transporters to induce anaesthesia. 135 
Such interactions need not be at the active site as with luciferase, but could be at 
any site on a protein, the occupancy of which leads to a functional change. 138
Franks and Lieb provided evidence139 that a range of anaesthetics were able to act 
competitively against the substrate luciferin, to inhibit luciferase from the firefly 
Photinus pyralis. The authors concluded that general anaesthetics, despite their 
chemical and structural diversity, acted by competing with endogenous ligands for 
binding to specific receptors. 139
These views substantiated the view of Harrison and Simmonds, 127 whereby the 
steroid anaesthetics potentiated the action of GABA via interaction with a receptor 
site.
In 1988, File and Simmonds hypothesised that the ability of a compound to reduce 
the potency of the muscimol antagonist picrotoxin, as a antagonist at the GABAa 
receptor complex would correlate with anticonvulsant properties. 140 Three 
steroids were chosen that were distinctly different from each other in terms of their 
interactions with the GABAa receptor complex (alphaxalone, pregnanolone and 
5p-alphaxalone) together with the veterinary anaesthetic saffan, to study as 
potential anticonvulsants. 140 In order to carry this out, experiments were designed 
to study the incidence of myoclunus following intravenous administration of the 
steroids in question. The potencies of the steroids, as potentiators of muscimol, 
were alphaxalone> pregnanolone> 5p-alphaxalone. 141 Alphaxalone was also 
administered intraperitoneally to investigate the importance of route of
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administration. 140
After administration of the steroids, to respective male mice, the incidence of 
myoclonic jerks were recorded. 140
All three of the steroids, as well as saffan, caused myoclonic jerks in doses that 
were insufficient to cause a loss of righting reflex. 140 This effect of alphaxalone 
was seen following either intravenous or intraperitoneal injection. There was little 
difference between the threshold doses of these steroids for the myoclonic activity 
although at the higher doses tested, the duration was greater for pregnanolone than 
for alphaxalone or 5(3-alphaxalone. 140
The findings did not support the initial hypothesis of File and Simmonds. 140 There 
was no evidence that the relative potencies of the three steroids, either as 
potentiators of muscimol, or as attenuators of picrotoxin, corresponded in any way 
with their potencies at inducing seizures. However, it was possible that the seizure 
activity was related to actions at sites outside the GABAa receptor complex.
Seeman reported123 that local anaesthetics induced conformational change of the 
sodium channels, that resulted in blockage of nerve conduction. They also 
inhibited mast cell secretion, since they inhibited calcium influx into mast cells by 
altering the calcium channels, as they altered the sodium channels in nerve 
membranes. 142
Suzuki et al143 investigated the effects of alphaxalone, alphadoloiie acetate, a 
mixture of the two (molar ratio 1:1), and betaxalone (3p-alphaxalone) on histamine 
release from rat mast cells. Purified mast cells were obtained from the peritoneal 
cavity of male rats, and the histamine release from the cells was stimulated by 
treatment with concanavalin A. The released histamine was determined by the
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method of Shore et a l}44
Alphaxalone inhibited histamine release from rat mast cells induced by 
concanavalin A . 143 Alphadolone acetate also inhibited the release induced by 
concanavalin A. These inhibitory effects were not due to the anaesthetic 
properties, or configurations, of the compounds, since betaxalone, an isomer of 
alphaxalone with no anaesthetic activity, was also inhibitory. Alphaxalone and 
alphadolone acetate also inhibited calcium ion uptake induced by concanavalin A, 
but did not influence 125I-concanavalin A binding to mast cells, indicating that they 
inhibited histamine release by blocking calcium channels of mast cells.143 It was 
also suggested that these drugs interfered with steps in the release cascade that 
occurred after the opening of calcium channels.
The steroidal structure appeared unlikely to be sufficient alone for inhibition of 
histamine release, since progesterone, p-estradiol, testosterone, and 
tetrahydrocortisone did not inhibit histamine release. 145 Althesin was well known 
to cause marked histamine release in humans. 145 But the intravenous 
administration of cremophor EL did not elicit histamine release into the blood 
plasma, although the effect of cremophor EL seemed to counteract the inhibitory 
effects of alphaxalone and alphadolone acetate. 146
In 1987, Harrison eta l147 established structure-activity relationships for steroid 
action on the GABA receptor complex. 147 The addition of a hydroxyl group at 
C-21 induced approximately a three-fold decrease in the potency of the molecule 
in modulating the GABA receptor complex. Another pharmacological action of 
alphaxalone was the inhibition of acetylcholine evoked currents. 148 These results 
indicated the involvement of the GABA system in mediating alphaxalone 
depressant actions at the level of the central nervous system.
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Recently, Benoit et a / 149 investigated the effects of alphaxalone on potassium and 
sodium currents of myelinated nerve fibres. 149 The results were interpreted as 
evidence that the steroid anaesthetic produced a ‘local-anaesthetic-like’ action on 
the peripheral nervous system by specifically interacting with potassium and 
sodium channel gating systems. If this was correct, it was thought the responses 
evoked by a structurally related analogue of alphaxalone, which had a different 
anaesthetic potency, should not be the same. In order to test this theory, Benoit et 
al150 examined the effects of alphadolone acetate on the voltage-clamped node of 
Ranvier of the frog isolated myelinated nerve fibres from the sciatic nerve of the 
frog. Differences were found not only in the potency of the two steroids, 
alphaxalone and alphadolone acetate, but also in their mechanism of action on 
potassium and sodium channels of the model membrane. 150
Benoit et al150 showed that external application of 0.05 to 0.5mM alphadolone 
acetate depressed both potassium and sodium currents in the frog node of 
Ranvier. 150 Alphadolone acetate was 3 to 9 times less effective than alphaxalone. 
However, there may be a direct one-to-one relationship between alphadolone 
acetate molecules, and both sodium and potassium channels. This was not found 
for alphaxalone. 150 It was also noted that the decrease in sodium current was less 
pronounced than that in potassium current at corresponding concentrations of 
alphadolone acetate, as previously described for alphaxalone. 149
Alphadolone acetate had no marked effect upon the time course or voltage 
dependence of the model potassium current. 150 Similar results were obtained for 
the general anaesthetic, ketamine. 151 This suggested that the potassium channels 
were indifferently blocked in their resting or open state. On the other hand, 
alphaxalone preferentially blocked open potassium channels. 149
Hille suggested that anaesthetic molecules were preferentially bound to
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inactivated sodium channels. 152 The effects off alphaxalone have already been 
interpreted in these terms. 149 That alphadolone acetate evoked a similar negative 
shift of the steady-state sodium inactivation-voltage curve provided further support 
for this hypothesis. 152
That the anaesthetic effects of alphaxalone and alphadolone acetate were strictly 
additive, 153 when mixtures were used, could be explained by their having different 
sites, by virtue of their differing chemical constitutions.
Although there were similarities between the effects of alphaxalone and 
alphadolone acetate upon the nodal sodium current, their effects upon the nodal 
potassium current differed markedly. 149,150 These results suggested that the 
receptor sites for the anaesthetic molecules, associated with potassium channels, 
were different from those associated with sodium channels. The simplest 
explanation of these results was that the anaesthetic recetor sites formed parts of 
the channel proteins, since several types of receptor sites through which 
anaesthetics exert their different actions, may exist upon potassium and sodium 
channels. 154
Returning to the membrane perturbation theory, in 1990 Makriyannis et al155 
studied the interactions of the anaesthetic steroid, alphaxalone and its inactive 
isomer, A16-alphaxalone, with model membrane bilayers, using differential 
scanning calorimetry, small angle X-ray diffraction and solid state NMR. Studies 
were carried out using aqueous multiamellar dispersions of dipalmitoylphosph- 
atidylcholine (DPPC) with specific 13C and 2H labels and also multiammellar 
bilayer dispersions of dimyristoylphosphatidylcholine with pre-deuterated acyl 
chains (DMPC-d54) as model membranes. Makriyannis et al also studied the 
interactions of a series of structurally related pregnane analogues possessing a 
wide range of anaesthetic potencies. 155 Results showed a good correlation between
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the motional properties and anaesthetic propeirtites of the steroids.
Differential scanning calorimetry was used to study the effects of the drugs on the 
phase properties of membranes,156 small angle X-ray diffraction to identify the 
exact location of the drug in the bilayer, 157 and solid state NMR to identify 
changes in membrane conformation and dynamics produced by the drug, 158 and 
thus to determine the orientation and conformation of the drug in the membrane.
It was shown that the anaesthetic steroid broadened the membrane phase transition 
and increased the ratio of gauche to trans conformers in the membrane. 155 
A16-Alphaxalone had only small effects on the membrane and incorporated, to a 
limited degree, in the bilayer. 155 The inactivity of A16-alphaxalone was attributed 
to a combination of a favourable packing, which led to insufficient lipid 
perturbation and the inability to incorporate substantially in the membrane. 155
The anaesthetic steroid alphaxalone, was located near the membrane interface155 
(the junction of the polar and hydrophobic regions of the phospholipids forming 
the bilayer). It acquired an orientation which placed its long axis parallel to the 
chains of the lipid membranes and its 3a-hydroxyl group near the Sn-2 carbonyl of 
the lipid membranes. The carbonyl at C(20) was probably buried in the membrane 
bilayer, Figure 5.
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Figure 5. Representation of a model showing the position and orientation of 
alphaxalone with respect to the DPPC layer. Alphaxalone anchors at the membrane 
interface and may form a hydrogen bond between its 3a-hydroxyl group and the 
Sn-2 carbonyl group of DPPC. From Makriyannis et al., Ciba Found. Symp., 1990,
153, 172.
Anchoring of the steroid at the membrane interface and imperfect packing with the 
bilayer chains may be involved in membrane perturbation and eventually lead to 
anaesthesia.155 Thus, the active steroid required more space155 in order to be 
accommodated between the phospholipid chains. The ability of a steroid to induce 
such perturbations was related to its stereochemical characteristics which were 
responsible for an imperfect steroid-bilayer packing.155
Experiments showed155 that steroids possessing anaesthetic activity caused an 
increase in the fluidity of the model membrane, whereas structurally related 
inactive analogues produced much less disorder. The two steroids alphaxalone and 
A16-alphaxalone, were seen to have very different motional properties in the lipid 
bilayer. Alphaxalone was more mobile than A16-alphaxalone, thus the biologically
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active steroid perturbed the phospholipid bilayer more effectively than its inactive 
analogue. 155
In the same journal, Backstrom et al159 published a report on "steroids in relation 
to epilepsy and anaesthesia". Clinical and experimental data was discussed which 
pointed to the effects of progesterone and its metabolites in anaesthesia and 
epilepsy. Injection of 5p-pregnan-3a-ol-20-one (produced by the human corpus 
luteum from 5p-pregnan-3,20-dione) caused no fever, 159 but did so in a paper by 
Kappas et a / , 160 in which it was injected in cremophor EL. The side-effects were 
attributed to the vehicle, cremophor EL.
The reduced progesterone metabolite, 5a-pregnan-3a-ol-20-one and its 
5p-analogue decreased the epileptic activity resulting from a penicillin-induced 
cortical focus in cats. 159
5a-Pregnan-3a-ol-20-one was found to be eight times more potent than 
methohexitone (the most potent anaesthetic barbiturate) . 161 The 5p-isomer was 
less active than its 5a-analogue but was still more potent than methohexitone. 
Hence the 5a- and 5P-pregnanolones were not equipotent or interchangeable.
It has not been definately established that the GABA-potentiating effect of the 
steroid anaesthetics is primarily responsible for causing anaesthesia in organisms. 
For instance, it has also been proposed that the steroids may act via a non-specific 
lipid bilayer mediated mechanism. 162 To distinguish between these two 
possibilities Oliver et al162 tested 21 aquatic species for susceptibility to 
anaesthesia by pregnanolone, and also to diethyl ether and short chain alkanols as 
positive controls. This served as a critical test of the bilayer mediated mechanism 
by which all organisms would be expected to respond to the steroid.
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Clinical concentrations of anaesthetic were addefd directly to water in which the 
test organisms were acclimatised. 162 In the case' of the steroid anaesthetic, 
pregnanolone was dissolved in a small physiologically, insignificant volume of 
ethanol, then injected into the water. In most cajses, lack of righting reflex or 
escape response was taken as indication of anaesthesia. 17 At onset of anaesthesia 
organisms were immediately transferred to clean water and their recoveries 
monitored. Inability of an organism to achieve full recovery was considered to be 
an indication of toxicity, rather than anaesthesia. Drug-naive animals were used in 
most cases.
Oliver et al162 found that all organisms tested were anaesthetized by diethyl ether, 
ethanol and w-butanol, but only the chordates responded to pregnanolone. 162 The 
behavioural anaesthetic effect caused by pregnanolone in vertebrates was 
consistent with two neurobiological findings about steroid anaesthetics. Firstly, 
structure-activity studies have shown that the hydroxyl group at C-3 must be in the 
a  position in order for the compound to cause the dramatic potentiation of 
GABA. 147 The 3p-isomer of pregnanolone had no anaesthetic effect.39 Secondly, 
the behavioural response to picrotoxin was consistent with the neurobiological 
data. The convulsant, picrotoxin is an antagonist to the GABAa receptor. It 
appeared to bind to the channel and block chloride ion flux, 163 thereby inhibiting 
the anaesthetic effect. In the presence of picrotoxin the average time required for 
the guppy to recover from anaesthesia was reduced by approximately half. The 
steroid anaesthetic was also seen to protect against, and reverse convulsions caused 
by picrotoxin. 162 Thus, the behavioural anaesthetic response to pregnanolone was 
stereospecific and picrotoxin-sensitive, both which are consistant with a 
GABAA-receptor site for steroid anaesthetic action.
Direct delivery of pregnanolone to the invertebrate neuron appeared not to affect a 
known GABA receptor. 162 Preliminary data162 suggested that inadequate delivery
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was not the reason for invertebrate insensitivity to the steroid anaesthetic. Since 
pregnanolone appeared to act by binding to the GABAa  ionophore complex, and 
also since GABA receptors occurred in both invertebrate and vertebrate species, 164 
it was suggested that a binding site at which steroid binding caused organismal 
anaesthesia developed on the GABA receptor early in chordate evolution. 162 
Evolutionary development of a membrane protein binding site has been previously 
documented. 165 Finally, because lipid bilayer membranes are universal 
components of animal cells, the insensitivity of invertebrates to pregnanolone 
appeared to exclude a bilayer site for steroid anaesthetics.
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Compound 55 was crystallised from ethyl acetate.
A crystal of approximate dimensions 0.2 x 0.2 x 0.5 mm was used for data collection.
Crystal data: C23H34O3, M = 358.5 orthorhombic, a = 7.925(1), b = 13.703(3), c = 19.147(4)A, U = 
2079.3 A3, space group P2{2{21, Z = 4, Dc =  1.15 gem'3, p(Mo-^a ) = 0.70 cm'1, F(000) = 784. Data 
were measured at room temperature on a CAD4 automatic four-circle diffractometer in the range
O
2<0<24 . 1899 reflections were collected of which 955 were unique with 7>2a(/). Data were corrected 
for Lorentz and polarization but not for absorption. The structure was solved by Direct methods and 
refined using the SHELX1,2 suite of programs. In the final least squares cycles all atoms were allowed to 
vibrate anisotropically. Hydrogen atoms were included at calculated positions except in the instance of 
H31, H51, H191 and H I92 where the protons were located in an advanced Difference Fourier and 
refined at a distance of 1 .0 0  A from the relevant parent atoms. Final residuals after 1 2  cycles of least 
squares were R = 0.0463, Rw = 0.0394, for a weighting scheme of w = 2.5234/[g2(F) + 0.000193(F)2]. 
Max. final shift/esd was 0 .0 0 0 . The max. and min. residual densities were 0.07 and -0.06 eA'3 
respectively. Final fractional atomic coordinates and isotropic thermal parameters, bond distances and 
angles are given in Tables 5, 9, and 10 respectively. Tables of anisotropic temperature factors are 
available as supplementary data. The asymmetric unit is shown in Fig. 6 , along with the labelling scheme 
used.
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1. Sheldrick G.M., SHELX86, a computer program for crystal structure determination, University of
Gottingen, 1986.
2. Sheldrick G.M., SHELX76, a computer program for crystal structure determination, University of
Cambridge, 1976.
Figure 6. X-ray structure of 20p-acetoxy-1,3(10—>lpH,5—^ ►3aH)abe<9pregn-10(19)-en-5-one (55).
- 2 9 6 -
Table 5 Fractional atomic co-ordinates (xlO4) and
equivalent isotropic temperature factors (A2 xlO3) for 55
Atom X y z U
0 (1) - 6 8 9 ( 5 ) - 7 1 8 5  (3) - 2 4 5 0  (2) 60 (2)
0 (2) - 8 8 4 (6) - 5 5 6 4 ( 3 ) - 2 3 5 4  (3) 90 (2)
0 ( 3 ) 493 (7) - 8 9 9 2  (4) 1 3 6 0  (3) 100 (2)
C ( l ) - 1 9 5 2 (8) - 1 0 2 8 9 ( 4 ) - 6 1 3  (3) 52 (2)
C (2) - 3 0 8 8 (8) - 1 0 8 3 4 ( 5 ) - 1 0 8  (3) 60 (3)
C (3) - 3 1 3 9 (9) - 1 0 4 8 0  (5) 618 (3) 5 9 ( 2 )
C (4) - 3 9 5 9 (10) - 1 1 0 1 3 ( 5 ) 1 2 22  (4) 89 (3)
C (5) - 2 0 8 7 (10) - 1 1 0 0 8  (5) 1 1 6 2  (4) 70 (3)
C (6) - 9 7 4 (10) - 1 0 4 3 9 ( 6 ) 1 64 7  (4) 96 (4)
C (7) 404 (10) - 9 8 6 3  (6) 1 27 1  (4) 77 (3)
C (8) 1 55 3 (8) - 1 0 3 7 5 ( 6 ) 774  (3) 7 6 ( 3 )
C (9) 746 (8) - 1 0 6 7 8 ( 4 ) 67 (3) 64 (3)
C ( 1 0 ) - 3 0 3 (7) - 9 8 7 8 ( 4 ) - 2 8 5  (3) 4 6 ( 2 )
C ( l l ) 666 (7) - 9 3 5 9 ( 4 ) - 8 5 6  (3) 47 (2)
C (12) 2 4 1 2 (7) - 8 9 2 7 ( 5 ) - 6 9 2  (3) 64 (3)
C (13) 2 7 7 9 (8) - 8 2 4 3  (5) - 1 3 1 1  (4) 7 5 ( 3 )
C (14) 1098 (7) - 8 1 8 2  (4) - 1 7 3 6  (3) 4 9 ( 2 )
C (15) - 2 7 2 (7) - 8 5 0 8  (4) - 1 2 1 5  (3) 4 5 ( 2 )
C (16) - 1 8 7 6 (7) - 8 9 2 2  (4) - 1 5 3 5  (3) 55 (2)
C (17) - 2 9 2 2 (7) - 9 4 8 5  (5) - 9 9 5  (3) 64 (3)
C ( 18 ) - 6 9 7 (8) - 7 6 7 3  (4) - 7 0 2  (3) 6 4 ( 2 )
C (19) - 4 0 1 9 (11) - 1 1 5 6 3  (6) - 3 2 7  (4) 88 (4)
C ( 20) 931 (7) - 7 1 9 1  (5) - 2 0 8 6  (3) 58 (2)
C ( 21) 2 3 0 5 (8) - 7 0 0 0  (5) - 2 6 1 0  (4) 88 (3)
C (22) - 1 4 0 0 ( 8 ) - 6 3 1 5 ( 5 ) - 2 5 5 5  (3) 58 (3)
C ( 23) - 3 0 1 1 (8) - 6 4 2 8  (5) - 2 9 6 2  (3) 7 6 ( 3 )
-2 9 7 -
Table 6 Fractional atomic co-ordinates (xlO4)
X y z
0 1 ) - 6 8 9 5) - 7 1 8 5 ( 3 ) - 2 4 5 0 2 )
0 2 ) - 8 8 4 6 ) - 5 5 6 4 ( 3 ) - 2 3 5 4 3)
0 3) 493 7) - 8 9 9 2  (4) 1360 3)
c 1 ) - 1 9 5 2 8 ) - 1 0 2 8 9  (4) - 6 1 3 3)
c 2 ) - 3 0 8 8 8 ) - 1 0 8 3 4  (5) - 1 0 8 3)
c 3) - 3 1 3 9 9) - 1 0 4 8 0  (5) 618 3)
c 4) - 3 9 5 9 1 0 ) - 1 1 0 1 3 ( 5 ) 1222 4)
c 5) - 2 0 8 7 1 0 ) - 1 1 0 0 8  (5) 1162 4)
c 6 ) - 9 7 4 1 0 ) - 1 0 4 3 9 ( 6 ) 1647 4)
c 7) 404 1 0 ) - 9 8 6 3  (6 ) 1271 4)
c 8 ) 1553 8 ) - 1 0 3 7 5 ( 6 ) 774 3)
c 9) 746 8 ) - 1 0 6 7 8  (4) 67 3)
c 1 0 ) - 3 0 3 7) - 9 8 7 8  (4) - 2 8 5 3)
c 1 1 ) 666 7) - 9 3 5 9 ( 4 ) - 8 5 6 3)
c 1 2 ) 2412 7) - 8 9 2 7  (5) - 6 9 2 3)
c 13) 2779 8 ) - 8 2 4 3 ( 5 ) - 1 3 1 1 4)
c 14) 1098 7) - 8 1 8 2  (4) - 1 7 3 6 3)
c 15) - 2 7 2 7) - 8 5 0 8  (4) - 1 2 1 5 3)
c 16) - 1 8 7 6 7) - 8 9 2 2  (4) - 1 5 3 5 3)
c 17) - 2 9 2 2 7) - 9 4 8 5  (5) - 9 9 5 3)
c 18) - 6 9 7 8 ) - 7 6 7 3  (4) - 7 0 2 3)
c 19) - 4 0 1 9 1 1 ) - 1 1 5 6 3  ( 6 ) - 3 2 7 4)
c 2 0 ) 931 7) - 7 1 9 1  (5) - 2 0 8 6 3)
c 2 1 ) 2305 8 ) - 7 0 0 0 ( 5 ) - 2 6 1 0 4)
c 2 2 ) - 1 4 0 0 8 ) - 6 3 1 5  (5) - 2 5 5 5 3)
c 23) - 3 0 1 1 8 ) - 6 4 2 8  (5) - 2 9 6 2 3)
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Table 7 Anisotropic temperature factors (A xlO3)
Un U22 U33 U13 Uj2
0 1 ) 5 7 ( 3 ) 59 3) 63 (3) 10 2 ) - 2 3) - 3 3)
0 2 ) 1 0 5 ( 4 ) 54 3) 109 (4) 5 3) - 3 0 4) - 1 2 3)
0 3) 1 1 9 ( 4 ) 93 3) 86 ( 4 ) - 7 3) - 8 4) - 1 4)
c 1 ) 50 (4) 51 4) 5 6 ( 4 ) - 4 3) 7 4) - 6 4)
c 2 ) 5 9 ( 5 ) 53 4) 67( 5) 3 4) 7 4) - 7 4)
c 3) 6 2 ( 4 ) 55 4) 5 8 ( 4 ) 13 4) 12 4) 6 4)
c 4) 94 ( 6 ) 91 5) 82 (5) 18 5) 32 5) 4 5)
c 5) 7 6 ( 6 ) 73 5) 61 ( 5 ) 5 4) 25 5) 4 5)
c 6 ) 110 (7) 119 6 ) 5 9 ( 4 ) 13 5) 8 6 ) 12 6 )
c 7) 7 2 ( 5 ) 97 6 ) 61( 5) 22 5) - 1 6 5) 4 6 )
c 8 ) 68 (5) 100 5) 6 1( 5 ) 24 5) - 3 4) 11 5)
c 9) 63 ( 5 ) 63 4) 6 5( 4 ) 8 4) 15 4) 12 4)
c 1 0 ) 4 5 ( 4 ) 45 4) 46 (4) 0 3) - 3 3) 3 3)
c 1 1 ) 3 6 ( 4 ) 49 4) 5 5 ( 4 ) 0 3) - 7 3) - 1 4)
c 1 2 ) 44 (4) 80 5) 68 (4) 12 4) - 3 4) - 1 4)
c 13) 5 3 ( 4 ) 88 5) 86 (5) 12 4) - 1 4) - 7 4)
c 14) 3 7 ( 4 ) 65 4) 4 6 ( 3 ) 3 3) - 2 3) - 2 3)
c 15) 4 2 ( 4 ) 52 4) 4 0 ( 3 ) - 9 3) 3 3) - 3 3)
c 16) 4 3 ( 4 ) 66 4) 5 7 ( 4 ) 14 3) - 3 3) - 4 4)
c 17) 44 (4) 72 4) 7 7 ( 5 ) 14 4) - 4 4) - 1 0 4)
c 18) 7 1 ( 4 ) 58 4) 63 ( 4 ) 1 3) 2 4) 8 4)
c 19) 98 ( 6 ) 81 6 ) 85 ( 6 ) - 1 5) 18 6 ) - 2 1 6 )
c 2 0 ) 50 (5) 72 4) 50 (4) 8 3) - 7 4) - 1 7 4)
c 2 1 ) 6 9 ( 5 ) 105 6 ) 91 (5) 22 5) 1 5) - 1 9 5)
c 2 2 ) 66 (5) 54 4) 54 (4) 8 4) 4 4) - 8 4)
c 23) 5 3 ( 5 ) 91 5) 84 (5) 10 4) - 1 4) - 5 4)
- 2 9 9 -
Table  8 Hydrogen fractional atomic co-ordinates (xlO4)
isotropic temperature factors (A2 xlO3)
X y z U
H 1 1 ) - 1 5 9 3 8 ) - 1 0 7 7 2  (4) - 9 4 5 3) 7 3 ( 4 )
H 41) - 4 5 7 2 1 0 ) - 1 1 6 0 6  (5) 1 1 3 8 4) 7 3 ( 4 )
H 41) - 4 5 0 3 1 0 ) - 1 0 6 5 0 ( 5 ) 1 5 8 8 4) 7 3 ( 4 )
H 61) - 1 6 6 4 1 0 ) - 9 9 8 9 ( 6 ) 1 9 0 4 4) 7 3 ( 4 )
H 62) - 4 4 6 1 0 ) - 1 0 8 8 6 ( 6 ) 1 9 6 5 4) 7 3 ( 4 )
H 81) 2 4 8 6 8 ) - 9 9 5 0 ( 6 ) 677 3) 7 3 ( 4 )
H 82) 1 9 5 9 8 ) - 1 0 9 5 7 ( 6 ) 998 3) 7 3 ( 4 )
H 91) 24 8 ) - 1 1 2 2 9  (4) 149 3) 7 3 ( 4 )
H 92) 1 6 3 6 8 ) - 1 0 8 6 2  (4) - 2 4 6 3) 7 3 ( 4 )
H 1 0 1 ) - 5 7 5 7) - 9 4 2 6  (4) 82 3) 7 3 ( 4 )
H 1 1 1 ) 7 92 7) - 9 9 2 5  (4) - 1 1 4 8 3) 7 3 ( 4 )
H 1 2 1 ) 2 39 1 7) - 8 5 6 9 ( 5 ) - 2 6 1 3) 7 3 ( 4 )
H 1 2 2 ) 3 2 4 5 7) - 9 4 3 4 ( 5 ) - 6 6 3 3) 7 3 ( 4 )
H 131) 3 1 0 2 8 ) - 7 6 0 9 ( 5 ) - 1 1 4 6 4) 7 3 ( 4 )
H 132) 3664 8 ) - 8 5 0 6 ( 5 ) - 1 5 9 7 4) 7 3 ( 4 )
H 141) 1020 7) - 8 6 0 3  (4) - 2 1 3 6 3) 7 3 ( 4 )
H 161) - 2 5 4 2 7) - 8 3 9 4  (4) - 1 7 1 6 3) 7 3 ( 4 )
H 162) - 1 5 7 6 7) - 9 3 5 6  (4) - 1 9 0 8 3) 7 3 ( 4 )
H 171) - 3 8 6 3 7) - 9 7 7 8 ( 5 ) - 1 2 3 2 3) 7 3 ( 4 )
H 172) - 3 3 2 9 7) - 9 0 2 9 ( 5 ) - 6 5 4 3) 7 3 ( 4 )
H 181) 322 8 ) - 7 4 1 7  (4) - 5 0 3 3) 7 3 ( 4 )
H 182) - 1 4 1 0 8 ) - 7 9 2 0  (4) - 3 3 7 3) 7 3 ( 4 )
H 183) - 1 2 7 7 8 ) - 7 1 6 4  (4) - 9 4 9 3) 7 3 ( 4 )
H 2 0 1 ) 1011 7) - 6 6 9 3 ( 5 ) - 1 7 3 5 3) 7 3 ( 4 )
H 2 1 1 ) 3 3 7 9 8) - 7 0 0 3 ( 5 ) - 2 3 7 8 4) 7 3 ( 4 )
a n d
-3 0 0 -
H ( 2 1 2 ) 2 1 26  ( 8 ) - 6 3 7 6  (5) - 2 8 2 5  (4) 7 3 ( 4 )
H ( 2 1 3 ) 2 28 7  ( 8 ) - 7 5 0 1  (5) - 2 9 6 1  (4) 7 3 ( 4 )
H ( 2 3 1 ) - 3 5 1 3  ( 8 ) - 5 7 9 9 ( 5 ) - 3 0 3 4  (3) 7 3 ( 4 )
H ( 2 32 ) - 3 7 8 0  ( 8 ) - 6 8 3 7  (5) - 2 7 0 9  (3) 7 3 ( 4 )
H ( 2 3 3 ) - 2 7 6 4  ( 8 ) - 6 7 2 0  (5) - 3 4 0 6  (3) 7 3 ( 4 )
H (31) - 3 1 6 9 ( 7 3 ) - 9 7 5 3  (15) 64 5  (28) 7 3 ( 4 )
H (51) - 1 6 5 7  (65) - 1 1 6 3 7  (22) 968  ( 25) 7 3 ( 4 )
H ( 1 91 ) - 3 8 3 2  (75) - 1 1 8 3 1  (35) - 8 0 6  (15) 7 3 ( 4 )
H ( 1 9 2) - 4 7 7 5  (56) - 1 1 9 1 9  (33) - 4  (22) 7 3 ( 4 )
- 3 0 1 -
Table 9 B o nd l e n g t h s  (A)
C (20) - 0 ( 1 ) 1 . 4 6 2  (7)
C ( 2 2 ) - 0  (2) 1 . 1 7 2  (7)
C (2)  - C  (1) 1 . 5 1 7  (9)
C ( 17 )  - C  (1) 1 . 5 2 9 ( 9 )
C ( 1 9 ) - C  (2) 1 . 3 1 0  (10)
C (5)  - C (3) 1 . 5 1 8  (11)
C ( 6 ) - C (5) 1 . 5 0 0  (11)
C ( 8 ) - C  (7) 1 . 4 9 2  (10)
C ( 1 0 )  - C  (9) 1 . 5 3 2  (9)
C ( 1 2 ) - C  (11) 1 . 5 3 8  (10)
C ( 1 3 ) - C  (12) 1 . 5 4 0  (10)
C ( 1 5 ) - C (14) 1 . 5 4 1  (9)
C ( 1 6 ) - C (15) 1 . 5 2 1  (9)
C ( 1 7 ) - C (16) 1 . 5 3 3 ( 9 )
C ( 2 3 ) - C (22) 1 . 5 0 4  (10)
C (22)  - 0 ( 1 ) 1 . 3 3 4  ( 8 )
C (7)  - 0 ( 3 ) 1 . 2 0 8  ( 8 )
C ( 1 0 )  - C ( l ) 1 . 5 5 6 ( 9 )
C (3)  - C (2) 1 . 4 7 3  (9)
C (4)  - C (3) 1 . 5 1 5  (10)
C (5)  - C  (4) 1 . 4 8 8  (11)
C (7)  - C  ( 6 ) 1 . 5 2 7  (11)
C (9)  - C ( 8 ) 1 . 5 5 4  (10)
C ( l l ) - C ( 1 0 ) 1 . 5 1 4  (9)
C (15)  - C ( l l ) 1 . 5 4 4  (9)
C ( 1 4 ) - C ( 1 3 ) 1 . 5 6 3  (9)
C ( 2 0 ) - C  ( 14 ) 1 . 5 2 0  (9)
C (18)  - C ( 15) 1 . 5 4 5  (9)
C (21)  - C  ( 2 0 ) 1 . 5 0 4  (10)
- 3 0 2 -
Table 10 B o n d  a n g l e s ( d e g . )
C ( 2 2 ) - 0 ( 1 ) - C  ( 20) 1 1 6 . 6 6 ) C ( 1 0 ) -C (1)  - C (2) 1 1 4 . 7  ( 6 )
C ( 1 7 ) - C ( 1 ) - C  (2) 1 1 1 . 1 6 ) C (17) - C ( l ) - C d O ) 1 1 0 . 7  (5)
C (3)  - C ( 2 ) - C  (1) 1 1 7 . 1 7) C (19) - C (2 ) - C ( 1 ) 1 2 0 . 3  (7)
C ( 19 )  - C ( 2 ) - C  (3) 1 2 2 . 5 7) C (4)  - C (3) - C (2) 1 2 5 . 0  (7)
C (5)  - C  (3)  - C  (2) 1 1 8 . 4 7) C (5)  - C ( 3 ) ~C (4) 5 8 . 8 ( 5 )
C (5)  - C  (4)  - C  (3) 6 0 . 7 6 ) C (4)  - C (5) - C ( 3 ) 6 0 . 5  ( 6 )
C ( 6 ) - C ( 5 )  - C  (3) 1 2 0 . 0 7) C (6) - C (5) - C ( 4 ) 1 2 2 . 7  ( 8 )
C ( 7 )  - C ( 6 ) - C  (5) 1 1 3 . 4 7) C ( 6 ) - C (7) - 0 (3) 1 1 9 . 1  (9)
C ( 8 ) - C  (7)  - 0 ( 3 ) 1 2 1 . 3 9) C ( 8 ) - C ( 7 ) - C ( 6 ) 1 1 9 . 6 ( 8 )
C (9) - C ( 8 ) - C ( 7 ) 1 1 5 . 5 7) C ( 1 0 ) - C  (9)  - C ( 8 ) 1 1 4 . 5  ( 6 )
C ( 9) - C ( 1 0 )  - C ( l ) 1 1 2 . 0 5) C ( l l ) - C ( 1 0 ) - C ( l ) 1 0 7 . 7  (5)
C ( 1 1 ) - C ( 1 0 ) - C  (9) 1 1 2 . 2 6 ) C (12) - C ( 1 1 ) - C ( 1 0 ) 1 1 9 . 3 ( 6 )
C ( 1 5 )  - C ( l l )  - C ( 1 0 ) 1 1 5 . 6 5) C (15) - C ( l l ) - C (12) 1 0 3 . 5  (5)
C ( 1 3 )  “ C ( 12)  - C ( l l ) 1 0 4 . 3 6 ) C (14) -C (13)  - C  ( 12) 1 0 5 . 8  (5)
C ( 1 5 ) - C ( 1 4 ) - C (13) 1 0 4 . 3 5) C (20) - C  (14)  - C  ( 13) 1 1 0 . 6 ( 6 )
C ( 2 0 ) - C ( 1 4 ) - C ( 15) 1 1 8 . 9 6 ) C (14) - C ( 1 5 ) - C  ( 11) 9 9 . 7  (5)
C ( 1 6 ) - C ( 15)  - C ( l l ) 1 0 7 . 5 5) C (16) - C ( 1 5 ) - C (14) 1 1 5 . 9  (5)
C ( 18 )  - C  ( 15 )  - C  ( 11) 1 1 2 . 4 5) C (18) - C ( 15)  - C  ( 14) 1 1 0 . 5 ( 5 )
C ( 1 8 ) - C ( 1 5 ) - C ( 1 6 ) 1 1 0 . 5 6 ) C (17) - C ( 1 6 ) - C ( 15 ) 1 1 1 . 6 ( 6 )
C ( 1 6 ) - C ( 1 7 ) - C  (1) 1 1 4 . 4 6 ) C (14) - C  ( 2 0 )  - 0 ( 1 ) 1 0 7 . 0  (5)
C ( 21 )  - C  ( 20 )  - 0 ( 1 ) 1 0 8 . 4 5) C (21) - C ( 2 0 ) - C  ( 14) 1 1 2 . 7  (7)
0  (2)  - C  ( 22 )  - 0  (1) 1 2 6 . 0 7) C (23) - C (2 2 ) - 0  ( 1 ) 1 1 0 . 1  (7)
C ( 2 3 ) - C ( 2 2 ) - 0 ( 2 ) 1 2 3 . 9 8)
Table 11 Selected non-bonded distances (A)
Intramolecular:
0 ( 2 ) - 0 ( 1 )  2 . 2 3 5  C ( 1 4 ) - 0 ( 1 )  2 . 3 9 6
- 3 0 3 -




Compound 117 was crystallised from ethyl acetate.
A crystal of approximate dimensions 0.3 x 0.3 x 0.3 mm was used for data collection.
Crystal data: C21H34O3, M -  334.5 orthorhombic, a -  6.6262(7), b = 12.554(1), c = 22.968(2)A, U 
-  1910.6 A3, space group />2 12 12 1, Z = 4, Dc = 1.16 gem'3, ^ (M o -^ )  = 0.70 cm'1, F(000) = 736. Data 
were measured at room temperature on a CAD4 automatic four-circle diffractometer in the range
o
2<0<24 . 1776 reflections were collected of which 1195 were unique with 7>2a(/). Data were corrected 
for Lorentz and polarization but not for absorption. The structure was solved by Direct methods and 
refined using the SHELX1,2 suite of programs. In the final least squares cycles all atoms were allowed to 
vibrate anisotropically. Hydrogen atoms were included at calculated positions except in the instance of 
HI and H2, (attached to 01 and 02  respectively) where the protons were located in an advanced 
Difference Fourier and refined at a distance of 0.96 A from the relevant parent atoms.
Examination of the gross molecular packing revealed that the lattice was dominated by 
intermolecular hydrogen bonds through the hydroxyl groups. Typically, H2 of the molecule as presented 
interacts with O l of the lattice neighbour generated via the operator 0.5+Jt, 0.5-y, 2 -z (H2  -Ol, 1.863 A), 
while 0 2  bonds to HI of the molecule generated via the operator 1 +jc,y,z ( 0 2  -HI, 1.813 A). The ultimate 
consequence of these intermolecular contacts is an array of infinite herringbone polymers parallel to the a 
axis. The backbone of each herringbone is composed of two 1-dimensional polymers, each containing 
molecules removed from each other by one unit cell translation along a and linked through 0 2  -HI
- 3 0 4 -
bonds. These polymers (related by the symmetry element 0.5+x, 0.5-y, -z) are, in turn, cross-linked by the 
H2-01 bonds.
Final residuals after 12 cycles of least squares were R = 0.0458, Rw = 0.0460, for a weighting scheme 
of w = 1.7976/[<j2(F) + 0.000606(F)2]. Max. final shift/esd was 0.000. The max. and min. residual 
densities were 0.08 and -0.08 eA' 3 respectively. Final fractional atomic coordinates and isotropic thermal 
parameters, bond distances and angles are given in Tables 12, 16, and 17 respectively. Tables of 
anisotropic temperature factors are available as supplementary data. The asymmetric unit is shown in 
Fig. 7, along with the labelling scheme used.
1. Sheldrick G.M., SHELX8 6 , a computer program for crystal structure determination, University of
Gottingen, 1986.

















0 1 7C5 C4
0 1 502'02 0 3 0 1 6
-3 0 6 -
Figure 8 . Solid state molecular packing of 117.
-307-
Table 12 Fractional atomic co-ordinates (xlO4) and
equivalent isotropic temperature factors (A2 xlO3) for 117
X y z U
0 1 ) 592 (5) 2580 (3) 9412 (1) 40 (1
0 2 ) 6 9 7 3 ( 5 ) 1536 (3) 9543  (1) 39 (1
0 3) 7 1 0 5 ( 7 ) - 5 0 9 7 ( 3 ) 7374 (2) 7 9 ( 2
c 1 ) 6690 (7) - 1 1 3 4 ( 3 ) 8665  (2) 32 (1
c 2 ) 7875  (7) - 87  (3) 8619  (2) 40 (2
c 3) 6604 (8 ) 923 (3) 8578 (2) 37 (2
c 4) 5463  (7) 1227 (4) 9130 (2) 35 (1
c 5) 3934 (7) 21 5 3 ( 4 ) 9034 (2) 41 (2
c 6 ) 1856 (7) 1732 (4) 9210 (2) 34 (2
c 7) 2356  (7) 877 (3) 9650  (2) 3 5 ( 2
c 8 ) 4093  (7) 305 (3) 9347 (2) 31 (1
c 9) 5003  (7) - 6 4 3 ( 3 ) 9681 (2) 3 5 ( 2
c 1 0 ) 6257 (7) - 1 4 4 6  (3) 9310  (2) 37 (2
c 1 1 ) 5274 (10) - 2 5 4 5 ( 4 ) 9358 (2) 54 (2
c 1 2 ) 6402 (10) - 3 4 3 6 ( 4 ) 9039  (2) 5 5 ( 2
c 13) 6760 (8 ) - 3 1 5 1  (4) 8404  (2) 3 8 ( 2
c 14) 8314 (8 ) - 3 8 3 8  (4) 8 0 7 5 ( 2 ) 41 (2
c 15) 9 0 2 6 ( 9 ) - 3 1 2 3 ( 4 ) 7574  (2) 5 5 ( 2
c 16) 8583 (10) - 1 9 6 2  (4) 7 7 5 9  (2) 58 (2
c 17) 7848 (8 ) - 2 0 6 7  (3) 8386  (2) 36 (2
c 18) 6148 (8 ) - 3 7 7  (4) 1 0 2 4 4  (2) 48 (2
c 19) 4761 (8 ) - 3 1 2 3  (4) 8064  (2) 5 6 ( 2
c 2 0 ) 7592  (9) - 4 9 1 5 ( 4 ) 7 8 7 3  (3) 5 3 ( 2
c 2 1 ) 7504 (13) - 5 7 8 1  (4) 8312  (3) 8 9 ( 3
-3 0 8 -
Table 13 Fractional atomic co -ordinates
X y z
0(1) 592(5) 2580 (3) 9412 (1)
0(2) 6973(5) 1536(3) 9543 (1)
0(3) 7105 (7) -5097 (3) 7374 (2)
C(l) 6690 (7) -1134 (3) 8665 (2)
C (2) 7875 (7) -87 (3) 8619 (2)
C (3) 6604 (8) 923 (3) 8578 (2)
C (4) 5463(7) 1227 (4) 9130 (2)
C (5) 3934 (7) 2153 (4) 9034 (2)
C (6) 1856 (7) 1732 (4) 9210 (2)
C (7) 2356 (7) 877 (3) 9650 (2)
C (8) 4093 (7) 305 (3) 9347 (2)
C (9) 5003(7) -643 (3) 9681 (2)
C (10) 6257 (7) -1446 (3) 9310 (2)
C(ll) 5274 (10) -2545(4) 9358 (2)
C (12) 6402 (10) -3436 (4) 9039 (2)
C (13) 6760 (8) -3151 (4) 8404 (2)
C (14) 8314 (8) -3838 (4) 8075 (2)
C (15) 9026 (9) -3123 (4) 7574 (2)
C (16) 8583 (10) -1962 (4) 7759 (2)
C (17) 7848 (8) -2067 (3) 8386 (2)
C (18) 6148 (8) -377 (4) 10244 (2)
C (19) 4761 (8) -3123(4) 8064 (2)
C (20) 7592 (9) -4915 (4) 7873 (3)
C (21) 7504 (13) -5781 (4) 8312 (3)
- 3 0 9 -
Table 14 Anisotropic temperature factors (A xlO3)
Un U33 U23 U13 Un
0 1 ) 27 (2 ) 42 2 ) 51 2 ) - 1 1 2 ) 0 (2 ) 1 2 )
0 2 ) 24 (2 ) 50 2 ) 43 2 ) - 1 6 2 ) 1 (2 ) -1 0 2 )
0 3) 99 (3) 59 2 ) 79 3) - 2 3 2 ) - 3 5 ( 3 ) 11 3)
c 1 ) 28 (2 ) 35 2 ) 34 2 ) - 1 2 ) - 2  (2 ) 1 2 )
c 2 ) 37 (3) 40 3) 44 3) - 5 2 ) 1 0 ( 3 ) -7 3)
c 3) 32 (3) 33 3) 45 3) 1 2 ) 9 ( 2 ) -1 1 2 )
c 4) 28 (2 ) 41 3) 36 3) 0 2 ) 0 (2 ) - 5 2 )
c 5) 29 (3) 41 3) 53 3) 2 2 ) 8 ( 3 ) -4 3)
c 6 ) 24 (2 ) 42 3) 37 3) - 8 2 ) 3 ( 2 ) -2 2 )
c 7) 26 (3) 42 3) 36 3) - 2 2 ) 1 (2 ) -6 2 )
c 8 ) 27 (2 ) 32 2 ) 34 2 ) - 3 2 ) 2 (2 ) - 3 2 )
c 9) 31 (3) 42 3) 31 2 ) 2 2 ) 4 (2) -1 2 )
c 1 0 ) 36 (3) 39 3) 36 2 ) - 3 2 ) 5 ( 2 ) 1 2 )
c 1 1 ) 73 (4) 46 3) 42 3) 5 3) 22 (3) 3 3)
c 1 2 ) 82 (4) 37 3) 46 3) 5 2 ) 17 (3) 9 3)
c 13) 37 (3) 42 3) 35 3) - 2 2 ) 0 (2 ) 3 3)
c 14) 34 (3) 43 3) 46 3) - 3 2 ) - 2 (2 ) 8 3)
c 15) 62 (4) 56 3) 46 3) - 1 0 3) 9 ( 3 ) 4 3)
c 16) 72 (4) 52 3) 51 3) - 6 3) 20 (3) - 2 3)
c 17) 40 (3) 39 2 ) 31 2 ) - 2 2 ) 1 (2 ) - 7 3)
c 18) 55 (3) 54 3) 35 3) - 4 2 ) - 1  (3) 15 3)
c 19) 46 (3) 50 3) 70 4) - 1 3 3) - 2 ( 3 ) -1 3)
c 2 0 ) 51 (3) 45 3) 63 4) - 1 4 3) - 2 ( 3 ) 11 3)
c 2 1 ) 131 (7) 46 4) 89 5) - 1 3 3) 30 (5) - 1 3 5)
- 3 1 0 -
Table 15 Hydrogen fractional atomic co-ordinates (xlO4)
and isotropic temperature factors (A2 xlO3)
X y z U
H 1) -729 (47) 2311 (46) 9477 27) 103 24)
H 2) 6462 (73) 1772 (35) 9903 12) 57 15)
H 11) 5445 (7) -1011 (3) 8462 2 ) 60 3)
H 21) 8707 (7) -125 (3) 8277 2 ) 60 3)
H 22) 8717 (7) -29(3) 8958 2) 60 3)
H 31) 5635 (8) 826 (3) 8272 2) 60 3)
H 32) 7488 (8) 1502 (3) 8481 2) 60 3)
H 51) 3926(7) 2363 (4) 8632 2) 60 3)
H 52) 4293(7) 2752 (4) 9272 2) 60 3)
H 61) 1066(7) 1436 (4) 8899 2) 60 3)
H 71) 2774 (7) 1178 (3) 10015 2) 60 3)
H 72) 1232 (7) 408 (3) 9713 2) 60 3)
H 81) 3697 (7) -114(3) 9017 2) 60 3)
H 91) 3778 (7) -996 (3) 9794 2) 60 3)
H 101) 7589 (7) -1441 (3) 9474 2) 60 3)
H 111) 5194 (10) -2731 (4) 9762 2) 60 3)
H 112) 3937 (10) -2499 (4) 9198 2) 60 3)
H 121) 5615(10) -4078 (4) 9058 2) 60 3)
H 122) 7679(10) -3551 (4) 9226 2) 60 3)
H 141) 9384 (8) -4043 (4) 8333 2) 60 3)
H 151) 10445 (9) -3218 (4) 7508 2) 60 3)
H 152) 8298 (9) -3293 (4) 7224 2) 60 3)
H 161) 7559(10) -1652 (4) 7516 2) 60 3)
H 162) 9784 (10) -1536 (4) 7739 2) 60 3)
H 171) 8993 (8) -2033 (3) 8641 2) 60 3)
H 181) 5371 (8) 117(4) 10471 2) 60 3)
- 3 1 1 -
H ( 1 82 ) 7 4 2 6  (8 ) - 6 3  (4) 1 0 1 4 8  (2) 60 (3)
H ( 1 8 3 ) 6364  ( 8 ) - 1 0 1 7  (4) 10 4 6 4  (2) 60 (3)
H ( 1 9 1 ) 3 7 9 9 ( 8 ) - 2 6 9 5  (4) 8271  (2) 60 (3)
H ( 1 9 2 ) 4 2 4 8 ( 8 ) - 3 8 3 5  (4) 8024  (2) 60 (3)
H ( 1 9 3 ) 4 9 8 9  ( 8 ) - 2 8 2 4  (4) 7 6 8 5  (2) 60 (3)
H ( 2 1 1 ) 7 9 3 5 ( 1 3 ) - 5 5 1 2  (4) 8 6 8 3  (3) 60 (3)
H ( 2 1 2 ) 8 3 7 5  (13) - 6 3 5 3  (4) 8194  (3) 60 (3)
H ( 2 1 3 ) 6 1 4 4 ( 1 3 ) - 6 0 3 9  (4) 8 34 2  (3) 60 (3)
- 3 1 2 -
Table 16 Bond l e n g t h s  (A)
C ( 6 ) - 0  ( 1 ) 1 . 4 3 2 ( 6 ) C (4)  - 0 ( 2 ) 1 . 4 3 3  ( 6 )
C (20)  - 0 ( 3 ) 1 . 2 1 2  (7) C ( 2 ) - C ( l ) 1 . 5 3 5 ( 8 )
C ( 1 0 ) - C ( l ) 1 . 5 5 8  ( 8 ) C ( 1 7 ) -C (1) 1 . 5 4 0  ( 8 )
C (3) - C (2) 1 . 5 2 5  ( 8 ) C (4)  - C (3) 1 . 5 2 3 ( 8 )
C ( 5 ) - C (4) 1 . 5 5 7  ( 8 ) C ( 8 ) -C (4) 1 . 5 5 3 ( 8 )
C ( 6 ) - C (5) 1 . 5 2 8  ( 8 ) C (7)  - C ( 6 ) 1 . 5 1 3 ( 8 )
C ( 8 ) - C (7) 1 . 5 2 4  ( 8 ) C (9)  -C ( 8 ) 1 . 5 3 9 ( 8 )
C (10)  - C (9) 1 . 5 6 0  ( 8 ) C (18)  - C (9) 1 . 5 3 7  ( 8 )
C d l ) - C ( l O ) 1 . 5 3 0  ( 8 ) C ( 1 2 ) - C  (11) 1 . 5 3 2  ( 8 )
C ( 1 3 ) - C (12) 1 . 5 2 0  ( 8 ) C (14)  - C (13) 1 . 5 4 1  ( 8 )
C ( 1 7 ) - C (13) 1 . 5 4 1  ( 8 ) C ( 1 9 ) - C (13) 1 . 5 3 8  (9)
C ( 1 5 ) - C (14) 1 . 5 3 4  ( 8 ) C ( 2 0 ) -C (14) 1 . 5 0 8  (9)
C ( 1 6 ) - C (15) 1 . 5 4 6 ( 9 ) C ( 1 7 ) - C (16) 1 . 5 2 6 ( 8 )
C (2 1 ) - C (2 0 ) 1 . 4 8 3 ( 8 ) H (1)  - 0 ( 1 ) 0 . 9 5 0  (20)
H (2 ) - 0 (2 ) 0 . 9 4 1 ( 2 0 ) H ( l l ) - C ( l ) 0 . 9 6 0
H ( 2 1 ) - C  (2) 0 . 9 6 0 H ( 2 2 ) - C  (2) 0 . 9 6 0
H ( 3 1 ) - C (3) 0 . 9 6 0 H ( 3 2 ) - C  (3) 0 . 9 6 0
H ( 5 1 ) - C (5) 0 . 9 6 0 H ( 5 2 ) - C  (5) 0 . 9 6 0
H ( 6 1 ) - C (6) 0 . 9 6 0 H ( 7 1 ) - C  (7) 0 . 9 6 0
H ( 7 2 ) - C (7) 0 . 9 6 0 H ( 8 1 ) - C  ( 8 ) 0 . 9 6 0
H ( 9 1 ) - C (9) 0 . 9 6 0 H ( 1 0 1 )  - C ( 1 0 ) 0 . 9 6 0
H ( 1 1 1 ) - C  (11) 0 . 9 6 0 H ( 1 1 2 )  - C ( l l ) 0 . 9 6 0
H ( 1 2 1 ) - C ( 1 2 ) 0 . 9 6 0 H ( 1 2 2 ) - C  (12) 0 . 9 6 0
H ( 1 4 1 ) -C (14) 0 . 9 6 0 H ( 1 5 1 ) - C  (15) 0 . 9 6 0
H ( 1 5 2 ) - C (15) 0 . 9 6 0 H ( 1 6 1 ) - C  (16) 0 . 9 6 0
H ( 1 6 2 ) -C (16) 0 . 9 6 0 H ( 1 7 1 ) - C  (17) 0 . 9 6 0
H ( 1 8 1 ) - C  (18) 0 . 9 6 0 H ( 1 8 2 ) - C (18) 0 . 9 6 0
0 9 6* 0  ( 1 2 ) 3 - ( 2 1 2 ) H
0 9 6 * 0  ( 6 1 ) 3 -  ( £ 6 1 ) H
0 9 6 * 0  ( 6 1 ) 3 -  ( 1 6 1 ) H
0 9 6 * 0  ( 1 2 ) 3 - ( £ 1 2 ) H
0 9 6 * 0  ( 1 2 ) 3 - ( 1 1 2 ) H
0 9 6 * 0  ( 6 1 ) 3 - ( 2 6 1 ) H
0 9 6 * 0  ( 8 1 ) 3 - ( £ 8 1 ) H
-exe-
- 3 1 4 -
Table 17 Bond angles (deg.)
C ( 1 0 )  - C  (1)  - C  (2) 1 1 2 . 0 4) C 17) - C  (1) -C (2) 1 1 1 . 6 ( 5 )
C < 1 7 ) - C  ( 1 ) - C  (10) 1 0 7 . 2 4) C 3 ) - C (2) - C (1) 1 1 5 . 7  (5)
C ( 4 )  - C  (3)  - C  (2) 1 1 5 . 6 5) C 3 ) - C (4) - 0  (2 ) 1 0 5 . 8  (5)
C ( 5 )  - C  (4)  - 0  (2) 1 1 0 . 2 5) C 5 ) - -C (4)  - C  (3) 1 1 3 . 1  (5)
C ( 8 ) - C  (4)  - 0  (2) 1 1 3 . 4 4) C 8 ) - C (4) - C (3) 1 1 1 . 8  (5)
C ( 8 ) - C ( 4 ) - C < 5 ) 1 0 2 . 8 4) C 6 ) - C ( 5 ) - C  (4) 1 0 6 . 9 ( 4 )
C ( 5 ) - C ( 6 ) - 0  ( 1 ) 1 1 0 . 9 4) C 7 ) - C ( 6 ) - 0 ( 1 ) 1 1 6 . 0 ( 4 )
C (7 ) - C  ( 6 ) - C  (5) 1 0 3 . 0 5) C 8 ) - C (7) -C ( 6 ) 1 0 1 . 2  (4)
C (7 ) - C  ( 8 ) - C  (4) 1 0 3 . 7 4) C 9 ) - ■C ( 8 ) -C (4) 1 2 0 . 5  (5)
C (9  ) - C  ( 8 ) - C  (7) 1 1 5 . 6 5) C 1 0 ) - C ( 9 ) - C  ( 8 ) 1 1 5 . 9  (4)
C ( 1 8 ) - C ( 9 ) - C (8) 1 1 6 . 4 5) C 18)
oi—iCJiCJ1 1 0 9 . 7  (5)
C ( 9 ) - C ( 1 0 ) - C ( l ) 1 1 7 . 1 4) C 1 1 ) - C ( 1 0 ) - C ( l ) 1 1 1 . 9  (4)
C ( 1 1 )  - C  (10)  - C  (9) 1 0 8 . 4 5) C 1 2 ) - C ( l l ) - C ( 1 0 ) 1 1 4 . 6 ( 5 )
C ( 1 3 ) - C ( 1 2 ) - C ( l l ) 1 1 1 . 2 5) C 14) -C ( 1 3 ) - C (12) 1 1 6 . 3 ( 5 )
C ( 1 7 ) - C ( 1 3 )  - C (12) 1 0 7 . 9 5) C 17) - C  ( 1 3 ) -C (14) 9 9 . 7 ( 5 )
C ( 1 9 ) - C ( 1 3 ) - C ( 1 2 ) 1 1 1 . 0 6 ) C 19) - C  ( 1 3 ) - C (14) 1 0 9 . 8  (5)
C ( 1 9 ) - C ( 1 3 ) - C ( 1 7 ) 1 1 1 . 7 5) C 15) - C  (14)  - C (13) 1 0 4 . 3  (5)
C ( 2 0 ) - C ( 1 4 ) - C ( 1 3 ) 1 1 6 . 1 5) C 2 0 ) - C ( 1 4 ) - C (15) 1 1 3 . 1  (5)
C ( 1 6 ) - C ( 1 5 ) - C  (14) 1 0 6 . 7 5) C 17) - C ( 1 6 ) - C (15) 1 0 3 . 8  (5)
C ( 1 3 ) - C ( 1 7 ) - C  (1) 1 1 5 . 3 5) C 16) -C ( 1 7 ) - C  (1) 1 1 9 . 1  (5)
C ( 1 6 ) - C ( 1 7 ) - C ( 1 3 ) 1 0 4 . 6 5) C 14) -C (20)  - 0 ( 3 ) 1 2 3 . 0  ( 6 )
C ( 2 1 )  - C  ( 20)  - 0 ( 3 ) 1 1 9 . 6 6 ) C 2 1 ) - C ( 2 0 ) - C (14) 1 1 7 . 5 ( 6 )
C ( 6 ) - 0 ( 1 )  -H (1) 1 0 9 . 0 39) C 4 ) - - 0 ( 2 )  -H (2) 1 1 4 . 6 ( 3 3 )
C (2)  - C (1)  -H ( 11) 1 0 5 . 6 3) C 1 0 ) - C d ) - H ( l l ) 1 1 0 . 0  (4)
C ( 1 7 ) - C ( 1 ) -H (11) 1 1 0 . 4 3) H 2 1 ) - C  (2) - C  (1) 1 0 7 . 9 ( 3 )
H (2 2 ) - C (2 ) - C ( 1 ) 1 0 7 . 8 3) H 22) - C ( 2 ) -H (21) 1 0 9 . 5
C ( 3 ) - C ( 2 ) - H ( 21) 1 0 7 . 9 3) C 3 ) - -C (2)  -H (22) 1 0 7 . 9 ( 3 )
- 3 1 5 -
H 3 1 ) - C ( 3 ) - C (2) 1 0 8 . 0  (3) H 32)  -C (3)  - C  (2) 1 0 7 . 8 ( 3 )
H 3 2 ) - C ( 3 ) - H ( 31) 1 0 9 . 5 C 4) - C ( 3 ) -H (31) 1 0 8 . 0  (3)
C 4)  —C (3)  -H (32) 1 0 7 . 9  (3) H 51)  - C  (5)  - C  (4) 1 1 0 . 1  ( 3 )
H 5 2 ) - C ( 5 ) - C  (4) 1 1 0 . 1 ( 3 ) H 52)  -C (5)  -H (51) 1 0 9 . 5
C 6 ) - C ( 5 ) -H (51) 1 1 0 . 1 ( 3 ) C 6 ) - C  (5)  -H (52) 1 1 0 . 1  (3)
H 6 1 ) - C ( 6 ) - 0 ( 1 ) 1 0 2 . 1  (3) H 61) -C ( 6 ) - C  (5) 1 1 5 . 4 ( 4 )
C 7 ) - C ( 6 ) - H ( 6 1 ) 1 1 0 . 0  (3) H 7 1 ) - C ( 7 ) - C (6) 1 1 1 . 5 ( 3 )
H 7 2 ) - C ( 7 ) - C (6) 1 1 1 . 5 ( 3 ) H 7 2 ) - C ( 7 ) - H (71) 1 0 9 . 5
C 8 ) - C  (7)  -H ( 71 ) 1 1 1 . 5 ( 3 ) C 8 ) -C (7)  -H (72) 1 1 1 . 5 ( 3 )
H Ul
0001r~1 
00 1 0 8 . 3 ( 3 ) H 81)  - C ( 8 ) - C  (7) 1 1 4 . 4  (3)
C 9)  - C  ( 8 ) -H (81) 9 4 . 3 ( 3 ) H 91)  - C  (9)  - C  ( 8 ) 9 9 . 2  (3)
C 1 0 ) - C ( 9 ) - H (91) 1 0 7 . 5  (3) C 1 8 ) - C ( 9 ) -H (91) 1 0 6 . 8  (4)
H 1 0 1 )  - C ( 1 0 )  - C ( l ) 1 0 1 . 7  (4) H 1 0 1 ) - C ( 1 0 ) - C (9) 1 0 5 . 8  (3)
C 1 1 ) - C ( 1 0 ) -H ( 1 01 ) 1 1 1 . 6 ( 4 ) H 1 1 1 ) - C ( 1 1 ) - C ( 1 0 ) 1 0 8 . 2  (3)
H 1 1 2 ) - C ( 1 1 ) - C ( 1 0 ) 1 0 8 . 1  (4) H 1 1 2 ) - C ( 1 1 ) - H ( l l l ) 1 0 9 . 5
C 12)  - C ( l l )  - H ( l l l ) 1 0 8 . 2  (3) C 12)  - C ( l l ) - H (112) 1 0 8 . 2  (4)
H 1 2 1 ) - C  (12)  - C ( l l ) 1 0 9 . 0  (4) H 1 2 2 ) - C ( 1 2 ) - C ( l l ) 1 0 9 . 0  (4)
H 1 2 2 ) - C ( 1 2 ) - H ( 1 21 ) 1 0 9 . 5 C 1 3 ) - C ( 1 2 ) - H (121) 1 0 9 . 0  (4)
C 1 3 ) - C ( 1 2 ) - H ( 1 22 ) 1 0 9 . 1  (4) H 1 4 1 ) - C ( 1 4 ) - C (13) 1 0 9 . 9 ( 3 )
C 1 5 ) - C ( 1 4 ) -H ( 1 4 1 ) 1 1 3 . 2  (4) C 2 0) -C ( 14 )  -H (141) 1 0 0 . 6 ( 4 )
H 1 5 1 ) - C ( 1 5 ) - C (14) 1 1 0 . 2 ( 4 ) H 1 5 2 ) - C ( 1 5 ) - C (14) 1 1 0 . 1  (4)
H 1 5 2 ) - C ( 1 5 ) - H ( 15 1 ) 1 0 9 . 5 C 16)  -C ( 15 )  -H (151) 1 1 0 . 3 ( 4 )
C 1 6 ) - C ( 1 5 ) - H ( 1 52 ) 1 1 0 . 1  (4) H 1 6 1 ) - C ( 1 6 ) - C (15) 1 1 1 . 0  (4)
H 1 6 2 )  - C ( 1 6 )  - C ( 1 5 ) 1 1 0 . 8  (4) H 1 6 2 ) - C ( 1 6 ) - H (161) 1 0 9 . 5
C 1 7)  - C ( 1 6 )  - H ( 1 61 ) 1 1 0 . 9  (4) C 1 7 ) - C ( 1 6 ) - H (162) 1 1 0 . 9 ( 4 )
H 1 7 1 ) - C ( 1 7 ) - C ( l ) 9 6 . 0 ( 3 ) H 1 7 1 ) - C ( 1 7 ) - C (13) 1 1 3 . 1  (3)
H 1 7 1 ) - C ( 1 7 ) - C ( 16) 1 0 8 . 7  (4) H 1 8 1 ) - C ( 1 8 ) - C (9) 1 0 9 . 5 ( 3 )
H 1 8 2 ) - C ( 1 8 ) - C (9) 1 0 9 . 4  (4) H 1 8 2 ) - C ( 1 8 ) - H ( 1 8 1 ) 1 0 9 . 5
H 1 8 3 ) - C ( 1 8 ) - C (9) 1 0 9 . 6 ( 3 ) H 1 8 3 ) - C ( 1 8 ) - H ( 181) 1 0 9 . 5
- 3 1 6 -
H ( 1 8 3 )  - C ( 1 8 ) - H ( 1 8 2 )  
H ( 1 9 2 ) - C  ( 1 9 ) -C (13)  
H ( 1 9 3 ) - C ( 1 9 ) - C ( 1 3 )  
H ( 1 9 3 )  - C  (19)  - H ( 1 9 2 )  
H ( 2 1 2 )  - C ( 2 1 )  - C ( 2 0 )
H ( 2 1 3 ) - C ( 2 1 ) -C (2 0)
H ( 2 1 3 ) ~C ( 2 1 ) -H ( 2 1 2 )
1 0 9 . 5 H ( 1 9 1)
1 0 9 . 5  (4) H ( 1 92 )
1 0 9 . 5  (4) H ( 1 93 )
1 0 9 . 5 H ( 2 11 )
1 0 9 . 5 ( 4 ) H (2 1 2 )
1 0 9 . 4  (5) H ( 2 13 )
1 0 9 . 5
C ( 1 9 ) -C (13) 1 0 9 . 5  (4)
C ( 1 9 ) -H (191) 1 0 9 . 5
C ( 1 9 ) - H (191) 1 0 9 . 5
C ( 2 1 ) -C (20) 1 0 9 . 4  (4)
C ( 2 1 ) -H (211) 1 0 9 . 5
C ( 2 1 ) -H (211) 1 0 9 . 5
- 3 1 7 -
Table 18 S e l e c t e d  
I n t r a m o l e c u l a r :
n o n - b o n d e d d i s t a n c e s  (A)
C ( 5 ) - 0 ( 1 ) 2 . 4 3 8 H ( 5 1 ) - 0  (1) 2 . 8 5 7
H ( 52)  - 0  (1) 2 . 4 8 3 H (61)  - 0 ( 1 ) 1 . 8 8 4
C (7)  - 0  (1) 2 . 4 9 8 H (71)  - 0 ( 1 ) 2 . 6 6 6
H ( 7 2 ) - 0  ( 1 ) 2 . 8 4 5 C (6 ) -H ( 1 ) 1 . 9 5 9
H ( 6 1 ) - H ( 1 ) 2 . 0 9 3 C ( 7 ) -H (1) 2 . 7 5 3
C (2 ) - 0 (2 ) 3 . 0 0 3 H (2 2 ) - 0  (2 ) 2 . 6 4 7
C (3) - 0 (2) 2 . 3 5 8 H ( 3 2 )  - 0 ( 2 ) 2 . 4 6 4
C (5)  - 0 ( 2 ) 2 . 4 5 4 H ( 5 2 ) - 0  (2) 2 . 4 2 3
C (7) - 0 ( 2 ) 3 . 1 7 9 C ( 8 ) - 0  (2 ) 2 . 4 9 6
C (9)  - 0 (2) 3 . 0 4 8 C (18)  - 0 ( 2 ) 2 . 9 4 2
H ( 1 8 1 ) - 0  (2 ) 2 . 9 7 5 H ( 1 8 2 ) - 0  (2 ) 2 . 4 6 0
C (4)  -H (2) 2 . 0 1 5 C ( 5 ) -H (2) 2 . 6 5 0
H ( 52)  -H (2) 2 . 3 8 4 C ( 7 ) - H ( 2 ) 3 . 0 0 0
H ( 7 1 ) -H (2) 2 . 5 6 8 C ( 8 ) -H (2) 2 . 7 3 6
C (18)  - H ( 2 ) 2 . 8 1 7 H ( 1 8 1 ) - H (2) 2 . 5 5 9
H ( 1 8 2 ) -H (2) 2 . 4 5 6 C (13)  - 0 ( 3 ) 3 . 4 0 8
C ( 1 4 ) - 0 ( 3 ) 2 . 3 9 4 H ( 1 41 )  - 0 ( 3 ) 2 . 9 8 1
C ( 1 5 ) - 0 ( 3 ) 2 . 8 2 3 H ( 1 52 )  - 0 ( 3 ) 2 . 4 2 4
C ( 1 9 ) - 0 ( 3 ) 3 . 3 2 6 H ( 1 92 )  - 0 ( 3 ) 2 . 8 8 5
C ( 2 1 )  - 0 ( 3 ) 2 . 3 3 3 H ( 2 12 )  - 0 ( 3 ) 2 . 5 9 7
H ( 2 1 3 ) - 0  (3) 2 . 5 9 7 H (2 1 ) - C ( 1 ) 2 . 0 4 5
H (2 2 ) - C  ( 1) 2 . 0 4 4 C (3)  - C ( l ) " 2 . 5 9 1
H ( 3 1 ) - C  (1) 2 . 7 1 3 C (4)  - C ( l ) 3 . 2 5 4
C (8 ) - C ( 1 ) 2 . 9 4 7 H ( 8 1 ) -C (1) 2 . 4 9 5
C (9) -C (1) 2 . 6 5 9 H ( 1 0 1 ) - C ( l ) 1 . 9 8 9
C ( 1 1 ) -C (1) 2 . 5 5 9 H ( 1 1 2 ) - C  (1) 2 . 7 8 6
- 3 1 8 -
C ( 1 2 ) - c  ( 1 ) 3 . 0 2 1 C 13)  - C ( l ) 2 . 6 0 2
C ( 1 6 ) - C (1) 2 . 6 4 3 H 1 6 1 ) - C (1) 2 . 7 7 7
H ( 1 6 2 )  - C ( l ) 2 . 9 9 6 H 1 7 1 ) - C (1) 1 . 8 9 8
C ( 1 9 ) - C  (1) 3 . 1 2 6 H 191)  - C ( l ) 2 . 8 8 6
C (2 ) - H ( 1 1 ) 2 . 0 1 7 H 2 1 ) - H ( 1 1 ) 2 . 4 6 8
C (3)  - H (11) 2 . 5 6 1 H 3 1 ) - H ( l l ) 2 . 3 5 1
C ( 8 ) - H ( 1 1 ) 2 . 7 6 8 H 8 1 ) - H ( l l ) 2 . 0 5 7
C ( 9 ) - H ( 11) 2 . 8 5 1 C 1 0 ) - H ( l l ) 2 . 0 9 1
C ( 1 1 ) -H (11) 2 . 8 1 9 C 1 3 ) - H ( l l ) 2 . 8 2 7
C ( 1 6 ) - H (11) 2 . 8 9 2 C 1 7 ) - H ( l l ) 2 . 0 7 9
C ( 1 9 ) - H (11) 2 . 8 4 2 H 1 9 1 ) - H ( l l ) 2 . 4 1 9
H (31)  - C (2) 2 . 0 3 8 H 3 2 ) - C (2) 2 . 0 3 6
C (4)  - C (2) 2 . 5 7 9 C 8 ) - C (2 ) 3 . 0 5 3
H ( 8 1 ) - C  (2) 2 . 9 1 6 C 9) - C (2) 3 . 1 7 1
C ( 1 0 ) -C (2) 2 . 5 6 4 H 101)  - C ( 2 ) 2 . 6 0 4
C ( 1 6 ) -C (2) 3 . 1 0 9 H 1 6 2 ) -C (2) 2 . 9 9 8
C ( 1 7 ) - C (2) 2 . 5 4 2 H 1 71)  - C ( 2 ) 2 . 5 5 2
H ( 2 2 ) - H ( 2 1 ) 1 . 5 6 8 C 3 ) -H (21) 2 . 0 3 7
H ( 3 1 ) - H (21) 2 . 3 5 9 H 3 2 ) -H (21) 2 . 2 4 5
C ( 1 6 ) -H (21) 2 . 5 9 7 H 1 6 2 ) -H (21) 2 . 2 7 5
C ( 1 7 ) - H ( 2 1 ) 2 . 5 1 6 H 1 7 1 )  - H ( 2 1 ) 2 . 5 4 4
C (3)  - H ( 22) 2 . 0 3 7 H 3 2 ) - H (22) 2 . 3 5 7
C (4) - H (2 2 ) 2 . 7 0 0 C 9 ) - H (22) 3 . 0 6 7
C ( 1 0 ) - H (2 2 ) 2 . 5 4 4 H 1 0 1 ) -H (22) 2 . 2 6 0
C ( 1 7 ) -H (22) 2 . 9 3 3 H 1 7 1 ) - H ( 2 2 ) 2 . 6 2 4
C (5)  - C (3) 2 . 5 7 0 H 51)  - C ( 3 ) 2 . 5 3 6
C ( 8 ) - C (3) 2 . 5 4 7 H 81)  - C ( 3 ) 2 . 5 3 4
C (9)  - C (3) 3 . 3 7 7 C 1 0 ) - C (3) 3 . 4 2 3
H ( 3 2 ) - H (31) 1 . 5 6 8 C 4 ) - H ( 3 1 ) 2 . 0 3 6
- 3 1 9 -
C (5)  - H (31) 2 . 6 6 5
C ( 8 ) - H (31) 2 . 7 5 1
C (4)  -H (32) 2 . 0 3 5
H ( 5 1 ) -H (32) 2 . 6 1 9
H ( 5 2 ) - C  (4) 2 . 0 9 1
H ( 6 1 ) - C  (4) 2 . 9 7 3
H ( 7 1 ) - C (4) 2 . 7 0 5
C (9)  - C (4) 2 . 6 8 5
C ( 1 8 ) -C (4) 3 . 2 8 8
C (7) - C (5) 2 . 3 8 0
C ( 8 ) - C (5) 2 . 4 3 1
H ( 5 2 ) - H (51) 1 . 5 6 8
H (61)  - H (51) 2 . 3 0 7
C ( 6 ) - H (52) 2 . 0 6 5
C ( 8 ) - H (52) 3 . 0 7 9
H ( 7 2 ) - C  ( 6 ) 2 . 0 6 7
H ( 8 1 )  -C ( 6 ) 2 . 6 5 7
H ( 7 2 ) - H (61) 2 . 2 7 5
H ( 8 1 ) -H (61) 2 . 6 2 7
C ( 9 ) - C (7) 2 . 5 9 3
C ( 1 8 ) - C ( 7 ) 3 . 2 6 3
H ( 7 2 ) -H (71) 1 . 5 6 8
C ( 9 ) - H (71) 2 . 8 2 9
H ( 1 8 1 ) - H (71) 2 . 4 1 6
H ( 8 1 ) - H (72) 2 . 3 7 9
H ( 9 1 ) -H (72) 2 . 4 4 7
C ( 1 0 ) - C ( 8 ) 2 . 6 2 6
H ( 1 8 1 ) - C (8) 2 . 7 2 7
C ( 9 ) -H (81) 1 . 8 7 4
H ( 5 1 ) - H (31) 2 . 3 8 5
H ( 8 1 )  - H ( 3 1 ) 2 . 4 4 3
C (5)  - H (32) 2 . 7 9 8
H ( 5 1 ) —C (4) 2 . 0 9 2
C ( 6 ) -C<4) 2 . 4 8 0
C ( 7 ) -C (4) 2 . 4 2 1
H ( 8 1 ) - C (4) 2 . 0 6 7
C ( 1 0 ) -C (4) 3 . 4 2 2
H ( 6 1 ) - C (5) 2 . 1 2 5
H (71)  -C (5) 2 . 6 7 7
H ( 8 1 ) - C (5) 2 . 8 5 0
C ( 6 ) -H (51) 2 . 0 6 6
C ( 8 ) -H (51) 3 . 0 6 3
C ( 7 ) - H (52) 2 . 8 1 9
H ( 7 1 ) - C (6) 2 . 0 6 8
C ( 8 ) - C  ( 6 ) 2 . 3 4 7
C ( 7 ) -H (61) 2 . 0 5 0
C ( 8 ) -H (61) 2 . 6 6 4
H (81)  - C (7) 2 . 1 1 0
H (91)  - C ( 7 ) 2 . 5 5 4
H ( 1 8 1 ) - C  (7) 2 . 9 0 8
C ( 8 ) - H (71) 2 . 0 7 8
C (18)  -H (71) 3 . 0 1 4
C ( 8 ) - H (72) 2 . 0 7 8
C (9)  - H (72) 2 . 8 2 7
H ( 9 1 ) - C  ( 8 ) 1 . 9 4 0
C ( 1 8 ) - C  ( 8 ) 2 .  613
H ( 1 8 2 ) - C ( 8 ) 2 . 9 1 1
H ( 9 1 ) -H (81) 2 . 1 0 1
- 3 2 0 -
c 1 0 ) -H (81) 2 . 4 7 5 H 1 0 1 ) - C (9) 2 . 0 4 1
c 1 1 ) - C  (9) 2 . 5 0 6 H 1 1 1 ) - C (9) 2 . 6 3 0
H 1 1 2 ) - C  (9) 2 . 6 7 5 H 1 8 1 ) -C (9) 2 . 0 6 6
H 1 8 2 ) - C  (9) 2 . 0 6 4 H 1 8 3 ) - C  (9) 2 . 0 6 7
C 1 0 ) - H (91) 2 . 0 6 3 C 1 1 ) -H ( 91) 2 . 4 0 2
H 1 1 1 ) - H (91) 2 . 3 7 3 H 1 1 2 ) -H (91) 2 . 3 3 4
C 1 8 ) - H ( 9 1 ) 2 . 0 3 4 H 1 8 1 ) -H (91) 2 . 3 4 2
H 1 8 3 ) -H (91) 2 . 3 0 3 H 1 1 1 ) - C  (10) 2 . 0 4 5
H 112)  - C ( 1 0 ) 2 . 0 4 4 C 1 2 ) - C ( 1 0 ) 2 . 5 7 7
H 1 2 2 ) - C ( 1 0 ) 2 . 8 1 2 C 1 3 ) - C  (10) 3 . 0 0 2
C 1 7 ) - C ( 1 0 ) 2 . 4 9 4 H 1 7 1 ) - C ( 1 0 ) 2 . 4 8 7
C 1 8 ) - C (10) 2 . 5 3 2 H 1 8 2 ) - C  (10) 2 . 7 0 6
H 1 8 3 ) - C  (10) 2 . 7 0 7 C 1 1 ) -H ( 1 0 1 ) 2 . 0 8 4
H 1 1 1 ) - H  ( 101) 2 . 3 6 2 C 1 2 ) - H ( 1 0 1 ) 2 . 8 0 9
C 1 7 ) -H ( 1 0 1 ) 2 . 6 2 5 H 1 7 1 ) - H ( 10 1 ) 2 . 2 5 2
C 1 8 ) - H ( 101) 2 . 4 1 4 H 1 8 2 ) -H (101 ) 2 . 3 2 5
H 1 8 3 ) - H ( 101 ) 2 . 4 7 3 H 1 2 1 ) - C  (11) 2 . 0 5 6
H 1 2 2 ) -C (11) 2 . 0 5 6 C 1 3 ) - C  ( 11 ) 2 . 5 1 9
C 1 7 ) —C (11) 2 . 8 7 3 H 1 7 1 ) - C  (11) 3 . 0 3 2
C 1 8 ) - C  (11) 3 . 4 4 8 C 1 9 ) - C ( 11) 3 . 0 7 7
H 1 9 1 ) - C  (11) 2 . 6 8 7 H 1 1 2 ) - H ( 1 1 1 ) 1 . 5 6 8
C 1 2 ) -H ( 111 ) 2 . 0 4 6 H 1 2 1 ) -H (111 ) 2 . 3 5 8
H 1 2 2 ) - H ( 1 1 1 ) 2 . 3 0 0 C 1 2 ) - H ( 1 1 2 ) 2 . 0 4 6
H 1 2 1 ) -H ( 112 ) 2 . 2 9 5 C 1 3 ) -H ( 1 1 2 ) 2 . 7 3 7
C 1 9 ) - H ( 11 2 ) 2 . 7 7 4 H 1 9 1 ) -H ( 112 ) 2 . 1 4 6
C 1 4 ) - C  (12) 2 . 6 0 0 H 1 4 1 ) - C  (12) 2 . 6 6 7
C 1 7 ) - C (12) 2 . 4 7 5 H 1 7 1 ) - C  ( 12) 2 . 6 2 4
C 1 9 ) - C (12) 2 . 5 2 0 H 1 9 1 ) - C  (12) 2 . 6 3 7
H 1 9 2 ) - C  (12) 2 . 7 7 9 C 2 0 ) - C ( 1 2 ) 3 . 3 5 2
- 3 2 1 -
C ( 2 1 ) - C ( 1 2 ) 3 . 4 6 2
H ( 1 2 2 ) -H ( 121) 1 . 5 6 8
C (14)  - H ( 1 2 1 ) 2 . 8 9 5
H ( 1 9 2 ) - H ( 121) 2 . 5 6 0
H ( 2 1 1 ) -H ( 121 ) 2 . 5 1 9
C (14)  - H ( 122 ) 2 . 7 0 1
C ( 1 7 ) - H ( 122 ) 2 . 6 8 4
H ( 1 4 1 ) - C (13) 2 . 0 7 5
H ( 1 5 2 )  - C  (13) 2 . 9 0 1
H ( 1 6 1 ) -C (13) 2 . 8 2 5
H ( 1 9 1 ) - C (13) 2 . 0 6 7
H ( 1 9 3 ) - C (13) 2 . 0 6 7
C ( 2 1 ) - C (13) 3 . 3 4 5
H ( 1 5 2 ) - C (14) 2 . 0 7 0
H ( 1 6 1 ) - C (14) 3 . 0 7 1
H ( 1 7 1 ) - C (14) 2 . 6 5 1
H ( 192)  - C (14) 2 . 6 9 7
C ( 2 1 ) - C (14) 2 . 5 5 7
C ( 1 5 ) - H ( 1 4 1 ) 2 . 1 0 6
C (16)  - H ( 1 4 1 ) 2 . 9 7 5
H ( 1 7 1 ) - H ( 1 4 1 ) 2 . 6 3 4
C ( 2 1 ) - H ( 1 4 1 ) 2 . 5 1 4
H ( 1 6 1 ) - C  (15) 2 . 0 9 1
C ( 1 7 ) - C (15) 2 . 4 1 8
C (19)  - C (15) 3 . 0 4 2
C ( 2 0 ) - C (15) 2 . 5 3 7
C ( 1 6 ) - H ( 1 51 ) 2 . 0 8 3
C ( 1 7 ) —H ( 1 51 ) 3 . 0 1 9
C ( 1 6 ) - H ( 1 52 ) 2 . 0 8 1
H ( 2 1 1 ) - C ( 1 2 ) 2 . 9 1 4
C ( 1 3 ) -H ( 1 21 ) 2 . 0 4 5
C ( 1 9 ) - H ( 1 21 ) 2 . 6 3 9
C ( 2 1 ) -H ( 1 21 ) 3 . 0 1 2
C ( 1 3 ) - H ( 1 22 ) 2 . 0 4 5
H ( 1 4 1 ) - H ( 1 22 ) 2 . 4 2 1
H ( 1 7 1 ) - H ( 1 22 ) 2 . 4 8 8
C ( 1 5 ) - C (13) 2 . 4 2 8
C ( 1 6 ) - C (13) 2 . 4 2 6
H ( 1 7 1 ) - C  (13) 2 . 1 1 1
H ( 1 9 2 )  - C  (13) 2 . 0 6 7
C ( 2 0 ) - C (13) 2 . 5 8 8
H ( 1 5 1 ) - C  (14) 2 . 0 7 2
C ( 1 6 ) - C ( 14) 2 . 4 7 1
C ( 1 7 ) - C (14) 2 . 3 5 5
C ( 1 9 ) - C  (14) 2 . 5 1 9
H ( 1 9 3 ) - C  (14) 2 . 6 9 7
H ( 2 1 1 ) - C  (14) 2 . 5 3 6
H ( 1 5 1 ) -H ( 14 1 ) 2 . 2 7 1
C ( 1 7 ) - H ( 1 41 ) 2 . 6 8 4
C ( 20)  -H ( 1 41 ) 1 . 9 3 1
H ( 2 1 1 ) -H ( 14 1 ) 2 . 2 2 9
H ( 1 6 2 ) - C (15) 2 . 0 8 9
H ( 1 7 1 ) -C (15) 2 . 8 0 8
H ( 1 9 3 ) -C (15) 2 . 7 1 3
H ( 1 5 2 ) -H ( 1 5 1 ) 1 . 5 6 8
H ( 1 6 2 ) - H ( 1 51 ) 2 . 2 2 1
C ( 2 0 ) -H ( 15 1 ) 2 . 9 6 9
H ( 1 6 1 ) -H ( 1 5 2 ) 2 . 2 2 1
- 3 2 2 -
C ( 1 9 ) -H (152) 3 . 0 4 3 H 1 9 3 ) - H ( 152) 2 . 5 0 5
C ( 2 0 ) -H (152) 2 . 5 6 7 H 171)  - C ( 1 6 ) 2 . 0 4 8
C (19)  -C (16) 3 . 0 0 5 H 1 9 3 ) - C (16) 2 . 6 2 0
H ( 1 6 2 ) - H ( 161) 1 . 5 6 8 C 1 7 ) -H (161) 2 . 0 7 3
C (19)  -H ( 161) 2 . 9 0 4 H 1 9 3 ) - H (161) 2 . 2 8 3
C ( 1 7 ) -H ( 162) 2 . 0 7 2 H 1 7 1 ) - H ( 162) 2 . 2 2 6
C ( 1 9 ) -C (17) 2 . 5 4 7 H 1 9 1 ) - C (17) 2 . 8 0 9
H ( 1 9 3 ) -C (17) 2 . 6 6 1 H 1 8 2 ) - H ( 181) 1 . 5 6 8
H ( 1 8 3 ) -H ( 181) 1 . 5 6 8 H 1 8 3 ) - H ( 182) 1 . 5 6 8
C ( 2 0 ) - C (19) 2 . 9 6 1 H 1 9 2 ) - H ( 191) 1 . 5 6 8
H ( 1 9 3 ) - H ( 191) 1 . 5 6 8 H 1 9 3 ) - H ( 192) 1 . 5 6 8
C ( 2 0 ) -H ( 192) 2 . 6 2 1 H 2 1 1 )  - C ( 2 0 ) 2 . 0 1 7
H ( 2 1 2 ) -C (20) 2 . 0 1 8 H 2 1 3 )  - C  (20) 2 . 0 1 7
H ( 2 1 2 ) -H (211 ) 1 . 5 6 8 H 2 1 3 ) - H (211) 1 . 5 6 8
H ( 2 1 3 ) - H ( 212) 1 . 5 6 8
I n t e r m o l e c u l a r :
0 (2 ) - 0  ( l a ) 2 . 7 4 9 0 ( 2 ) - O ( l b ) 2 . 7 9 8
H ( 2 )  - O ( l b ) 1 . 8 6 3 H ( 7 1 ) - 0  ( l b ) 2 . 7 6 6
H ( 1 8 1 ) - 0 ( l b ) 2 . 9 0 8 0 ( 2 )  -H ( l a ) 1 . 8 1 3
H ( 2 )  - H ( l a ) 2 . 2 0 9 C ( 4 )  - H ( l a ) 2 . 9 7 6
H (2 ) - H ( l b ) 2 . 3 3 7 H ( 71)  - H ( l b ) 2 . 4 3 8
C ( 6 ) - 0 (2 c) 3 . 3 3 4 C ( 6 ) - H ( 2 d) 2 . 7 8 4
H ( 1 1 ) - 0 (3e) 2 . 8 0 4 H (31)  - 0 ( 3e ) 2 . 6 1 6
H ( 1 6 2 ) - 0 ( 3 f ) 2 . 7 5 4 H ( 6 1 ) - C ( 2 c ) 2 . 9 2 2
H ( 6 1 ) - H ( 2 2 c ) 2 . 4 1 3 H ( 7 2 ) - H ( 2 2 c ) 2 . 4 6 9
H ( 6 1 ) - H ( 3 2 c ) 2 . 5 5 9 H ( 2 1 3 ) - H ( 5 1 g ) 2 . 5 7 5
H ( 1 5 2 ) - H ( 5 1 h ) 2 . 5 9 1 H ( 1 5 2 ) - H ( 6 1 h ) 2 . 6 3 7
H ( 1 2 2 ) - H ( 9 1 i ) 2 . 4 3 4 H ( 1 8 3 ) - H ( 1 1 2 i ) 2 . 6 4 2
- 3 2 3 -
C ( 1 8 ) - H ( 1 2 2 j )  2 . 9 2 9
H ( 2 1 2 ) - C  ( 1 6k) 3 . 0 7 2
H ( 2 1 2 ) - H ( 1 6 2 k )  2 . 4 7 8
H (18 3 ) - H (122  j ) 2 . 6 0 1
C ( 2 0 ) - H ( 1 62k)  3 . 0 2 4










DATE 7 - 6 - 9 3  
TIME 15:56
SF 36 0 .1 3 4
SY 12 0 .0
01 5 8 0 0 .0 0 0
SI 32768
TD 3276B
SW 40 0 0 .0 0 0
HZ/PT .244
PW 5 . 0
RD 0 . 0









CX 2 7 .0 0
CY 0 . 0
FI 9 . 300P
F2 - . 150P
HZ/CM 126 .049
PPM/CM .350
SR 3 9 8 0 .6 6
(57)
k
1— |— r—i— I— I | " i i— r—i— |— r—i— i—i—|—r
9 . 0  8 . 5  8 . 0  7 .5
i—i—|—i—i— i— i—|—i— i— i— i—|—i—r—i— i—|—i—i— i— i— |— r
7 . 0  6 . 5  6 . 0  5 . 5  5 . 0 4 . 5
PPM
- i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— r—
4 . 0  3 . 5  3 . 0  2 . 5
J j r g a n o n
An a l y t i c a l  Cnemls











N M R  data o f
3oc-terrb utyld im ethylsiloxy-20(3-acetoxy-5 ,10 -se c o p r e g n -1(10 )-en -5 -o n e
FIEL930604, AF88259. 10MG. CDCL3 
B |  R
AF88259.HI  
DATE 7 - 6 - 9 3  
TIME 15: 56
SF 360. 134




















F2 0. 0 P
HZ/CM 2 0 . 1 6 4  
PPM/CM .056  
SR 3 9 8 0 . 6 6
1 . 4 0 1.30
VAAA.
1 '• | ••• *T I n  ' 1 ' I .......................... r 1 I ' ■ ■ ■ I ■ I |
4 . 9 0  4 . 8 0  4 . 7 0  4 . 6 0  4 .5 0  4 . 4 0  4 . 3 0
PPM
O r g a n o n
A n a l y t i c a l  Chemistry
1H a t  3 6 0 . 1 3  MHz
Sample FIEL9306Q4
Or 1 g i n NEWHS
Cone. _ 1 0 M G _ _
Sol vent .CDCL3_______
1 .20 1 . 10 1 .00 .90 .80
PPM
.70 .60 .50 .40 .30 .20 . 10
-325
AF88259. FIEL930604. 10MG. C6D6
AF88259. H1B 
DATE 8 - 6 - 9 3  
TIME 9: 39
SF 36 0 .1 34  
SY 120 .0
5 80 0 .0 0 0
SI 32768  
TD 32768








FW 5000  








2 7 .0 0
5 .300P  
4 . 460P 
11.20 3  
.031 






5 . 0 55 . 2 5 5 . 0 0 4 .955 .2 0 5.  15
A n a l y t i c a l  Chemistry
1H a t  3 6 0 . 1 3  MHz
sample FIEL930604







Tt—i—rT r t—r Ti— i— i— r T T ! i—r T
PPM
O r g a n o n  
CF00259. SMX ^ *
FI PROJ:
q p p p p f p l  A n a l y t i c a l  Chemi stry
F2 PROJ:
SPECFIEL 1H at  360 .  13 MHz
AU PROG:____ ____________________
COSY.AU 
DATE l l - 6 - 9 a . n l ,  FIEL930604
SI2 2048 ln NEWH_________
SI1 1024 9 -----------------------
* SW2 1901.  MX 10MG
•5 SW1 9 5 0 . 5 7 6------------------------






1 R SSB1 0— 1 . o MC2 M
- PLIM ROW:
- FI 4 .911 P
* F2 - .089P
- d n AND lCOLUMN:— c . u FI 4 .9 1  IP
- F2 - .094P
" SR2 3 9 9 0 . 9 9 2
■ SRI 3 9 9 0 . 9 9 2
- 2 . 5 01 1 .0000000
* PI 6 . 8 0
DO .0000030
- P2 3 .4 0
- “3 Ci RD 0 . 0— J . U PW 0 . 0
- DE 3 3 1 .3 0
- NS 8
- DS 2
- n  r NE 256
-
3 .5 IN .0005 260




I O r g a n o n
GW88259. SMX v  *
FI PROJ:
RPFCIH A n a l y t i c a l  Chemi stry
F2 PROJ:
SPEC1H 1H a t  3 6 0 . 1 3  MHz
AU PROG:____ ____________________
COSY. AU 
DATE l l - 6 - 9 a , n , .  FIEL930504
1 r SI2 2048 NEWHOUSE
SI1 1024 9-------------------------
SW2 1901.  L 

















FI 2 .5 67 P
F2 1 .531P
AND COLUMN:
FI 2. 567 P




PI 6 . 8 0
DO .0000030
P2 3 . 4 0
RD 0 .0
PW 0 . 0
DE 3 3 1 .3 0
NS 8
OS 2
NE 512
IN .0005260
PPM
